-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 E4mNes1UQnTV6YFd/aKgtCgH/JLwOOE1UUc3NWcfyy7qBYHLkEtyEgItjbYCdYgT
 ReMIIK5SumJMNUjjL9nZaw==

<SEC-DOCUMENT>0001193125-10-080471.txt : 20100409
<SEC-HEADER>0001193125-10-080471.hdr.sgml : 20100409
<ACCEPTANCE-DATETIME>20100409155037
ACCESSION NUMBER:		0001193125-10-080471
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20100409
FILED AS OF DATE:		20100409
DATE AS OF CHANGE:		20100409

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		10742597

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>Form 6-K </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:arial" SIZE="3"><B>Report of Foreign Private Issuer </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="3"><B>Pursuant to Rule&nbsp;13a-16 or
15d-16 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="3"><B>of the Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">For the month of&nbsp;April 2010 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Commission File Number 000-31062 </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:arial" SIZE="6"><B>Oncolytics Biotech Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>(Translation of registrant&#146;s name into
English) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Suite&nbsp;210, 1167 Kensington Crescent NW </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2"><B>Calgary, Alberta, Canada T2N 1X7 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(Address of principal executive offices) </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Indicate by check mark whether the registrant files or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Form&nbsp;20-F&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2">
</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Form&nbsp;40-F&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:arial"
SIZE="2"></FONT></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T
Rule&nbsp;101(b)(1):&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>Note:</B> Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a Form&nbsp;6-K if submitted solely to provide an attached annual report to security holders. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;<FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="2"><B>Note:</B> Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a Form&nbsp;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under
the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are
traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a
Form&nbsp;6-K submission or other Commission filing on EDGAR. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Indicate by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Yes&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:arial"
SIZE="2"></FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">No&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with
Rule&nbsp;12g3-2(b):&nbsp;82&nbsp;-&nbsp;_________<U></U> </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>EXHIBIT</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>NUMBER</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>DESCRIPTION</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:arial" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Annual Report</FONT></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>SIGNATURES </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Oncolytics Biotech Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial"
SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Date:&nbsp;April 9, 2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">/s/&nbsp;&nbsp;Doug Ball</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Doug Ball</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Chief Financial
Officer</FONT></P></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML><HEAD>
<TITLE>Annual Report</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g91036g29t10.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Oncolytics
BIOTECH INC </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">technology changing life </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">annual report 2009 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g91036g70l30.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Oncolytics
Biotech&reg; Inc. is focused on the development of oncolytic viruses as a novel and effective approach to cancer treatment. Oncolytics&#146; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers
using REOLYSIN&reg;, its proprietary formulation of the human reovirus. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Oncolytics trades on the Toronto Stock
Exchange </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">(symbol ONC) and on the NASDAQ (symbol ONCY). </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Letter to Shareholders 1 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Management&#146;s Discussion and Analysis 4 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"
COLOR="#FFFFFF">Statement of Management&#146;s Responsibility 36 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Auditors&#146; Report 37 </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Financial Statements 39 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Notes to Financial Statements 42 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Corporate
Information IBC </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Annual and Special Meeting </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">The Annual and Special Meeting of the Shareholders will be held at the Hilton Toronto Hotel, 145 Richmond Street West,
Toronto, Ontario at 4:30 pm Eastern Time on Tuesday, May 11, 2010. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="5">2009 Message to Shareholders </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">In the last 12 months Oncolytics has made substantial clinical progress, strengthened our intellectual property position and balance sheet, and scaled up
manufacturing to near commercial levels. We have executed on our business plan focused on preparing the Company for late stage clinical testing and ultimately commercial launch. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2">Transitioning to Late Stage Clinical Testing </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="1">In 2009, Oncolytics&#146; clinical program took a
major step forward as we announced we had reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the design of a Phase 3 trial examining REOLYSIN<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP> in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. The SPA process generates an agreement between Oncolytics and the
FDA, confirming that the design and planned analyses of the Phase 3 study is adequate to provide the necessary data that, depending upon outcome, could support a license application submission for REOLYSIN. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We intend to conduct the first stage of the trial, at up to 25 centres in multiple jurisdictions including the United States, U.K., and Belgium and, on that basis,
also secured approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) subsequent to year-end. Conducting the trials in these markets allows us to access many of the physicians and centres that have already completed clinical
trial work with REOLYSIN as well as head and neck cancer specialists like Dr.&nbsp;Jan Vermorken at the University Hospital in Antwerp. We are currently awaiting approval from the Belgian authorities, which does not impact our ability to commence
enrollment in other jurisdictions. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We believe we are the first company to reach an agreement with the FDA on a Phase 3 trial design for an
intravenously-administered oncolytic virus under the SPA process. As specified in the SPA agreement, the randomized, two-arm, double-blind, multicentre, two-stage, adaptive Phase 3 trial will assess the intravenous administration of REOLYSIN with
the chemotherapy combination of paclitaxel and carboplatin versus chemotherapy alone in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN), or squamous cell cancer of the nasopharynx, who have progressed on or
after prior platinum-based chemotherapy. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The decision to pursue a Phase 3 trial in head and neck cancers was predicated on positive results seen in the
Company&#146;s U.K. Phase I and Phase II combination REOLYSIN and paclitaxel/carboplatin clinical trials, as well as significant preclinical work demonstrating synergy in combination with taxane or platinum-based drugs. Updated results reported in
November 2009, confirmed that REOLYSIN was well tolerated when administered intravenously in combination with paclitaxel and carboplatin. Of 19 evaluable patients with head and neck cancer, mostly SCCHN refractory to prior platinum-based
chemotherapy for recurrent/metastatic disease, eight experienced partial responses and six had stable disease. The total clinical benefit rate observed in head and neck cancer patients in the trial was 74%. Of four patients with malignant melanoma
on the trial, one experienced a partial response and one had stable disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Growing Clinical Success </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">These were not the only positive clinical results we reported in the last year. In March 2009, we presented updated clinical results from our U.K. combination REOLYSIN
and docetaxel clinical trial for patients with advanced cancers (REO 010). Twenty-four patients were treated in the trial, with 17 evaluable for response. Fifteen of the 17 evaluable patients experienced Stable Disease (SD) or better, including five
patients who experienced minor and Partial Responses (PR), giving a clinical benefit rate (SD + PR + CR) of 88%. These results were especially compelling given how difficult heavily pre-treated patients are to treat and the robust nature of the
response rate, which included a significant objective tumour response. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">In April, we announced positive results from our U.K. Phase II clinical trial to
evaluate the objective tumour response rate of REOLYSIN in combination with low-dose radiation in patients with advanced cancers. A total of 16 heavily pretreated patients with advanced cancer were treated. Of 14 patients evaluable for response, 13
patients had stable disease or better in the treated target lesions. Of these, partial responses were observed in four patients (lung, melanoma (2)&nbsp;and gastric) and minor responses were observed in two patients (thyroid, ovarian), for a total
disease control rate (SD + PR + CR) of 93% in the treated lesions and suggesting that REOLYSIN is broadly active. This represents another very high disease control rate in patients that were previously treated with other therapies. In addition, the
combination was well tolerated, with only mild (Grade 1 or 2) toxicities noted. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Late in the year, we reported updated results from a Phase 2 study of
intravenous REOLYSIN in patients with sarcomas metastatic to the lung (REO 014). The investigators reported that the treatment had been well tolerated to date, and that 19&nbsp;of 44 evaluable patients experienced stable disease ranging from two to
20 months, resulting in a total clinical benefit rate of 43%. The response objective for the study was three or more patients having prolonged stabilization of disease (&gt;6&nbsp;months) or better, for the agent to be considered. The trial exceeded
its established objective with six patients experiencing stable disease for more than six months. Two patients had experienced stable disease for more than 19&nbsp;months. One had synovial cell sarcoma that relapsed following surgery, while the
other has Ewing&#146;s Sarcoma and had previously progressed following multiple treatments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Evolving Clinical Program </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="1">While we continued to conclude trials and report data, we also started enrollment on a number of other trials. During the year we started
enrollment on a U.K. translational clinical trial investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases (REO 013); a U.S. Phase 2 clinical trial using
intravenous administration of REOLYSIN<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP> in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with <I>Kras</I> or
EGFR-activated tumours (REO 016); and a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with metastatic melanoma being conducted by the Cancer Therapy&nbsp;&amp;
Research Center at the University of Texas Health Science Center in San Antonio (CTRC at UTHSCSA). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">While our own clinical program continues to evolve,
we have been able to cost effectively expand it by leveraging relationships with groups like the National Cancer Institute and St. James Hospital in the U.K., who conduct trials using REOLYSIN provided by Oncolytics. In 2009, we entered into an
expanded relationship with the CTRC. The clinical collaboration involves up to five, open-label, Phase 2 studies exploring the use of REOLYSIN in combination with chemotherapy for various cancer indications. These indications are expected to
include, pancreatic cancer, squamous cell lung, liver and <I>Kras</I> mutated colorectal cancers in combination with standard chemotherapeutics, in addition to the trial in melanoma that is already enrolling. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Strengthened Balance Sheet </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Obtaining adequate funding to advance our
increasingly late stage clinical program remains a core focus. Despite poor economic conditions through much of 2009, we conducted two financings raising gross proceeds of Cdn$6.9 million and US$14.7 million. We also raised an additional Cdn$14.8
million through the exercise of warrants as we accelerated their expiry dates based on meeting certain trading criteria. Early in the year, we successfully completed the acquisition of an inactive private company with net cash of $2.1 million by
issuing 1,875,121 common shares. In total we raised 37.1&nbsp;million in 2009 and our strong efforts in this regard, have given us sufficient resources to fund the enrollment and data analysis for the first 80-patient phase of our Phase 3 head and
neck cancer trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Advancing Toward the Commercial Endpoint </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="1">In an effort to support our mid-term objective of attracting a large pharmaceutical partner, we appointed Dr.&nbsp;Alan Warrander to the role of Senior Vice President, Global Licensing and Business Development. In his 32-year career, Alan
has held a number of progressively senior positions within the biotechnology and pharmaceutical industries, most recently as Director, Global Licensing, AstraZeneca. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1">One of our most important assets remains our intellectual property portfolio and we were able to add two new U.S. patents during the year, bringing our total issued to 33, with more than 200 issued worldwide.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="1">Bringing REOLYSIN to market will require commercial scale manufacturing capability. During the year, with the support of contract
manufacturer, SAFC Pharma<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>, a division of Sigma-Aldrich Corporation, we successfully completed an initial 100-litre production run of REOLYSIN under cGMP conditions. This
run is anticipated to be the first of a series to be completed over the next several years as we work to support our clinical program and advance toward commercial launch of REOLYSIN. We also successfully completed our lyophilization (freeze-drying)
formulation development program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Looking to the Future </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="1">Looking ahead, our primary focus remains moving through our first Phase 3 clinical trial. With enrollment expected to commence in the near-term, we hope to complete the first 80-patient phase of the study in late 2010 or early 2011. Our
decision to move into head and neck cancer was based on signals of efficacy observed in earlier-stage trials. A secondary goal for 2010 remains the identification of additional indications we can advance into late stage clinical testing and we
expect to announce results from a number of Phase II trials, including our study in non-small cell lung cancer. These results will inform our decisions with respect to next steps in our clinical program as we work to find the most commercially
viable indications. Finally, we will make decisions on which other indications we want to take into the clinic focusing on synergies between our broadly active agent and currently approved therapies, identified through our preclinical&nbsp;work.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">2010 promises to be another exciting year for Oncolytics and I would like to thank all our stakeholders for their continued support through our
substantial recent progress. I look forward to updating you in the quarters ahead. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g91036g92h46.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Dr.&nbsp;Brad Thompson </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">President and
CEO </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">2</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>MANAGEMENT&#146;S DISCUSSION &amp;
ANALYSIS 2009 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Table of Contents </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>FORWARD-LOOKING STATEMENTS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
DEVELOPMENT UPDATE FOR 2009</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Clinical Trial Program</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Clinical Trial &#150; Special Protocol Assessment</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Clinical Trial &#150; 2009 Results</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>U.K. Phase I/II Combination REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Paclitaxel/Carboplatin Clinical Trial</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>U.S. Phase II Sarcoma Clinical Trial</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>U.K. Phase I/II Combination REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Gemcitabine Clinical Trial</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>U.K. Phase II Combination REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Radiation Clinical Trial</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>U.K. Phase I/II Combination REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Docetaxel Clinical Trial</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Clinical Trials &#150; Commencement of Patient Enrollment</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>U.S. Phase II Combination REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Paclitaxel and Carboplatin Clinical Trial for Non-Small Cell Lung Cancer</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>U.K. Transitional Clinical Trial for Metastatic Colorectal Cancer</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Clinical Trials &#150; Clinical Collaboration</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Pre-Clinical and Collaborative Program</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Publications</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Presentations</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Manufacturing and Process Development</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Intellectual Property</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Financing Activity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Acquisition of Inactive Private Company</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Public Offerings</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Warrants</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Financial Impact</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash Resources</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
DEVELOPMENT FOR 2010</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>CRITICAL ACCOUNTING POLICIES AND ESTIMATES</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>SELECTED ANNUAL INFORMATION</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>RESULTS OF OPERATIONS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>SUMMARY OF QUARTERLY RESULTS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>FOURTH QUARTER</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>LIQUIDITY AND CAPITAL RESOURCES</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>OFF-BALANCE SHEET ARRANGEMENTS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>TRANSACTIONS WITH RELATED PARTIES</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>RISK FACTORS AFFECTING FUTURE PERFORMANCE</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">29</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>OTHER MD&amp;A REQUIREMENTS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Disclosure Controls and Procedures</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="6">Management&#146;s&nbsp;Discussion&nbsp;and&nbsp;Analysis </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5">of Financial Condition and Results of Operations </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;8, 2010 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following information should be read in conjunction with our 2009 audited consolidated financial statements and notes thereto, which were prepared in accordance with Canadian generally accepted accounting
principles (&#147;GAAP&#148;). </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="5">Forward-Looking Statements </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:arial" SIZE="2">The following discussion contains forward-looking statements, within the meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended and under applicable Canadian provincial securities
legislation. Forward-looking statements, including our belief as to the potential of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, a therapeutic reovirus, as
a cancer therapeutic and our expectations as to the success of our research and development and manufacturing programs in 2010 and beyond, future financial position, business strategy and plans for future operations, and statements that are not
historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development
projects, the efficacy of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> as a cancer treatment, the success and timely completion of clinical studies and
trials, our ability to successfully commercialize REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, uncertainties related to the research, development and
manufacturing of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, uncertainties related to competition, changes in technology, the regulatory process and
general changes to the economic environment. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">With respect to the forward-looking statements made within this MD&amp;A, we have made
numerous assumptions regarding among other things: our ability to obtain financing to fund our development program, our ability to receive regulatory approval to commence enrollment in our clinical trial program, the final results of our co-therapy
clinical trials, our ability to maintain our supply of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and future expense levels being within our current
expectations. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates and expectations of management at the time such forward-looking statements are made, and such
assumptions, projections, estimates and/or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake to update these forward-looking
statements except as required by applicable law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="5">REOLYSIN<FONT STYLE="font-family:ARIAL" SIZE="3"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Development Update For 2009 </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Oncolytics Biotech Inc. is a Development
Stage Company </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">Since our inception in April of 1998, Oncolytics Biotech<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Inc. has been a development stage company and we have focused our research and development efforts on the development of REOLYSIN<FONT STYLE="font-family:arial"
SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, our potential cancer therapeutic. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue
research and development efforts. We do not expect to generate significant revenues until, if and when, our cancer product becomes commercially viable. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:arial" SIZE="2">We have been developing our product REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> as a possible cancer therapy since our
inception in 1998. Our goal each year is to advance REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> through the various steps and stages of development required

</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">4</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">
for potential pharmaceutical products. In order to achieve this goal, we believe that we have to actively manage the development of our clinical trial program, our pre-clinical and collaborative
programs, our manufacturing process and REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> supply, and our intellectual property. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Clinical Trial Program </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">We began 2009 with
12 clinical trials, either underway or approved to commence, two of which were sponsored by the U.S. National Cancer Institute (&#147;NCI&#148;). We had also announced, at the end of 2008, that we would be pursuing a Phase II/III, randomized trial
using the combination of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> with paclitaxel and carboplatin in patients with head and neck cancers. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">During 2009, our clinical program expanded to include a U.K. transitional clinical trial for patients with metastatic colorectal cancer sponsored
by the University of Leeds (&#147;Leeds&#148;), and a broad U.S. clinical collaboration involving up to five phase II studies sponsored by the Cancer Therapy&nbsp;&amp; Research Center at The University of Texas Health Center in San Antonio
(&#147;CTRC&#148;). Enrollment commenced in three clinical trials during the year and we completed enrollment in two of our U.K. co-therapy clinical trials and our mono-therapy sarcoma clinical trial in the U.S. We continued to announce positive
clinical results throughout 2009 and reached an agreement with the U.S. Food and Drug Administration (&#147;FDA&#148;) under the Special Protocol Assessment (&#147;SPA&#148;) process for the design of our first Phase III examining REOLYSIN<FONT
STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We exited 2009 with eight clinical trials, either underway or approved to commence, of which four are sponsored by us including our Phase III head and neck clinical
trial. The remainder of our clinical trials are being sponsored by the NCI, CTRC or Leeds. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">CLINICAL TRIAL &#150; SPECIAL PROTOCOL ASSESSMENT
</FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">In October 2009, we reached an agreement with the FDA under the SPA process for the design of a Phase III trial examining
REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. The
SPA is an agreement between us and the FDA that the design and planned analyses of the Phase III study is adequate to provide the necessary data, that depending upon outcome, could support a license application submission for REOLYSIN<FONT
STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">As
specified in the SPA, the randomized, two-arm, double-blind, multicentre, two-stage, adaptive Phase III trial will assess the intravenous administration of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> with the chemotherapy combination of paclitaxel and carboplatin versus the chemotherapy alone in patients with metastatic or recurrent squamous cell carcinoma of the
head and neck, or squamous cell cancer of the nasopharynx, who have progressed on or after prior platinum-based chemotherapy. All patients will receive treatment every three weeks (21-day cycles) with paclitaxel and carboplatin and will also
receive, on a blinded basis, either intravenous placebo or intravenous REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. All dosing takes place in the first five
days of each cycle with all patients receiving standard intravenous doses of paclitaxel and carboplatin on day one only, and on days one through five, either intravenous placebo or intravenous REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> at a dose of 3x10</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">10</SUP></FONT><FONT
STYLE="font-family:arial" SIZE="2"> TCID</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">50</SUB></FONT><FONT STYLE="font-family:arial" SIZE="2">. Patients may continue to receive the
trial combination therapy for up to eight, 21-day cycles and, thereafter, blinded placebo or blinded REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> until the
patient has progressive disease or meets other criteria for removal from the trial. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">The primary endpoint for the trial is overall
survival (&#147;OS&#148;); secondary endpoints include progression free survival (&#147;PFS&#148;), objective response rate (complete response (&#147;CR&#148;) + partial response (&#147;PR&#148;)) and duration of response, and safety and
tolerability of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> when administered in combination with paclitaxel and
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
carboplatin. The first stage of the trial is non-adaptive, and is designed to enroll 80 patients. The second stage is adaptive, and is designed to enroll between 100 and 400 patients with the
most probable statistical enrolment being 195 patients in this stage. This adaptive trial design allows frequent data evaluation to determine if the probability of reaching a statistically significant endpoint has been achieved. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">CLINICAL TRIAL &#150; 2009 RESULTS </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:ARIAL" SIZE="2">U.K. Phase
I/II Combination REOLYSIN<FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Paclitaxel/Carboplatin Clinical Trial </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2009, updated clinical results were presented in a poster entitled &#147;Phase I/II Trial of Oncolytic Reovirus (REOLYSIN) in Combination with
Carboplatin/Paclitaxel in Patients with Advanced Solid Cancers with Emphasis on Squamous Cell Carcinoma of the Head and Neck (SCCHN)&#148;. This poster was presented at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference
held in Boston, Massachusetts. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">Our investigators reported that REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> was well tolerated when administered intravenously in combination with paclitaxel and carboplatin. Of the 19 evaluable patients with head and neck cancer, mostly
SCCHN refractory to prior platinum-based chemotherapy for recurrent/metastatic disease, eight experienced PR and six had stable disease (&#147;SD&#148;). As a result, the total clinical benefit rate (CR + PR + SD) observed in head and neck cancer
patients was 74% and the response rate (PR + CR) was 42%. Typically, in patients previously treated with platinum agents, the response rate is generally in the 3-10% range. As well, there were four patients with malignant melanoma on the trial, one
experienced a partial response and one had stable disease. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">This Phase I/II trial had two components. The first was a Phase I,
open-label, dose-escalating, non-randomized study of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> given intravenously in combination with paclitaxel and
carboplatin every three weeks. In this portion of the trial, standard dosages of paclitaxel and carboplatin are delivered to patients with escalating intravenous dosages of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours such as head and neck, melanoma, lung and ovarian that are
refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The second component of the trial was a Phase II, 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN<FONT
STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with
advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">U.S. Phase II
Sarcoma Clinical Trial </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During the first half of 2009, we completed full enrollment of 52 patients in our U.S. Phase II sarcoma clinical trial and
announced positive interim results at the American Society of Clinical Oncology (&#147;ASCO&#148;) annual meeting held in Orlando, Florida. During ASCO a presentation entitled &#147;A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in
the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung&#148; was delivered by Dr.&nbsp;Monica Mita, the study principal investigator at the Institute of Drug Development (&#147;IDD&#148;), at CTRC. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The interim results demonstrated that the treatment was well tolerated, with 15 of 36, or 42%, of evaluable patients experiencing SD for more than 16 weeks, including
five patients who have had SD for more than 24 weeks. One patient had SD for more than 80 weeks. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">6</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These results were updated at the 15th Annual Connective Tissue Oncology Society Meeting held in Florida in November 2009. A poster was presented entitled &#147;A
Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung,&#148; was delivered by Dr.&nbsp;Kamalesh Sankhala, part of principal investigator Dr.&nbsp;Monica
Mita&#146;s team at the IDD. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The investigators reported that the treatment has been well tolerated, and that 19 of 44 evaluable patients experienced
stable disease ranging from two to 20 months, resulting in a total clinical benefit rate of 43%. The response objective for the study was three or more patients having prolonged stabilization of disease (&gt;6 months) or better, for the agent to be
considered. The trial exceeded its established objective with six patients experiencing stable disease for more than six months. Two patients have experienced stable disease for more than 19 months. One has synovial cell sarcoma that relapsed
following surgery, while the other has Ewing&#146;s Sarcoma and had previously progressed following multiple treatments. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:ARIAL" SIZE="2">U.K. Phase
I/II Combination REOLYSIN<FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Gemcitabine Clinical Trial </FONT></P> <P
STYLE="margin-top:2px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">During the first part of 2009, we completed patient enrolment in our U.K. clinical trial to evaluate the anti-tumour effects of intravenous
administration of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in combination with gemcitabine (Gemzar<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) in patients with advanced cancers including breast, and head and neck. A total of 15 patients were enrolled in the trial of which ten patients were evaluable for
response. Two of these ten patients (breast and nasopharyngeal) experienced a PR and five of these ten patients experienced SD for 4-8 cycles. The total disease control rate (CR+ PR + SD) was 70% for these evaluable patients. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">This trial was an open-label, dose-escalating, non-randomized study of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> given intravenously with gemcitabine every three weeks. Gemcitabine (1000 mg/m2) was administered to patients in combination with escalating dosages of REOLYSIN<FONT
STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> intravenously. Eligible patients included those who had been diagnosed with advanced or metastatic solid tumours including
pancreatic, lung and ovarian cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:arial" SIZE="2">The primary objective of the trial was to determine the Maximum Tolerated Dose (&#147;MTD&#148;), Dose-Limiting Toxicity (&#147;DLT&#148;), recommended dose and dosing schedule and safety profile of REOLYSIN<FONT
STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> when administered in combination with gemcitabine. Secondary objectives included the evaluation of immune response to the drug
combination, the body&#146;s response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:ARIAL"
SIZE="2">U.K. Phase II Combination REOLYSIN<FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Radiation Clinical Trial </FONT></P> <P
STYLE="margin-top:2px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">During 2009, we announced positive results in our U.K. Phase II clinical trial to evaluate the objective tumour response rate of REOLYSIN<FONT
STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in combination with low-dose radiation in patients with advanced cancers. A total of 16 heavily pretreated patients with
advanced cancer (5 &#150; melanoma, 4 &#150; colorectal, 1 of each gastric, pancreas, ovarian, lung, cholangiocarcinoma, sinus and thyroid) were enrolled in this trial. Most patients had received prior chemotherapy and/or radiation. Of 14 patients
evaluable for response, 13 patients had stable disease or better in the treated target lesions. Of these, partial responses were observed in four patients (lung, melanoma (2)&nbsp;and gastric) and minor responses were observed in two patients
(thyroid, ovarian), for a total disease control rate of 93% in the treated lesions. The combination was well tolerated, with only mild (Grade 1 or 2) toxicities noted. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:arial" SIZE="2">This trial was an open-label, single-arm, multi-centre Phase II study of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
delivered via intratumoural injection to patients during treatment with low-dose fractionated radiotherapy. 20 Gy of
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">
radiation was given in five consecutive daily 4 Gy fractions combined with two intratumoural injections of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (1x10</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">10</SUP></FONT><FONT
STYLE="font-family:arial" SIZE="2"> TCID</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">50</SUB></FONT><FONT STYLE="font-family:arial" SIZE="2">) on days two and four. The primary
endpoint was objective tumour response rate in treated lesions. Secondary endpoints were to evaluate viral replication, immune response, and safety. Eligible patients included those diagnosed with advanced or metastatic cancers that are refractory
(&#147;have not responded&#148;) to standard therapy or for which no curative standard therapy exists. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:ARIAL" SIZE="2">U.K. Phase I/II Combination
REOLYSIN<FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Docetaxel Clinical Trial </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">During the early part of 2009, updated clinical results from our U.K. co-therapy trial with docetaxel were presented by Professor Hardev Pandha of the Royal Surrey County Hospital at the Fifth International Meeting
on Replicating Oncolytic Virus Therapeutics held in Banff, Alberta. Twenty-four patients were treated in the trial, with 17 evaluable for response. Fifteen of the 17 evaluable patients experienced SD or better, including five patients who
experienced minor and partial responses, giving a clinical benefit rate of 88%. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">CLINICAL TRIALS &#150; COMMENCEMENT OF PATIENT ENROLLMENT </FONT></P>
<P STYLE="margin-top:4px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:ARIAL" SIZE="2">U.S. Phase II Combination REOLYSIN<FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Paclitaxel and Carboplatin Clinical Trial for Non-Small Cell Lung Cancer </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:arial" SIZE="2">In March 2009, we commenced patient enrolment in our Phase II clinical trial using intravenous administration of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with <I>Kras</I> or EGFR-activated tumours. The Principal
Investigator is Dr.&nbsp;Miguel Villalona-Calero, Professor, Division of Hematology/Oncology and Department of Internal Medicine and Pharmacology at The Ohio State University Comprehensive Cancer Center. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">This trial is a single arm, single-stage, open-label, Phase II study of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> given intravenously with paclitaxel and carboplatin every 3 weeks. Patients will receive four to six cycles of paclitaxel and carboplatin in conjunction with
REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, at which time REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> may be continued as a monotherapy. It is anticipated that up to 36 patients will be treated in this trial. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Eligible patients include those with metastatic or recurrent NSCLC with <I>Kras</I> or EGFR-activated tumours, who have not received chemotherapy treatment for their
metastatic or recurrent disease. Patients must have demonstrated mutations in <I>Kras</I> or EGFR, or EGFR gene amplification in their tumours (metastatic or primary) in order to qualify for the trial. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">U.K. Transitional Clinical Trial for Metastatic Colorectal Cancer </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:arial" SIZE="2">In January 2009, patient enrolment began in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in patients with metastatic colorectal cancer prior to surgical resection of liver metastases sponsored by the University of Leeds. The principal investigator is
Professor Alan Melcher of St. James&#146;s University Hospital. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">This is an open-label, non-randomized, single centre study of
REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> given intravenously to patients for five consecutive days in advance of their scheduled operations to remove
colorectal cancer deposits metastatic to the liver. Patients will comprise two groups receiving REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, either at an
early (21 to 10 days) or late time point (less than 10 days) before surgical resection. After surgery, the tumour and surrounding liver tissue will be assessed for viral status and anti-tumour effects. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">The primary objectives of the trial are to assess the presence, replication and anti-cancer effects of reovirus within liver metastases after
intravenous administration of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> by examination of the resected
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">8</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">
tumour. Secondary objectives include assessing the anti-tumour activity and safety profile of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, and monitoring the humoral and cellular immune response to REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Eligible patients include those with histologically proven
colorectal cancer, planned for potentially curative surgical resection of liver metastases. Up to 20 patients will receive one cycle of treatment in this trial, with approximately 10 in each of the early and late virus groups. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">The University of Leeds is supporting the costs of the trial, while we will provide REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">CLINICAL TRIALS &#150; CLINICAL COLLABORATION </FONT></P> <P
STYLE="margin-top:4px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">In February 2009, we entered into a broad clinical collaboration involving up to five, open-label, Phase II studies exploring the use of
REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in combination with chemotherapy for various cancer indications with the CTRC. These indications are expected to
include melanoma, pancreatic cancer, squamous cell lung, liver and K-RAS mutated colorectal cancers in combination with standard chemotherapeutics. This research program is in addition to Phase II trials in sarcoma and refractory head&nbsp;&amp;
neck cancers, sponsored by us that are currently underway at this site. The CTRC will support the costs of the trials while we will provide REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">In September 2009, the first clinical trial
under this clinical collaboration commenced patient enrollment. This trial is a U.S. Phase II clinical trial using intravenous administration of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in combination with paclitaxel and carboplatin in patients with metastatic melanoma. The Principal Investigator is Dr.&nbsp;Devalingam Mahalingam, M.D., Ph.D.,
MRCP(UK), MRCP(I), clinical investigator in GI/thoracic oncology and drug development at the CTRC. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">The trial is a single arm,
open-label, Phase 2 study of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> given intravenously with paclitaxel and carboplatin every three weeks. It is
anticipated that up to 43 patients will be treated in the study. Eligible patients include those with metastatic, malignant melanoma who have failed one or more prior therapies, or those who are not considered to be a candidate for standard,
first-line treatment. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The primary objective is to measure the objective response rate (PR + CR) to the treatment combination. The secondary objectives
are to assess progression-free survival and overall survival for the treatment regimen in the study population, to assess disease control rate and duration in the study population, and to assess the safety and tolerability of the combination
treatment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Pre-Clinical and Collaborative Program </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL"
SIZE="2">Publications </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During 2009, the following articles were published: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="41%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Title</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Senior&nbsp;Author</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Publication</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Description/Conclusion</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><I>Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma</I></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Prof. Hardev Pandha</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Clinical&nbsp;Cancer Research (online issue September 22, 2009)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">The research demonstrated that the innate cancer killing activity of reovirus can be enhanced with a variety of commonly available therapeutic agents
in models of malignant melanoma. Further, this work demonstrated that the combination of reovirus with cisplatin had the ability to nearly abrogate the production of inflammatory cytokines by the tumor cells, which is believed to augment virus
replication in the tumor and improve its anti-cancer activity.</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><I>Synergistic Antitumor Activity of Oncolytic Reovirus and Chemotherapeutic Agents in Non-Small Cell Lung Cancer Cells</I></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Dr. Shizuko Sei</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Molecular Cancer (online issue July 14, 2009)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The investigators examined <I>in vitro</I> combination effects of reovirus alone and in combination with
cisplatin, gemcitabine or vinblastine. When reovirus was used alone, it demonstrated significant cytolytic activity in 7 of 9 NSCLC cell lines examined. The combinations demonstrated strong synergistic effects on cell killing. The combination of
reovirus and paclitaxel was invariably synergistic in all cell lines tested, regardless of their level of sensitivity to either agent.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">The investigators concluded that the oncolytic activity of reovirus can be potentiated by taxanes and other chemotherapeutic agents, and that the reovirus-taxane
combination most effectively achieves synergy through accelerated apoptosis triggered by prolonged mitotic arrest.</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">10</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Presentations </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During 2009, the following presentations were made:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="41%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Title</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Presenter</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Location</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Description/Conclusion</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><I>Anti-Tumor Activity of Reovirus is Synergistically Enhanced in Combination with Temozolomide and Low Dose Irradiation in Primary Patient Glioma
Xenografts Resistant to Treatment with Either Therapy Alone</I></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Dr. Jacqueline Parker</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">28th American Society for Virology Annual Meeting in Vancouver, British Columbia</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The poster covered preclinical work using reovirus in combination with low dose irradiation (IR) and
temozolomide (TMZ). A panel of glioma cell lines and primary patient glioma explant cells were tested for susceptibility to reovirus, IR, TMZ, or a combination of these therapies <I>in vitro</I>. The combination index analyses revealed moderate to
strong synergy in primary patient glioma cells treated with reovirus plus IR and TMZ <I>in vitro</I>. This effect was also seen <I>in vivo</I> in flank tumor xenografts from primary patient tumors resistant to reovirus therapy alone.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">The investigators concluded that the data supports the use of reovirus in combination with
standard radiation and chemotherapies for the treatment of malignant glioma in humans.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><I>Combination of Oncolytic Reovirus and Rapamycin in a B16.F10 Mouse Melanoma Model</I></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Prof. Hardev Pandha</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Fifth International Meeting on Replicating Oncolytic Virus Therapeutics in Banff, Alberta</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The investigators examined the <I>in vitro</I> and in vivo oncolytic activity of reovirus against the
mouse melanoma cell line B16.F10 in combination with the mTOR inhibitor rapamycin. The investigators concluded that in vitro synergy between rapamycin and reovirus is only seen when rapamycin is administered after reovirus, and that simultaneous
administration of rapamycin and reovirus decreases apoptotic cell death and viral replication.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:arial" SIZE="2">However, unlike the <I>in vitro</I> observations, the combination of rapamycin and reovirus is synergistic <I>in vivo</I>. Further sequencing is being assessed to enhance this effect.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><I>Immune-Mediated Anti-Tumor Activity of Reovirus is Independent of Direct Viral Oncolysis and Replication</I></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Professor Alan Melcher</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">Fifth International Meeting on Replicating Oncolytic Virus Therapeutics in Banff, Alberta</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">The investigators concluded that the immune response is critical to reovirus tumor therapy and is of direct translational relevance to fulfilling the
potential of this novel anti-cancer agent.</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Manufacturing and Process Development </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:arial" SIZE="2">During 2009, we continued to increase the scale of our manufacturing process by successfully completing two 100-litre production runs of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> under cGMP conditions. As well, in conjunction with the National Research Council Biotechnology Research Institute of Montreal and Lyophilization Technology, Inc. of
Ivyland, Pennsylvania we successfully completed our lyophilization (freeze-drying) formulation development program for REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>
</FONT>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Intellectual Property </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2009, three
U.S. patents were issued. We have been issued over 200 patents including 33 U.S. and 11 Canadian patents as well as issuances in other jurisdictions. We also have over 180 patent applications filed in the U.S., Canada and other jurisdictions.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Financing Activity </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During 2009, we received
cash inflow from financing activities of $37 million as follows: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Acquisition of Inactive Private Company </FONT></P> <P
STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2009, we completed the acquisition of an inactive private company. The cash available from the private company, at the time of closing, was $2.13 million and
we issued 1,875,121 common shares in our capital based on a previously determined exchange ratio of $1.69. Net proceeds from this acquisition were $1.8 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL"
SIZE="2">Public Offerings </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May 2009, we closed a public offering whereby we issued 3,450,000 units at $2.00 per unit for gross proceeds of $6.9
million. Each unit consisted of one common share and one common share purchase warrant. Each common share purchase warrant entitles the holder to purchase one common share at an exercise price of $2.40 per share for a three year period, subject to
an acceleration of the expiry date in certain circumstances. Net cash proceeds from this public offering were $5.9 million. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2009, we closed
a public offering whereby we issued 4,887,500 units at US$3.00 per unit for gross proceeds of US$14,662,500. Each unit consisted of one common share and 0.40 of one common share purchase warrant. Each whole common share purchase warrant entitles the
holder to purchase one common share at an exercise price of US$3.50 per share for a five year period subject to an acceleration of the expiry date in certain circumstances. Net cash proceeds from this public offering were $13.9 million. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrants </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During 2009, and in conjunction with the terms of our
warrant indentures, we accelerated the expiry date of our warrants issued in December 2008, with an exercise price of $1.80, and the expiry date of our warrants issued in May 2009, with an exercise price of $2.40. We received proceeds of $5.8
million from the exercise of our $1.80 warrants and $9.1 million from the exercise of our $2.40 warrants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Financial Impact </B></FONT></P> <P
STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We estimated at the beginning of 2009, and in conjunction with our available cash resources, that our cash requirements to fund our base level of activity for 2009
would be approximately $11,000,000. During the second quarter of 2009, we raised an additional $8.3 million through our financing activities. As a result, we
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">12</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
re-evaluated and expanded our planned research and development to include additional clinical and manufacturing activities. Additional clinical activities included increasing patient enrollment
in certain clinical trials and increasing related clinical trial support costs. Additional manufacturing activities include the 100-litre production run that was completed in the second quarter of 2009, the requisite fill, label, and packaging of
our 100-litre run and expanded process validation studies. The cost of this additional activity for 2009 was approximately $4.0 million. We also reduced our accounts payable and accrued liabilities balance by $0.3 million when compared to the end of
2008. As a result, our combined cash used in operating activities 2009 was $16.1 million (see &#147;Liquidity and Capital Resources&#148;). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our cash
usage in our operating activities for 2009 was in line with our revised expectations. Our net loss for the year was $16,231,249. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash Resources </B>
</FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We exited 2009 with cash resources totaling $34,128,876 (see &#147;<I>Liquidity and Capital Resources</I>&#148;). </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="5">REOLYSIN<FONT STYLE="font-family:ARIAL" SIZE="3"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Development For 2010
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">Our planned development activity for REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in 2010 is made up of clinical, manufacturing, intellectual property and collaboration programs. Our 2010 clinical program includes the commencement of patient
enrollment in our Phase III clinical trial examining REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in combination with paclitaxel and carboplatin in patients
with platinum-refractory head and neck cancers along with completion of Stage 1 of this trial (approximately 80 patients). As well, we expect to complete our non-small cell lung cancer trial and support those clinical trials that are sponsored by
CTRC, Leeds and the NCI. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">Our 2010 manufacturing program includes two 100-litre production runs along with the related fill,
labeling, packaging and shipping of REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> to the various clinical sites as required, and performing smaller process
development studies examining formulation, stability and additional scale up. Our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio. Finally, our 2010
collaboration program will finish the studies in place at the end of 2009 and contemplates the addition of future studies that may be required. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
estimate that the cash requirements to fund our operations for 2010 will be approximately $24,000,000 (see &#147;<I>Liquidity and Capital Resources</I>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL"
SIZE="5">Critical Accounting Policies and Estimates </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In preparing our financial statements, we are required to make certain estimates, judgments and
assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets at the date of the financial statements and the reported amounts of expenses during the periods
presented. Significant estimates are used for, but not limited to, the treatment of our research and development expenditures, the assessment of realizable value of long-lived assets, the amortization period of intellectual property and the
calculation of stock based compensation. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The significant accounting policies which we believe are the most critical to aid in fully understanding and
evaluating our reported financial results include the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">RESEARCH AND DEVELOPMENT </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We account for
our research and development activity in conjunction with the Canadian Institute of Chartered Accountants&#146; (the &#147;CICA&#148;) Handbook Section&nbsp;3064 <I>&#147;Goodwill and Intangible Assets&#148;</I> (&#147;Section 3064&#148;) and
expense all of our research and development costs as incurred. Under Section&nbsp;3064, development costs should only be capitalized if all the criteria below are met: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">The technical feasibility of completing the intangible asset so that it will be available for use or sale. </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Our intention to complete the intangible asset and use or sell it. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Our ability to use or sell the intangible asset. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">How the intangible asset will generate probable future economic benefits. Among other things, we are able to demonstrate the existence of a market for the output of the
intangible asset or the intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset. </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Our ability to measure reliably the expenditure attributable to the intangible asset during its development. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that we do not meet all of the above criteria and for this reason, our research and development costs are expensed and not capitalized. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We will monitor our progress against these criteria and will capitalize our development costs once we can conclude we meet the above criteria. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">FUTURE ACCOUNTING CHANGES </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">International Financial Reporting Standards
</FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Canadian Institute of Chartered Accountants&#146; Standards Board announced that Canadian publicly accountable enterprises are required to adopt
IFRS, as issued by the International Accounting Standards Board (IASB), effective January&nbsp;1, 2011. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have commenced the process to transition from
current Canadian GAAP (&#147;GAAP&#148;) to IFRS. Our transition plan, which in certain cases will be in process concurrently as IFRS is applied, includes the following three phases: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Scoping and diagnostic phase &#151; This phase involves performing a high-level diagnostic assessment to identify key areas that may be impacted by the
transition to IFRS. As a result of the diagnostic assessment, the potentially affected areas are ranked as high, medium or low priority. This phase was finalized in 2008. </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Impact analysis, evaluation and design phase &#151; In this phase, each area identified from the scoping and diagnostic phase will be addressed in order of
descending priority. This phase involves specification of changes required to existing accounting policies, information systems and business processes, together with an analysis of policy alternatives allowed under IFRS.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Implementation and review phase &#151; This phase includes execution of changes to information systems and business processes, completing formal authorization
processes to approve recommended accounting
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">14</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0%"><FONT STYLE="font-family:arial" SIZE="2">
policy changes and training. At the end of the implementation and review phase we will be able to compile financial statements compliant with IFRS. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2009, we performed our impact analysis with respect to IFRS 1 &#147;<I>First Time Adoption of International Financial Reporting Standards</I>&#148;, analyzed other
known GAAP to IFRS differences and commenced the preparation of our IFRS accounting policies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">IFRS 1 &#147;</FONT><FONT STYLE="font-family:arial"
SIZE="2"><I>First Time Adoption of International Financial Reporting Standards</I></FONT><FONT STYLE="font-family:ARIAL" SIZE="2">&#148; </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon review of
IFRS 1, and as at December&nbsp;31, 2009, we expect to utilize the exemption relating to investments in subsidiaries, jointly controlled entities and associates. We may also wish to utilize the exemption relating to cumulative translation
differences if it is applicable upon adoption. We do not expect there to be a significant impact on our financial statements as a result of using these exemptions. As well, based on the transactions we have incurred to date and our specific facts,
we believe it will not be necessary to utilize the other exemptions made available by IFRS 1. As we move towards actual implementation and reporting under IFRS, we will continue to monitor our transactions and make use of any exemptions that are
determined to benefit Oncolytics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">OTHER GAAP TO IFRS DIFFERENCES </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2">Functional Currency </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There are differences in the determination of an entity&#146;s functional currency between GAAP
and IFRS. We are reviewing the facts of each of the entities within our corporate structure and we expect that our functional currencies should not change. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL"
SIZE="2">Foreign Currency Translation </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The foreign currency translation of our subsidiaries may differ under IFRS compared to GAAP. This is dependent on
our conclusion relating to the functional currency of each of our subsidiaries. We expect the impact of this difference to be insignificant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Income
Taxes </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The IFRS standard, IAS 12 &#147;<I>Income Taxes</I>&#148; continues to be under review and it is expected to change before 2011. We expect that,
regardless of the results of the review, there will be differences between IFRS and GAAP, but will depend on the final standard. The potential impact is not expected to impact our balance sheet or income statement, but will impact our valuation
allowance within our income tax disclosure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Treatment of Warrants with an Exercise Price Denominated in a Foreign Currency </FONT></P> <P
STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There is a difference between GAAP and IFRS on the treatment of warrants with an exercise price denominated in a currency other than the entity&#146;s functional
currency. Currently, IFRS would require accounting for these warrants as a liability measured at fair value with changes in fair value recorded in the consolidated statement of loss. GAAP requires these warrants to be accounted for as an equity
instrument. The current impact on our consolidated financial statements would be to increase our liabilities and decrease our equity by $1.0 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">15</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Fair Presentation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Stock Based
Compensation </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As required by the fair value based method for measuring stock based compensation, we have chosen to use the Black Scholes Option Pricing
Model (&#147;Black Scholes&#148; or the &#147;Model&#148;) to calculate the fair value of our options. Though there are other models available to calculate the option values (for example, the binomial model), Black Scholes is currently widely used
and accepted by other publicly traded companies. Therefore, we have concluded that Black Scholes is the appropriate option pricing model to use for our stock options at this time. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Black Scholes uses inputs in its calculation of fair value that require us to make certain estimates and assumptions. For 2009, we used the following weighted average assumptions: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>1.21%</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expected hold period to exercise</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>3.0&nbsp;years</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Volatility in the price of the our shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>57%</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Zero</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A change in these estimates and assumptions will impact the value calculated by
the Model. For instance, the volatility in the price of our shares is based on the quoted trading price. We assume that weekly trading prices best reflect our trading price volatility. However, an entity can choose between daily, weekly, or monthly
trading prices in the volatility calculation. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Model also uses an expected hold period to exercise in its calculation of fair value. When we are
estimating the expected hold period to exercise we take into consideration past history, the current trading price and volatility of our common shares and have concluded that 3.0 years is an appropriate estimate. However, our options have a 10-year
life and given the fluctuations in our stock price the expected hold period could be different. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Consequently, in complying with GAAP and selecting what
we believe are the most appropriate assumptions under the circumstances, we have recorded non-cash employee stock based compensation expense for the year of $424,273. However, given the above discussion, this expense could have been different and
still be in accordance with GAAP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrant Values </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since
inception, we have raised cash through the issue of units and the exercise of warrants and options. Each issued unit has consisted of one common share and portion of one common share purchase warrant with each whole warrant exercisable at a
specified price for one additional common share for up to 60 months from the issue date. GAAP requires that when recording the issued units, a value should be ascribed to each component of the units based on the component&#146;s fair value. The fair
value of our common shares is established based on trading on stock exchanges in Canada and the U.S. However, as the warrants do not trade on an exchange, the Black Scholes Option Pricing Model has been used to determine the fair value of the
warrants. In the event that the total calculated value of each individual component is greater than the price paid for the unit, the value of each component is reduced on a relative basis until the total is equal to the unit&#146;s issue price.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">16</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For reasons discussed above under &#147;Stock Based Compensation&#148;, the Model can produce a range of calculated values for our warrants. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="5">Selected Annual Information </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>16,231,249</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17,550,204</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,950,426</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Basic and diluted loss per share</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2), (3)</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>0.33</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.42</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.39</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1),
(3)</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>35,593,391</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,987,195</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">26,297,567</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash dividends declared per share</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Nil</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">Nil</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">Nil</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Notes: </FONT></P> <P
STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Subsequent to the acquisition of Oncolytics Biotech Inc. by SYNSORB in April 1999, we applied push down accounting. </FONT></TD></TR></TABLE> <P
STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Included in net loss and net loss per share is stock based compensation expense of $424,273 (2008 &#150; $64,039; 2007 &#150; $539,156). </FONT></TD></TR></TABLE> <P
STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We issued 17,719,211 common shares for net cash proceeds of $37,052,900 in 2009 (2008 &#150; 2,650,000 common shares for net cash proceeds of $3,421,309; 2007 &#150; 4,660,000
common shares for net cash proceeds of $12,114,394). </FONT></TD></TR></TABLE> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We have not declared or paid any dividends since incorporation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL"
SIZE="5">Results of Operations </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net loss for the year ended December&nbsp;31, 2009 was $16,231,249 compared to $17,550,204 and $15,950,426 for 2008 and
2007, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Research and Development Expenses (&#147;R&amp;D&#148;) </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Clinical trial expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>3,766,234</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">5,797,085</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3,897,235</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Manufacturing and related process development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>3,720,251</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3,062,951</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">4,325,271</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>968,849</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">1,244,388</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">1,070,655</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pre-clinical trial expenses and collaborations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>509,600</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">687,679</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">822,891</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Quebec scientific research and experimental development refund</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(75,833</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(56,562</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other R&amp;D expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2,641,580</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">2,635,605</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">2,326,253</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>11,606,514</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">13,351,875</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">12,385,743</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">17</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">CLINICAL TRIAL EXPENSES </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Clinical trial
expenses include those costs associated with our clinical trial program in the U.S. and the U.K. as well as those incurred in the preparation of commencing other clinical trials. Included in clinical trial expenses are direct patient enrollment
costs, contract research organization (&#147;CRO&#148;) expenses, clinical trial site selection and initiation costs, data management expenses and other costs associated with our clinical trial program. </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Clinical trial expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,766,234</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,797,085</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,897,235</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our clinical trial expenses in 2009 were $3,766,234 compared to $5,797,085 and
$3,897,235 in 2008 and 2007, respectively. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During 2009, we continued to complete patient enrollment and re-treatments in our Oncolytics&#146; sponsored
clinical trials and exited 2009 with four enrolling trials compared to nine enrolling trials at the end of 2008. As well, we incurred grant costs in 2009 associated with our clinical trial research collaboration with the CTRC that were not incurred
during 2008. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We exited 2009 with a clinical trial program that included eight clinical trials, either underway or approved to commence, of which four
are sponsored by Oncolytics and the remainder being sponsored by the NCI, CTRC or Leeds. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2008, our clinical trial program expanded from eight active
clinical trials at the beginning of the year to 12&nbsp;clinical trials by the end of 2008 of which two are sponsored by the NCI. Of the ten clinical trials being conducted by us, nine trials were actively enrolling patients throughout 2008 compared
to seven actively enrolling trials in 2007. As well, the patients enrolled in our Phase II clinical trials and those enrolled at the top dose of the dose escalation component of our Phase I trials received more re-treatments in 2008 compared to
2007. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">In 2007, we incurred direct patient costs in our seven ongoing clinical trials and completed patient enrollment in our Phase
Ia/Ib REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>/radiation clinical trial. As well, we incurred clinical site start up costs for our four co-therapy trials
in the U.K. and our Phase II sarcoma clinical trial in the U.S. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">We expect our clinical trial expenses to increase in 2010 compared
to 2009. We expect to commence enrollment in our Phase III clinical trial examining REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in combination with
paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers along with completion of stage one of this trial (approximately 80 patients). As well, we expect to complete our non-small cell lung cancer trial and support those
clinical trials that are sponsored by CTRC, Leeds and the NCI. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">MANUFACTURING&nbsp;&amp; RELATED PROCESS DEVELOPMENT EXPENSES (&#147;M&amp;P&#148;)
</FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">M&amp;P expenses include product manufacturing expenses and process development. Product manufacturing expenses include third party direct manufacturing
costs, quality control testing, fill and packaging costs. Process development expenses include costs associated with studies that examine components of our
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">18</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
manufacturing process looking for improvements and costs associated with the creation and testing of our master and working viral and cell banks. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Product manufacturing expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>3,367,631</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,774,747</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,113,832</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Technology transfer expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">388,673</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Process development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>352,620</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">288,204</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">822,766</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Manufacturing and related process development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>3,720,251</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,062,951</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,325,271</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our M&amp;P expenses for 2009 were $3,720,251 compared to $3,062,951 and
$4,325,271 for 2008 and 2007, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During 2009, we completed the production and fill of our first cGMP 100-litre production run and completed
the bulk production of a second cGMP 100-litre production run towards the end of the year. We also incurred costs associated with the fill, labeling, and packaging of the product from our 40-litre runs from 2008 for shipment to our clinical sites.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">During 2008, we transferred and completed two 40-litre cGMP production runs of REOLYSIN<FONT STYLE="font-family:arial"
SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> that are being used to supply our clinical trial program. As well, we incurred costs associated with the fill, packaging, and shipping of these
production runs. In 2007, we completed and packaged the production runs that had commenced at the end of 2006 and initiated additional production runs to manufacture REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> at the 20-litre scale. We also incurred technology transfer costs towards the end of 2007 related to the transfer of our 40-litre production process to a second cGMP
manufacturer located in the U.S. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our process development activity in 2009 was focused on developing a lyophilization formulation plan which was
completed in the second quarter of 2009 and we commenced validation studies that are anticipated to be part of our path to registration. In 2008, we continued to examine further scale up to the 100-litre level, lyophilization and process validation
studies. We completed our 100-litre scale up studies towards the end of 2008. Our main process development focus in 2007 centered on the scale up of our production process, which included scale up studies at 40-litre and 100-litre levels.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect our M&amp;P expenses for 2010 to increase compared to 2009. We expect to complete multiple 100-litre cGMP production runs including fill and
finish activities in 2010. We also expect to perform a number of small scale process development studies focusing on formulation, process validation, stability and scale up. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2">INTELLECTUAL PROPERTY EXPENSES </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property expenses include legal and filing fees associated with our
patent portfolio. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>968,849</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,244,388</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,070,655</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our intellectual property expenses for 2009 were $968,849 compared to $1,244,388 and $1,070,655 for 2008 and 2007, respectively. The
change in intellectual property expenditures reflects the timing of filing costs associated with our portfolio of patents and a change in the geographic focus of our worldwide patent filing strategy. At the yearend, we had been issued over 200
patents including 33 U.S. and 11 Canadian patents as well as issuances in other jurisdictions. We also have over 180 patent applications filed in the U.S., Canada and other jurisdictions. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">PRE-CLINICAL TRIAL AND RESEARCH COLLABORATION EXPENSES </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pre-clinical
trial expenses include toxicology studies and are incurred by us in support of expanding our clinical trial program into other indications, drug combinations and jurisdictions. Research collaborations are intended to expand our intellectual property
related to reovirus and identify potential licensing opportunities arising from our technology base. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pre-clinical trial expenses and research collaborations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>509,600</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">687,679</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">822,891</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2009, our pre-clinical expenses and research collaborations expenses were
$509,600 compared to $687,679 and $822,891 in 2008 and 2007, respectively. Our research collaboration activity in 2009 continued to focus on the interaction of the immune system and the reovirus and the use of the reovirus as a co-therapy with
existing chemotherapeutics and radiation. In 2009, we completed the collaborative agreements we had entered into in 2008 and we continued to be selective in the types of new collaborations we entered into throughout the year. Over the last three
years we have seen a decline in these expenses as we have entered into fewer collaborative agreements each year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect that pre-clinical trial
expenses and research collaborations in 2010 will remain consistent with 2009. We expect to complete our ongoing collaborative program carried over from 2009 and will continue to be selective in the types of new collaborations we enter into in 2010.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">OTHER RESEARCH AND DEVELOPMENT EXPENSES </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other R&amp;D
expenses include compensation expenses for employees (excluding stock based compensation), consultant fees, travel and other miscellaneous R&amp;D expenses. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">R&amp;D consulting fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>279,321</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">197,773</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">241,811</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">R&amp;D salaries and benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2,097,501</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,926,148</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,713,849</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other R&amp;D expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>264,758</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">511,684</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">370,593</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2,641,580</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,635,605</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,326,253</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2009, our Other R&amp;D expenses were $2,641,580 compared to $2,635,605 and
$2,326,253 for 2008 and 2007, respectively. During 2009, the increase in R&amp;D salaries and benefit cost was a result of yearend bonuses that
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">20</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
were not paid in 2008. In 2008, the increase in our R&amp;D salaries and benefits costs was a result of increases in staff and salary levels for 2008 compared to 2007. Our Other R&amp;D expenses
in 2009 decreased compared to 2008 as there was less travel activity in 2009 associated with supporting our clinical trials, in the U.S. and the U.K. and fewer conferences, symposiums and meetings were attended in 2009 compared to 2008. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2010, we expect that our Other R&amp;D expenses will remain consistent with 2009. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>Operating Expenses </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Public company related expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2,423,161</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,099,583</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,578,100</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Office expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>1,359,346</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,211,992</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,248,095</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>3,782,507</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,311,575</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,826,195</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Public company related expenses include costs associated with investor
relations and business development activities, legal and accounting fees, corporate insurance, and transfer agent and other fees relating to our U.S. and Canadian stock listings. In 2009, we incurred public company related expenses of $2,423,161
compared to $3,099,583 and $2,578,100 for 2008 and 2007, respectively. During 2009, our investor relations consulting, transfer agent and listing fees, and related travel costs decreased. As well, we did not incur the professional fees associated
with the expansion of our corporate structure that were incurred in 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Office expenses include compensation costs (excluding stock based
compensation), office rent, and other office related costs. In 2009, we incurred office expenses of $1,359,346 compared to $1,211,992 and $1,248,095 in 2008 and 2007, respectively. In 2009, we began to incur additional expenses associated with
supporting our expanded corporate structure that were not incurred in 2008 or 2007. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Stock Based Compensation </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stock based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>424,273</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">64,039</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">539,156</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Non-cash stock based compensation recorded for 2009 was $424,273 compared to
$64,309 and $539,156 in 2008 and 2007, respectively. Stock based compensation in 2009 related to 332,500 options that were granted along with compensation expense relating to options that vested over the year compared to a grant of 15,500 options
and 532,543 options in 2008 and 2007, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">COMMITMENTS </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="2">As at December&nbsp;31, 2009, we are committed to payments totaling $650,000 during 2010 for activities related to clinical trial activity and collaborations. All of these committed payments are considered to be part of our normal course of
business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">21</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="5">Summary of Quarterly Results </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
following unaudited quarterly information is presented in thousands of dollars except for per share amounts: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Dec.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Sept. </FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">June</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">March</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Dec.</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Sept. </FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">June</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">March</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"> (3)</SUP>
</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>5,245</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2,694</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>4,335</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>3,958</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,760</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,141</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,255</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,394</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Basic and diluted loss per<BR>common share</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$0.05</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$0.09</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$0.09</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">$0.11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">$0.09</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">$0.13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">$0.08</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1),
(4)</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>35,593</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>10,240</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>12,755</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>9,802</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,987</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,542</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">22,854</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total cash</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2),
(4)</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>34,129</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>9,655</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>11,983</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>9,292</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,277</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,680</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17,930</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">21,963</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash dividends declared</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Nil</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Nil</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Nil</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Nil</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">Nil</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">Nil</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">Nil</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">Nil</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Subsequent to the acquisition of Oncolytics Biotech Inc. by SYNSORB in April 1999, we applied push down accounting. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Included in total cash are cash and cash equivalents plus short-term investments. </FONT></TD></TR></TABLE> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Included in net loss and loss per common share between December 2009 and January 2008 are quarterly stock based compensation expenses of $396,110, $7,982, $8,544, $11,637,
$9,084, $17,339, $18,023, and $19,593, respectively. </FONT></TD></TR></TABLE> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We issued 17,524,211 common shares for net cash proceeds of $37,052,900 in 2009 (2008 &#150; 2,650,000 common shares for net cash proceeds of $3,421,309).
</FONT></TD></TR></TABLE> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We have not declared or paid any dividends since incorporation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL"
SIZE="5">Fourth Quarter </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Statement of loss for the three month period ended December&nbsp;31, 2009 and 2008 </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>3,600,282</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3,701,280</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>1,078,998</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">1,060,746</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stock based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>396,110</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">9,084</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign exchange (gain) loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>137,371</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(48,224</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amortization &#150; intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">90,375</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amortization &#150; property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>15,318</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">13,520</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>5,228,079</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">4,826,781</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(5,225</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(66,312</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>22,000</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>5,244,854</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">4,760,469</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Fourth Quarter Review of Operations </B></FONT></P> <P
STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the three month period ended December&nbsp;31, 2009, our net loss was $5,244,854 compared to $4,760,469 for the three month period ended December&nbsp;31, 2008.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">22</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">RESEARCH AND DEVELOPMENT EXPENSES (&#147;R&amp;D&#148;) </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Clinical trial expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>805,188</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,644,934</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Manufacturing and related process development expenses (&#147;M&amp;P&#148;)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>1,599,609</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">642,308</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>201,854</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">309,635</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pre-clinical trial expenses and research collaborations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>185,906</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">385,810</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other R&amp;D expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>807,725</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">718,593</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>3,600,282</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,701,280</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">Clinical Trial Expenses</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Clinical trial expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>805,188</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,644,934</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our clinical trial expenses for the fourth quarter of 2009 were $805,188
compared to $1,644,934 for the fourth quarter of 2008. We continued to complete patient enrollment and patient re-treatments in our Phase&nbsp;2 clinical trial program during the fourth quarter of 2009. At the end of the third quarter of 2009, we
had four Oncolytics&#146; sponsored trials enrolling patients compared to seven clinical trials enrolling patients at the end of the fourth quarter of 2009. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL"
SIZE="2">Manufacturing&nbsp;&amp; Related Process Development Expenses (&#147;M&amp;P&#148;) </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Product manufacturing expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>1,553,558</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">469,812</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Process development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>46,051</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">172,496</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Manufacturing and related process development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>1,599,609</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">642,308</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During the fourth quarter of 2009, our M&amp;P expenses were $1,599,609
compared to $642,308 for the fourth quarter of 2008. In the fourth quarter of 2009, we completed our second cGMP 100-litre production run and had commenced the fill process. During the fourth quarter of 2008, we were completing the process of
filling and testing the 40-litre cGMP production runs that had occurred in 2008. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our process development activity in the fourth quarter of 2009 focused
on optimization and validation studies. In the fourth quarter of 2008, we focused on lyophilization and process validation studies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Intellectual
Property Expenses </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">201,854</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">309,635</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">23</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our intellectual property expenses for the fourth quarter of 2009 were $201,854 compared to $309,635 for the fourth quarter of 2008. The
change in intellectual property expenditures reflects the timing of filing costs associated with our patent base and a change in the geographic focus of our worldwide patent filing strategy. At the end of the fourth quarter of 2009, we had been
issued over 200 patents including 33 U.S. and 11&nbsp;Canadian patents as well as issuances in other jurisdictions. We also have over 180 patent applications filed in the U.S., Canada and other jurisdictions. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Pre-Clinical Trial Expenses and Research Collaboration Expenses </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research collaboration expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>185,906</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">372,406</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pre-clinical trial expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,404</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pre-clinical trial expenses and research collaborations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>185,906</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">385,810</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our pre-clinical trial expenses and research collaboration costs were $185,906
in the fourth quarter of 2009 compared to $385,810 in the fourth quarter of 2008. During the fourth quarters of 2009 and 2008, our research collaboration activities continued to focus on the interaction of the immune system and the reovirus and the
use of the reovirus as a co-therapy with existing chemotherapeutics and radiation. During the fourth quarter of 2009, the number of collaborations decreased compared to the fourth quarter of 2008. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Other Research and Development Expenses </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">R&amp;D consulting fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>18,437</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">74,565</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">R&amp;D salaries and benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>711,774</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">524,219</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Quebec scientific research and experimental development refund</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(75,833</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other R&amp;D expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>77,514</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">195,642</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>807,725</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">718,593</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our other research and development expenses were $807,725 in the fourth quarter
of 2009 compared to $718,593 in the fourth quarter of 2008. In the fourth quarter of 2009, our R&amp;D salaries and benefits increased as a result of annual bonuses that were paid in 2009, but were not paid in 2008. Also, our Other R&amp;D expenses
decreased in the fourth quarter of 2009, as there was less travel related activity compared to the fourth quarter of 2008. In the fourth quarter of 2008, there was an increase in the level of travel activity associated with supporting our clinical
trials in the U.S. and the U.K. as well as attending conferences, symposiums and meetings relating to the various presentations that occurred during that period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2">OPERATING EXPENSES </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Public company related expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>668,046</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">757,268</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Office expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>410,952</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">303,478</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>1,078,998</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,060,746</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">24</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our operating expenses in the fourth quarter of 2009 were $1,078,998 compared to $1,060,746 for the fourth quarter of 2008. In the fourth quarter of 2009, our public
company related expenses declined compared to the fourth quarter of 2009. Specifically, our investor relations activity, transfer agent and listing fees, and related travel costs decreased. As well, in the fourth quarter of 2008, we incurred
professional fees associated with the expansion of our corporate structure that were not incurred in the fourth quarter of 2009. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">STOCK BASED
COMPENSATION </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">(unaudited)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stock based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>396,110</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,084</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our non-cash stock based compensation expense recorded in the fourth quarter of
2009 was $396,110 compared to $9,084 in the fourth quarter of 2008. In the fourth quarter of 2009, an additional 332,500 options were granted compared to 15,500 options granted in the fourth quarter of 2008. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="5">Liquidity and Capital Resources </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>2009 Financing Activities </B>
</FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During 2009, we received cash inflow from financing activities of $37 million as follows: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Acquisition of Inactive Private Company </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2009, we completed the acquisition of an inactive private company.
The cash available from the private company, at the time of closing, was $2.13 million and we issued 1,875,121 common shares in our capital based on a previously determined exchange ratio of $1.69. Net proceeds from this acquisition were $1.8
million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">PUBLIC OFFERINGS </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May 2009, we closed a
public offering whereby we issued 3,450,000 units at $2.00 per unit for gross proceeds of $6.9 million. Each unit consisted of one common share and one common share purchase warrant. Each common share purchase warrant entitled the holder to purchase
one common share at an exercise price of $2.40 per share for a three year period, subject to an acceleration of the expiry date in certain circumstances. Net cash proceeds from this public offering were $5.9 million. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2009, we closed a public offering whereby we issued 4,887,500 units at US$3.00 per unit for gross proceeds of US$14,662,500. Each unit consisted of one
common share and 0.40 of one common share purchase warrant. Each whole common share purchase warrant entitles the holder to purchase one common share at an exercise price of US$3.50 per share for a five year period subject to an acceleration of the
expiry date in certain circumstances. Net cash proceeds from this public offering were $13.9 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">EXERCISE OF WARRANTS </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">$1.80 Warrants </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On October&nbsp;23, 2009, we announced that pursuant to
the provision of written notification on September&nbsp;23, 2009, of the accelerated expiry of our $1.80 warrants issued on December&nbsp;5, 2008, and those warrants amended on December&nbsp;18, 2008, we received total proceeds of $5,823,000 from
the exercise of these warrants. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">25</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">$2.40 Warrants </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On November&nbsp;3, 2009,
we announced that pursuant to the provision of written notification on October&nbsp;2, 2009, of the accelerated expiry of our $2.40 warrants issued on May&nbsp;13, 2009, we had received total proceeds of $9,108,000. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>2008 Financing Activities </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On December&nbsp;5, 2008, pursuant
to a public offering under our base shelf prospectus, we issued 2,650,000 units for net cash proceeds of $3,421,309. Each unit consisted of one common share and one common share purchase warrant. Each common share purchase warrant entitled the
holder to acquire one common share upon payment of $1.80 until December&nbsp;5, 2011, subject to acceleration of the expiry date under certain circumstances. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="2">On December&nbsp;18, 2008, we amended the terms of 320,000 previously issued broker warrants for cash consideration of $41,600. The amendments included adjusting the exercise price from $5.65 to $1.80 per warrant and extending the expiry
date from December&nbsp;29, 2008 to December&nbsp;29, 2009, subject to acceleration of the expiry date in certain circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Investment
Activities </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On October&nbsp;20, 2009, we made an investment in British Canadian Biosciences Corp. (&#147;BCBC&#148;), a privately held biotechnology
company specializing in the development of peptides for the treatment of a variety of conditions, including cancer. Oncolytics purchased all of the convertible preferred shares of BCBC in exchange for 200,000 common shares of Oncolytics. At that
time, if converted to common shares, Oncolytics would own approximately 10% of the outstanding BCBC common shares. In addition, we obtained a right, under certain circumstances, to purchase the rights to BCBC&#146;s oncology product which is
entering Phase II studies for use in solid tumours. The purpose of the transaction is to gain access, at a future date, to a potential new oncology product. Beyond this transaction, we have no commitments for future program support to BCBC. None of
our directors, officers, or related parties own shares in or have any commercial interests in BCBC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Liquidity </B></FONT></P> <P
STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As at December&nbsp;31, 2009 and 2008, we had cash and cash equivalents, short-term investments and working capital positions as follows: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>32,448,939</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,429,895</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>1,679,937</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,846,634</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Working capital position</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>31,366,458</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,008,408</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The increase in our cash and cash equivalent and short term investment
positions reflects the cash usage from our operating activities of $16,063,879 along with the cash provided by financing activities of $37,052,900 for the year ending December&nbsp;31, 2009. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We desire to maintain adequate cash and short-term investment reserves to support our planned activities which include our clinical trial program, product
manufacturing, administrative costs, and our intellectual property expansion and protection. To date, we have funded our operations through the issue of additional capital via public and private offerings and acquisition of a private company.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">26</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a result of our financing activities in 2009, we raised over $37 million to be used to support our clinical trial, manufacturing, intellectual property and
collaboration programs. We anticipate that the cost of operations in 2010 will be $24 million. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Despite the anticipated increase in our cash requirements
compared to 2009, we continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources. Additional activities continue to be subject to adequate resources and we believe we will have sufficient
cash resources to fund our presently planned operations into 2011. Factors that will affect our anticipated cash usage in 2010 and for which additional funding might be required include, but are not limited to, any expansion in our clinical trial
program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&amp;D activity with our clinical trial research
collaborations, the number and timing of manufacturing runs required to supply our clinical trial program and the cost of each run, and the level of collaborative activity undertaken. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">During 2009, we were able to raise funds through a public offering, the acquisition of a private company and through the exercise of existing warrants and options. As well, we were able to raise funds in December
2008 through a public offering of units. We have no assurances that we will be able to raise funds through the sale of our common shares, consequently, we will continue to evaluate all types of financing arrangements. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also want to be in a position to evaluate potential financings and be able to accept appropriate financings when available. As a result, we filed a base shelf
prospectus on June&nbsp;16, 2008 which qualified for distribution up to $150,000,000 of common shares, subscription receipts, warrants, debt securities and/or units. Establishing our base shelf provides us with additional flexibility when seeking
capital as, under certain circumstances, it shortens the time period to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. We were able to take advantage of our base shelf
in 2009 with our two public offerings along with the exercise of the related warrants raising approximately $35 million. Our base shelf expires in 2010 and we will renew it accordingly. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>Contractual Obligations </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have the following contractual obligations as at December&nbsp;31, 2009:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Payments Due by Period</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="2">Contractual Obligations</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Total</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Less&nbsp;than<BR>1&nbsp;year</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">1-3&nbsp;years</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">4&#150;5&nbsp;years</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">After&nbsp;5&nbsp;years</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Alberta Heritage Foundation</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">150,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">150,000</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">Nil</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating leases</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">126,693</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">89,430</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,263</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchase obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">650,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">650,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other long term obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">Nil</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total contractual obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">926,693</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">739,430</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,263</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">150,000</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Note: </FONT></P> <P
STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Our Alberta Heritage Foundation obligation requires repayments upon the realization of sales (see note 7 of our audited 2009 consolidated financial statements).
</FONT></TD></TR></TABLE> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Our operating leases are comprised of our office lease and exclude our portion of operating costs. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">27</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to fund our capital expenditure requirements and commitments with existing working capital. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Investing Activities </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under our Investment Policy, we are
permitted to invest in short-term instruments with a rating no less than R-1 (DBRS) with terms less than two years. Our portfolio consists of guarantee investment certificates. As of December&nbsp;31, 2009, we had $1.68 million invested under this
policy, currently earning interest at an effective rate of 0.17%. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="5">Off-Balance Sheet Arrangements </FONT></P> <P
STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As at December&nbsp;31, 2009, we had not entered into any off-balance sheet arrangements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="5">Transactions with Related Parties </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2009 and 2008, we did not enter into any related party transactions. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="5">Financial Instruments and Other Instruments </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our financial
instruments consist of cash and cash equivalents, short-term investments, investment, accounts receivable, and accounts payable. As at December&nbsp;31, 2009, there are no significant differences between the carrying values of these amounts and
their estimated market values. These financial instruments expose us to the following risks: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Credit Risk </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Credit risk is the risk of financial loss if a counter-party to a financial instrument fails to meet its contractual obligations. We are exposed to credit risk on our
cash and cash equivalents and short-term investments in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and
cash equivalents and short-term investments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts
with Schedule I banks in Canada. For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or
payroll. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also mitigate our exposure to credit risk by restricting our portfolio to investment grade securities with short-term maturities and by
monitoring the credit risk and credit standing of counterparties. Currently, 100% of our short-term investments are in guaranteed investment certificates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="2"><B>Interest Rate Risk </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in
market interest rates. We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments. We mitigate this risk through our investment policy that only allows investment of excess cash resources
in investment grade vehicles while matching maturities with our operational requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">28</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Currency Risk </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Currency risk is the risk that
future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. We are exposed to currency risk from the purchase of goods and services primarily in the U.S. and the U.K. The impact of a $0.01 increase in the
value of the U.S. dollar against the Canadian dollar would have increased our net loss in 2009 by approximately $63,757. The impact of a $0.01 increase in the value of the British pound against the Canadian dollar would have increased our net loss
in 2009 by approximately $17,395. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We mitigate our foreign exchange risk through the purchase of foreign currencies in sufficient amounts to settle our
foreign accounts payable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Balances in foreign currencies at December&nbsp;31, 2009 are as follows: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">U.S.&nbsp;dollars</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">British<BR>pounds</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">&pound;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>13,000,437</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">316,168</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>423,905</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">486,087</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>12,576,532</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(169,919</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Liquidity Risk </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the
management of our capital structure as outlined in Note 16 of our audited financial statements. Accounts payable are all due within the current operating period. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="5">Risk Factors Affecting Future Performance </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>General Risk Factors </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative. It is not possible to predict, based upon
studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be developed through the clinical trial process to support a successful
product application and approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at
a commercially reasonable price may not be successful. There can be no assurance that we will generate adequate funds to continue development, or will ever achieve significant revenues or profitable operations. Many factors (e.g. competition, patent
protection, appropriate regulatory approvals) can influence the revenue and product profitability potential. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">29</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In developing a pharmaceutical product, we rely upon our employees, contractors, consultants and collaborators and other third party
relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that this reliance and these relationships will continue as required. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress being
made by Oncolytics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:ARIAL" SIZE="2">Our product REOLYSIN<FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is in the research and development stage and will require further development and testing before they can be marketed commercially. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly,
investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals, or early studies
in humans, whether REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> will prove to be safe and effective in humans. REOLYSIN<FONT STYLE="font-family:arial"
SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> will require additional research and development, including extensive clinical testing, before we will be able to obtain the approval of the United
States Food and Drug Administration (the &#147;FDA&#148;) or from similar regulatory authorities in other countries to market REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> commercially. There can be no assurance that the research and development programs conducted by us will result in REOLYSIN<FONT STYLE="font-family:arial"
SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> or any other products becoming commercially viable products, and in the event that any product or products result from the research and development
program, it is unlikely they will be commercially available for a number of years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="2">To achieve profitable operations, we , alone or
with others, must successfully develop, introduce and market our products. To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe
for human use and that the product shows efficacy. Unsatisfactory results obtained from a particular study relating to a program may cause us to abandon our commitment to that program or the product being tested. No assurances can be provided that
any current or future animal or human test, if undertaken, will yield favorable results. If we are unable to establish that REOLYSIN<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">There are inherent risks in pharmaceutical research and development. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="2">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk. The marketability of any product developed by us will be affected by numerous factors beyond our control, including:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use;
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">preliminary results as seen in animal and/or limited human testing may not be substantiated in larger controlled clinical trials; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">manufacturing costs or other factors may make manufacturing of products impractical and non-competitive; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">proprietary rights of third parties or competing products or technologies may preclude commercialization; </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">30</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">requisite regulatory approvals for the commercial distribution of products may not be obtained; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">other factors may become apparent during the course of research, up-scaling or manufacturing which may result in the discontinuation of research and other
critical projects. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our product under development has never been manufactured on a commercial scale, and there can be no assurance
that such products can be manufactured at a cost or in a quantity to render such products commercially viable. Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our
business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges, or others that may arise in the course
of development. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Pharmaceutical products are subject to intense regulatory approval processes. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The regulatory process for pharmaceuticals, which includes preclinical studies and clinical trials of each compound to establish its safety and efficacy, takes many
years and requires the expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed. Failure to comply with applicable regulatory
requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Further, government policy may change, and additional government regulations
may be established that could prevent or delay regulatory approvals for our products. In addition, a marketed drug and its manufacturer are subject to continual review. Later discovery of previously unknown problems with the product or manufacturer
may result in restrictions on such product or manufacturer, including withdrawal of the product from the market. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA in the United States and other
relevant regulatory authorities may deny approval of a new drug application (&#147;NDA&#148;) or its equivalent in the relevant jurisdiction if required regulatory criteria are not satisfied, or may require additional testing. Product approvals may
be withdrawn if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA may require further testing and surveillance programs to monitor the pharmaceutical product that has been
commercialized. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions and criminal prosecutions. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in or with our
customers&#146; other drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and other jurisdictions,
as the case may be. Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly and time consuming. We cannot predict how long the
necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales
could be adversely affected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">31</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the
pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to approval of the facility to
manufacture a specific drug, there can be considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to
manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The pharmaceutical regulatory regime
in Europe and other countries is, by and large, generally similar to that of Canada and the United States. We could face similar risks in these other jurisdictions, as the risks described above. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Our operations and products may be subject to other government manufacturing and testing regulations. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product
development and marketing. Approval to market products may be for limited applications or may not be received at all. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The products anticipated to be
manufactured by us will have to comply with the FDA&#146;s current Good Manufacturing Practices (&#147;cGMP&#148;) and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines.
Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend
time, money and effort in production, and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing
facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the cGMP requirements, the facilities may become subject to possible FDA or other regulatory action and
manufacturing at the facility could consequently be suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA
requirements, then the FDA could take any of the following actions: (i)&nbsp;restrict the release of the product; (ii)&nbsp;suspend manufacturing of the specific lot of the product; (iii)&nbsp;order a recall of the lot of the product; or
(iv)&nbsp;order a seizure of the lot of the product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to regulation by governments in many jurisdictions and, if we do not comply with
healthcare, drug, manufacturing and environmental regulations, among others, our existing and future operations may be curtailed, and we could be subject to liability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal and foreign law, including requirements regarding occupational health, safety, laboratory
practices, environmental protection and hazardous substance control, and may be subject to other present and future local, provincial, state, federal and foreign regulations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">32</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Our products may fail or cause harm, subjecting us to product liability claims, which are uninsured. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The sale and use of our products entail risk of product liability. We currently do not have any product liability insurance. There can be no assurance that we will be able to obtain appropriate levels of product
liability insurance prior to any sale of our pharmaceutical products. An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization
of products developed by us. The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition and future prospects. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Our technologies may become obsolete. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The pharmaceutical industry is
characterized by rapidly changing markets, technology, emerging industry standards and frequent introduction of new products. The introduction of new products embodying new technologies, including new manufacturing processes, and the emergence of
new industry standards may render our products obsolete, less competitive or less marketable. The process of developing our products is extremely complex and requires significant continuing development efforts and third party commitments. Our
failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may be unable to
anticipate changes in our potential customer requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the
increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant
technical and business risks. We may not be successful in using our new technologies or exploiting the respective niche markets effectively or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry
standards. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">We have no operating revenues and a history of losses. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit. As of December&nbsp;31, 2009, we
had an accumulated deficit of $118.8 million and we incurred net losses of $16.2 million, $17.6 million, and $16.0 million, for the years ended December&nbsp;31, 2009, 2008, and 2007, respectively. We anticipate that we will continue to incur
significant losses during 2010 and in the foreseeable future. We do not expect to reach profitability at least until after successful and profitable commercialization of one or more of our products. Even if one or more of our products are profitably
commercialized, the initial losses incurred by us may never be recovered. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">We may need additional financing in the future to fund the research and
development of our products and to meet our ongoing capital requirements. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We anticipate that we may need additional financing in the future to fund
research and development and to meet our ongoing capital requirements. The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our
pre-clinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting and enforcing our patent claims and costs associated with obtaining regulatory approvals. In
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">33</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence
of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities. There can be no assurance that additional funding will be available or, if available,
that it will be available on acceptable terms. If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production and marketing of our
proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product. There can be no assurance that we will be able to raise additional capital if our current
capital resources are exhausted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">The cost of director and officer liability insurance may continue to increase substantially or may not be available to
us and may affect our ability to retain quality directors and officers. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We carry liability insurance on behalf of our directors and officers. Given a
number of large director and officer liability insurance claims in the U.S. equity markets, director and officer liability insurance had until recently become increasingly more expensive with increased restrictions. Consequently, there is no
assurance that we will continue to be offered this insurance or be able to obtain adequate coverage. The inability to acquire the appropriate insurance coverage will limit our ability to attract and maintain directors and officers as required to
conduct our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">We incur some of our expenses in foreign currencies and therefore are exposed to foreign currency exchange rate fluctuations.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We incur some of our manufacturing, clinical, collaborative and consulting expenses in foreign currencies, primarily the U.S. dollar and the British
pound (&#147;GBP&#148;). We are therefore exposed to foreign currency rate fluctuations. Also, as we expand to other foreign jurisdictions there may be an increase in our foreign exchange exposure. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">We earn interest income on our excess cash reserves and are exposed to changes in interest rates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We invest our excess cash reserves in investment vehicles that provide a rate of return with little risk to principle. As interest rates change the amount of interest income we earn will be directly impacted.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="5">Other MD&amp;A Requirements </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have 61,549,969 common
shares outstanding at March&nbsp;8, 2010. If all of our warrants (1,955,000)&nbsp;and options (3,929,693)&nbsp;were exercised we would have 67,434,662 common shares outstanding. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our 2009 Annual Information Form on Form 20-F will be available on www.sedar.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Disclosure Controls and
Procedures </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="2">Our chief executive and financial officers reviewed and evaluated our disclosure controls and procedures. Based on that evaluation, they have concluded that our disclosure controls and procedures are effective in providing them with timely
material information relating to the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">34</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">MANAGEMENT&#146;S ANNUAL REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="2">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, and has designed such internal control over financial reporting to provide reasonable assurance regarding the reliability of
financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with Canadian generally accepted accounting principles (GAAP), including a reconciliation to U.S. GAAP. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls and procedures over financial reporting will
prevent all error and all fraud. A control system can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can
provide absolute assurance that all control issues and instances of fraud, if any, within Oncolytics Biotech Inc. have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that
breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of
controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions. Because of the inherent
limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Management has evaluated the design
and operation of our internal control over financial reporting as of December&nbsp;31, 2009, and has concluded that such internal control over financial reporting is effective as of December&nbsp;31, 2009. There are no material weaknesses that have
been identified by management in this regard. This assessment was based on criteria for effective internal control over financial reporting described in Internal Control&nbsp;&#150;&nbsp;Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There were no changes in our internal control over financial reporting that occurred during the last fiscal year that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">35</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">STATEMENT OF MANAGEMENT&#146;S RESPONSIBILITY </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="6">Statement&nbsp;of&nbsp;Management&#146;s&nbsp;Responsibility </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Management is responsible for the preparation and presentation of the consolidated financial statements, Management&#146;s Discussion and Analysis (&#147;MD&amp;A&#148;) and all other information in the Annual
Report. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In management&#146;s opinion, the accompanying consolidated financial statements have been properly prepared within reasonable limits of
materiality and in accordance with the appropriately selected Canadian generally accepted accounting principles and policies consistently applied and summarized in the consolidated financial statements. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The MD&amp;A has been prepared in accordance with the requirements of securities regulators as applicable to Oncolytics Biotech Inc. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The consolidated financial statements and information in the MD&amp;A generally include estimates that are necessary when transactions affecting the current accounting
period cannot be finalized with certainty until future periods. Based on careful judgments by management, such estimates have been properly reflected in the accompanying consolidated financial statements and MD&amp;A. The MD&amp;A also includes
information regarding the impact of current transactions and events, sources of liquidity and capital resources and risks and uncertainty. Actual results in the future may differ materially from our present assessment of this information because
future events and circumstances may not occur as expected. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Systems of internal controls, including organizational and procedural controls and internal
controls over financial reporting, assessed as reasonable and appropriate in the circumstances, are designed and maintained by management to provide reasonable assurance that assets are safeguarded from loss or unauthorized use and to produce
reliable records for financial purposes. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We, as the Chief Executive Officer and Chief Financial Officer, will certify to our annual filings with the CSA
and the SEC as required in Canada by National Instrument 52-109 (Certification of Disclosure in Issuers&#146; Annual Interim Filings) and in the United States by the Sarbanes-Oxley Act. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The external auditors conducted an independent examination of corporate and accounting records in accordance with generally accepted auditing standards to express their opinion on the consolidated financial
statements. Their examination included such tests and procedures as they considered necessary to provide reasonable assurance that the consolidated financial statements are presented fairly. The external auditors have full and free access to our
Board of Directors and its Committees to discuss audit, financial reporting and related matters. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Board of Directors is responsible for ensuring that
management fulfills its responsibilities for financial reporting and internal control. The Board exercises this responsibility through the Audit Committee of the Board. This Committee meets with management and the external auditors to satisfy itself
that management&#146;s responsibilities are properly discharged and to review the consolidated financial statements and MD&amp;A before they are presented to the Board of Directors for approval. </FONT></P> <P
STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><I>


<IMG SRC="g91036g92h46.jpg" ALT="LOGO">
</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><I>


<IMG SRC="g91036g75a99.jpg" ALT="LOGO">
</I></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Brad Thompson, PhD</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Doug Ball, CA</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Chairman, President and CEO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Chief Financial Officer</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">36</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="6">Auditors&#146;&nbsp;Report </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"></FONT><FONT STYLE="font-family:ARIAL" SIZE="2">To the Shareholders of Oncolytics
Biotech Inc. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have audited the consolidated balance sheets of Oncolytics Biotech Inc. as at December&nbsp;31, 2009 and 2008 and the consolidated
statements of loss and comprehensive loss and cash flows for each of the years in the three year period ended December&nbsp;31, 2009 and for the cumulative period from inception on April&nbsp;2, 1998. These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
conducted our audits in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States).&nbsp;Those standards require that we plan and perform an audit to obtain
reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In our opinion, these consolidated financial statements present fairly, in all material respects, the financial position of the Company as at December&nbsp;31, 2009
and 2008 and the results of its operations and its cash flows for each of the years in the three year period ended December&nbsp;31, 2009 and the cumulative period from inception on April&nbsp;2, 1998 in accordance with Canadian generally accepted
accounting principles. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States),
Oncolytics Biotech Inc.&#146;s internal control over financial reporting as of December&nbsp;31, 2009, based on criteria established in Internal Control &#150; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission and our report dated March&nbsp;8, 2010, expressed an unqualified opinion thereon. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="3">
 <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g91036g91g08.jpg" ALT="LOGO"></P>
 <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Chartered Accountants</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Calgary, Canada</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">March&nbsp;8, 2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">37</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">INDEPENDENT AUDITORS&#146; REPORT </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="6">Independent&nbsp;Auditors&#146;&nbsp;Report </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5">on&nbsp;Internal&nbsp;Control&nbsp;Over&nbsp;Financial&nbsp;Reporting
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Under the Standards of the Public Company Accounting Oversight Board
(United States) </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">To the Shareholders of Oncolytics Biotech Inc. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="1">We have audited Oncolytics Biotech Inc.&#146;s internal control over financial reporting as of December&nbsp;31, 2009, based on criteria established in Internal Control &#150; Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (the COSO criteria). Oncolytics Biotech Inc.&#146;s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal
control over financial reporting included in the accompanying Management Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#146;s internal control over financial reporting based on our
audit. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require
that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over
financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in
the circumstances. We believe that our audit provides a reasonable basis for our opinion. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">A company&#146;s internal control over financial reporting is
a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#146;s
internal control over financial reporting includes those policies and procedures that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the
company; (2)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company
are being made only in accordance with authorizations of management and directors of the company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the
company&#146;s assets that could have a material effect on the financial statements. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">In our opinion, Oncolytics Biotech Inc. maintained, in all material respects, effective
internal control over financial reporting as of December&nbsp;31, 2009, based on the COSO criteria. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We have also audited, in accordance with Canadian
generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Oncolytics Biotech Inc. as at December&nbsp;31, 2009 and 2008 and the consolidated
statements of loss and comprehensive loss, and cash flows for each of the years in the three-year period ended December&nbsp;31, 2009, and for the cumulative period from inception on April&nbsp;2, 1998, and our report dated March&nbsp;8, 2010,
expressed an unqualified opinion thereon. </FONT></P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Calgary, Canada</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2">
 <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g91036g91g08.jpg" ALT="LOGO"></P>
 <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="1">Chartered Accountants</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">March&nbsp;8, 2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">38</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="6">Consolidated&nbsp;Balance&nbsp;Sheets
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">As at December&nbsp;31</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">ASSETS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>32,448,939</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">7,429,895</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Short-term investments </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 17]</FONT><FONT STYLE="font-family:arial"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>1,679,937</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">5,846,634</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>64,787</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">86,322</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prepaid expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>507,408</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">179,668</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>34,701,071</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">13,542,519</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Property and equipment </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 5]</FONT><FONT STYLE="font-family:ARIAL"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>208,320</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">263,926</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Intellectual property </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 6]</FONT><FONT STYLE="font-family:ARIAL"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">180,750</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long term investment </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 21]</FONT><FONT STYLE="font-family:ARIAL"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>684,000</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>35,593,391</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">13,987,195</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">LIABILITIES AND SHAREHOLDERS&#146; EQUITY</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable and accrued liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>4,226,933</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">4,534,111</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Commitments and contingency </FONT><FONT STYLE="font-family:arial" SIZE="1">[notes 7, 8, 9 and 15]</FONT><FONT STYLE="font-family:ARIAL"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Shareholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share capital </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 10]</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Authorized: unlimited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Issued: 61,549,969 (2008 &#150; 43,830,748)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>131,908,274</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">95,234,924</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Warrants </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 10]</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>4,511,441</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3,425,110</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contributed surplus </FONT><FONT STYLE="font-family:arial" SIZE="1">[notes 2, 10, 11 and 12]</FONT><FONT STYLE="font-family:arial"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>13,734,743</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">13,349,801</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deficit </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 4]</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(118,788,000</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(102,556,751</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>31,366,458</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">9,453,084</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>35,593,391</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">13,987,195</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">See accompanying notes </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On behalf of the Board: </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top">
<I>

<IMG SRC="g91036g78e73.jpg" ALT="LOGO"></I>
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">
<I>

<IMG SRC="g91036g19w84.jpg" ALT="LOGO"></I>
</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Fred Stewart</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Jim Dinning</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">39</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="6">Consolidated&nbsp;Statements&nbsp;of&nbsp;Loss&nbsp;and Comprehensive&nbsp;Loss </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">For the periods ended December&nbsp;31</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Cumulative<BR>from&nbsp;inception<BR>on April&nbsp;2,<BR>1998 to<BR>December&nbsp;31,<BR>2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Rights revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">310,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">310,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development </FONT><FONT STYLE="font-family:arial" SIZE="1">[notes 9 and 10]</FONT><FONT STYLE="font-family:arial" SIZE="2">
</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>11,606,514</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">13,351,875</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">12,385,743</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">86,138,291</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>3,782,507</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">4,311,575</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3,826,195</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">28,619,532</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stock based compensation </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 11]</FONT><FONT STYLE="font-family:arial"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>424,273</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">64,039</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">539,156</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">5,193,117</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign exchange loss (gain)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>179,716</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(68,283</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">8,862</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">769,143</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amortization &#150; intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>180,750</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">361,500</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">361,500</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3,615,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amortization &#150; property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>64,930</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">48,754</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">40,714</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">562,081</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>16,238,690</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">18,069,460</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">17,162,170</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">124,897,164</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Loss before the following</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>16,238,690</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">18,069,460</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">17,162,170</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">124,587,164</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(29,441</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(519,256</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(1,211,744</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(6,563,446</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Gain on sale of BCY LifeSciences Inc. </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 22]</FONT><FONT STYLE="font-family:ARIAL"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(299,403</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Loss on sale of Transition Therapeutics Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">2,156,685</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>16,209,249</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">17,550,204</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">15,950,426</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">119,881,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Income taxes </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 14]</FONT><FONT STYLE="font-family:ARIAL" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>22,000</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(1,093,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss and comprehensive loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>16,231,249</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">17,550,204</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">15,950,426</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">118,788,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Basic and diluted loss per common share </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 13]</FONT><FONT STYLE="font-family:ARIAL"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(0.33</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(0.42</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(0.39</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">See accompanying notes </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">40</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="6">Consolidated&nbsp;Statements&nbsp;of&nbsp;Cash&nbsp;Flows </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">For the periods ended December&nbsp;31</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Cumulative<BR>from&nbsp;inception<BR>on April&nbsp;2,<BR>1998 to<BR>December&nbsp;31,<BR>2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">OPERATING ACTIVITIES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss and comprehensive loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(16,231,249</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(17,550,204</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(15,950,426</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(118,788,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Add/(deduct) non-cash items</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amortization &#150; intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>180,750</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">361,500</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">361,500</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3,615,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amortization &#150; property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>64,930</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">48,754</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">40,714</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">562,081</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stock based compensation </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 11]</FONT><FONT STYLE="font-family:arial"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>424,273</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">64,039</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">539,156</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">5,193,117</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other non-cash items </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 20]</FONT><FONT STYLE="font-family:arial"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>110,800</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">1,494,337</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net change in non-cash working capital </FONT><FONT STYLE="font-family:arial" SIZE="1">[note 20]</FONT><FONT STYLE="font-family:arial"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(613,383</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">1,787,279</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">586,964</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3,654,738</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(16,063,879</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(15,288,632</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(14,422,092</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(104,268,727</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">INVESTING ACTIVITIES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Acquisition of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(9,324</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(111,577</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(92,221</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(823,068</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchase of short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(1,679,937</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(347,901</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(949,496</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(51,096,801</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Redemption of short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>5,846,634</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">13,000,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">6,573,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">48,998,380</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Investment in BCY LifeSciences Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">464,602</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Investment in Transition Therapeutics Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">2,532,343</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>4,157,373</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">12,540,522</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">5,531,283</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">75,456</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">FINANCING ACTIVITIES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceeds from exercise of stock options and warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>15,210,210</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">41,600</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">51,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">30,511,278</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceeds from private placements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">38,137,385</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceeds from acquisition of private company </FONT><FONT STYLE="font-family:arial" SIZE="1">[note&nbsp;10]</FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>1,800,120</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">1,800,120</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceeds from public offerings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>20,042,570</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3,421,309</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">12,063,394</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">66,320,777</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>37,052,900</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3,462,909</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">12,114,394</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">136,769,560</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net increase in cash and cash equivalents during the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>25,146,394</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">714,799</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3,223,585</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">32,576,289</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Impact of foreign exchange on cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(127,350</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(127,350</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents, beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>7,429,895</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">6,715,096</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3,491,511</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents, end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>32,448,939</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">7,429,895</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">6,715,096</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">32,448,939</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash interest received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>47,573</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">769,529</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">1,392,866</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">See accompanying notes </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">41</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="6">Notes&nbsp;to&nbsp;Consolidated&nbsp;Financial&nbsp;Statements </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Incorporation and Nature of Operations </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Oncolytics Biotech Inc. (the
&#147;Company&#148; or &#147;Oncolytics&#148;) was incorporated on April&nbsp;2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April&nbsp;8, 1998, we changed our name to Oncolytics Biotech Inc. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have
not been successfully treated with conventional therapeutics. Our product being developed may represent a novel treatment for Ras mediated cancers which can be used as an alternative to existing cytotoxic or cytostatic therapies, as an adjuvant
therapy to conventional chemotherapy, radiation therapy, or surgical resections, or to treat certain cellular proliferative disorders for which no current therapy exists. </FONT></P> <P
STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Basis of Financial Statement Presentation </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">On April&nbsp;21, 1999,
SYNSORB Biotech Inc. (&#147;SYNSORB&#148;) purchased all of our shares. In connection with this acquisition, the basis of accounting for our assets and liabilities was changed to reflect SYNSORB&#146;s cost of acquiring its interest in such assets
and liabilities (i.e. reflecting SYNSORB&#146;s purchase cost in our consolidated financial statements). The amount by which SYNSORB&#146;s purchase price exceeded the underlying net book value of our assets and liabilities at April&nbsp;21, 1999
was $2,500,000. This amount was credited to contributed surplus and charged to intellectual property and was amortized to income based on the established amortization policies for such assets. Subsequent to April&nbsp;21, 1999, SYNSORB&#146;s
ownership has been diluted through public offerings of our common shares, sales of our shares by SYNSORB and a distribution of SYNSORB&#146;S ownership interest in the Company to their shareholders. As a result, SYNSORB no longer has any ownership
in the Company. </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Summary of Significant Accounting Policies </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">These consolidated
financial statements have been prepared in accordance with Canadian generally accepted accounting principles (&#147;Canadian GAAP&#148;). These policies are, in all material respects, in accordance with United States generally accepted accounting
principles (&#147;U.S. GAAP&#148;) except as disclosed in note 23. The consolidated financial statements have, in management&#146;s opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant
accounting policies summarized below. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">PRINCIPLES OF CONSOLIDATION </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1">The consolidated financial statements include our accounts and the accounts of our incorporated subsidiaries. All intercompany transactions and balances have been eliminated. </FONT></P> <P
STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">USE OF ESTIMATES </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Because a precise determination of many assets and
liabilities is dependent upon future events, the preparation of financial statements in conformity with Canadian GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant.
Significant estimates made by management affecting our consolidated financial statements include the inputs used to determine our stock based compensation, expense for the year and our assessment of our future income tax assets and related valuation
allowance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">42</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">PROPERTY AND EQUIPMENT </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Property and equipment are recorded at cost.
Amortization is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Amortization is recorded using the declining balance method at the following annual rates: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Office equipment and furniture</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">20%</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Medical equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">20%</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Computer equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">30%</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Straight-line over the term of the lease</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2">INTELLECTUAL PROPERTY </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Intellectual property costs related to the initial acquisition of our business by SYNSORB.
These costs were amortized on a straight-line basis over a 10-year period (the expected useful life) commencing July&nbsp;1, 1999 and are now fully amortized. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL"
SIZE="2">FOREIGN CURRENCY TRANSLATION </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Transactions originating in foreign currencies are translated into the functional currency of the entity at the
exchange rate in effect at the date of the transaction. Monetary assets and liabilities are translated at the year-end rate of exchange and non-monetary items are translated at historic exchange rates. Exchange gains and losses are included in net
loss for the period. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">RESEARCH AND DEVELOPMENT COSTS </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="1">Research costs are expensed as incurred. Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all of the development costs have been expensed. </FONT></P> <P
STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">LOSS PER COMMON SHARE </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Basic loss per common share is determined using
the weighted average number of common shares outstanding during the period. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We use the treasury stock method to calculate diluted loss per common share.
Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed
exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#147;in the money&#148; options and warrants were exercised at the later of the beginning of the period or the date
of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL"
SIZE="2">STOCK OPTION PLAN </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We have one stock option plan (the &#147;Plan&#148;) available to officers, directors, employees, consultants and suppliers
with grants under the Plan approved from time to time by our Board of Directors (the &#147;Board&#148;). Under the Plan, the exercise price of each option equals the trading price of our stock on the date of grant in accordance with Toronto Stock
Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than 10 years from the date of grant. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2">STOCK BASED COMPENSATION </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Officers, Directors and Employees </FONT></P> <P
STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We use the fair value based method of accounting for employee awards granted under the Plan. We calculate the fair value of each stock option grant using the Black
Scholes Option Pricing Model and the fair value is recorded over the option&#146;s vesting period on a straight-line basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">43</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Non-Employees </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Stock based compensation
to non-employees is recorded at fair market value based on the fair value of the consideration received, or the fair value of the equity instruments granted, or liabilities incurred, whichever is more reliably measurable, on the earlier of the date
at which a performance commitment is reached, performance is achieved, or the vesting date of the options. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">FINANCIAL INSTRUMENTS </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Financial Assets </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Financial assets are comprised of cash and cash
equivalents, accounts receivable (mainly goods and services tax receivable), short-term investments and long term investment. Financial assets are initially recorded at fair market value and are classified as follows: </FONT></P> <P
STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cash and Cash Equivalents </I></B></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Cash and cash equivalents
consist of cash on hand and interest bearing deposits with our bank and have been designated as held for trading. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Accounts Receivable </I></B>
</FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Accounts receivable have been designated as loans and receivables. Changes in fair value are recognized in net income on de-recognition, impairment, or
write-down. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Short-term Investments </I></B></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We
determine the appropriate classification of our short-term investments at the time of purchase and re-evaluate such designation as of each balance sheet date. We classify our short-term investments as held-to-maturity as we have the positive intent
and ability to hold the securities to maturity. Held-to-maturity securities are stated at original cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method. Such
amortization and interest on securities classified as held-to-maturity are included in interest income. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Long Term Investment </I></B></FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Our Long Term Investment is comprised of equity securities in a private company with no active market for these securities. We do not intend to dispose of this
financial asset within the year. As such, we have designated this investment as available-for-sale and classified it as long term. As there is no quoted market price in an active market for these securities, our long term investment is measured at
cost. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Financial Liabilities </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Our financial liabilities
are comprised of trade accounts payable and are non interest-bearing and are recorded at fair market value. Our trade accounts payables are designated as Other Financial Liabilities and are subsequently measured at amortized cost using the effective
interest rate method. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Transaction Costs </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Transaction
costs are expensed as incurred for financial instruments designated as held for trading. Transaction costs for financial assets classified as available for sale, loans and receivables, and financial liabilities classified as other than held for
trading are recognized immediately in income. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">FUTURE INCOME TAXES </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1">We follow the liability method of accounting for income taxes. Under the liability method, future income taxes are recognized for the difference between financial statement carrying values and the respective income
tax basis of assets and liabilities (temporary differences). Future income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be
recovered or settled. The effect on future income tax assets and liabilities of a change in tax rates is included in income in the period of the change. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">44</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Future Accounting Changes </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>International Financial Reporting
Standards (&#147;IFRS&#148;) </I></B></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The Canadian Institute of Chartered Accountants&#146; Standards Board announced that Canadian publicly accountable
enterprises are required to adopt IFRS, as issued by the International Accounting Standards Board (IASB), effective January&nbsp;1, 2011. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We have
commenced the process to transition from current Canadian GAAP (&#147;GAAP&#148;) to IFRS. Our transition plan, which in certain cases will be in process concurrently as IFRS is applied, includes the following three phases: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">Scoping and diagnostic phase &#151; This phase involves performing a high-level diagnostic assessment to identify key areas that may be impacted by the
transition to IFRS. As a result of the diagnostic assessment, the potentially affected areas are ranked as high, medium or low priority. This phase was finalized in 2008. </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">Impact analysis, evaluation and design phase &#151; In this phase, each area identified from the scoping and diagnostic phase will be addressed in order of
descending priority. This phase involves specification of changes required to existing accounting policies, information systems and business processes, together with an analysis of policy alternatives allowed under IFRS.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">Implementation and review phase &#151; This phase includes execution of changes to information systems and business processes, completing formal authorization
processes to approve recommended accounting policy changes and training. At the end of the implementation and review phase we will be able to compile financial statements compliant with IFRS. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">In 2009, we performed our impact analysis with respect to IFRS 1 &#147;<I>First Time Adoption of International Financial Reporting Standards</I>&#148;, analyzed other
known GAAP to IFRS differences and commenced the preparation of our IFRS accounting policies. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>IFRS 1 &#147;</I></B><I>First Time Adoption of
International Financial Reporting Standards</I><B><I>&#148; </I></B></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Upon review of IFRS 1, and as at December&nbsp;31, 2009, we expect to utilize the
exemption relating to investments in subsidiaries, jointly controlled entities and associates. We may also wish to utilize the exemption relating to cumulative translation differences if it is applicable upon adoption We do not expect there to be a
significant impact on our financial statements as a result of using these exemptions. As well, based on the transactions we have incurred to date and our specific facts, we believe it will not be necessary to utilize the other exemptions made
available by IFRS 1. As we move towards actual implementation and reporting under IFRS, we will continue to monitor our transactions and make use of any exemptions that are determined to benefit Oncolytics. </FONT></P> <P
STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Other GAAP To IFRS Differences </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Functional Currency </I></B>
</FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">There are differences in the determination of an entity&#146;s functional currency between GAAP and IFRS. We are reviewing the facts of each of the
entities within our corporate structure and we expect that our functional currencies should not change. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Foreign Currency Translation </I></B>
</FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The foreign currency translation of our subsidiaries may differ under IFRS compared to GAAP. This is dependent on our conclusion relating to the
functional currency of each of our subsidiaries. We expect the impact of this difference to be insignificant. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Income Taxes </I></B></FONT></P> <P
STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The IFRS standard, IAS 12 &#147;<I>Income Taxes</I>&#148; continues to be under review and it is expected to change before 2011. We expect that, regardless of the
results of the review, there will be differences between IFRS and GAAP, but will depend on the final standard. The potential impact is not expected to impact our balance sheet or income statement, but will impact our valuation allowance within our
income tax disclosure. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">45</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Treatment of Warrants with an Exercise Price Denominated in a Foreign Currency </I></B></FONT></P> <P
STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">There is a difference between GAAP and IFRS on the treatment of warrants with an exercise price denominated in a currency other than the entity&#146;s functional
currency. Currently, IFRS would require accounting for these warrants as a liability measured at fair value with changes in fair value recorded in the consolidated statement of loss. GAAP requires these warrants to be accounted for as an equity
instrument. The current impact on our consolidated financial statements would be to increase our liabilities and decrease our equity by $1.0 million. </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Deficit </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Amount</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">85,006,547</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss and comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">17,550,204</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">102,556,751</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss and comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">16,231,249</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2009</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>118,788,000</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Property and Equipment </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Cost</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Accumulated<BR>Amortization</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Net Book Value</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Medical equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>100,816</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>47,504</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>53,312</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Office equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>36,385</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>27,006</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>9,379</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Office furniture</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>111,076</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>73,457</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>37,619</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Computer equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>271,194</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>185,905</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>85,289</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>139,616</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>116,895</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>22,721</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>659,087</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>450,767</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>208,320</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="6"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Cost</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Accumulated<BR>Amortization</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Net Book Value</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Medical equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">100,816</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">35,592</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">65,224</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Office equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">36,385</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">24,910</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">11,475</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Office furniture</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">108,315</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">67,926</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">40,389</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Computer equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">264,631</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">156,552</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">108,079</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">139,616</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">100,857</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">38,759</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">649,763</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">385,837</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">263,926</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">46</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Intellectual Property </FONT></TD></TR></TABLE> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Cost</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Accumulated<BR>Amortization</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Net&nbsp;Book<BR>Value</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>3,615,000</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>3,615,000</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&#151;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Cost</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Accumulated<BR>Amortization</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Net&nbsp;Book<BR>Value</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,615,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,434,250</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">180,750</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Alberta Heritage Foundation Loan </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We received a loan of $150,000
from the Alberta Heritage Foundation for Medical Research. Pursuant to the terms of the agreement, the Company is required to repay this amount in annual installments from the date of commencement of sales in an amount equal to the lesser of:
(a)&nbsp;5% of the gross sales generated by the Company; or (b)&nbsp;$15,000 per annum until the entire loan has been paid in full. </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Commitments </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We are committed to payments totaling $650,000 during
2010 for activities related to our clinical trial program and collaborations. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We are committed to monthly rental payments (excluding our portion of
operating costs) of $7,453 under the terms of a lease for office premises, which expires on May&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Under a clinical trial agreement entered
into with the Alberta Cancer Board (&#147;ACB&#148;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified
product. We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a)&nbsp;5% of gross sales of a specified product; or (b)&nbsp;$100,000 per annum. </FONT></P> <P
STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Contingencies </FONT></TD></TR></TABLE> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Assumption Agreement </I></FONT></P> <P
STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">During 1999, the Company entered into an agreement that assumed certain obligations (the &#147;Assumption Agreement&#148;) in connection with a Share Purchase
Agreement (the &#147;Agreement&#148;) between SYNSORB and the former shareholders of the Company to make milestone payments and royalty payments. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:arial" SIZE="1">As of December&nbsp;31, 2009, a milestone payment was still outstanding for $1.0 million, due within 90 days of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell
REOLYSIN<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP> to the public or the approval of a new drug application for REOLYSIN<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="1">In addition to the milestone payment, payments may become due and payable in accordance with the Agreement upon realization of sales
of REOLYSIN<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>. In 2003, the Company completed amendments and revisions to the contingent obligations to its five founding shareholders with respect to these other
contingent payments. The amendments and revisions reduced the amount and clarified the determination of potential obligations of the Company to these shareholders arising from the Agreement and Assumption Agreement entered into in 1999. Also,
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">47</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">
on September&nbsp;23, 2004, the Company reached an agreement that further reduced its contingent payments to its founding shareholders through the cancellation of a portion of these contingent
payments from one of its non-management founding shareholders. The consideration paid by the Company consisted of $250,000 cash and 21,459 common shares valued at $150,000 and has been recorded as research and development expense. The value of the
common shares was based on the closing market price on September&nbsp;23, 2004. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">As a result of the amendments and the cancellation agreement, if the
Company receives royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, the Company is obligated to pay to the founding shareholders 11.75% (formerly in 2003
&#150; 14.25% and 2002 &#150; 20%) of the royalty payments and other payments received. Alternatively, if the Company develops the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the
foregoing sentence will be amended to a royalty payment of 2.35% (formerly in 2003 &#150; 2.85% and 2002 &#150; 4%) of Net Sales received by the Company for such products. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>BRI &#147;Work In Kind&#148; Contribution </I></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We entered into an engineering and process development agreement
with the Biotechnology Research Institute of the National Research Council of Canada (&#147;BRI&#148;). The terms of this Agreement include a &#147;work in kind&#148; contribution from BRI. In exchange for this &#147;work in kind&#148; contribution,
we agreed to provide a royalty, contingent upon receiving Sales Revenue, at the lesser of 0.5% of Sales Revenue or $20,000 per year. The total royalty under this Agreement is equal to two times the &#147;work in kind&#148; contribution. As of
December&nbsp;31, 2009, we estimate that the accumulated work in kind totals approximately $186,000. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">48</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">10.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Share Capital </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Authorized: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unlimited number of no par value common shares </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Issued:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Shares</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Warrants</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Number</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Amount</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Number</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Amount</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 1998</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,145,300</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">4</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued on exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">76,922</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">77</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,222,222</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">81</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">July&nbsp;29, 1999 share split&nbsp;<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(a)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">6,750,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">81</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to July&nbsp;30, 1999 private placement (net of share issue costs of $45,000)&nbsp;<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(b)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,500,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">855,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to August&nbsp;24, 1999 private placement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,399,997</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,049,998</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued on initial public offering (net of share issue costs of $317,897)<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;(c)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,000,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">3,082,103</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to exercise of share purchase warrants </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">20,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">15,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 1999</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">13,669,997</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">5,002,182</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued on exercise of stock options and warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">573,910</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">501,010</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to July&nbsp;17, 2000 private placement&nbsp;<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(d)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">244,898</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,998,645</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued on public offering (net of share issue costs of $998,900)<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;(e)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,000,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">13,101,100</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2000</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">17,488,805</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">21,602,937</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued on exercise of stock options and warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,702,590</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,210,016</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2001</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,191,395</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">23,812,953</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued on exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">40,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">34,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued on acquisition of the interest in Transition Therapeutics Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,913,889</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">4,689,028</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to December&nbsp;11, 2002 private placement&nbsp;<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(f)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,000,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,896,714</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">550,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">114,286</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Share issue costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(241,123</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">49</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Issued:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Shares</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Warrants</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Number</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Amount</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Number</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Amount</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2002</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">22,145,284</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">30,191,572</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">550,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">114,286</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to February&nbsp;10, 2003 private placement<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;(g)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">140,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">265,540</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">77,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">16,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to June&nbsp;19, 2003 private placement&nbsp;<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(h)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,120,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">5,912,113</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,272,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">543,287</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to August&nbsp;21, 2003 private placement<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;(</SUP><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">i</SUP><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,363,900</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">3,801,778</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">813,533</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">349,176</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to October&nbsp;14, 2003 public offering<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;(j)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,200,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">5,528,972</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">720,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">617,428</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">64,700</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">149,615</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">174,378</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">593,194</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(174,378</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(41,927</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Share issue costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(1,730,195</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2003</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">27,208,262</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">44,712,589</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">3,258,155</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,598,250</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to April&nbsp;7, 2004 private placement<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;(k)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,077,100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">5,924,050</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">646,260</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,028,631</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to pursuant to November&nbsp;23, 2004 public offering<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;(l)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,504,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">8,693,120</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">864,800</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,521,672</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued pursuant to cancellation of contingent payment <I>[note&nbsp;9]</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">21,459</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">150,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,907,175</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">8,178,546</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(1,907,175</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(798,096</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Expired warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(6,700</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(2,827</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">197,500</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">778,951</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Share issue costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(1,796,758</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2004</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">31,915,496</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">66,640,498</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,855,340</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">3,347,630</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to December&nbsp;29, 2005 private placement<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;(m)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,200,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">14,176,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,920,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,908,800</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">771,252</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">3,417,271</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(771,252</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(329,984</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Expired warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(1,219,288</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(1,496,514</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">350,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">297,500</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Share issue costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(1,689,398</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">50</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Issued:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Shares</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Warrants</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Number</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Amount</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Number</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Amount</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">36,236,748</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">82,841,871</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,784,800</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">4,429,932</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">284,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">241,400</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Expired warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(112,800</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(213,192</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2006</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">36,520,748</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">83,083,271</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,672,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">4,216,740</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to February&nbsp;22, 2007 public offering&nbsp;<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(n)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">4,600,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">11,362,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,300,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,438,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">60,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">51,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Expired warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(752,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(1,308,480</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Share issue costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(1,736,606</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">41,180,748</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">92,759,665</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">4,220,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">5,346,260</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to December&nbsp;5, 2008 public offering&nbsp;<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(o)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,650,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">3,127,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,915,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">946,050</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Expired warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(1,920,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(2,908,800</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Warrants&nbsp;<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(p)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">320,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">41,600</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Share issue costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(651,741</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">43,830,748</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">95,234,924</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">5,535,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">3,425,110</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued on acquisition of private company&nbsp;<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(q)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,875,121</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,113,275</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to May&nbsp;13, 2009 public offering&nbsp;<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(r)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">3,450,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">5,623,500</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">3,795,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,442,100</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for cash pursuant to November&nbsp;23, 2009 public offering<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;(s)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">4,887,500</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">13,380,549</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,955,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,073,981</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">281,600</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">318,541</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">7,030,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">17,360,750</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(7,030,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(2,429,750</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Issued for investment in BCBC<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;(t)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">200,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">684,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Sale of intellectual property&nbsp;<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(u)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(5,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(16,550</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Share issue costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(2,790,715</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, December&nbsp;31, 2009</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">61,549,969</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">131,908,274</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">4,255,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">4,511,441</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to subsection 167(1)(f) of the Business Corporations Act (Alberta), the Articles of the Company were amended by subdividing the 2,222,222 issued and outstanding common
shares of the Company into 6,750,000 common shares. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a private placement, 1,500,000 common share purchase warrants were issued entitling the holders thereof to acquire one additional share at $0.75 per share until
November&nbsp;8, 2001. At December&nbsp;31, 2001, all of the warrants had been exercised. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to the initial public offering, the agent was issued common share purchase warrants entitling it to acquire 400,000 common shares at $0.85 per share until May&nbsp;8,
2001. At December&nbsp;31, 2001, all of the warrants had been exercised. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a private placement, 244,898 common shares were issued at an issue price of $12.25 per share net of issue costs of $1,355. </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a special warrant offering, we sold 3,000,000 special warrants for $4.70 per warrant for net proceeds of $13,101,100. Each warrant entitled the holder to one common
share upon exercise. At December&nbsp;31, 2001, all of the warrants had been exercised. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(f)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a private placement, 1,000,000 units were issued at an issue price of $2.00 per unit net of issue costs of $241,123. Each unit included one common share (ascribed
value of $1.897) and one-half of one common share purchase warrant (ascribed value of $0.103) for a total of 500,000 warrants. Each whole common share purchase warrant entitled the holder to acquire one common share in the capital of the Company
upon payment of $3.00 per share until June&nbsp;11, 2004. In addition, we issued 50,000 common share purchase warrants on the same terms to the brokerage firm assisting with the transaction. The ascribed value of these broker warrants was $11,000
($0.22 per broker warrant) and has been included in the issue costs. The ascribed values of the warrants were based on the Black Scholes Option Pricing Model (&#147;Black Scholes&#148;). </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">51</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(g)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a private placement, 140,000 units were issued at an issue price of $2.00 per unit net of issue costs of $37,369. Each unit included one common share (ascribed value
of $1.897) and one-half of one common share purchase warrant (ascribed value of $0.103) for a total of 70,000 warrants. Each whole common share purchase warrant entitled the holder to acquire one common share in the capital of the Company upon
payment of $3.00 per share until August&nbsp;10, 2004. In addition, we issued 7,000 common share purchase warrants on the same terms to the brokerage firm assisting with the transaction. The ascribed value of these broker warrants was $1,540 ($0.22
per broker warrant) and has been included in the issue costs. The ascribed values of the warrants were determined using Black Scholes. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(h)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a private placement, 2,120,000 units were issued at an issue price of $3.00 per unit net of issue costs of $637,986. Each unit included one common share (ascribed
value of $2.789) and one-half of one common share purchase warrant (ascribed value of $0.211) for a total of 1,060,000 warrants. Each whole common share purchase warrant entitled the holder to acquire one common share in the capital of the Company
upon payment of $4.00 per share until December&nbsp;19, 2004. In addition, we issued 212,000 common share purchase warrants on the same terms to the brokerage firms assisting with the transaction. The ascribed value of these broker warrants was
$95,400 ($0.45 per broker warrant) and has been included in the issue costs. The ascribed values of the warrants were determined using Black Scholes. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a private placement, 1,363,900 common shares and 681,943 common share purchase warrants were issued for gross proceeds of $4,091,738. Each common share and whole
common share purchase warrant have ascribed values of $2.787 and $0.425, respectively. Each common share purchase warrant entitled the holder to acquire one common share in the capital of the Company upon payment of $4.00 per share until
February&nbsp;21, 2005. Share issue costs related to this private placement were $367,839. In addition, we issued 131,590 common share purchase warrants on the same terms to the advisors assisting with the transaction. The ascribed value of these
additional warrants was $59,216 ($0.45 per additional warrant) and has been included in the issue costs. The ascribed values of the warrants were determined using Black Scholes. </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(j)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a public offering, 1,200,000 units were issued at an issue price of $5.00 per unit net of issue costs of $687,001. Each unit included one common share (ascribed value
of $4.607) and one-half of one common share purchase warrant (ascribed value of $0.393) for a total of 600,000 warrants. Each whole common share purchase warrant entitled the holder to acquire one common share in the capital of the Company upon
payment of $6.25 per share until April&nbsp;14, 2005. In addition, we issued 120,000 common share purchase warrants with an exercise price of $5.00 that expires on April&nbsp;14, 2005 to the brokerage firms assisting with the transaction. The
ascribed value of these broker warrants was $146,400 ($1.19 per broker warrant) and has been included in the issue costs. The ascribed values of the warrants were determined using Black Scholes. </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(k)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a private placement, the Company sold 1,077,100 units at an average price of $6.25 per unit for gross cash proceeds of $6,731,875. The units were comprised of
1,077,100 common shares and 538,550 common share purchase warrants and have ascribed values of $5.50 and $1.50, respectively. Each common share purchase warrant entitled the holder to acquire one common share in the capital of the Company upon
payment of $7.75 per share until October&nbsp;7, 2005. Share issue costs related to the private placement were $728,918. In addition, we issued 107,710 common share purchase warrants to our advisor entitling the holder to acquire one common share of
the capital of the Company upon payment of $7.00 per share until October&nbsp;7, 2005. The ascribed value of these additional warrants was $220,806 ($2.05 per additional warrant) and has been included in the share issue costs above. The ascribed
values of the warrants were determined using Black Scholes. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(l)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a public offering, the Company sold 1,504,000 units at an issue price of $6.65 per unit for gross cash proceeds of $10,001,600. Each unit included one common share
(ascribed value of $5.78) and one-half of one common share purchase warrant (ascribed value of $0.87) for a total of 752,000 warrants. Each whole common share purchase warrant entitled the holder to acquire one common share in the capital of the
Company upon payment of $8.00 per share until November&nbsp;23, 2007. Share issue costs related to this public offering were $1,063,890. In addition, we issued 112,800 common share purchase warrants with an exercise price of $7.06 that expires on
May&nbsp;23, 2006 to the brokerage firm assisting with the transaction. The ascribed value of these broker warrants was $213,192 ($1.89 per broker warrant) and has been included in the share issue costs above. The ascribed values of the warrants
were determined using Black Scholes. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(m)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a private placement, 3,200,000 units were issued at an issue price of $5.15 per unit net of issue costs of $1,689,398. Each unit included one common share (ascribed
value of $4.43) and one-half of one common share purchase warrant (ascribed value of $0.72) for a total of 1,600,000 warrants. Each whole common share purchase warrant entitled the holder to acquire one common share in the capital of the Company
upon payment of $6.15 per share until December&nbsp;29, 2008. In addition, we issued 320,000 common share purchase warrants with an exercise price of $5.65 expiring on December&nbsp;29, 2008. The ascribed value of these broker warrants was $604,800
($1.89 per broker warrant) and has been included in the issue costs. The ascribed values of the warrants were determined using Black Scholes. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(n)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a public offering, 4,600,000 units were issued at an issue price of $3.00 per unit for gross proceeds of $13,800,000. Each unit included one common share (ascribed
value of $2.47) and one-half of one common share purchase warrant (ascribed value of $0.53) for a total of 2,300,000 warrants. The ascribed value was determined using the relative fair value method. Each whole common share purchase warrant entitles
the holder to acquire one common share in the capital of the Company upon payment of $3.50 per share until February&nbsp;22, 2010. Share issue costs for this offering were $1,736,606. The ascribed values of the warrants were determined using Black
Scholes. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">52</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(o)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a public offering, 2,650,000 units were issued at an issue price of $1.50 per unit for gross proceeds of $3,975,000. Each unit included one common share (ascribed
value of $1.18) and one- common share purchase warrant (ascribed value of $0.32). The ascribed value was determined using the relative fair value method. Each common share purchase warrant entitles the holder to acquire one common share in the
capital of the Company upon payment of $1.80 per share until December&nbsp;5, 2011 subject to acceleration of the expiry date under certain circumstances. Share issue costs for this offering were $651,741. In addition, we issued 265,000 broker
common share purchase warrants with an exercise price of $1.80 expiring on December&nbsp;5, 2011 subject to acceleration of the expiry date under certain circumstances. The ascribed value of these broker warrants was $98,050 ($0.37 per broker
warrant) and has been included in the share issue costs. The ascribed values of the warrants were determined using Black Scholes. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Under the terms of the warrant indenture and the broker warrant certificates, if the 10-day volume-weighted average trading price of our common shares (the &#147;Common
Shares&#148;) on the Toronto Stock Exchange exceeded $2.50 per Common Share, then, at any date subsequent to this date, at our sole discretion and upon sending the holder written notice of such accelerated exercise date and issuing a news release
announcing such accelerated exercise date, the expiry date of the warrant shall be the day that is 30 days following the later of (i)&nbsp;the date on which such notice is sent to the holder; and (ii)&nbsp;the date on which such announcement is made
by news release. As of the close of business on September&nbsp;18, 2009, the 10-day volume-weighted average trading price of the Common Shares exceeded $2.50 and we elected to accelerate the exercise date to October&nbsp;23, 2009, the date of our
news release. All of these warrants were exercised. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(p)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">On December&nbsp;18, 2008, we amended the terms of 320,000 previously issued broker warrants for cash consideration of $41,600. The amendments included adjusting the exercise
price from $5.65 to $1.80 and extending the expiry date from December&nbsp;29, 2008 to December&nbsp;29, 2009, subject to acceleration of the expiry date in certain circumstances. All of these warrants were exercised in 2009.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(q)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">On April&nbsp;9, 2009, we completed our acquisition of an inactive private company pursuant to a plan of arrangement under the Business Corporations Act (Alberta). We issued
1,875,121 common shares in exchange for all of the issued and outstanding securities of the private company. The exchange ratio was at an agreed premium to the private company&#146;s net cash per security at closing and was calculated using an
ascribed value per common share of $1.69 (being the 20 day volume weighted average trading price of our common shares on the Toronto Stock Exchange up to and including March&nbsp;2, 2009). We have treated this acquisition as a financing transaction
for accounting purposes and we have allocated the net cash from the private company to the value of the common shares we issued net of related transaction costs. The private company had no other assets or liabilities. </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(r)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a public offering, 3,450,000 units were issued at an issue price of $2.00 per unit for gross proceeds of $6,900,000. Each unit included one common share (ascribed
value of $1.63) and one common share purchase warrant (ascribed value of $0.37). The ascribed value was determined using the relative fair value method. Each common share purchase warrant entitles the holder to acquire one common share in the
capital of the Company upon payment of $2.40 per share until May&nbsp;13, 2012 subject to acceleration of the expiry date under certain circumstances. Share issue costs for this offering were $952,854. In addition, we issued 345,000 broker common
share purchase warrants with an exercise price of $2.40 expiring on May&nbsp;13, 2012 subject to acceleration of the expiry date under certain circumstances. The ascribed value of these broker warrants was $165,600 ($0.48 per broker warrant) and has
been included in the share issue costs. The ascribed values of the warrants were determined using Black Scholes. On October&nbsp;2, 2009, the acceleration provisions under the warrant indenture were met allowing us to accelerate the expiry date of
these warrants to November&nbsp;2, 2009. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Under the terms of the warrant indenture and the broker warrant certificates, if the 10-day volume-weighted average trading price of our Common Shares on the Toronto Stock
Exchange exceeded $3.35 per Common Share, then, at any date subsequent to this date, at our sole discretion and upon sending the holder written notice of such accelerated exercise date and issuing a news release announcing such accelerated exercise
date, the expiry date of the warrant shall be the day that is 30 days following the later of (i)&nbsp;the date on which such notice is sent to the holder; and (ii)&nbsp;the date on which such announcement is made by news release. As of the close of
business on October&nbsp;2, 2009, the 10-day volume-weighted average trading price exceeded $3.35 and we elected to accelerate the exercise date to November&nbsp;2, 2009. All of these warrants were exercised. </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(s)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Pursuant to a public offering, 4,887,500 units were issued at an issue price of US$3.00 per unit for gross proceeds of US$14,662,500. Each unit included one common share
(ascribed value of US$2.60) and 0.40 of one common share purchase warrant (ascribed value of US$0.40). The ascribed value was determined using the relative fair value method. Each common share purchase warrant entitles the holder to acquire one
common share in the capital of the Company upon payment of US$3.50 per share until November&nbsp;23, 2014 subject to acceleration of the expiry date under certain circumstances. Share issue costs for this offering were $1,524,706. The ascribed
values of the warrants were determined using Black Scholes. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(t)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">On October&nbsp;20, 2009 we made an investment in British Canadian Biosciences Corp. (&#147;BCBC&#148;), a privately held biotechnology company specializing in the development of
peptides for the treatment of a variety of conditions, including cancer. We purchased all of the convertible preferred shares of BCBC in exchange for 200,000 common shares of Oncolytics. </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(u)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">On October&nbsp;26, 2009, we received and cancelled 5,000 of our common shares in consideration for clinical trial data that we had obtained as part of our acquisition of Private
Company in April 2009. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">53</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The following table summarizes the weighted average assumptions used in the Black Scholes Option Pricing Model with respect to the
valuation of warrants and broker warrants issued in those years: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2006</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2005</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2004</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2003</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2002</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1.22%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1.68%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4.08%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3.82%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2.82%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3.01%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3.41%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Expected hold period to exercise</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1.80</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2.00</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3.00</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1.92</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1.39</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">0.76</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1.00</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Volatility in the price of the Company&#146;s shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>61.43%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">55.6%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">63%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">66%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">71%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">72%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">57%</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Dividend yield</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Zero</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">Zero</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">Zero</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">Zero</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">Zero</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">Zero</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">Zero</FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The following table
summarizes our outstanding warrants as at December&nbsp;31, 2009: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Exercise</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL"
SIZE="1">Price</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Outstanding,<BR>Beginning of<BR>the Year</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Granted<BR>During the<BR>Year</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Exercised<BR>During the<BR>Year</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Expired<BR>During the<BR>Year</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Outstanding,<BR>End of Year</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Life (years)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">$1.80</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,235,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,235,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">$2.40</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,795,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,795,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">US$3.50</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,955,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,955,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4.83</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">$3.50</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,300,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,300,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">0.15</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,535,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,750,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">7,030,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,255,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2.30</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">11.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Stock Based Compensation </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">STOCK OPTION PLAN </FONT></P> <P
STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at December&nbsp;31: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Stock</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Options</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Weighted<BR>Average</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Share Price</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Stock</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Options</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Weighted</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Average</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Share Price</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Outstanding, beginning of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>3,885,993</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>4.59</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,870,493</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4.61</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Granted during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>332,500</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>3.06</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,500</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1.45</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cancelled during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(350</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>2.35</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Exercised during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(281,600</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>0.99</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Outstanding, end of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>3,936,543</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>4.72</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,885,993</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4.59</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Options exercisable, end of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>3,875,026</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>4.75</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,747,293</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4.65</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">54</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The following table summarizes information about the stock options outstanding and exercisable at December&nbsp;31, 2009: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Range of</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL"
SIZE="1">Exercise</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Prices</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Number<BR>Outstanding</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Weighted<BR>Average<BR>Remaining<BR>Contractual</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Life (years)</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Weighted<BR>Average<BR>Exercise</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Price</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Number<BR>Exercisable</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Weighted<BR>Average</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Exercise</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Price</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">$1.45 - $2.37</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">799,693</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">6.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2.08</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">776,026</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2.09</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">$2.70 - $3.33</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,115,750</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">6.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3.13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,090,750</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3.13</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">$4.00 - $5.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,208,250</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4.86</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,195,750</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4.86</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">$6.77 - $9.76</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">684,500</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8.67</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">684,500</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8.67</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">$12.15 - $13.50</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">128,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">0.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12.69</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">128,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12.69</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,936,193</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4.72</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,875,026</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4.75</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The outstanding options vest annually or after the completion of certain
milestones. We have reserved 4,128,975 common shares for issuance relating to outstanding stock options. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">As we are following the fair value based method
of accounting for stock option awards, compensation expense related to options granted to employees was $424,273 (2008 &#150; $64,039 and 2007 &#150; $539,156) with an offsetting credit to contributed surplus. There were no options issued to
consultants for the years 2009, 2008, and 2007. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The estimated fair value of stock options issued during the year was determined using the Black Scholes
Option Pricing Model using the following weighted average assumptions and fair value of options: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1.21%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1.85%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3.91%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Expected hold period to exercise</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>3.0&nbsp;years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4.0&nbsp;years</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3.5&nbsp;years</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Volatility in the price of the Company&#146;s shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>57%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">56%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">56%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Zero</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">Zero</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">Zero</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Weighted average fair value of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>$1.19</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">$0.60</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">$0.94</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We use historical data to estimate the expected dividend yield and expected
volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada marketable bond rate in effect at the time of grant and the expected life of the options represents the
estimated length of time the options are expected to remain outstanding. </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">12.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Contributed Surplus </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The following table summarizes the change in
contributed surplus as at and for the year ended December&nbsp;31: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, beginning of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>13,349,801</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,376,962</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Stock based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>424,273</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">64,039</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Expired warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,908,800</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(39,331</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Balance, end of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>13,734,743</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">13,349,801</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">55</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">13.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Loss Per Common Share </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Loss per common share is calculated using the
weighted average number of common shares outstanding for the year ended December&nbsp;31, 2009 of 49,370,175 (2008 &#150; 41,369,515: 2007 &#150; 40,428,825). The effect of any potential exercise of our stock options and warrants outstanding during
the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive. </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">14.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Income Taxes </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The recovery of income taxes recorded in the
consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(16,209,249</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(17,550,204</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(15,950,426</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Statutory Canadian corporate tax rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>29.00</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>%&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">29.50</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">32.12</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Anticipated tax recovery</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(4,700,682</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(5,177,310</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(5,123,277</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Foreign jurisdiction tax rate difference</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>3,360,634</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">373,868</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Employee stock based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>123,039</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">18,892</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">156,355</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Change in tax rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>151,038</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">465,321</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Tax return adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>1,725,970</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(290,082</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(314,156</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Non-deductible expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>42,929</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">11,456</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">9,311</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Change in valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(680,928</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">5,063,176</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">4,806,446</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Future income tax recovery</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Current income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>22,000</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">As at December&nbsp;31, 2009, we have non-capital losses for income tax
purposes in Canada of approximately $26,615,000 which are available for application against future taxable income and expire in 2026 ($9,809,000), 2027 ($12,170,000) and 2029 ($4,636,000). As at December&nbsp;31, 2009, we have non-refundable federal
investment tax credits of approximately $3,730,000 (2008 &#150; $3,730,000) which are available to reduce future taxes payable. We have unclaimed scientific research and experimental development expenditures available to reduce future years&#146;
taxable income of approximately 16,884,000 (2008 &#150; $16,884,000) over an indefinite future period. We have not recorded the potential benefits of these tax pools in the consolidated financial statements. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The components of our future income tax asset are as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net operating losses carried forward</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>6,871,568</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">7,305,636</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Scientific research and experimental development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>4,220,931</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">4,220,930</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Investment tax credits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>2,797,690</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,797,690</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>153,474</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">92,054</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Share issue costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>814,857</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">425,459</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(14,858,519</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(14,841,769</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Future income tax asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">15.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Indemnification of Officers and Directors </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Our corporate by-laws
require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect
of any civil, criminal or administrative action or proceeding as it relates to
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">56</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">
their services to the Company. The by-laws provide no limit to the amount of the indemnification. We have purchased directors&#146; and officers&#146; insurance coverage to cover claims made
against the directors and officers during the applicable policy periods. The amounts and types of coverage have varied from period to period as dictated by market conditions. We believe that we have adequate insurance coverage; however, there is no
guarantee that all indemnification payments will be covered under our existing insurance policies. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">There is no pending litigation or proceeding
involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification. </FONT></P> <P
STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">16.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Capital Disclosures </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Our objective when managing capital is to
maintain adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection. We include shareholders&#146; equity, cash and
cash equivalents and short-term investments in the definition of capital. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>32,448,939</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">7,429,895</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1,679,937</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,846,634</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Shareholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>31,366,458</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">9,453,084</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="1">We do not have any debt other than trade accounts payable
and we have potential contingent obligations relating to the completion of our research and development of REOLYSIN<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board of
Directors (the &#147;Board&#148;). The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash
requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#146;s activity. Budget to actual variances are prepared monthly and reviewed by management and are presented
quarterly to the Board. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share
purchase warrants that upon exercise are converted to common shares. Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market
conditions, and the availability of capital. There are no assurances that funds will be made available to us when required. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">On June&nbsp;16, 2008, we
filed a short form base shelf prospectus (the &#147;Base Shelf&#148;) that qualifies for distribution up to $150,000,000 of common shares, subscription receipts, warrants, debt securities and/or units (the &#147;Securities&#148;). Under our Base
Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration
requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, or at prices related to such prevailing
market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Establishing the Base Shelf provides us with
additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our
company. Funds received from a Prospectus Supplement will be used in line with our Board approved budget and multi-year plan. The Base Shelf expires on July&nbsp;16, 2010 and we have registered 10,987,500 units under this shelf. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2009. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">57</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">17.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Short-term Investments </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Short-term investments which consist of
Government of Canada treasury bills, are liquid investments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value. The objectives for holding short-term investments are to invest our
excess cash resources in investment vehicles that provide a better rate of return compared to our interest bearing bank account with limited risk to the principal invested. We intend to match the maturities of these short-term investments with the
cash requirements of the Company&#146;s activities and treat these as held-to-maturity short-term investments. We do not hold any asset backed commercial paper. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Face</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Value</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Original<BR>Cost</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Accrued<BR>Interest</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Carrying</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Value</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Fair</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Value</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Effective<BR>Interest<BR>Rate</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">December&nbsp;31, 2009</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1,679,937</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1,679,937</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Nil</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1,679,937</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1,679,937</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>0.17%</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">December&nbsp;31, 2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,850,305</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,828,500</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">18,134</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,846,634</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,847,527</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1.81</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Fair value is determined by using published market prices provided by our
investment advisor. </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">18.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Financial Instruments </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Our financial instruments consist of cash and
cash equivalents, short-term investments, long term investment, accounts receivable, and accounts payable. As at December&nbsp;31, 2009, there are no significant differences between the carrying values of these amounts and their estimated market
values. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Credit Risk </I></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Credit risk is the risk of
financial loss if a counter-party to a financial instrument fails to meet its contractual obligations. We are exposed to credit risk on our cash and cash equivalents and short-term investments in the event of non-performance by counterparties, but
we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and short-term investments. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada. For our foreign domiciled bank accounts, we use referrals or
recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="1">We also mitigate our exposure to credit risk by restricting our portfolio to investment grade securities with short-term maturities and by monitoring the credit risk and credit standing of counterparties. Currently, 100% of our short-term
investments are in guaranteed investment certificates. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Interest Rate Risk </I></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates. We are exposed to interest rate risk through our cash and cash equivalents
and our portfolio of short-term investments. We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the
investments held. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">58</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Currency Risk </I></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Currency risk is the risk that future cash flows
of a financial instrument will fluctuate because of changes in foreign exchange rates. We are exposed to currency risk from the purchase of goods and services primarily in the U.S. and the U.K. and to the extent cash is held in foreign currencies.
The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have increased our net loss in 2009 by approximately $63,757. The impact of a $0.01 increase in the value of the British pound against the Canadian
dollar would have increased our net loss in 2009 by approximately $17,395. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We mitigate our foreign exchange risk through the purchase of foreign
currencies in sufficient amounts to settle our foreign accounts payable. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Balances in foreign currencies at December&nbsp;31, 2009 are as follows:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">U.S. dollars</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">British pounds</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">&pound;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">13,000,437</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">316,168</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(423,905</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(486,087</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">12,576,532</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(169,919</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Liquidity Risk </I></FONT></P> <P
STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the
management of our capital structure as outlined in Note 16. Accounts payable are all due within the current operating period. </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">19.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Economic Dependence </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:arial" SIZE="1">We are economically
dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical grade REOLYSIN<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP> required for our clinical trial program.
Any significant disruption of the services provided by our primary toll manufacturer has the potential to delay the progress of our clinical trial program. We have another toll manufacturer in the U.K. that has also produced clinical grade
REOLYSIN<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP> at a smaller scale. We have attempted to mitigate this risk by producing sufficient REOLYSIN<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP> in advance of patient enrollment in a particular clinical trial. </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">20.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Additional Cash Flow Disclosure </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Net Change In Non-Cash Working
Capital </I></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Cumulative from<BR>inception on<BR>April&nbsp;2, 1998 to<BR>December&nbsp;31,&nbsp;2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Change in:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>21,535</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(6,237</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,918</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(64,787</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Prepaid expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(327,740</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">80,632</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">378,240</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(507,408</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accounts payable and accrued liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(307,178</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,712,884</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">204,806</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">4,226,933</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Change in non-cash working capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(613,383</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,787,279</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">586,964</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">3,654,738</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net change associated with investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net change associated with operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(613,383</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,787,279</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">586,964</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">3,654,738</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">59</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">OTHER NON-CASH ITEMS </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Cumulative from<BR>inception on<BR>April&nbsp;2, 1998 to<BR>December&nbsp;31,&nbsp;2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Gain on disposal of clinical data [note 10]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(16,550</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(16,550</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Unrealized foreign exchange loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>127,350</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">552,536</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Donation of medical equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">66,069</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Loss on sale of Transition Therapeutics Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">2,156,685</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Gain on sale of BCY LifeSciences Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(299,403</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cancellation of contingent payment obligation settled in common shares [note 9]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">150,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Future income tax recovery</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(1,115,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>110,800</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,494,337</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">21.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Long Term Investment </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">As at December&nbsp;31, 2009, we owned all of
the convertible preferred shares of British Canadian Biosciences Corp. (&#147;BCBC&#148;), a privately held biotechnology company specializing in the development of peptides for the treatment of a variety of conditions, including cancer. The common
shares of BCBC do not have a quoted market price in an active market. </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">22.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">BCY LifeSciences Inc. </FONT></TD></TR></TABLE> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">On May&nbsp;7, 2002, the shareholders of
SYNSORB and the Company approved an arrangement whereby the Company would release from escrow 4,000,000 common shares held by SYNSORB. As consideration, SYNSORB provided the Company with 1,500,000 common shares of BCY LifeSciences Inc.
(&#147;BCY&#148;) along with the rights to receive an additional 400,000 common shares of BCY upon the attainment of certain milestones by BCY at no cash cost to the Company. The Company received 200,000 of these 400,000 common shares on
November&nbsp;27, 2002. These 1,700,000 common shares in BCY were recorded as an investment at $170,000 based on the quoted market price of the BCY common shares at that time with an offsetting credit recorded to contributed surplus. On
April&nbsp;23, 2002, the Company acquired 694,445 common shares of BCY, a public company, for $0.18 per share, and warrants exercisable until April&nbsp;23, 2004 to purchase up to 694,445 common shares in BCY at an exercise price of $0.27 per share
for total consideration of $127,123 (including costs of $2,123). After these transactions, the Company held a total of 2,394,445 BCY shares which were all subsequently sold for net cash proceeds of $591,725, recording a gain on sale of investment of
$299,403. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">60</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="3">23.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="3">Reconciliation of Canadian GAAP to U.S. GAAP </FONT></TD></TR></TABLE> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Our consolidated
financial statements are prepared in accordance with Canadian GAAP which, in most respects, conforms to U.S. GAAP. Significant differences between Canadian and U.S. GAAP are as follows: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1">Years Ended December&nbsp;31</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Cumulative<BR>from&nbsp;inception<BR>on&nbsp;April&nbsp;2,&nbsp;1998<BR>to&nbsp;December&nbsp;31,<BR>2009</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Notes</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2007</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss and comprehensive loss &#150; Canadian GAAP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>16,231,249</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">17,550,204</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">15,950,426</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">118,788,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Change in fair value of warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(1,050,930</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(1,050,930</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Amortization of intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(180,750</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(361,500</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(361,500</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(3,615,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Future income tax recovery</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">1,115,000</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss and comprehensive loss &#150; U.S. GAAP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>14,999,569</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">17,188,704</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">15,588,926</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">115,237,070</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Basic and diluted loss per common share &#150; U.S.&nbsp;GAAP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(0.30</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(0.42</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(0.39</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">There are no differences between Canadian GAAP and U.S. GAAP in amounts
reported as cash provided by (used in) operating, financing and investing activities. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Balance sheet items in accordance with U.S. GAAP are as follows:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">December&nbsp;31, 2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">December&nbsp;31, 2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Notes</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Canadian&nbsp;GAAP</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">U.S. GAAP</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Canadian&nbsp;GAAP</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">U.S. GAAP</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">180,750</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1,023,051</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Future income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Share capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>131,908,274</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>131,908,274</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>4,511,441</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>2,437,460</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Contributed surplus</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>13,734,743</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>11,234,743</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12,197,801</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">9,697,801</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">(1),(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>118,788,000</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>115,237,070</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">102,556,751</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">100,237,501</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">1. &#147;Push-Down&#148; Accounting and In Process Research and Development
</FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Intellectual property of $2,500,000 recorded as a consequence of SYNSORB&#146;s acquisition of the Company&#146;s shares comprised intangible assets
related to research and development activities. Under U.S. GAAP, this would not be capitalized on acquisition. As a result of removing the $2,500,000 from intellectual property in 1999 for U.S. GAAP purposes, the amortization of the intellectual
property, the future income tax recovery, and contributed surplus amounts recorded for Canadian GAAP purposes have been reversed. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">2. Presentation of
Stock Based Compensation Expense </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Under U.S. GAAP, stock based compensation expense is to be presented within the appropriate category of expenses on the
consolidated statements of loss. As a result, stock based compensation on the consolidated statement of loss would be reduced by $424,273 in 2009 (2008 &#150; $64,039; 2007 &#150; $539,156) and research and development and operating expenses would
increase by $211,263 and $213,010, respectively (2008 &#150; $64,039 and $nil, respectively; 2007 &#150; $375,156 and $164,000, respectively). Cumulative from inception stock based compensation would be reduced by $5,193,117 and cumulative from
inception research and development and operating expenses would increase by $2,946,387 and $2,246,730, respectively. There is no impact on the Company&#146;s net loss. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;
</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">61</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">3. Treatment of Warrants with a Foreign Currency Exercise Price </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1">Under U.S. GAAP, the prescribed accounting treatment for warrants with an exercise price denominated in a foreign currency is to treat these warrants as a liability measured at fair value with changes in fair value
accounted for through the consolidated statement of loss. The fair value of these warrants is determined using the Black Scholes Option Pricing Model. As a result of this prescribed accounting treatment, for U.S. GAAP, we have reclassified the
warrants issued in our November 2009 unit offering from equity to liabilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">ADDITIONAL STOCK BASED PAYMENT DISCLOSURE </FONT></P> <P
STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">As at December&nbsp;31, 2009, the aggregate intrinsic value of the stock options outstanding and the stock options exercisable were $535,955 and $520,357,
respectively. The total intrinsic value of the options exercised in 2009 was $519,245 (2008 &#150; $nil; 2007 &#150; $90,000). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">A summary of our
non-vested options as at December&nbsp;31, 2009 and 2008 and changes during the year ended December&nbsp;31, 2009 and 2008 are as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2009</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">2008</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Stock</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Options</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Weighted<BR>Average<BR>Grant&nbsp;Date</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Fair Value</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Stock<BR>Options</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Weighted<BR>Average<BR>Grant&nbsp;Date</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">Fair Value</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px dotted #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Non-vested options, beginning of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>138,700</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1.14</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">208,550</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1.19</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Granted during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>&#151;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">5,500</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">0.64</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Vested during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(77,183</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1.32</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(75,350</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1.24</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Forfeited during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>(350</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>0.92</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Non-vested options, end of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>61,167</B></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>0.92</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">138,700</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1.14</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">As at December&nbsp;31, 2009, there was $2,206 (2008 &#150; $33,313) of total
unrecognized compensation costs related to non-vested stock options granted under our stock option plan. This cost is expected to be recognized over a weighted average period of 0.92 years. The total fair value of shares vested during the years
ended December&nbsp;31, 2009, 2008 and 2007 was $101,617, $93,572, and $75,500, respectively. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The Company issues shares from treasury to satisfy any
exercise of stock options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">ADDITIONAL FINANCIAL INSTRUMENT DISCLOSURE </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2">Financial Liabilities </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Financial liabilities include the warrant liability which has been designated as held for
trading and has been measured at fair value determined by the Black Scholes Option Pricing. These warrants have not been listed on an exchange and therefore do not trade on an active market. Changes in fair value are recorded as a gain or loss in
income. The inputs used for determining fair value on December&nbsp;31, 2009 are: risk free interest rate &#150; 1.46%, expected hold period to exercise &#150; 1.4 years, volatility in the price of our shares &#150; 61.5%, and expected dividend
yield. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Fair Value Measurement </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The accounting guidance
for fair value measurements prioritizes the inputs used in measuring fair value into the following hierarchy: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:arial" SIZE="1">Level 1 &#150; Quoted
prices (unadjusted) in active markets for identical assets or liabilities; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:arial" SIZE="1">Level 2 &#150; Inputs other than quoted prices included
within Level 1 that are either directly or indirectly observable; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g91036g78e78.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3">62</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"> <P STYLE="text-indent:2.00em" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">TECHNOLOGY CHANGING LIFE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2009&nbsp;ANNUAL&nbsp;REPORT</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:arial" SIZE="1">Level 3 &#150; Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the
assumptions that market participants would use in pricing. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The fair value of our Warrant Liability is based on level 2 (significant observable inputs).
</FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Accounting for Uncertainty in Income Taxes </I></B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial"
SIZE="1">The tax years 2003 &#150; 2008 remain open for audit examination by the respective Canadian taxing jurisdictions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3">63</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g91036g42o49.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate Information </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Officers</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Auditor</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brad Thompson, PhD</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ernst &amp; Young LLP</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman, President and CEO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1000 Ernst &amp; Young Tower</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">440 2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd </SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">Avenue SW</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Doug Ball, CA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Calgary, Alberta, T2P 5E9</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Matt Coffey, PhD</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Operating Officer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computershare Trust Company of Canada</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karl Mettinger, MD, PhD</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Calgary, Alberta</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Medical Officer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="3"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For change of address, lost stock
certificates</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">and other related inquiries contact:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.800.564.6253 or</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">George Gill, MD</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical and Regulatory Affairs</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">www.computershare.com</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mary Ann Dillahunty, JD, MBA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Legal Counsel</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Intellectual Property</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">McCarthy T&eacute;trault LLP / S.E.N.C.R.L., s.r.l.
</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Directors</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite 3300, 421-7</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th </SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">Avenue SW</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">Calgary, Alberta, T2P 4K9</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brad Thompson, PhD</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman, President and CEO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Shareholder Information</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oncolytics Biotech Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For public company filings please go
to</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Doug Ball, CA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">www.sedar.com or contact us at:</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">CFO, Oncolytics Biotech Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oncolytics Biotech Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ger van Amersfoort</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite 210, 1167 Kensington Crescent NW</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biotech Consultant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Calgary, Alberta, Canada T2N 1X7</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">William A. Cochrane, OC, MD</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">T: 403.670.7377</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biotech Consultant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">F: 403.283.0858</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jim Dinning</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">www.oncolyticsbiotech.com</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman, Western Financial Group</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ed Levy, PhD</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjunct Professor, University of British Columbia</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">J. Mark Lievonen, FCA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Sanofi Pasteur Limited</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bob Schultz, FCA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fred A. Stewart, QC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Fred Stewart and Associates Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g91036g31c41.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Oncolytics
</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">BIOTECH INC </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">www.oncolyticsbiotech.com </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g91036g19w84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g91036g19w84.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0HX4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````3P```)\````&`&<`,0`Y
M`'<`.``T`````0`````````````````````````!``````````````"?````
M3P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!YP````!````<````#@`
M``%0``!)@```!X``&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``X`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))3ELR<O_`)SW8CG'[']AJMK9`CU?5O9<X'Z7\WZ"T774LL94
M^QK;+9]-A(#G;1N?L;])^S\Y<P_K#C];\G]FTOZH:\!E;FT/K%==C+[_`%F6
MW7V5UML?[&;:_4L_0?I/YM2Z;B=(^LV1U#J>5BN-C;&858O8&9&.<=OJ/;3;
M6YS\>YF5DW.];'M_ZY_-I*>H267T'*R;*LC!S+!;F=-N./;:(FQA:S(Q+WM;
M]&V[$OI]?\S[3ZWI_HUI,L8^=C@[:2UT&8(^DT_RDE,DDDDE(<?+Q<KU/L]K
M+?0L=3<&$$LL9].JS]RQL_11E69T_"KS'YU=+*\NT!MUS&AKK``&L%[F_P`]
MZ>W]'ZG\W^8K*2E)*%K7/K>QCS6YS2&O$$M)'TV[I;[53Z55U:AMN/U*UF4*
MR/L^6T;'V,(U^U4-'IUWUO\`SZ?T5W^CI_FTE-])0MMJIJ?=<]M=5;2^RQY#
M6M:T;G/>YWM:UK4[7->T/80YK@"UP,@@\$%)3__0]56*]S^O/LHJ>ZKI%;G5
M7VL+J[,BQCMEM-%S2Q]6'4YGIW7U?TI_Z*FRNJI_VBUUBR]U5>!BN=7D9[O2
M]9G-58!?DY.X?S;V4M]/'L_[F78RN8]%.-17CT,%=-+&UU5MT#6-&QC&_P`E
MK0DIY;.M?TOKN:[`H%%6/TS#IK>*YHI:_)R*W7^E5L_0XE3W9#ZF^G^BQ[??
M5_.*HWIOU9NR,NW(LL^L^5DV,MJ96TOL:X5UXVVRS'=3TZC>ZK?ZUOV*NMGZ
M/_1K=P/_`!7=7_\`"F#_`-5G+;24\GT;IGUDZ-9:,;$Q[:NI'UW-LO</LE@&
MP8]ESF9&1GT^@W'K8]G^&KN]E&/97Z<^G^MT2SJ.!U"NZ]_4;WYE%^'C6&MS
M\AD7XS35ZS,>VFVE_P"DRK:=]=M=OJ?SRZE))3Q^-E=<?]5?V$</-_;?V0X;
M\A[176RPL=2W*^W^IZ5M57MM]3&??D/_`-']H1W,^L_4.B'HCL%V'8_&^S7=
M3R;ZW:[!4_(IJP;++K+'?3K]5V-_PG^B74I)*>,RF_6_)ZQT;+_9+FV=,%[,
MBQV32*+'7UMH];]&_P"T>A6]OK?T/UO]'2M7%'UUQ\=M%S<#,LJ&W[4^VVIU
MQ!]K[**L2RO&=L^GZ=E_O6\DDIS!D_6*!NZ?B[HUC+?$^7ZBI-R>O3[L#'`@
MQMRG$S^;SAL]JT4DE/,?6?*ZJ>G,Q\G`Q35EY>+0&NR2[=OOJVLLJ=B;7-?M
MV6L_2>S_`$JN=.Z1F86>RW$93@8-@+\O#J>^QKK"W:/L];ZZ:L38_:Y]M'](
M_P`)C[_TJ)U8>OU?H^)R!;;EO`_=HK-39T^BW(S,?^WL6NDI_]'T/%W9'6LV
MYP]N&UF+5Y.>UF9DN&G^%;;A[O\`B%I+*Z`26]0W#:_[?D;F>'N'IZ_\+3Z6
M1_U[T_Y:U4E.1@"H_6/JSVP;!5B5O(,D`"^QK'#\W^=W_P!M:ZR>D,8>K];N
M:W5V1567ZZ[,;']O]AUCEK)*4DDDDI22222E))))*4DDDDIR;K"?K7AU[=&X
M&4X.\2Z[`&W^SL6LJ&?T>C.S<3,LMNK=A;MM=3@UE@<ZF[9D>W>ZMMV)19M9
M97_H[?4J_1J^DI__TO0\GI^53EV=0Z6:VY%P:,JB[<*[M@VU.]6O<[&R&-_1
M_:?1R-]/Z*VBWTL?T*^3U+ZQ/J-.%TAS,IX<UM^1?2,9ACVVN-%E^9:S^1]C
M9_UO^<7S>DDI^G>C].=T[!;1;<<G)<76Y62X!ILNL.^ZS8WVL9N]E-7^!H].
MG\Q75\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9
M.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`
M+@`P`````0`X0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D0`````'_
MVP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__`
M`!$(`$\`GP,!$0`"$0$#$0'_W0`$`!3_Q`"```$``@,``P$`````````````
M"`D&!PH#!`4"`0$!`0```````````````````0(0``$$`@(!!0``!0$)````
M``0"`P4&`0<`"`D1$A,4%2$B,B,6%S%!84,EUAB861$!`0`!!`("`P$`````
M``````$1(3%!47$"88$B,D)2_]H`#`,!``(1`Q$`/P#OXX#@.!!)[L'?F/)M
M']5,O`N:NE>B4QV#2/D(5,D)?H#L!!:X6\W(I8^\Z#(UVRI2MA3OQ-N"I4E/
MN6O/"XTS\IV\(<!P'`<!P'`<!P'`<!P'`<!P'`__T._C@.`X%:D[.P1'F'U;
M61XY;5EB/&IOJ=EI;(@:&S8*Q=HNM\?78Y)Z'E'DKBSZO*.J9=;2RQ@S"FE*
M4Z[A$Y:_G[;X[L;WO77K0YEPU/7*M<=PVC86H=2:FJ5T?L0]8G+SMW:%3U^(
MN;74P)*QKB:W$SQDR6@-E3ZQ(UU*<XSG&<5),U%.H]BNV_42=I]=\BA>J;WJ
MG8UA368'MKI.&G*M4]:W*7?`8K=8["T^<&:C]>4Z>)<>%CK:R>3'X/6P,>@3
MYD/JBXEV6O\`*R<!P'`<"(_;O6/9K85?UC+]4-S0^H=FZYVM7+>>-<QC9+66
MR**X/(0%WHFPH2-C9&0EXXN`F'B04,_6>9E!QW6BA'D-E,EF.6\]4S6PINCP
MSVV*Q$U'983*8R[Q-9D"YFF+L(;;>#9.B3IXP4C-4J7RO!,:^6.(>D=S#1@P
MQC;X[1&Q>`X$8.PG<KK;U3L6HZYV%VC`ZH5NV8LL%1K!;UN1-,_0J<8'*R^+
M-<BD-URGB)8D6$-$29`P[KSR487ZY_@62W9)QMQMYMMYEQ#K3J$N-.MJ2MMQ
MM:<*0XVM.<I6A:<XSC.,YQG&>$?O@.`X'__1[^.`X&LMP[FU7U_U[8MK;GO=
M>USKVJ`D2$W9K(;@41EL<=XKZ@0[:73YB8+;'4D4`-H@XQW&&V&G',I3D29V
M<]1]T[/]NO+UJRT:*>NO1\!SH!>7R+%N?6U5L6SKYHR+[+0P!AL9J6U"R:-?
MR=EOC\6\"F;P.;^4&X3E&$$--O3EO2>M\L[V9*]J.L'=KHSI7M[V&IN[ND5S
MV+:MAQ6]MOP%`UM9*?M73FC=M6FM5.^64)^(A<+<OS\/,0ACWQ.$/`I%2MSV
M.M9&EELFJQ387;;QN=IZ3M+K5/\`;+K5:HS8-.M%&MM?:W%16C$@2Z/\<*(B
MRWIP=+4W&2)[3H+XKOV6#$-/L*PMM*TUG%FN'D\5>^IOL5T5TC>+09)RUKKX
M$]JBT6"7;':D+3.:@L<IKDRU%8&)*;638L5Q);R_5&7'W5J^-O&<(2A[3%2D
M@^PVI;)OF^=:8>RO%;CUK1JGL:X5A4%/#CQM4NI9P4"<U/D1K5?/>>>!]7&&
M"7'6TNH]4_UX0,:9;3<L,`U/B51V<AVK0?#R-A!K;DF$B?-@(@V+C9:<$AU/
MXD28>,D9L(<@E#:F6'BV$+4E3K>%$+!88"IPDK9K3.0]:K<$"1*3=@L$F%#0
MD-&B-Y>+D965D7Q@(\$5I.5.//.(;0G'KG.,<#['`QZO6ZJ6Y$RY5+/7K.BN
MV&6J-@77IJ-FD05K@'DC3M8F51I).(RPPI"L-EA/^PD9><)<0G/\.!CFO-N:
MMVX/8R]6[$I>Q!:?9Y.E6HBF62)LC->ML*I"96N3#D244@"8!^5.7&',I7C"
ML9]/3.,\#8G`<#$+OK^D;*KTK5+]58.W5Z;B9:#DXJ=CASQR(J=!<C9</&7D
M9='0>"ZIMQ32D+RG/\,XSC&<#9@G7[153ZVZN@-/4.9NDM2*BEP*HBWFR/6N
M2K-=0EIF)J,;,EL-2+U>KXC*60DEN$E):Q_<?=5_-PMN6ZN$0.'\EW3'_7G8
M'7.:W'%TZ_:ZL^*1(RUV!D*OK.;N[$-#34U1ZQM>489U[*WJM,3S#9\&J19E
MVW4O>P9QL=]QME<7&4\>$?_2[^.!K/;FW*-I&DGWR_2:PHL<D"(B(L`=<E9[
MG;9LE$=5:#0ZX-G,G;[_`'29>:`AH<)#ILB<\VRRA2E<$F43M.=<[[M2QT;L
MCW7&A)[;U4F)"WZ2TY$$%NZXZPC3PQC00N1&3,PNQ]WQL+)?3D[46R^V&^UE
MN%P.UAPDPN>(@3OGM)K72/F*V?>YUV4DW-">'3<]AL=?C8YW]&7D*OM2"W[F
MM0))R@8<J7D]>4X\ECY"F1_<PI"W4*QG')RLF?7[?3OGC3N';T7K=V8[,]A8
M>^7NL[OH?8&Z:ZE'9>Q]1H35(;;Y1^DM=ZZ+/@X%\2.BBFV%VB:#=EI=UAQ9
M?Q((>:47.,R/'VD>Z.;`<M/4#IYU"ZW]A>RM]CYRA&6"@Z,UA/Z9ZO2Q[2(W
M&PNR6QJY73!Z5'T\@O)J8@9)<U(DA_30.AQU.>$F=[=&.]1H_P`A/CU`)Z$P
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M<`S!L$L+?R^#$J;^HC#JT-(SE>"6<YC1W7RP]PO&5LWM+/=@NG>Y>PU-[8[+
M7V7$(\?418-_0.M]J7TTY6R:232-ASU.MT>R7*K_`$'9(9+PSN5H2EMME"$L
M-EN/;&*KX\?.O/)O*ZD[N=;M'Z$WGU1M?9#>UGW;7>Q/8FJ7GKW!:BKJTCGB
MA0<FS%'WFU;$ODA'@0[XT8`2#"QWV2U/%>[+&&JW&EM7BZVW3YDBH1V'M_17
MK'#RU2IS;CEDL7<$UD795@B!!Q7Q*Q'5766PSXB4LQ*%D#(FGQ`F$J]I!R58
M]RFK/X]ULVC]EO(F[`MKV3XTU@6?[).'1Z/VRT5+0.`\*Q]139D](0L@HE2/
M7Y$Y8PA.?Z<YY4Q.V8?^27=7_P";]R_]H.N/_<O!B=OLPW8OMH_^K_D'CSV7
M&?##'/PGXW8+K'._H6%OXOS8N5^[LBN_C0Q?JOYSV?OOC^U/L#>]V?:-.WJR
MG8[N"S($MPGCKV%(12%XP&9*=CNM$/(/M^Q.5+)C!+W.#"+PYE6,)06_C*<8
MSZXSGTP,3M73XZ[7MWMSUXWJUL?HK2)/4._>PW9W:/MWQLZJ/Z^D)([;!D"?
M0"*K'4?8=R?FZS98DUG,@[##A8>C'UM$(=2PEV+=+-4S>NG7;MA1M2=E=<;>
M.UA-4NYT9=;Z]:&B]];HO=?H#QU:NP%N@9[LY9]74_?HE/NTK,QB!UX%FY.I
MC#OJC'EH^L(R+9F6/__3[^.!7)K2""[>]E;!V(MD;&3^CNM5IM6J.KT/)C`2
M\7-[AJ,\NM[J["H#.BLKC['3KE7SJ96RF"GDLCA212,-.DHR@NTQRL;X14%J
MZ:-L/FB[@UB8^$^#@.DV@HL"/)92^/\`0F[A8).3%?9>^1EYDHHUW*TY3[5)
M5G&<9Y.6OYGE(LGQ@>/\R0*D".JNJG,&R9$L5$?F')JKQ!9RY$D55-1(IJ7X
MSQ+JO='8"P!EK.6OA^+^3EPF;VF-2J%1=:UZ/J.N:74Z!4X@8<*)K%*KD/5:
M]&!B,(&$$CX6"#`C0AAAFDMMMMM)0A"<)QC&,8QPC+.!\R8A8:PQQ,//Q,9.
M1)J/C,BY@`63CBV\_P#+)"-:?&?1_P`%)SC@?'K5$H]+JH-%IU-JE3I$9%L0
M<;3JU7HB"JL?""@,Q0L.#7HL,6($BQHL=L9L=ME+*&$);PG"$XQ@,B#"#CA6
M`8\08`(9&&Q@PV&A11V\9SG#;`["$--(QG/^Q.,8X'L\!P'`<!P'`<#5^[MH
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M;C+CGJK./7/",UX%..E&'L^;ONX3AEWZZ>G76MA3_P`:_AP\J=EW$LY=]/9A
MU2$95A/KZYQC.?\`=R<M7]9Y7'<K)P'`<!P'`<!P'`<!P'`<"OKRFH,D>BNZ
M*4$^,$K<,GISKX9)E".GXA(;L=O766AYZPC`M&QV3).NPFQ2#@VEO(:<*';2
MYZMY5C,K7KO$_P`88<,=@01AD405EH8449I#`XP["$M,,,,-)2VRRRVG"4I3
MC"4IQC&,>G*R\W`__]7L.M#;VQ/(=K6L'Y')KO6_KG-;N`#^BM)$?LO>%HM&
MF*O-J/,!>$)3_IY4+D&VD)YDL3!+OSYRR6VA9>$ZN$.!7OU\D8\[R!>108(\
M(PF'K72^.EQQ2F"'XJ0=U[LR7:`D6FEK<!-<BI44I+3N$KR.2TYC'L<0K);M
M%A'"'`<!P'`<!P'`<!P'`<!P*OO+5/34/UUU''Q:_8#:N[G2.!LB?K-O_+"C
M]D:!:&$?*MM:@O2Q5L!7RHRA6?;\?K[7%)S*UZ[K0>5DX'__UNO7JA+LV_M7
MY'K?#%NR=7`W9IW5#9[GSL(%NFL^O5!=O5=8!.2P<VU"EVX5>2$-?2*64I0[
MKN4NY26[18'PAP*X>I-8C1.[GE:N;2B?V)_>G6.L')6ZC(>(VH])M$2L4IAG
M#6'&R5%7<SYE96K"T8;QA*?;G*IVU=O58]RLG`<!P'`<!P'`<!P'`<!P(F]X
M-&;`[&]:[CJS5-GJM.V4_:M-WZC6"\QTG*T\6SZ9W7KO<L.+9`85QJ5=B)<R
M@I#>4/G+K2",KPE?M]N2RXN6==:]=[0UAJ*!K>ZMI$[DVP5)VFTWV]J8+CX<
MJPW&S2UF)@Z;"&EFNUZAU)J41%0H&%^T>.#:Q[4YSE.!6^.$?__7ZT'C,]4^
M]-ML,[7D`:([PA4O[FUE?E1\%KOLOKFLFUJ*IUT.69'"PE=VY1H<;$,<4VZ\
M=;_^G8=6Z>(RDN\\+*.$8;L'8VO=35"7V#M2]TW6="@/H?O7?8-HA*94(3]6
M3"A(O]>RV,Z-AHW]*9DAQ!_F>1\Q1#;2/5:TIR$(?&Z&W;M5[1[0NCS;97<C
M?.R-]PI-D,E'YTK4[D@S0-!J."D#"&(<=6E*3!NA!LM"J%CGAV7VDD-NXP6]
M=+$.$.`X#@.`X#@.`X#@.`X#@.`X#@?_T.Z;=HFFS]2[``["+H#>DS:S(";+
M7M,V$C=?(JI*,,R"[5(V-\6%`C$X6G.7WW6\-+]JDJ2O"<X$SQNAO6NK%\JD
M.'/='^YTQ1M7V0<67K%$V+78_MIH>.A'PQF8IC5:C;U2KU6*<V)EUX0*-MV8
MQ#KC?QMX%:0-DN>XC5V`Z.MWV/\`\U\J_D0C[GUUK5IK$P%JX&O4WIEUR<G1
M)L,N#C=FD3.R;X;L`8PUM3`PQ\TR]E3N/B7\B$*Q/*R_YFJZ8+Z?TQ/SOJ_G
M_58^A]+XOI_3^)'U?J?!_8^K\'M^/V?R>ST]/X<K+V>`X#@.`X#@.`X#@.`X
)#@.`X#@.!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g91036g29t10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g91036g29t10.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-0FAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYP<FEN=&UG<B!F:6QE/"]R9&8Z;&D^"B`@("`\+W)D9CI!
M;'0^"B`@(#PO9&,Z=&ET;&4^"B`@(#QX;7!2:6=H=',Z57-A9V5497)M<SX*
M("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L
M="(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<%)I9VAT<SI5<V%G951E<FUS
M/@H@("`\27!T8S1X;7!#;W)E.D-R96%T;W)#;VYT86-T26YF;PH@("`@27!T
M8S1X;7!#;W)E.D-I061R17AT861R/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE!
M9')#:71Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE!9')296=I;VX](B(*("`@
M($EP=&,T>&UP0V]R93I#:4%D<E!C;V1E/2(B"B`@("!)<'1C-'AM<$-O<F4Z
M0VE!9')#=')Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE496Q7;W)K/2(B"B`@
M("!)<'1C-'AM<$-O<F4Z0VE%;6%I;%=O<FL](B(*("`@($EP=&,T>&UP0V]R
M93I#:55R;%=O<FL](B(O/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@/"]R9&8Z
M4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP
M86-K970@96YD/2)W(C\^_^X`#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("
M`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@#*@)[`P$1``(1
M`0,1`?_$`*```0`!!0$!`0$````````````'!08("0H$`@,!`0$!`0$`````
M`````````````0(#$``!!`,``0,#`@,$!0<*!P```@,$!0$&!P@1$@DA$Q0Q
M%2(6"D$R(Q=18227&(%",]4X6'A28E.S-+76MQDYM"4U=79W61$!`0`"`@(!
M!`("`@,```````$1`B$Q01)187&!,B)"D0.Q$\'1X?_:``P#`0`"$0,1`#\`
M[^``````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``!CKW?RW\:O&2`F=W;M&B<Y6\UAZ)3W%PV_M%DWG&?:NJU&K3/VBU1G*?3W
M1XCB?7]<EDMZ&IOH?]0_X8:R^_$T/2NW]1<9<6A$^OU>DU"DD83_`'7&)&W[
M#6W7VUY_3*J].?3^PUZ4RA%K^I0Y+F3[7_%?J;</W8Q]]K>]+>D^WU^N?Q5Q
MV&O7T_L^]_RE_P"NIEDES+^H'\%]UDQ(.[1.O\?D2%X0[.VW26;^@C95G&/<
M[9:!;[7.2UCU^JE0T8Q@ETJMMG'N_<3\@=?QM'$^IZ/TZDPEM4B5I^PU]N]7
MJ<]?8S;U[#V;*FE9]N?\&6RR[C^U)FRSL2\0````````````````````````
M````````````````````````````````````````````````````````````
M4#:MJUK1M;O-QW*^J=7U76JR7<[!L5[.CUE/354%I3\R?8SY;C4>+&CM)SE2
ME*QC_E`Y//./YS.J=>VA_AO@)`OZ&CMK'^6XG58-!+L^K]%GR%JC(C<MU;,2
M5)UBOFKSG\>4Y&>N7T^UQMN%G'UZZZ8YJ+'\;O@5\F.^3<=1\O.E3>1HV5U-
MK954R0KI'<;[\GV2%.[):6=A(I-;ER$KSZ_DR;26TKU2[';5CVB[R=#=!S+X
M-?COY[$9;N>6[%UBR;2C[MMTW?=FL%O.IQCW.9IM:FZOK2$K5C^YB%[<8^GU
M,>^RIW=^*GX['HV8B_$;D*6LIPCWLT\R/*],?VXFL6#<S"O_`#L.>[_6/;;Y
M&+O6_@6\!NAQ92M+US?>)W+C2_Q)_/\`>+:RK&)&<?P.2-=WQ>VUSS&%?JVS
M^-G./IA:1-]AI,[[\/'G-X-WSO;O%O>[_J%1K&7)[6V<>7;:;V;7Z^/_`(JU
MV^CPYTQ>RUR&\9R^W6R;%+J,*RY#2WZFYO+Q49S?'?\`.\QM-I2<7\X':K7+
M^5(;I-?[["AM4FO3[/[WXK-;U>D:2U#U*P<?_P`+-M%0U6X=],26(>,*>S-M
M/,'3<R\S(9:D1W6WV'VT/,/LK2ZR\RZG"VW6G$94AQMQ"L92K&<XSC/K@YJ_
M0```````````````````````````````````````````````````````````
M``````````````````````?#CC;3:W75H;:;0IQQQQ6$-MMHQE2UK6K.$H0A
M./7.<_3&`.+?Y,/.?J/R-^0E-X=>*K5KL?(HFYMZMKM1K[V6?\\M\KY"\2]R
MNY.%(8:YSK"XKKU?F0K$1$:.Y:2,_P#08C]=9B9O:.@'XX_B^Y/X+ZC!V*SC
MU>_^1MY6)1NG49$3[K5)^6UC\S4^<,RV\/4&L1_7+3C^$HG6F<9<D92C+<=G
M&VUOV5M*,@````-$?RG_`!`Z?Y/TNQ]R\>Z.IU#R2@QI%I<T<)N-5ZUVYIAK
M*Y%?=,IPW"K=^?;1Z0[;T0F6[Z,SLJ0I$B/O7;'%Z&#WPJ_)/LNE[?6>!_DK
M8VD>*NSDZIQ*_P!M^_&N]+VRND.PY'$MIS8>R6S$>E,.,4N'O\6%-1FNSZMN
M14,W?7S$=7IS4```````````````````````````````````````````````
M`````````````````````````````````-)?SG>7\[QU\66N4Z7;.5O2_)*3
M:Z5'EPW\LV%%S6NBL.='N8[C3B7HS]C$L(U.ROTQG'[FXXC.%L_3>DS<B&?@
M1\'*WEG&\^7.]4K6>D=IKWH?-D38V/OZ=Q]J2E$>9!2YC"HEAT2=$_,<<3C"
MLU;4-*58PX\E3>\X1T-&%```````<EGS\^%#.@;7K'G%RJ$Y1Q]LOZK6>Q_L
M:<PEU/064I>T/IT9<7*5PYUUFO\`P9LA.$__`)A'A.^N7I#BL]-+_6HWJ_&9
MY:9\R/$7GG3[B2R[T2C0_P`\ZPRUA*/3?]3:BL3[7[*?HTUM57(B6Z$XQA#>
M)_V\?W#&TQ<*S^(`````````````````````````````````````````````
M``````````````````````````````````#BA^5^TN/,+Y9=9\<JB<MRLH+G
MD/CO3_:SG[=?)VR77;)OEHG"<^B9$-S;G4NK_7V5R/7Z)QZ==>-<H[0M9URF
MT[6]?U'7(+-7KVK4E5KE#61T^V/74U)`8K*N"PG']UF)"BH;3C^S"3DJN```
M`````8Y^77#ZWR1\9NV\2LHZ)&=_Y[?U=/E>,?['M4:*JTT^S;SG&?:[5;3!
MAR4YQ]?5HLN+D<SO].+U^QU_L_?_`!]MWLQXFY:/5=)KZUY2L9B[7S^Y9U;8
MF6$9^B)$NJVF/][^W*:]/K_=P=-YQE(Z[CDJR]RZ1SOG34!_H.^Z7HK-JX^S
M5O;EM-'K#5D]%0VY):@.7<Z"B8Y';=2IQ+>591A6,Y],9P!4=5W'4=ZJ4WVD
M[5KFXT:Y#\1%UJMY6;#4KE1LX3)C)L:B5+AJD1U*QA:,+]R,Y^N,`7&!'/\`
MG#R3^;?Y!_S2YS_/?YW[7_)7\[ZS_-O[G]G\C]N_ES]S_>/SOL?Q_9^S]SV?
M7T]/J!(P`"G6MO4T4"1:WEI74U7#1ER796LV-70(K>/U<D3)CK,=A&/]*E8P
M!CS.\S_$"LF_MMAY3>.\.?[LHS$?[-SM#R5X^F4+1G8O5"\9_7&?3."XOP)@
MTSIG-^C1W)?/>@Z1OD1I.%.RM,VNAVB.VG.<8PIQZCGSFT)SG.,>N<X_4@O<
M`!$^\]YX=S%]47I'9.5Z!+2GW9B;IT'4]8E^W.,9QG$6ZMH3^?7&?[$EQ1:.
MN>7'BKM\IN!JWDKP789[R\-LP:CKN@SYK[BL^B4,Q(]^N0\K.?IZ)3GZC%&0
M;3K;S;;S+B'674(=:=:6EQMQMQ.%(<;6G.4K0M.<9QG&<XSC)!]@4+9=IUG3
M*>5L6X;'1:IK\'+"9M[LMO7T5/#5)?;BQDRK.TD184?,B2\AM&%KQ[UJPG'K
MG.,`>/4=YTGH%:]<:'N.K;M41Y;E>_:ZCL-3LE:Q/::9>=A/3J:7-BMRVF9#
M:U-*5A:4K3G./3./4+I``1([W[A#%V[K3_:^2,[&Q:+HW]?=Z/IS=VS=MRLP
MG*=VJ7<XGMVC<W'V51\MX>P[_!E/N^A<42V0`(J7W7B#>Q8U!?8^5(VS-NC7
M\:NOH6HIV+-\Y)3#;I,4F;?%EFW<F*PTF-]K[V7,X3A/N^A<42%<W5-KE5/O
M=AMJRAHZJ*[-M+FYGQ:NJK8;*?<]+GV,YUB)#BM)^JG'%I0G'ZY((C_XFO&[
M_O!<0_WKZ'_U^7%#_B:\;O\`O!<0_P!Z^A_]?C%#_B:\;O\`O!\0_P!Z^A_]
M?C%$P5=K67E;`N:6Q@7%/:Q(]A5VM7,CV%;90);27XLV!.B./19D22RO"VW&
MU*0M.<9QG.,D%)VO<]/T.JS?;QM>M:91XDL0LW.UWM7KM5B9*RK$:)FQMY4.
M'B3(RC/VV_?[E^F?3&?0#ZU7<=1WJI1?Z3M.N;C1./OQ6[K5;RLV&I7*BJ]D
MJ,BQJ)4N&I^,O/HXC"_<C/TSC`%Q@`(6W7R1\>.;2W8'0N[\=T>P8SE+U?MG
M2]-U^P:4G^]A<&UN8LM.4^GU]4?0N*/'J?E#XU;[*9@Z3Y!\2VV?(5A#$#7.
MIZ/<SWE*SC"4MPH%X_*7E6<^F/1'UR,43KC/K]<?7&?KC./[2`!!W0O)KQRY
M+*=@=/[QQ_G]DQGT>J]OZ/J-!:MY^N?15796T>PQGZ?^C+BWH6%0^=OA7L\E
M,.B\K_'F?*7GVMQT]=T9AUQ7_DMHE7;"G%9S^F$^N<CUOP,F:6]I-DKF+?7;
MFJOJF5CW1K.EL(EI72,>F,^K$V"\_&>QZ9Q_=5G]2"J@````````````````
M````````````````!Q5^,D5/0OG_`+^;;)P[F'Y/^2M\VAW/OPAS3M?Z.U3I
MQE7K]8F*UGV?Z/MX]#K?T1VJ')0````````!Q3?&DPWH?S<[/J=7_@UO^97E
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MKH,OW>OI[O57W_7W>O\`%Z^O]IT_I^$\NWTY*UY_)1YX4G@3P7&^-5,3:>G;
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MV8&S$R.43Y?ODP[E;]\F^#WBQLUKI,6HMM=T;?\`;=3G.U6X[MT/</VUMC1*
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M_P`VT+JFFR%RM4Z-J&O;KKS[J4H?54;+51;:$B2VA:TLRV6)6$.H]<^QQ*D^
MOT.5XX5JU^=M"'/C>ZJAQ"'$9W7COJE:<*3GTZ;K6<>J58SC/IDWI^PQN_IQ
M&FFO$KM"6FT-ISY%6N<I;0E&,Y_RWYWCUSA.,8SGTP-^R.A8P`&@KY:OB&I/
M*"%<>1'CO05%-Y&5<-4S:]889B5U9VZ!`8_@2X[Z-1Z_I4-AK"(<]>4HL$)3
M'E*QG#+[.]=L<7H0!\1?RQW4BZI/"SS!LK*!O5=8_P`D<KZ1MZ9$*YEV]>\J
ML:Y/T_-EAN7%W"')9_$K9TG"7)CB<1)/^U?;<D7;7S$7W\M'RT66@V=QX<^(
M$^?<]ON9K>G=!Z!JK3MG8:+8VKB8'^7G/6H*'G[/JUB[(2P\^RE>:93GVV\*
MGY_V1KKYO0D7XF_B(J/&F/4^1_DA25U_Y)V[*[+6==G?CV\'C$>S;RMYY4I?
MWVK;J%@V\K\ZQPIQ,#"U,1EJ5EY]Z;;9XG2MV'6N4:#W+FVX\CZC0M[1S[?J
M9^@VJ@<FV%<FSJY"VW%L?G5,N#91%I=:0M*V7FUI4G&<9,=<C6]_]#WXR_\`
MN[*_WF=6_P#C4U[;#ED\<_%[B6^_*[_PO[5J"K/BK/D%W+1\:M^[VL24YK&C
MQ^AO:W6O;!!E1KU7XBZ"+AQW#Z7WDMYPM>?<K.>EM]<^<(ZF5?!W\92L93GQ
MV7Z*QG&?3IO5\9],X],^F<;KC.,G/VV5M`TG3-8YSIVJ\_TJGC:_I^DZ[3:I
MJU%#RZJ+4:_K]?'JJBM86^X](<;AP(K;>%.+6XKV^JE*5G.<Y[&E/^H9;;=\
M!ZE+K:'$_P#$'S'/M6E*T^N*C=?3/HK&<>N#I_K_`&_"5Z_Z>]MMKP`>2VA#
M:?\`/GJ>?:A*4)]<M:SZY]$XQCUR3?\`96[:YN*O7JBUO[N='K*6CK9UQ;V4
MMS#42OJZR*[-GSI3N?HW'B1&%N+5_8E.<F!Q[]!\VO+/Y>/*V!XM>-F]7/"/
M'^YEW:D.TDJ?47-CSC7O\2\Z-TRUJ)4.ZL<V,;+6(.O1I4:%AZ5'COJ<<RY(
M3UQ-9F]HW)<A^"[X^>;TT=C<.:V_;]I6TVJVV_INU;`X_83LHQ^5)8H=9L:#
M7H++SOJI*,QWG$ISZ*=7G&59S[[*JW0/@W^-W>L1UP^*6?/)3#S3N9?.M^W*
ME6^EMS"U,NP[*WNZM"'DX]JE-1VW<8SZI6E7HK$]]AM`YYS[3^4Z1K'.-`I6
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M%)4Y7,F-)<=F3&)<_P!J$MI?2W[TK7:WL;##(```````````````````````
M`````````#BBYQ+_`,COZ@2P8LTYA1K7RTZ)4-_=_P`/'XG;M?V#.OJ]5>F/
M9)=WB)A/]F?=@ZW]$\NUTY*````````?#KK;#3CSSB&F64+===<5A#;;;:<K
M6XM:LX2E"$XSG.<_3&`.*?XAG'^Q_+WM?58*%/US<CR<ZL[(QC*D-P-PM;*A
MK'%*^N,8=SO+6$G7;C7".ULY*Y<?ZEG_`/2O#C_]W[C_`.[^8G3_`%^4K9%X
MG^//)_+[XFO&;D/9=?1?ZK>\/U%$:4RI$>]U>_J(LJ!5;3JUIE#KE1L5(ZA6
M67DX4A2<K9=0XPXZTO-N-K8K0=1VWE3\#?E;^S[`BQZ/XV=+L/NR?PD.1=6Z
MYJ<):6LW5(V^XN#J';-+@O)^_%4O&'4^C:U.P7F7V]\;SZHM&NWK1NI_.?S/
MJG,]AB;3H73O([DV^ZQ=1$N-?>@['H>NRWX<V*\E$FOMZBQ^_#FQG4I=CRF'
M$*QZX']!W%G)7-Y_4:<5W;;>/<*[;KT";::IQ[9=QI-_1$;<?Q05W18^L-TV
MT3&FTJRS5Q[?6$P7WU>B&G)S/NSA*LYQO2\X2LB/@=[_`,VWWPIU/B=3>5<?
MIW$[3<X&W:>Y)99NW*;8]UO-JH=NBP5*2_-I+&-?IC+DMX4AJ9'<:7E*O;[F
M\N<JW=F```<%'R):AMGBI\J>X]%W*GFN4MAWK4O)349GV'<QMITR1M=+MDU-
M4\I.$2WJBR@3*MY"<YRT_'QC/IA2,Y[3G7".['3-RUCH>I:WO>E7<#8]1V^E
MKMBUR^JWT28%K3VT5N9`FQGD9SA3;S#N,^F?12<^N%8QG&<'%5S`<5O]0MTC
M4]U\RM"T_5Y[-S=<MXY7ZYN+==_M;D#9MEVFXV&!K:L,?<4Y:L4\J*^IA.,K
M3F<A/I[L^AUTZ2NISP,YMLO'_#'QDYKN45Z!M>I\:TB!L-;)2I$FJMWJ=B=.
MJ)*%_P`3<FI?EYC.)_YJVLX.=[5AG\['_P!N#JO_`/->/?\`S-UHUI^PQO\`
MZ<C_`+)?:/\`Q$VO_P`N.>#?LCH2,```Y@_Z@SQ&Y)0Z%JOF/J=7_*O6+'I6
ML<[W=VE;;B5^]0K:DV&?5[#<LLX;RC;M>>UQIIJ>WZ//QE_;>RO[3"F^FEO7
MA'H_I]_$?D][H&S>9FVU[FV]=9Z1MF@:=)O<(G0=(AU=923+?8:A$C[KCVX;
M+(OW4/V+N5/,QD_;9RC[LA3K>^)T1TZ'-0`!P_\`B'_]]Y[_`,5_D_\`_@NN
M':_I^$=P!Q4`T7_U"O\`V":G_P`0?,O_`'3NIT_U_M^$KU_T^7_8">__`+XZ
ME_ZG62;_`+*VS^07/[+K'!^T\NIIB(%QT;E/0='JIKCF6FHMEM6IVU'!>?<3
MC*D1VY4Y&7,X^OL]3,XHXN_AIZCKOB5\@DW5/(/[?,;"]U#=>$VS^W^E0QI?
M1OYAUJRA55_)E_;:J6;.?K#D!$AW*6,O2&,Y7AMS"SKM,Z\([H$J2M*5H4E:
M%IPI*DYPI*DJQZI4E6/7&4YQGUQG!Q5]``/R?88E,/193+4F-):<8D1WVT/,
M/L/(RV\R\RYA3;K3K:LI4E6,X5C/IGZ`:L.Z_#!\?_>+F9L=AR65S78+)UU^
MQL..7LC0XDZ0]GW+DOZNRQ/TM,A2LYSE:*U"EYS_`!Y4:F^T&OG?OZ>B+I3$
MW9O$CRSZCS?<J]MR71P-O=1&A/RVL9<9CN[GSC^3KJE0M6,8_(_"G>S]<MJ_
M0U[_`#$PQC^)KY-?+63Y7Z1XI]NW>V[GI>]VVTZ:U8["]%V/;])V'6:B[LTW
MM9N\5M-ALVL95KSC,G$YV6C\=U,EAU&$Y2[=M9C,'7L<E```````````````
M`````````````````!QK?/5RO9>&>;/*_*;36W8*>D4>K;#6W#:/MLQ.L\0L
M:UI*%N(]/1Q[7T4;R?7T4YAIW]?;G)UTN9A'6+X]=HUCR*XAR[M^GO-N4'3-
M-IMHCM-K^XJMF3(R47-'(5GZXG:_=-2(,A.?JE^.O']ASLQ<*F0@```````U
MZ_*3Y)1/&#PF[-NC,YN)N&VT,CEG.6O?E,F1NG0(LJEBRHF$YPK+FO5#DRV5
MG],-P%?ZC6LS1J#_`*;[@,BMU_O?DM9PW&H]])I>+Z/)<QZ?D5^NY1L^\26<
MJQ[EQW;6951_?C^'+T)U/ZISZ:WOA(ZACFK5%\H?QMWGR&0.+1J/K55RQ[DT
M_>I3ZK73Y>V-7C6Y1=882EG$38:%<!RO7KGKGU^[AW#W_-RG^+6NWJ,S?$'@
MTSQ@\:>/<!L-H8W2;R[4FM;D;1&JET<>X<1.FS<R&*IV?9N0FD8F8;2E3[BL
MX1ZYSZY],2W-R*]Y%^.G)_*CE&R<;[+K3.QZAL3.%-N)RB/=:Y<QTN?M>T:M
M:_;<>I=CIGG,KCR$8SCTRIMQ+C+CC:TMG,&B?QO^`O8/'SR:Y-W!KR;J=HUO
ME/1X.ZQ-=>Y=*K+Z\KZI<I4&NEVC6ZR:V'/?2ZC#[S<93?KA64-X]<)QN[YF
M$=)1S53;FFJ-BJ;.@V"JKKRBNH,JKN*:XA1K*JM:R<RN--K[*OF-O1)L*7'<
M4VZTZA2'$*SA6,XR!HNZ[\#/%)>]HZIXH=GZ?XC[W%F/V58WITJ3?:Q3S7<X
M6K&N-XN->V_6XCJ\>BH[%PN(E'\"&$HQA!OWOGD5.I\+_F0U]A-+6_*#J-C2
MM^C+=GL?%J>ZV/$?'T^XN5:4]C+?DX3C'U<FKSG/KZJ]?J,Z_`FOAOQ\>3^F
M];U'M';?DH\A>M7NL2%..Z-25-%IO,KF!)6TJRU^YU2;(VBEFU%DAE*7%LPH
M<QO*4K9>:<2E>)=IC$@VRF1C%Y3^'O`O,K0D:!W;3&M@B0'GIFL[)7/YJ-TT
MNSD-X:=LM3V2.A4NL>?0A.'F58=ARL(2F0RZE*<8LMG0U.Z;\3'F?XQ8?J/"
M_P"2#:]*T!<R7-A<[Z?H$+::&M=ENY==RS&S-M-;3(?5GW//1*>`IY?JI2<Y
MSZFO:7N"\[CPP^8K?8BZ+=/DZT[5Z22G+,R7S/C5=1[#EA>/:Y^-:5-;J5G%
M>]N<^BF9C*L9_16!G7X$D>(7PP>-OC-NL;K^]7NT>2/:XEFY?0=VZ<B/^S4V
MQ.OYE+V6HU)#U@A_9ORE*=38VLRTEM.Y^XRMIW'O)=K>/`W"&1AGY]>*<[S2
M\9-Q\?ZW=8O/IVRW.F7$;9YU&[L42(K4]JJMB7'?JV+2G>=3.:KU-84E].6U
M*PKT5C&<9NMQ<C4?Q?X;O.+QTH+75N&?)1*YAK=W<*V"VI=9Y3)17SKQ<*)7
M+M'69^XSO9,<@0&&E*1E/N0RCUQGVX-W;6]Q$Q?_`$\?E-__`-<-K_W4L?\`
MQ$3VU^%;8_&GFO3>1\8U#0^Q=DN.^=(J<6SVS]2NZN-2RM@DV5U8645EFKBN
M/IB0::OE-0F,+<<<6VQA:E>JO3&;S>!.Y!@'\D'A99^>/C[7\5J.@P>:SJ[I
M.L;\C8+'7']HBO(U^MV&M=JUUT:XI'FU247V5I=P]G",M>F49PKUQK6XN1^O
MQQ>%]GX(^/4KB5OT&#TJ=+Z)M6]N;#7:Z_K$1M&Q1:2&U6(KI-O=O+5%;IL*
M4[E['O4YG&$XPGURVN;D9[F0``:)>-?#?L7*_D$?\U)/?*:ZI%=9ZMTYGGS'
M/9L&U]O1XVWLQJ9W8G-NE1,9J5[3C+CZ8?\`C88^B$>[^'?M_'`WM&``P(^1
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M>1AEYV^`=_YH3-%M:7RJ[;P&?SQN8[05?/94;&INW,Q:LN;):5U=)UK8IM\B
M-[8[;N;?#3#&,X::0IQU3FI<#""H^/WY>><.8B\X^4QK8JEGVMQF^HZ98[%(
M2PC'M0E:MG:Z&_ZI1CT],2/3_67VU^!\[9\<'RD=XK9&H^0/R<LP]#M6EP[^
MBY5SERDS;USW\,F#-_8G.<YG1'V\Y2IF0ZZPO&?1:%8^@FVLZG*,U_!OXM?&
MKP5>D;1H\:ZWSK-C5KI[#JF]N09-U$K)&6U3:K4ZFOBQ*?4:N<IE'WL1VURW
MTIPAZ0XC&$XEVM5LE,@````````````````````````````````-?OR8^'+/
MFOXK;AS6J:B(Z9K3K>_\@LI66V4,;W01I6&*:1+7C'XU;M]5*DU4A6580U^6
MEY7KEE)K6XN1H)^#?SS5P;?;OP?[W*E:KKNV[A9)YG(V;&:]>@]>5,S7;-S2
M\3,RA55'VVRBYS%2O*4,7C;C6<>^=C*=[S,S$=?!R4`````#SRY<6!%DSITF
M/"A0H[TN9,EO-QXL2+';4](DR9#RD-,1V&D94M:LX2E.,YSG&,`<1GR0>46Y
M_*5YE<^\=O&Y#VR\YU?9I&A<C0Q]U%;NNVV;F&=TZ]9YPGUCZI75T%?XLAS&
M,,4D-Z5Z)S*6C'76>LS4=@/C!X_ZEXM\$YCP;2L?=IN>:U%JGK-;269.P7SZ
MW+'9MFFH3E7MF[%L$R3,<3ZJPC+WLQGVIP<[<W*IZ(``````````````````
M````````````````````````````````````````````````````````````
M``!S<?,C\3EGUZ5=>6GC%KJIG4&8J9G7N84C/VYG1H]<RA+>\Z?&8]F7.A5T
M1A*9D1'HY<,M(6U_MK?ME]-=O%1$'QF?-_"HJVC\?O."[FQ,T^&M?T[R`LVI
M+SC;<16(<?7^S-91F?$GP,M_9Q?>Q6%>W&+%+:TN2W&VGF#J2I+REV6HKK_7
M+>KOZ*WB,SZF[I+"):U%I!D)PMB;764%Y^'-B/HSZH<:6I"L?7&<G-54```+
M&Z/TSGO(-/N.@=1W/7-!TJ@CJDVVR[3:Q*BJB(2A:TM?D2W&\/RY'LREEAO"
MWWU^B&T*5G&,NQR%_)!\MF^>:UMCQ3\.Z3<F>6;=:LZO.GU=;/;Z5WV?*>^P
MSKE-0QD_N=%HDYS^_%<PF=9M8]9>(\;[C"^NNOKS4;COB4^+Z%X5:>]U7K46
MLMO)G?J=$.TS&<9L*WE&JR5-2LZ+KLUOW,R[B8ZTVNZL&L^Q]UM$=C.8[/W)
M&-ML]=*W/F0`YY?EULK:3YP?&_I3<^GEZ]M<KJ[%WI>[=2VCE/,]J0SG5EH9
MW78]8S(EP8C&$^YEU,24M3^&V?MJ2ZI.=Z]48M^8;TWQMG<CZU6;+RGQ]TS6
M^F:U_,B/"WS)Z5UCR$W6KENNM3=4H.8=0SIO.=BJ)F/1V7ER!-?8:9]?:IO+
MC:[.4=3^J;#$V[5M:VROC6L*!L]!3;#"AWM=(I[N)$NJZ-91HUQ4RT-RJNU8
M9DI1(C.IPXP]A2%8QE.3FJO@:1O*W9+R!\SWQNZ_$V.Z@T]KR[MSEA01;NPB
M5%JM&M[JK#D^G8E-P+!:,QF\X4ZTO*<MISC^[CTU/UHW<F0`T(>6^^[7=_*#
MRKA7E)O&V\L\%+[E\BPT)-;N-[R[G'7>O?AK>>U_I'0]>LZ*1+DQ)B76X]+(
ML8[#GV8O^$O\M7W=S]<SL2KYE\-\$N)^-/5>I:7M%9P#H&JZ%L5[R[H'(>QW
M^G;Q(W^!5OR=-KJ=JHW!M.[/W5^W'C+@269B);;RL9PG/HXF2VW`RL^-'HG?
M>J^%7$]Z\EX-E%ZO<T]MFQF753BAO-@H(E_9P]0V>ZIL1H7X5GL&LL19+F?L
ML_D87A_V)^[Z#:27$&=QD8\=A\7^%=JLT[5T[1$;/?5E"NF@S\['M]*MBL9=
MF3FHR6M=V"H8S[)4QQ>',I^[C*O[WIC'I<V#2W\,'CEQKR`\19?2.P4%KTC=
M8O<NET3&R;#O_0)TQNIUR;4)IJW'LVM$;\:!A>?1&4>BLJSE7NSG/KK:V5'1
M4E.$IPE./1*<83C'^C&,>F,?\F#"OZ!RV7[<O?\`Y:?.[5=B8Y%OM%K6O\OD
MTVL>0WDET3B^I:TY)T[24NR=+9U.MV5JPLI7W58DLYB,H9;5A>',*=4E?3^L
M1NH\+M&YAIT+:)%'0<%U7HULM#=W3\-[QM?;ZQ_4JUQ&::?.G;C`H;.LD_N,
MY]#C;<##./\`#_QEY5[$9MOX5G69%!VF5?0=8V.;JU;&N-GAT-O*URHF2/Q(
M=K?1Z^0[45LN5[D?C1IU@AMIQSUQ[$JSGUQZ`<]_QY2>:>6-9TNY^1;IMAMO
MES6=/V6IN_'?K^_7_.:7DFL0\QFZ2MTSABK[7-<E5<QW$AU5HF#-6KU2TI[W
MMJ6[NYGZ]#<AP;F'BWR[8-OJN`*TZNOIL2MD[;K6K]#G[,JNA)>D-UTI>J2M
MHN8FLQY#^'$X<CQ8J9"TYPK*\I^F;GR,GB`!H#Z!N?>(GSEV>L<<EZWL$O\`
MX,:Z6]I/3.A[IJG/FH&=@2Y,N&8>L4>X8S?HF882UG-9G"VW',J=1G"?7?\`
M06)\PN]^7VO\I\;G>C1>3<XUZ7Y9\MBIN.)=BZC/V:?99A["Y%J+.+;Z!SV(
MO7Y$=#[KN?R7U??99QAK.,J4EKC\X'1N8`````:3?E/V.[I/*SXCH55L-S2Q
M;OR\_#M(59=6%7&NHV;+G#&8=G%ARH[-K&RS+=1]IY+B/:ZO'IZ+5C.]>K]A
MNR,`!H)^6>AG=%\S?C/XSGI/1N;TG4]C[3K\ZXYMN=MI]_`M,5NEOZY?0':^
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ME(FX?7G'\"L^AG.W0ST(```````````````````````````````````-.GGU
M\-W!_,67;])TB4UP_OL[#DF;N5'5MR]2WJ;AO/L5T/4V'(:9=@^XE.%6T)R/
M8>F<Y>_*PE+>-3:S[#GW7RSY>?BBM)[ND-=!:YE%EO2G[#0([O9>"7#7O4E5
MA9ZH]`GKU%V4C&<K=DU]/,^OT=SZ>XZ?QV1E-S#^I(ZY4LLP.P^.7/MUE1DI
M9EV>@;I=:#-=<1C"7''Z2^K-XC-/JSC.5)3(;3C/Z)QCZ$ND\&4_._U*O/\`
M$;W,^).^KE^W_H7NIZPS%]WIGZ9EMZS(>]OK_;]CU_U$_P"OZF6+74OZBWR4
MW3+U!P[B'-N;S;#UCP)MQ.ONL[:VXYGVMYK:N+%U.G7+]<X]J7(<Q&5?\S/Z
M%FD\F4):KX,_*O\`)OMM7N_>;'>*#3\OXDQ-V\@')FI:W10I65.K7SWCT*+7
MSLJ<;SG[>8E5`BNY],.2T^ON'MKKT.F+P4^,'QW\%:[%QJD)_H'9)\%<*_[+
MM\2+G8%L2$83+JM1K&<O0=(U]_T]%QXJG),A/TDR9'HGVXNUOV5L?,@``L'=
MN4\NZ9F!GH_-M!Z!FJ3)15YW;3M=VO-:B9EE4Q$#-[73_P`-,K,9O+F&_;AS
M+:?=Z^W'HS8+>UOQ[X%IMJQ>ZAP_D&JW<5251KC6^::71VL=2<X4E3%A5TL6
M6RI*L>N,I7CTR7-$OD`"VIVF:?:;'2[C9ZIK5CMVMQYD37=JG457+V.ABV+:
MFK"-2WDB*Y9U<>>TO*7D,.MI=3G.%8SC(%R@`*#LNK:QN=/*U[<-<H=KH)V,
M)FT>RU%?>T\S"?7VXE5EI'E0I&$^OT]Z,^@$4Z_XO>-&I6T:^U;QXX;K5Y"=
MP_"N:'DVA5%K#?QGUP[$L*^@CRXSF,Y]<90M.?4N:)T(`#.,9QG&<>N,_3.,
M_7&<9_7&<`6YJVG:CHU7FDTG5=<T^E5,EV"JC5J.LU^K583W/O3IV8%3%B1,
MS)KW\3KOL][BOJK.<@7&``B+:/'[@V\7,S8MUXER+;]@L%,JGWNT<VTW8+F<
MJ/':B1U3+.VI9<V2IB*RAI&5K5[6T)3CTQC&"YHJ.D\5XWS2QEV_..2\SY_;
M3X?[=.M-)T/5M4L9M?\`?;D_@2YM%50),B'^2RAS[2U91[TX5Z>N,9(),``1
MMO/&N0=/<C/=*Y5S;H;L-/LB.[SHVL;:Y%1Z^OMC+OZNP4PGUS^B<XP,CU:1
MRCEO,D26^;\UT#GS<Q"6Y;>D:=KNJ(E(0KWH1)30UT!+Z$+^N,*]<8S]0+_`
M`6WC3-/3M2M[3JFMXW==3B@7N6**KQM2Z)+^).*56PXB_NZJG$G'W,1LO?9]
M_P#%[?7Z@?S9]+T[=XL&#NFIZUMT&LM(EW6P]GHJN_BU]U`]_P"#;P8]K%EL
MQ+2%]U7V9#>$NM^[/M5CUR!<H`````6W>:9I^SS]?M=EU36]AM-2L<W&JV5Y
M15=M/UFVSA"<VFOS)\61(IK'*6TX^_&4V[Z)Q_%],`7(``MFXTO3MAN->V&_
MU/6;R_U&1(EZI>7%#5V=QK$N8AMN7*UZSFQ7YM+(E-M(2XN,MI2\)QA6<XQ@
M#]=IU'5-XII&N;KK&O;AKTM;+DNBVFEK=@II3D=S#K"Y%7;1I<)Y;#J<*1E2
M,Y2K'KCTR!5*VMKJ:O@U%1`A5555Q(U?65E;%8@U]=`ALHCQ(,&%%;:C1(D5
MAM*&VFTI0A"<83C&,8P![0*'L>L:UN%3)H=MUZCVFBF8QB92['4P+NIE8QZX
MQB376<>5#?QC"L_WD9_4",-<\:_'/3K2/>:CP'BFK741YN1$M]<Y7HM':17V
MEX<:?CV%9119;+S;F,*2I*\*PK'KC/J7-$UD````````````````````````
M`````````````!`G0?%?QGZPZ_(Z7X_\:WF9)SE3]CL_-]1MK5Q6?7U5FUEU
M+ECA6?7]<.XR66SH0<S\8OQ\L2ORV_$+AOWO=A7HYI4!YC&<9SG'I$>]\7&/
M7/Z>ST+[;?(R/Y[P#A7)/MYY;QKEO.W&T?;2_I6@ZMK,K*/KZX7+IZN)*=]?
M7]5+SDF:)=(`````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M```````````````````````````````````````````````````````++8W_
M`%N3T*SY>U)DYV^HT^FWJ;$S"DIB(UV^N+NAK9*+#*/Q'9#MEK\I*F4JRXA*
M,*SC&%8SFXN,^!>A```1MS?IM1TU&\KJ(%E`QH?2=MYE98LL1<9F6^GR(\>=
M/@_BR9/K6RE2<99RY['?3&?<A);,)+E))%``$>=9Z/5<AYKNO3KR#8V=1H^O
MSMAL*^IQ&592XL!'W'&(6)DB)%S(7C^[]QQ"?].<%DS<"_V7</,M/)QG"76T
M.IPKT]<8<3A>,9],YQZXQD@_0``````$;:UTVHV?HO3>;0X%E'MN6LZ0]<3Y
M.(N*ZP3O51/N*[%9EJ2Y*5F&Q7J2_P#=;:]%JQ[/=CUSBXQ,_(DD@````"SY
M6V/QM\IM)3JVS2(UMJ][LCFY1X"5ZC5/4ME1US>O6=EEW"X]_<(N52(C.$9P
MXQ#?5ZX]GIFXXR+P(```!`VH=Y@;SH7-.@ZWH^[V=5TC=7]/3%AU\.9-U-F+
M:[/42]IVK\2<]&@ZS$F:RK#CZ'',H_*9QE/JK.,:NN+9\)E5;'L3#77HW':'
M3-JVNYBT-+M.Z7]4O7H>M:#0;+.O*W7I=Y)NKVLL;&7;2]<F>R+6QIKZ&F<N
M+2E.4^LQQDSSA,A%````````````````````````````````````````````
M``````````````&`M)RO74^>N\6^+?H'Y43B'/MY;95TO>UUJ[>UZ5T^-)KW
MZI5_FOD:HRU%1F/3.-JJXR\K6TPA2U9STM_A.DQRBFMW;7>O[5UK9NJQ_*JY
M;J>G;US_`)S3\>H.[UNE:/KW/KR5J35O76G*VX5=?;O=7%5)GS9<QZ9F-EQN
M(AMM#*DK8Q))A.^;E=4/I/:+GDG)>86EKT'3-NZ3Y`WO$T=1VK6'M)Z/8\DU
MF!M^Z,[W&J+BLBXIMZVW0-7:KDRE1,8;LGGI;3>%(0G#$S;XQDYPR,J?'V5S
MW=M(VGE._;G4T\:;,@]0U#>=ZWKHM+ONO3*F:VQ/BIW'8+U^@WFJOTQ)#,Z(
MME#\?[[#Z%I6C*,^V9RN,=,?.#\3I^G6GDQ8;MLN]NTS'E)V:#K.M:IO>WZ!
M6T;Z9M6N??OO:1=4$Z[V*7-<5]IZ:Z^U$8;;0PVA2GE.:MQC'PDF<_=9]CNG
M5[3Q2Y]7PNG;+"WJO\NJ/B#?2U/I<V2SH->\DK'G42RV#"$MQ;N?+UF`TF:B
M0A;$]Y.5/H7A:\9N)-KQQC_P>/RF#?M!9X)OWCSMF@;ATI4C=NT5'+^B5NV=
M(W3=Z?>Z3;=3V^4NSMZO:[JVKX.Q5-S2QI4677M0\HQ]QGV_97[,9E]I9<=+
MC%5#6-7SY)]%[?==`V7=VM'YGTB7R'0^?:GO&V:%51I.KZ]K]EL>[[#(TFXH
M+6^V&YN]@<;AXDOKC08,9K+36''7'%+?63'?9.4']7N=EI_'WSVX=L.S7.[0
M^0:C!F:;M>RR_P!QVA_2NC:@G8*S7MEME8Q(N[75;.'-C(G/Y5*DP<QE/J6[
M[W%V?MKM\GT9![BS:]>[[6\3G;+LVM\TT;CM!T[;JS3]@M=1N=_O]RV2]UG6
MZ6RV2@E0-ABZEK\+4ITB3'A28RIDJ4QAY:FFLMKS.-<^<G=P\U*[/\?^\,\V
MK=@VS9N5[_R+>^BT.M;5L=QN5OHFU<NM=8CW4+7]AV.99;$K5MLIMP94F'+D
MR41)T/.6%(0^IO%_;7/G)U<+<XWR>V[)QW4>Y;3T[I,/LW3=9A=%I=DH=^VF
MNU?G:MGBXO-<U37>?1+5K19VK:[`E,1)<>PKYB[7V/+DK6MWU2VN+B?K"<S*
M,>7[WT"A\>?#'R!V/=-BN8=;8-Z;W+,V\LIE7=ZQU.[D:BQN5NW*E2$RGM(W
MM%1(8DN86Y&K')2<+PA2C5DNUU_PG.)65VMW-YO?DUOKT2XM&=`XGIE1H2ZF
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MVGE.G[I$Q?6ES+58[+`TJXV&1^#^:^](<82TPXMS"<8S;)F7':?,0GL.PZOH
MF.2;IQI7E9.O'>M\>US9>F=$E=@C:)OVK[OO%%J6R?S;5]5L8%-9MWL2Z4N"
MJJJ&UQ9V65L9990KTLEN9<='V3[+U&VZOY:]HT_:-[WIGENK<JXE:_Y?:[N&
MR:K`M-CV"PZ@RJPDV6N6=7<1(+<6I_QXL61';G/?97)^[B.TG&<XUEG>5\_1
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MY+G6YQG_`.G5C8$8::L.6WUY1>-?A*BDN;2H1>>4JJ&Z363I,)-O1S=K[8_,
MIK+$=QO$VKE/1&EN,.>YM:FDYSC.4X.E[V^W_IGX^Z4-$YIK51YK]ZV+%KT!
MU^@YER#;VH[W1]ZFU\B;L5KVC%G#FTTB_<KK6DBMQ\?M];(;<@UR\J5%::RK
M.26_PGW7'*!N>;53=AYW'ZEO\SS+3U;H+$S::#:N9ZAWIO3>91+*1(?U.DY[
M2:O!QSR_I*"KS'1(>FQ;%-T\EYR0MQ#N$(U>+B8PG^<MCG!=HW?<^.<ZV7I5
M!8:QOUGK4+.WTUG42:":Q?1,N0;"4Y23&VI52W:/Q<RVHZTX4RT^E.?T.>TD
MMDZ6=)<(H```````````````````````````````````````````````````
M````"!+;D^UM]^K^TZIM])70++1*;G.^ZI>ZO+MWK2BU_8[W9:N?J]Y"V.G_
M`&"YQ)V*0R[F3&GQUM>S.&\*3ZYUF>N*GG*T%<:Z[H6S;W9<,Z-I-'J_2MDG
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MS`_._>$Z_4[%5YI<*_+B_@YE9OO?]_T=]GVO3[>?=ZXDN/\`"H^N..])U;H&
MY=`X9O>J:XCI;]=9[[H_0M2M=IU25M=95Q*)K>-=?U_9]5MJ*\FTE=%C6#"E
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MY$)]A,"4O&&%M[LN<XS?E/\`A)VFQ>?\A^/K2M#\@ELZ?47/'9VM3-2LWT,[
M-*E;%3VMI$TJAKI"UV%GOD>%*2TQ$9PY+_-9_AQ[DYSB7.V^=>\G6O+(3Q2Y
MWL?-^&Z97;U*E6/2]DBKWKJ-M8I1BTLM_P!O]EM?9LLM8PTJ55?=;K\>S&$8
M:AH2G^'&#.USMQTLZ2?T_G.N];T#:.<[6F9^Q[56J@29%;)S#M*Z0T\S-K+F
MHF82O\.XI+2*S,B.^U6&Y#"%92K&/3,EQ<Q>T`3>(=PWN+KNE]@['JFR\TH+
MO7[NZ;U/GL_4]XZ?G5;.)=4E7NML[N%Q15-6];UT=^S;J8$?-CAK+2<QF7%M
MYUG6<ZSE.?PF#4.7JU;J_8>FYNL34]68YRRFFQ`_'S1_R%16=,I69WY;O[A^
MZ9L/N>GVF?L^SV_Q^OKC-N9)\*BW;/%Z+N%1Y*T\_<9<!'D!M&H[;`G5]1'5
M*TBWTG6-'JJ)[#4R5(A[$VS>Z-'G.-.H8;>:6J.K'IZN9U[=?1,=K6WW@/D!
MV'7ZRJZ+VO1JF1I^QZ?NNH)T#F-O"I[7=='V.KV&ENNA0K[?K2;<TN'JY6,U
M$"37-8==P\I]S++2<)MK+Q#%J=M5Y=)U_KG1>K2[YFP?Z#I?,-5?J&*M4)JO
MD<]=W5Z18MR5V$M3S5RYM_\`"SE.,Q\,>F5N>[U3FWC"^5@;5QNAKD>5FX;;
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M_P#']WW<_<^U[_1/N]N);FY).,,4^@<PT[AW`/'O4=MWW:-8LN2;925^H>0&
MM:[7JK>=;*_6;!!;V+?JNSG38,/G.R0I[M)9HD*=BJ_/:PZXQZID,[EMVM^4
MO$6'ZO=+\G?&IQ'=]>\@-IT"_P!SW2ZSS"HK*CG',]!7SK9M=<L;R+2[)N>,
M[=NNU759&BKG6BEY89>Q%C--XD+<=:WC$/,;1#FTQ)H/%]RCYKP;GV=T3)5Q
M3L#?5%VO[%EK&QI19[W8_LB8?[JY^UYS_.F$?D?<?_\`9_7[?\?HG7MS;\Q,
M);HN7YINS]%ZTJY3)1OND\ZT_%#^!]O-9G0Y^[S53U6&93F)>+3&X83]O[+?
MVOQ_7W+]_HF9_CA?.4*5'">Y<ZH;/FO'NR:AK?+94RX<U7.T<YG[+O\`RRJO
M9TJPDT&H6\;<JC7[ROII,UW]GS:U[JX#.6V7/RFVDXS?:7FSE,7\,EN?:35<
MWTC5M#HW[.75:G20*2)-NY[]K<V"83"6W+&WLI&<O3K2P>PIZ0[GT][KBLXQ
MC'IC$MS<KTO`@```````````````````````````````````````````````
M`````````````````````!1I&N:]+M(UW+HJ:5=0\83$MY%7">M(J4Y]4XC3
MW&%2V,)S^GM7CT`JCK##^6LO,M/98<2\SEUM#F67DXSA+K65XS]MQ.,Y]%8]
M,X]0/U`````````49C7->C6K][&HJ:/=RDY3)N&*N"U:R$J^BDOV#;"9;R58
M_7"EY]0*R``^'6FWVW&7FT/,O(6TZTZA+C;K;B<H<;<;7C*5H6G.<9QG&<9Q
MD"F5%#1Z^PY%H::II(SKN7G8]170ZUAQY7TRZXU#99;6[G^U6<9R!5@`````
M`````````````````````````````````````````````````````````:N>
ME>;6^:ETGI&MZU*YQ<PJ&!VBJH*.VK%UUI6[=RO6X5U7)M_M=$<W&YBW$S\I
M#^,Z[41'HJ4.U\N4E&77MS683*]-J[SY"T>Q[_S^#;<K?N^;578MHL-ME\^V
MK$#8:WG_`#K@_1J"DAZPQT7W5,J:[UN56RY:K&3C+,-M]IE+JEMX22F7BO?.
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M````````````````````````````````````````````````````````````
M```````````````````'BS6URGW92H$)4E];;CTC,5C+[RV6'(S*W7<M_<<6
MU&=6VG.<YRE"LIQ],YP!Z,LLY4I66FLJ7A6%JRVG*EX6E"%85GT]584AM.,^
MOZX3C']F`/QQ`@8>=D8A1,/OM-L/OXC,X>>992XAIEUSV>]QII#R\)3G.<)P
MO.,?KD#^1:^!"2E,*##B)0VVRA,6,S'2AEI&&VFDX:0C"6VVTX2E./IC&/3`
M'T_!A24--R8<60VQ(1,90_':=0S+:<RZU*:2XA6&Y#;N<J2O'HK"L^N,^H%`
MUK2M7U#]TSKM/&KG+J[V#8;-].77Y4JUVBZF;%=OJE2G'I"69ES8//X92K#+
M:EYPA"4^F,.Q7XT&%";;9APXL1EI3RVFHT=EAMM<A:G'UMH:0E*%/.+RI><8
MQE2LYSGUSD#^.P(#[&8ST*(]&RXIW,=V,RXQEU:U.+<RTM&6_N+<6I65>GKG
M.<Y_7('RBMKF\PU(@0D*KOO?MZD16$Y@_D(RV_\`AYPWC,;[[:LI7[/;[L9]
M,^N`&:VN4F<A5?"4BS]?W)&8K&4V'N9Q'5^<G+?I+]S"<(S]SW>J,>GZ?0#U
M-MMM-H::0AMIM"6VVVTX0VVVC&$H0A"<82A"$X],8Q],8`^P````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
9``````````````````````````````'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g91036g31c41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g91036g31c41.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-0FAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYP<FEN=&UG<B!F:6QE/"]R9&8Z;&D^"B`@("`\+W)D9CI!
M;'0^"B`@(#PO9&,Z=&ET;&4^"B`@(#QX;7!2:6=H=',Z57-A9V5497)M<SX*
M("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L
M="(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<%)I9VAT<SI5<V%G951E<FUS
M/@H@("`\27!T8S1X;7!#;W)E.D-R96%T;W)#;VYT86-T26YF;PH@("`@27!T
M8S1X;7!#;W)E.D-I061R17AT861R/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE!
M9')#:71Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE!9')296=I;VX](B(*("`@
M($EP=&,T>&UP0V]R93I#:4%D<E!C;V1E/2(B"B`@("!)<'1C-'AM<$-O<F4Z
M0VE!9')#=')Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE496Q7;W)K/2(B"B`@
M("!)<'1C-'AM<$-O<F4Z0VE%;6%I;%=O<FL](B(*("`@($EP=&,T>&UP0V]R
M93I#:55R;%=O<FL](B(O/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@/"]R9&8Z
M4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP
M86-K970@96YD/2)W(C\^_^X`#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("
M`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@#*@)Z`P$1``(1
M`0,1`?_$`)\``0$!``,!`0$!```````````%`P8'"`(!!`D!`0$!`0$`````
M```````````"`0,$$`$```8``@D#`@0"!@@'`````0(#!`4&$0<2,W.S5!66
MU@@3TY0A%#%1(A9!<6&1,E(C-O"!L=%"@E,7DF,D-$0F&!$!``(`!@$#!0`"
M`P$```````$1(3&1T0(205%A<8&A(C(#P4+PL1,S_]H`#`,!``(1`Q$`/P#U
MO7R.0^O7_P#K[[KZW_YEQ_ZLW_S'NJ'E9>8Y#Q]]^9<?<*@/,<AX^^_,N/N%
M0'F.0\???F7'W"H#S'(>/OOS+C[A4!YCD/'WWYEQ]PJ`\QR'C[[\RX^X5`>8
MY#Q]]^9<?<*@/,<AX^^_,N/N%0'F.0\???F7'W"H#S'(>/OOS+C[A4!YCD/'
MWWYEQ]PJ`\QR'C[[\RX^X5`>8Y#Q]]^9<?<*@/,<AX^^_,N/N%0'F.0\???F
M7'W"H#S'(>/OOS+C[A4!YCD/'WWYEQ]PJ`\QR'C[[\RX^X5`>8Y#Q]]^9<?<
M*@/,<AX^^_,N/N%0'F.0\???F7'W"H#S'(>/OOS+C[A4!YCD/'WWYEQ]PJ`\
MQR'C[[\RX^X5`>8Y#Q]]^9<?<*@/,<AX^^_,N/N%0'F.0\???F7'W"H#S'(>
M/OOS+C[A4!YCD/'WWYEQ]PJ`\QR'C[[\RX^X5`>8Y#Q]]^9<?<*@/,<AX^^_
M,N/N%0'F.0\???F7'W"H#S'(>/OOS+C[A4!YCD/'WWYEQ]PJ`\QR'C[[\RX^
MX5`>8Y#Q]]^9<?<*@/,<AX^^_,N/N%0'F.0\???F7'W"H#S'(>/OOS+C[A4!
MYCD/'WWYEQ]PJ`\QR'C[[\RX^X5`>8Y#Q]]^9<?<*@/,<AX^^_,N/N%0'F.0
M\???F7'W"H#S'(>/OOS+C[A4!YCD/'WWYEQ]PJ`\QR'C[[\RX^X5`>8Y#Q]]
M^9<?<*@/,<AX^^_,N/N%0'F.0\???F7'W"H#S'(>/OOS+C[A4!YCD/'WWYEQ
M]PJ`\QR'C[[\RX^X5`>8Y#Q]]^9<?<*@/,<AX^^_,N/N%0'F.0\???F7'W"H
M#S'(>/OOS+C[A4!YCD/'WWYEQ]PJ`\QR'C[[\RX^X5`>8Y#Q]]^9<?<*@/,<
MAX^^_,N/N%0'F.0\???F7'W"H#S'(>/OOS+C[A4!YCD/'WWYEQ]PJ`\QR'C[
M[\RX^X5`>8Y#Q]]^9<?<*@/,<AX^^_,N/N%0'F.0\???F7'W"H#S'(>/OOS+
MC[A4!YCD/'WWYEQ]PJ`\QR'C[[\RX^X5`>8Y#Q]]^9<?<*@/,<AX^^_,N/N%
M0'F.0\???F7'W"H#S'(>/OOS+C[A4!YCD/'WWYEQ]PJ`\QR'C[[\RX^X5`M^
M89#Q][_RYQ_^[N/X_P`^L_BFH^XX[7Z^OV];O9EC(```````````````````
M``````````````````````````````````````````````````````````%O
MVVG<2:_7U^WK=[,H9```````````````````````````````````````````
M```````````````````````````````````M^VT[B37Z^OV];O9E#(``````
M````````````````````````````````````````````````````````````
M```````````%OVVG<2:_7U^WK=[,H9``````````````````````````````
M````````````````````````````````````````````````M^VT[B37Z^OV
M];O9E#(`````````````````````````````````````````````````````
M````````````````````````%OVVG<2:_7U^WK=[,H9`````````````````
M````````````````````````````````````````````````````````````
M`M^VT[B37Z^OV];O9E#(````````````````````````````````````````
M`````````````````````````````````````%OVVG<2:_7U^WK=[,H9````
M````````````````````````````````````````````````````````````
M``````````````M^VT[B37Z^OV];O9E#(```````````````````````````
M``````````````````````````````````````````````````%OVVG<2:_7
MU^WK=[,H9```````````````````````````````````````````````````
M```````````````````````````M^VT[B37Z^OV];O9E#(``````````````
M````````````````````````````````````````````````````````````
M```%OVVG<2:_7U^WK=[,H9``````````````````````````````````````
M````````````````````````````````````````M^VT[B37Z^OV];O9E#(`
M````````````````````````````````````````````````````````````
M````````````````%OVVG<2:_7U^WK=[,H9`````````````````````````
M`````````````````````````````````````````````````````M^VT[B3
M7Z^OV];O9E#(````````````````````````````````````````````````
M`````````````````````````````%OVVG<2:_7U^WK=[,H9````````````
M````````````````````````````````````````````````````````````
M``````M^VT[B37Z^OV];O9E#(```````````````````````````````````
M``````````````````````````````````````````%OVVG<2:_7U^WK=[,H
M9```````````````````````````````````````````````````````````
M```````````````````M^VT[B37Z^OV];O9E#(``````````````````````
M```````````````````````````````````````````````````````%OVVG
M<2:_7U^WK=[,H9``````````````````````````````````````````````
M````````````````````````````````M^VT[B37Z^OV];O9E#(`````````
M````````````````````````````````````````````````````````````
M````````%OVVG<2:_7U^WK=[,H9`````````````````````````````````
M`````````````````````````````````````````````M^VT[B37Z^OV];O
M9E#(````````````````````````````````````````````````````````
M`````````````````````%OVVG<2:_7U^WK=[,H9````````````````````
M``````````````````````````````````````````````````````````M^
MVT[B37Z^OV];O9E#(```````````````````````````````````````````
M``````````````````````````````````%OVVG<2:_7U^WK=[,H9```````
M````````````````````````````````````````````````````````````
M```````````M^VT[B37Z^OV];O9E#(``````````````````````````````
M```````````````````````````````````````````````%OVVG<2:_7U^W
MK=[,H9``````````````````````````````````````````````````````
M````````````````````````M^VT[B37Z^OV];O9E#(`````````````````
M````````````````````````````````````````````````````````````
M%OVVG<2:_7U^WK=[,H9`````````````````````````````````````````
M`````````````````````````````````````M^VT[B37Z^OV];O9E#(````
M````````````````````````````````````````````````````````````
M`````````````%OVVG<2:_7U^WK=[,H9````````````````````````````
M``````````````````````````````````````````````````M^VT[B37Z^
MOV];O9E#(```````````````````````````````````````````````````
M``````````````````````````%OVVG<2:_7U^WK=[,H9```````````````
M````````````````````````````````````````````````````````````
M```M^VT[B37Z^OV];O9E#(``````````````````````````````````````
M```````````````````````````````````````%OVVG<2:_7U^WK=[,H9``
M````````````````````````````````````````````````````````````
M````````````````M^VT[B37Z^OV];O9E#(`````````````````````````
M````````````````````````````````````````````````````%OVVG<2:
M_7U^WK=[,H9`````````````````````````````````````````````````
M`````````````````````````````M^VT[B37Z^OV];O9E#(````````````
M````````````````````````````````````````````````````````````
M`````%OVVG<2:_7U^WK=[,H9````````````````````````````````````
M``````````````````````````````````````````M^VT[B37Z^OV];O9E#
M(```````````````````````````````````````````````````````````
M``````````````````%OVVG<2:_7U^WK=[,H9```````````````````````
M```````````````````````````````````````````````````````M^VT[
MB37Z^OV];O9E#(``````````````````````````````````````````````
M```````````````````````````````%OVVG<2:_7U^WK=[,H9``````````
M````````````````````````````````````````````````````````````
M````````M^VT[B37Z^OV];O9E#(`````````````````````````````````
M````````````````````````````````````````````%OVVG<2:_7U^WK=[
M,H9`````````````````````````````````````````````````````````
M`````````````````````M^VT[B37Z^OV];O9E#(````````````````````
M`````````````````````````````````````````````````````````%OV
MVG<2:_7U^WK=[,H9````````````````````````````````````````````
M``````````````````````````````````M^VT[B37Z^OV];O9E#(```````
M````````````````````````````````````````````````````````````
M``````````%OVVG<2:_7U^WK=[,H9```````````````````````````````
M```````````````````````````````````````````````M^VT[B37Z^OV]
M;O9E#(``````````````````````````````````````````````````````
M```````````````````````%OVVG<2:_7U^WK=[,H9``````````````````
M````````````````````````````````````````````````````````````
MM^VT[B37Z^OV];O9E#(`````````````````````````````````````````
M````````````````````````````````````%OVVG<2:_7U^WK=[,H9`````
M````````````````````````````````````````````````````````````
M`````````````M^VT[B37Z^OV];O9E#(````````````````````````````
M`````````````````````````````````````````````````%OVVG<2:_7U
M^WK=[,H9````````````````````````````````````````````````````
M``````````````````````````M^VT[B37Z^OV];O9E#(```````````````
M````````````````````````````````````````````````````````````
M``%OVVG<2:_7U^WK=[,H9```````````````````````````````````````
M```````````````````````````````````````M^VT[B37Z^OV];O9E#(``
M````````````````````````````````````````````````````````````
M```````````````%OVVG<2:_7U^WK=[,H9``````````````````````````
M````````````````````````````````````````````````````M^VT[B37
MZ^OV];O9E#(`````````````````````````````````````````````````
M````````````````````````````%OVVG<2:_7U^WK=[,H9`````````````
M````````````````````````````````````````````````````````````
M`````M^VT[B37Z^OV];O9E#(````````````````````````````````````
M`````````````````````````````````````````%OVVG<2:_7U^WK=[,H9
M````````````````````````````````````````````````````````````
M``````````````````M^VT[B37Z^OV];O9E#(```````````````````````
M``````````````````````````````````````````````````````%OVVG<
M2:_7U^WK=[,H9```````````````````````````````````````````````
M```````````````````````````````M^VT[B37Z^OV];O9E#(``````````
M````````````````````````````````````````````````````````````
M```````%OVVG<2:_7U^WK=[,H9``````````````````````````````````
M````````````````````````````````````````````M^VT[B37Z^OV];O9
ME#(`````````````````````````````````````````````````````````
M````````````````````%OVVG<2:_7U^WK=[,H9`````````````````````
M`````````````````````````````````````````````````````````M^V
MT[B37Z^OV];O9E#(````````````````````````````````````````````
M`````````````````````````````````%OVVG<2:_7U^WK=[,H9````````
M````````````````````````````````````````````````````````````
M``````````M^VT[B37Z^OV];O9E#(```````````````````````````````
M``````````````````````````````````````````````%OVVG<2:_7U^WK
M=[,H9```````````````````````````````````````````````````````
M```````````````````````M^VT[B37Z^OV];O9E#(``````````````````
M```````````````````````````````````````````````````````````%
MOVVG<2:_7U^WK=[,H9``````````````````````````````````````````
M````````````````````````````````````M^VT[B37Z^OV];O9E#(`````
M````````````````````````````````````````````````````````````
M````````````%OVVG<2:_7U^WK=[,H9`````````````````````````````
M`````````````````````````````````````````````````M^VT[B37Z^O
MV];O9E#(````````````````````````````````````````````````````
M`````````````````````````%OVVG<2:_7U^WK=[,H9````````````````
M````````````````````````````````````````````````````````````
M``M^VT[B37Z^OV];O9E#(```````````````````````````````````````
M``````````````````````````````````````%OVVG<2:_7U^WK=[,H9```
M````````````````````````````````````````````````````````````
M```````````````M^VT[B37Z^OV];O9E#(```````'H/D%\<]MY\Y+,7-ID<
M7I?+S4*'[_?^9VSSPMM8U2PEIQKSTXU*E2WIY',5;>6,].VEJTY99>$]:I2D
MC":,<N<<?E7'C?P[XO>8GP>Y/S3X7E_R8S7R0S5G_P`*YYA<TL[<X#6+ZZI_
MTU*V#U>ULZLE7&U)H<9(UK&A/&7A_P`2I#^N,U_2<YIM\(RBW\='Y/\`QMV&
M;]AO_P`).7%MB:L/IS7_`"WV*^UC8+*6;^F->VJ4+#'0NJM.$>,LLUS1EFC_
M`!CP;TY1ERD[<?,,]Q^,7+OF/I6:YK_$+;LQN^'URA&^W;DYM5&2GS4TJSC+
M&>>\LJ-"$/[DQE*$DT80IPJ3S22Q^E7N9X322HYS$USP]_!/&)B^+PG",(PA
M&$>,(_K"+HA^@```````````````````````````````````````````````
M`````````````````M^VT[B37Z^OV];O9E#(``````%'#XC([!F,1@,10C=9
M;.Y3'87%VT(1C&XR.5O*-A8T?T_7A4N;B6$?Y09EC(]U?,?;;/EK8:Q\..75
MU"VT7E3CL7>\QKRSC]*IS`YI92TM\ME,CFIZ?1FNK;%QN*<].C4XPDN)^C&'
M"VH]#G_.+_.<Y7RP_&,H>!'5`#L/E3S1V_DQONO\QM'OJEEG<!=2U)J/U)Y;
M/,XR>>3S+`9:E)-+"YQ>6MY8TZDL>/1CT:DO"I))-">41RBIR;$S$W#T/\TM
M#U7%[KIW.'ES:26/+GY#ZC;\RL+CJ,DLE#![#<1H?W?@I):<LE&E&WO[NG7F
MIR2RR4ZMQ4DEA"62$$_SF:ZSG&#>41=QE+QGTI>ET>E+TOX]'C#I</Y\/XNB
M7[&:$(PA&,(1C^D(1C"$8_Y?S!^@S^M2Z71^K3Z7^[TY>E_JX\0:`S^M2Z71
M^K3Z7^[TY>E_JX\0:`_(32S<>C&$>$>$>$81X1_E'A_"($TTLOZS30EA&/"$
M9HPA^O\`+]?\0?H/GIR='I=.7H_[W2AT?Y?QX\/X@^?K4O\`U:?_`,<O_>#[
MZ4O1Z72AT>''I<8='A#^,>/\.$`(1A&$(PC",(_K",(\81A_.$8?Q!\S5*<G
M#ISR2<?X=*:67C_EQC#B#ZA&$80C",(PC_",(\81_P`HP!G-6HR3=&>K3EF_
MW9JDLLW^J,81!I",(PA&$81A'^$8?K"/^40?H```````````````````````
M```````````````````````+?MM.XDU^OK]O6[V90R``````!Z`^*,MK-\F^
M0LM[T(V\>:6J1C"IPZ$:\M_+-90CQ_3C^^A3X?Z>".?Z3\-X_M'RF_)>:^G^
M1?/6;)]+]]_[L[W"MTN/&$DNPWTMK"''_P`$+.%.$O\`AT>'#]&\/UCX.7[3
M\ND5,``>[><\:LWP5^'<^1X_O)=MYQ4\1&?C]2.!\\O^GT./Z_1A7DHPAP_3
M_9_T.?'_`.G+Z+G](=N<D*O)/6OA%9;#SBY<XC9M;V[G[F.76T[398NUEWW5
M,-E,#"\Q^QZUG*=M/E);G7,ICZ5:%O+/&%2C-4EA)/&/TYYY=I_I^,XTV*ZX
MY6^L#\;K?E/RL^8%UD*6N<Q],R_)7![CR3YL6^.L,C9Y?#SY'-2U+W%7D]*X
MC@-EL9:UO)?4:522>6?H3RQFIS2Q@GG<\?$WB=:B?2G07PHY1:/S3W/F+D-X
MQ4VW4>67++-[[@^7,ES<6W]^9O']*6TQEU^SFEOKK'4*LLDM2A1CQJU:]*$W
M&3I23U_3E,1$1YE/&(F<77M?Y7<S*LUS)1PW)O$8.M+5HRZ?:<D.5?\`;>-H
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M23Z^3R/[.C0C?7]:,8].M5Z52;_&,3^<S?+Y.41A\/+/*KF1><K-TQ6XV>`U
M?;;>TFC0RFL;AA<=GM?V#$UIY/WN-NK?(6MW+:U:LM.$:5U1A"M;U(0FA&:7
MI23URCM%)B:E_H'D.6?Q5U+`67S2M;3*YSE5L%Q"VT?X[W]G/+&ESFDKY2.0
MU7.YB?ZUI5Y?X*MBJES++&$\E2G+&3C5I0IT*O.)YS/_`)_[>OLNN/[>'@VX
MYP[95YD9'FE;8[2,?G[^:[EI8BAH>I7FF8NRNK?]G)CL;I^5Q%_@):%E:0A)
M2J5*%2XA-#ZLU2-6,T\>G6*I%XV]V;GS3SV)^&?)GFSC];Y44-^VSFEN6MY_
M.?\`LMRGJ2WV&Q,VS0L+2&-JZ?/B[:-"&/H_\2E1DJ3=#^J:/&/'G$1WF,:K
MUE4S^,3A;R%R.OIM]^4/*._VFQPN0_NCG!I<<YCJ.!PV.P%Y3N\[84;BTEUS
M&V-K@K;'U:,.C&WI6\E&,./]/ZQX].6'":]$QCRCY<QYJZ+KFQ?-O<.6]6YL
MM-U7.\^H:G5N;"A:6%CK^(R><M+&K-8V\LE.PLX4:5:,*4.C"E)/&$8PX<8,
MB9C^=^:;,7RKW=C_`".YEY/X^<W]JY-\HM"T#EMJFBSXW'6=QDN76I;;M^Y4
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MS.#Q^$LL;:T(7M:PJQK].WI5IZT)IIH<(RQC?"8GCADGE$Q.+SZM(```````
M``````````````````````````````````````"W[;3N)-?KZ_;UN]F4,@``
M````5<#F\EK.=PFRX:K]#+Z[F,9GL56XQA"ED</?4,C93QC#]>C"YMI>/\X<
M69X#W!\TM/L=VJZQ\NN7EO\`NN7'.O'8R;:H6L(U8Z1S0L+.EB\W@<WT(S1M
M*F0GL?Z)ZG1A4NJ56$/TGI=/G_.:_"<X7SB_RC*7@IU0`YQRVY<[9S;WC7N7
MFD8^ID=CV6^DM+6262>:WL+:$837^9R526$86V*Q%KTJ]Q5FX0EDEX0XS32P
MCDS'&+G)L1,S49O3?S6W+5Y]LT3D;R^OI,CHGQRTZCR]MLE1FEFH9K;YHV]3
M=,M)&2,U.:>-[9TJ%2:6,TL;FE6Z,8RQA%'\XFNTYRWE/B,H=%VFX\W\CR>A
MRJL++-Y'E-3W"OND+6QU">]MI-IH6D;:YN_[DM<75O(0M[:I_P`2A^X^E)QX
MS2PXJKCV[?[,N:KP^M;Y^\VM1Y9;5R=PFWW%'EMN-.ZIYO6;RRQV1MI9+V$/
MW\,3<W]K7O<%"^C#I5H6E2E+4G_KC#IQC-%/'C,]IS+F(KPX+@<_N/+O8[#8
M-<RF?TS:\3&G=X_)V%6\PV7LY+RVEJTYY8QA2JS6M_95Y8]&>6:C<4*D.,)I
M)OUV8B8J<C&)]W?MO\B^?6WWMSE+'6](V;9:71J7^VX_X^<M<WM<*M:$T);J
M_P`O;:/=S?O;B,L8_6J2?5GFA&/&,>*>G&,,=6]I^OP\\XS/[)JVR6^QX;)Y
M76=KP^4J7]KD\9/6PN6Q.5DJU(U9J$+:6VGL*LE2>:2:E"622$L8TXR]'C*K
M"8KPG)Z5AS_^1-]-)N];2=2R^3Z'F4.9%Y\<="R.8JU*<(UHYNKM,VCS6MS>
M20I1J1NY^E/QEC/&;C",4]>.6.JNTY_X>==JVO<>9>S7FQ[=F\WN>V9^M1I7
M&1R%6MD<I?U(PEM[2SMJ5*6,9:4DL84[>VH22TY(<):<D(<(*B(B*C),S>;T
M)EOD_P#(;'XW5\+M^-U6XMM9P%EK.K?W_P`C=!R60M,#A:%&TML?9WVTZ?6O
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M%KC+:/2EI4K>E3H4X\82RPCQ5$1$5&3)N\<W7[6`````````````````````
M`````````````````````````+?MM.XDU^OK]O6[V90R```````!Z0^/_P`D
M<_R0J9W7<C@L=S$Y1[Q3_:\P.5FQ1EGPV;HS2249LCC*E6E<4\3GZ5&26$M:
M%.>G5A))"I+&,E*I2CEPCECER5QY5\.Z[SDG\0.;L\<SR:^1%MR8OKZ;ZM7E
MGSTL:UO0Q%:?^J>UQFXRWE.WN+&G/'HT^-;(U.C#^JIQ_1/;GQ_:+^&S'&<I
MI_/+\.N5VN5);WF1\S^06+P<G">M#1;^OO.?KT^'2Z%GB[:XM:L:T\/TAPIU
MN$?_``Q_@?\`I,Y<9LZQ&<PVV/Y)<JN2^H9OEK\/,%G,=?;+:1QF[?(#<I)*
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ME8WY+PI'YD[_`)KFCNN9WK8*&/M<KFO+J=:WQ=&O2LZ%OB<798;'TI9KNXO+
MVZK28_'TH5;BXK5;BXJ]*I4GFFFC%L145!,W-RTM^8><MN6V2Y84X4_),GNN
M(WBK>1KWL+^E?8?`9?7J..HPEN(6D,77M<S4J5)(TXS1J22\(PAQA'*B[+PI
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MBL;*VL[;,6M_BY*%S)LE6:K/-0C6A&E)"2>66,\)LF+FVWA3^/F7S`RW-+=L
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M%W<7.!V'6;ZUR$+N22OA=HQ=?#Y>E:WV-N[#+8?(365Q-]&\M*]&XH3_`*RS
M<(S2S5,7%,B:<?SN4L,K<4*F.P]3#4*%&:E&WJYW*Y^>I--5FJ?4_=96>-2C
M"$)N$)*<LLO^,>,T8QB8AM``````````````````````````````````````
M````````%OVVG<2:_7U^WK=[,H9`````````<./Z1_6`/R$LL/X0A#_*$(?]
M@/T`````````````````````````````````````````````````````````
M`````````%OVVG<2:_7U^WK=[,H9```````M:WA*FR[%@-;HWUAC*^PYK%X.
MWR.5J5:.,LKC+WU#'V]SD:U"C<5J-E1K7$L:L\M.>,LG&/"/!DX18[8J?'W>
MK7$X?-Y2O@\1C\G1YJW%[/?W=W"MK=OR@EO/[CJ[!;T+&M4M(9.MCZM+&PI_
M5C=U).'"1G:,O.'W;4JTWQDYBRW$]O\`N=;C"3FK0Y3_`%X9&Z^C->W&%DV&
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M<[>D>&]7%KSDME\3@Y;_`&#;-(US8[K$9[/X;0LSE,A;[-G,-KN5RF%O+FQN
MJ>)JZO0O,AD<)>28VRN<A1N\E^WC]"G-&>E"IO;'"Z93G^M_&V\GWC`:[G-G
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MM.76-Q61V_-Y_)V^=VO<M`U_=)[*RJX74[J]M:5*RS5*ZOJMQ;TK'$RW5.C-
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M7<<9G]AO-EUW3-3UF;"V^7V?9_.JEE)D]DJW=/`X:SL-=Q&=S60R61EQUS5Z
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MQ3B#6``````````````````````````````````````````````````+?MM.
MXDU^OK]O6[V90R```````XS0X1DGFISRQA-)4DCT9Z<\(\99Y)H?K+/)-#C"
M/^$8`]!;A\D=ZW7'[_C<GC];MJ',3'Z;CLK-C[*[HU,93U/I5+ZMA/J7M62T
MK[O>U:ESF8S0GA<5:DW0A3ECP3'&(KV5/*9OW?7_`/2F_>528K]GKW0DY1S<
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MI2NODCL5SE,Y>?V=IM/%[7LV\[-MVL__`+'7P^PU.9.NX?7]SQEQ5N,]4RUE
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M2<6=O5_19_)'=Z-U8Y2_QN`S&<MMEYDYV^S5S'.6-UFL;S<MX4=]U2_HX;,X
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MI/GN4V`Y07]S-)>37$V#U_+87,V^7EFC=='SZ[N\'3^O/-"-",*D_1IRQC",
M-ZQ][9?_`$XIN>W9#>,Y+G\G;V=K=RX/5L#"E8RUI;?]IJ6LXC5<?5X5ZM>I
M^XN+##4ZE:/2Z,:LTT982R\)8;$5A#,W%6@`````````````````````````
M````````````````````````"W[;3N)-?KZ_;UN]F4,@````````````````
M````````````````````````````````````````````````````````````
M`6_;:=Q)K]?7[>MWLRAD````````````````````````````````````````
M`````````````````````````````````````"W[;3N)-?KZ_;UN]F4,@```
M````````````````````````````````````````````````````````````
M``````````````6_;:=Q)K]?7[>MWLRAD```````````````````````````
M``````````````````````````````````````````````````"W[;3N)-?K
MZ_;UN]F4,@``````````````````````````````````````````````````
M```````````````````````````6_;:=Q)K]?7[>MWLRAD``````````````
M````````````````````````````````````````````````````````````
M```"W[;3N)-?KZ_;UN]F4,@`````````````````````````````````````
M````````````````````````````````````````6_;:=Q)K]?7[>MWLRAD`
M````````````````````````````````````````````````````````````
M````````````````"W[;3N)-?KZ_;UN]F4,@````````````````````````
M`````````````````````````````````````````````````````6_;:=Q)
MK]?7[>MWLRAD````````````````````````````````````````````````
M`````````````````````````````"W[;3N-:_7U_P#EOKZW>S&HR]-FH>FS
M4/39J'ILU#TV:AZ;-0]-FH>FS4/39J'ILU#TV:AZ;-0]-FH>FS4/39J'ILU#
MTV:AZ;-0]-FH>FS4/39J'ILU#TV:AZ;-0]-FH>FS4/39J'ILU#TV:AZ;-0]-
MFH>FS4/39J'ILU#TV:AZ;-0]-FH>FS4/39J'ILU#TV:AZ;-0]-FH>FS4/39J
M'ILU#TV:AZ;-0]-FH>FS4/39J'ILU#TV:AZ;-0]-FH>FS4/39J'ILU#TV:AZ
M;-0]-FH>FS4/39J'ILU#TV:AZ;-0]-FH>FS4/39J'ILU#TV:AZ;-0]-FH>FS
>4/39J'ILU#TV:AZ;-1:]._\`+O\`T_\`*S7-K__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g91036g42o49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g91036g42o49.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0@H4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````'0```($````&`&<`-``R
M`&\`-``Y`````0`````````````````````````!``````````````"!````
M'0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!8P````!````<````!D`
M``%0```@T```!7``&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``9`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P"E\`23H`-22>``M!^!@8A]/J658W)_/QL2MMAJ[[<B^U[*?5_X&K^;
M2^KX)ZQCEK?4L8+;*:R)#K&56V4C_MQN]9K#N8'$EQ=[BXZDEWN<]W\I[O<B
MIOV]/I?CV973L@Y5=`WY%-C/3R*F3'K.K:7UWT-_PEM/\S_A%25WH3GMZW@[
M!)?<*W-B06/!9>QP_=]+<C872L')P`_US3DV9C\7&#B/2<UC6VMK>Z-U=MM>
M_P!"[^:]38Q)3F)+39TNDW]28QMN2<"YU56+4]C+7UA[ZSDO?8U^^JG;^D]"
MKZ?[BC3TUC_MKC1>Z[$<P#I[;&"X-</?=;::_P!+74_V?J]._P#TB2G.26L_
MHM1RLC&I-C[J\'[4S')8;67RS]2N<P-KM<W?^9Z:#A=-IOMNPLIUF%F4S:2Y
MH>STF#?DUNK'N9DMK_2T/W^E9_-I*<]):73L?I.8[,W5WMKHHLR:";F-<YM>
MS939^A>WU;-V[>S_`#$-F'BV]-^V>H:'/SFXPWN#FLI>WU/5MAK'/=3^?9^C
M24T4EIYO2A1>**\3*%8O;2W)=94_U6N)V.HK:RJOU+V?I,?]-Z?^F3]7Z7CX
M=#+Z-X:ZTU!MSB+=&[SOQK,:CZ/YUU-]V/O_`$:2G+22220__]"I5;;1=7?2
M[9;4X/K?S#FG<TP?I*]8.D9SG7B_]EY#_=;COK?9CEY_G'XMM.Y]5;_I^A:S
MV?X/V+/2"*G0&1@=/:_]GVOR\VQKJ_MCF&JNICQML^RU6?I;+W^]GVA_T&*J
MQ^"W"LI=B[LIQ_1Y7J.`8SV_H_0_FK/HO^E_I/Y""DDIFUV,+,=SZ-]=0;ZU
M>\CU"'/<]S;/I8_J5.KI_1_Z/U/SU,V8/VJNQN(/LS-N['+W^XC^=<VT.]6K
MU/\`C/8@I)*24.Q&4W,NQA98\#T'M<Y@J=[M[O3:[]+OW-_G=Z0=C?9?2-$W
M[I%^YT;?;M9Z4BOV[7^_W_SG\A#224E=9B.Q14,>,@1.1ZCC,.>YWZ#^;]U3
MJZO^M^HH4NI9<U]U?K5B=U>XMD1^^WW-]WN44DE)*3A,QK*[L7U;G!PJN#RP
M,ENUOZ%OZ.QK;?TW\O\`XO\`G$YV+]G8QE&W(:3ZE^XG>)<6MV3LKV-VL^C_
M`"T-))2DDDDD/__9.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@
M`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`
M<P!H`&\`<``@`#8`+@`P`````0`X0DE-!`8```````<`"``!``$!`/_N``Y!
M9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!
M`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`__``!$(`!T`@0,!$0`"$0$#$0'_W0`$`!'_Q`![``$``P`#
M`0``````````````!@<(!`4)`P$!`0$!`0````````````````$"`P00```'
M``(!!`$#`P4!``````$"`P0%!@<`"!,1$A05%B(7&"$C)#$R4B8)&1$!`0$!
M``("`@,```````````$1(3%!46$"$G&1,O_:``P#`0`"$0,1`#\`R]STN38&
M;]19&;SZ-V7:-.I/7/'IU99*JV.^(S4U<-#^*=5%ZMFF95=D_M-L81[E,J:[
MTX,HXAC@`.#"!@+-[D[5SY3*%Z@Y5J:WX]UX[<9UI.E+&4)"YK>Z9<,0F+DY
M]PIM(FE3]Q^93I:P22@`5LR=2#!143``#[A]O)^V>9PR>JQ-8:].U*=EZQ9X
MB1K]BK\B[B)N$EVB["4B91@N=L]8/V3DB:[5TU73,0Y#E`2B'-(Z;@.`X#@.
M`X#@.`X#@.`X#@?_T(-URSAGL&_8MELB8Q(K0-0H]3F#IJF153A9JQQ[*941
M4(8ARKIQ:JHD]H@83@'H(#_7GHMR6N4\Q)^V6ORFU;S?[0X/\:M1,R\IF;5I
MN46\/2<PJ#I>#HM1@HTH)MHR/B8%HE[TT4TBJNCK+F+Y%3B+\9DA>UG,ASIG
M(HF<R:B9BG34(82G(<H@8IR&*(&*8I@]0$/Z@/*/1_=XB5[,U#HGJ<B\02US
M=5[+UVO%GDS*'):+%E%QIM2J6@6-P@BN_?2[VIZ%&M))T?RN'!HOW^T1$/=F
M<_:>EO<0;8/_`#_V3%8K8K':92HR%2RFNUNTQMPKKR2E*UI478-,A,J=H4R3
M^L0(6;J-IFRHS3!\5HY8'2,`E,!T#*V?E+A9BNGW6="H5:@V#6=DSK*Y/4:8
MRT2DU&8B])L\^XHTP9\E7;1/'HE&LT3`Q]D58*?#1,Y6?BD7RJMDB"F)V_$3
M'!KW7$RF5U'9=(U"D9+2=#L5CK6??D4=>[%/6]>FKQ;6X2["(H]2L9&=?K3F
M801<+NUT%E%C^Q!%;T,(-[DAB0RW3?28"\Z919:;IP.<XP9_V+1GHR0DI&N7
M;.4(F%FXM_4W)HEI)>:>CYQ,S=-^T8J)F(<JQ4Q``%OA<5QB6%SF]OK/6:38
M*VGHD5!'G*?G<NX>,I_4C,O*M,5ZB.?B*0[RVL(Y(7*,<X<-W$@0IB-055*)
M!6Y_"2:G%GZR(9[HM=RG3=BSRF7>0@6[^V12;2Y6TF;VB0=M48S.;<YJ%;F4
M0NIFKH%7B+07+:-.44'"Y5@$@-WLG%S$KN'320K'9BH=5([6Z%:=,L&@H9O/
M&C(J]L(2E3KUQ$-X]26D)RK1I95D]^T,8#QH/!3!N?W@43)@9^W-SAG<0N`Z
MO3SJN:3?KG>Z1F^:YCHYLCD[I8@M4HE8]%%O,/$:M3H&J5J>GY5\:-A57BBC
ME!DV09_K.J!@\?&^/E,<W'>K+O=+_>*1GFIT*:3IT`E88^2187L)704EU8]L
M$3GE#6J*%[L<^T=R`$=-O@)%1(BJJ"AT0(HHMST8J_:\AE\2NIJ3-OG+Y^6*
M8RBGSJ3I.?2+/YAW"1F$A6]2IU)L2#QLJU,!E$FR[,X"'C7.8#E)9=%1\!P'
M`__1H[/KK,9K?J1HU=%$+!0+?6KK!BX*)VX3%5FF4[&"N0HE,=$'K`GN`!`1
M+Z\]-[QR;4[/=>U[Z\FNUG6F'E=`P+3Y60MDTQKK5U.V3"+G,J_:6O.-+B6+
M<[^"0AIAXK]7(JI_!?QQT#D6.8?4V9<Y?*V>YX9EQSKOLN]3Z4!E]#G+`(&5
M-*SQVIXZH5ADV(HJ^EK9;I`&]?K<4P01.=59VX3#]/M*!E!*0=6R>4S6H=EO
M==8:;U9Z_P#7Z_5J0@.L\E#PL)L$NN1*AV3;KA?(^TW_`$TKI=H[(7.F5G39
M-6RRB+@IXJ(*J'F2.039D\V^U^)'UO5V['1=GN/4.8[`9#8:=VHT"D6^ZR\/
M-1SS(H2UZ%>H6W*32TXI5V4GE[2,M"+9Q8&[)DU(D@S`3(*ID2]S)_K/!WQJ
M#X]HVNZM$1^=O[?@CF/RNKHMJ._[!4BD6J7A(!_/LX-*J4Z7F:';[-,QD,ZL
MYY(D2N#J-C&J#ATFDD5,_NMR='39K?="B$;%U]>:'ASRATF9O-TB4M:K;#1\
M_1L%1BY%[//<VF@H]QD&1KA'U\000:_&93J@H%.1191,!6>_9])IE^K;Y>K1
MNV^'UG(@LK#-"T>V0VGPL0NSO&>R[!5N6D9_FS:D257"'81U+0;@S3:1K-DF
MJB3]`*F])9)D.]ZK2E25XM%F-V/K,_BN=6S%[/1['!5R+KT55%WDW732ELA)
MN"SNIU5W#R3&.?U0A'[ITDBV%RY;)+''S?TO/!]N@HM.MF\W2SZ"\TG+JC:G
MFB0LK*/]$GTJFG*6:_2UAFUIF.9,X9ZR-$QLC$J'?@1---J#E`I4S%/Z%7G,
M/+IW?8O5WV^$[,NIYHKKY+JRT`M@^DAR,@L\>L@LS=_0ILR0PH(F;$#P^'QF
M`OZ@'U'U9,STGVF4;M&NT"E2#P+90+=4-[G[%;+=FUCKM5O;!O:H.279#:)>
MI62O/&-+LCHTDH>/?Q9V[H[3U)Y"I@"?&2G4RTH]SQ.Q2$L[E.GNE$TMT]K:
MK2BT/);?7:^6CM8%J#Z.BCT&'7S<%E)]1J#INFQ=S*K%P\<?)3!H]73ORO\`
M2%]LIS4)O1(E/4]"H.B/ZO48VC55YE[5HSH,#2:L^DVT)7*FE&5>J0QX%HJN
MNLW6:(K)."K^7S*&.(\3,XE^V7N4.`X'_]++W/2Y+ZZ\_P`EOS8W\7/WC_/?
MB?Y?[,?EOWGU?E+[_M_Q/^[]-Y?3R?*_Q?\`ER7/9-]-0]FO_J!^(N?Y-?R:
M_;OVI?:??_D7[>?[C>#[_P"@_P"I^?W>OC^;_<_U]O)/T]9JW?;SDYI#@.`X
/#@.`X#@.`X#@.`X#@?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g91036g70l30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g91036g70l30.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-0FAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYP<FEN=&UG<B!F:6QE/"]R9&8Z;&D^"B`@("`\+W)D9CI!
M;'0^"B`@(#PO9&,Z=&ET;&4^"B`@(#QX;7!2:6=H=',Z57-A9V5497)M<SX*
M("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L
M="(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<%)I9VAT<SI5<V%G951E<FUS
M/@H@("`\27!T8S1X;7!#;W)E.D-R96%T;W)#;VYT86-T26YF;PH@("`@27!T
M8S1X;7!#;W)E.D-I061R17AT861R/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE!
M9')#:71Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE!9')296=I;VX](B(*("`@
M($EP=&,T>&UP0V]R93I#:4%D<E!C;V1E/2(B"B`@("!)<'1C-'AM<$-O<F4Z
M0VE!9')#=')Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE496Q7;W)K/2(B"B`@
M("!)<'1C-'AM<$-O<F4Z0VE%;6%I;%=O<FL](B(*("`@($EP=&,T>&UP0V]R
M93I#:55R;%=O<FL](B(O/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@/"]R9&8Z
M4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP
M86-K970@96YD/2)W(C\^_^X`#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("
M`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@#*@)Z`P$1``(1
M`0,1`?_$`*L``0`!!`,!`0`````````````&!`4'"`$""0,*`0$!`0$!````
M`````````````0(#!!````8"`0(!!@H)`P($`P0+`@,$!08'``$($1(3(105
MEA=7,=15E=465M:7"4$B4I.STS1TUU$R(V$S<20E&(&10E-C-389\+%R@M)#
M5$4G*!$!`0$``@("`@("`P$!`0````$1(3%!85$2<0*!D:$BL3)"P='A_]H`
M#`,!``(1`Q$`/P#S<6O+SYXL_P#6';^K4_\`^26__;F?_?YZ$4WIEY^6';YR
M6_S\!Z9>?EAV^<EO\_`>F7GY8=OG);_/P'IEY^6';YR6_P`_`>F7GY8=OG);
M_/P'IEY^6';YR6_S\!Z9>?EAV^<EO\_`>F7GY8=OG);_`#\!Z9>?EAV^<EO\
M_`>F7GY8=OG);_/P'IEY^6';YR6_S\!Z9>?EAV^<EO\`/P'IEY^6';YR6_S\
M!Z9>?EAV^<EO\_`>F7GY8=OG);_/P'IEY^6';YR6_P`_`>F7GY8=OG);_/P'
MIEY^6';YR6_S\!Z9>?EAV^<EO\_`>F7GY8=OG);_`#\!Z9>?EAV^<EO\_`>F
M7GY8=OG);_/P'IEY^6';YR6_S\!Z9>?EAV^<EO\`/P'IEY^6';YR6_S\!Z9>
M?EAV^<EO\_`>F7GY8=OG);_/P'IEY^6';YR6_P`_`>F7GY8=OG);_/P'IEY^
M6';YR6_S\!Z9>?EAV^<EO\_`>F7GY8=OG);_`#\!Z9>?EAV^<EO\_`>F7GY8
M=OG);_/P'IEY^6';YR6_S\!Z9>?EAV^<EO\`/P'IEY^6';YR6_S\!Z9>?EAV
M^<EO\_`>F7GY8=OG);_/P'IEY^6';YR6_P`_`>F7GY8=OG);_/P'IEY^6';Y
MR6_S\!Z9>?EAV^<EO\_`>F7GY8=OG);_`#\!Z9>?EAV^<EO\_`>F7GY8=OG)
M;_/P'IEY^6';YR6_S\!Z9>?EAV^<EO\`/P'IEY^6';YR6_S\!Z9>?EAV^<EO
M\_`>F7GY8=OG);_/P'IEY^6';YR6_P`_`>F7GY8=OG);_/P'IEY^6';YR6_S
M\!Z9>?EAV^<EO\_`>F7GY8=OG);_`#\!Z9>?EAV^<EO\_`>F7GY8=OG);_/P
M'IEY^6';YR6_S\!Z9>?EAV^<EO\`/P'IEY^6';YR6_S\!Z9>?EAV^<EO\_`>
MF7GY8=OG);_/P'IEY^6';YR6_P`_`>F7GY8=OG);_/P'IEY^6';YR6_S\!Z9
M>?EAV^<EO\_`>F7GY8=OG);_`#\!Z9>?EAV^<EO\_`>F7GY8=OG);_/P'IEY
M^6';YR6_S\!Z9>?EAV^<EO\`/P'IEY^6';YR6_S\!Z9>?EAV^<EO\_`>F7GY
M8=OG);_/P'IEY^6';YR6_P`_`>F7GY8=OG);_/P'IEY^6';YR6_S\"3^F'CY
M7=?_`,D=?_Q);\/^O_?^'`AZW^M6?W:G^.9@4V`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!38#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M
M_K5G]VI_CF8%-@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,"4?<?`L"W^M6?W:G^.9@4V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!38#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI
M_CF8%-@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,"4?<?`L"W^M6?W:G^.9@4V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!38#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"4?<?
M`L"W^M6?W:G^.9@4V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!38#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"4?<?`L"W^M6
M?W:G^.9@4V`P&`P&`P&`P)Y&*JM2;,SG(X55]D3*.LNS-/$@B<#E<D8VO9.N
MXX+@[LK0N;T8B0ZZCT88'8->7?36!`M;UOK_`--[#O7P;T(.]A$'>M^70@BU
MO6];\NMZP.<!@,"M-;7(A`D=3VUP(:G`Y4F;W0Y"J*;'!2@\+S],@<#"@HUJ
MA!XY?C@*&(9/B![]![M=0HL"L1MSBXD+E3>W."]*U)-.#JI0HE2Q.UM^SRDN
ME[F>G*,*;T.U1Y97C';`7X@PA[NX6M;"CP&`UK>]ZUK6][WO6M:UKKO>]^36
MM:UY=[WO`GJBJ+72)35RNJK02H22MGG+5-=S(A&20'7<(\U4:R`(+)"'R[&(
M6@ZUY>N-@AQ+<XJ4"MV3MR]0TH#4B=>ZD(E1S6@4.'B^CTZYQ**$C1GK_-S/
M``8,(CO#%V:%V[Z!1X'&A:WO8=;UO8>G777RZZ]>G77Z.O3`YP&!6'-KDF1(
M7)2VN*9M<Q*PMCDH0JR&YS$@,`2O"VKC20)5XD!Q@0'Z)&/9(Q:"/MWO6L"_
MQ*"3.>*EJ.&QIUD1S8F+6.@T!`-(VI(<;YN0H=7-48G;&LI2H_XR=J#BM'&?
MJ`[A>3`M+XQ/<8=US!)&AR87QK-"0XM#PB4-[BB-&46>6%0D5%EG`"<G-`86
M+IVF%#",.]A%K>P^"QK=&XIO/<6MR;R'9'IQ:3U[>K1$.S<(TP@+BUG*B2BW
M)O$>4,&CR=C*V,`@]W4.]:"AP&`P*P3:Y%MY+N8VN!;0I6'MZ9W&A5`:E+@E
M**/5-Z9R$5I$>O3$'@,,)`9LTL`PB$'6A:WL*/`N[#'I#*W=%'XK'WV4O[D,
M1;<PQEF<I`]N!@`",&!"T-"58X*Q@+!L0M%EBWH.M[WY-8%M4)U"10H2*R#T
MJM(><E5)5)1B=2E5)S!$J$RE.<$!R=0G.`(!A8]:&`>MZWK6];U@?+`8#`8#
M`YUK8MA"$.Q"%O00A#K8A"$+>M!"$.M;V(0M[Z:UKR[W@53@WN#2M5-CLWKV
MIS0G"3KFQT1*6YQ0J`=-C3K4"THA6D/!K>NH#`!%KKY=8%)@,!@5"%&L=%J9
MM:T:MS<EJ@I&B;FU*>O<%JQ0(($Z1&A2%G*E2H\8M!`66`0QBWK6M;W@?(TH
MTDTPDXLPDXDP9)Q)P!%'$G%"V`TDXH>@F%&E&!V$01:T((M;UO6MZP.F`P*U
M`V.3J<:G:FUQ=%!*14O.3MB%4X*"4"`D2E>O-(1E'&E(4"8`C#SA:T626'8A
MB"'6]X%#K?7RZ\NM^76]?IP.<!@5B-M<G'SOT:VN#CZ/1'N;AZ/0JEWF#8D[
M/.W-=YJ2;YFW)?$#XIYO:47W:[A:ZZP*/`8#`8#`8#`XT+0M=0[UO7E\NM]=
M>3?3?E_Z;U@<X#`8#`8#`8#`8#`8#`8#`8$H^X^!8%O]:L_NU/\`',P*;`8#
M`8#`8#`FM:15).K*KB#."_T4WS:P83#U[GWZ+VW(91)VIB6+@F;\A8TB9>(S
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M.#5LOM%^C4RB7(UU:WXAD71L^)0^"M:^HWJ2I3!KV<XUP6MY197@K#`F"#O;
M_8;#K.*O"Z'\A(YP3G3Q?QW(1W<(=7<GY!,$@A1-10F]IVU-:EKB22I%L9,D
M$FKYB?WY(U.#H-]2KC#/%/)+"6'6L;<V=";QJCX9*:0X!<:[X>7>')GKEG^8
M#2JF1QU>A3!C5K@5UK$X0O7G.;>X$*XGNR$R1.N+T`LXQ$>(0#"A:[M3>[/0
MU-J:A*S@%>NUN<HVJRO/VCE=%>.,.KROWZ/Q5Z>)+#PKGJ[G1<LD\;DB<;?!
MS#&5$'6BP:VI<!!%L6^W6K=O$^!NCRSBM=/_`"/_`#<UM8.%P5T.M*D?'RQ6
M,$IBAT8LZ8!O"O&M8S^BVZ)I3T=5F(G-.H(:QG>D"W-*$T2P1?\`P[DZ@U_F
M=#\%Z$L!CXS\A7R_D%K[B417VSR#BCU%AU;3,VG<.03)O9$5/@ASU+;#B</3
M/B(AW5@=4SBH'LX24G78$&7;>9T)O17"6D);0E66@X5WR;Y,@GKM,4-LS3BM
M)X6HUQA3,,K5L#1MZI)1$9;9TV7+X\F!(!;/`WD'HC@DD?\`+KJ)?VNYP/*5
MZ;FUGF3JT,KHH>V9IEJUL:'I6TK&!8[M;>^&)&YS6,+AH+@QK%Z0D!IR,_6C
MDI@A%#_6!O-#]-'*.0VJU?F%2DU!^;9!N/D016961PJ0>+2NPA9#&DF.0@YQ
MC:Z$#BY50?\`KH-&F^;J'4#88%;H2@T&Q&:UB=9FC0*Z:7F,X7_F1$MS),:4
M?E_.?C3#6?CPG=8X1`%BZYYA82>(N4O2,25R;W-2VA4$.+4I:EX6\D#H<(OS
M@L1>PI>OP+$FXJ\+Y=R$D?!*#O%^$<A6APF%<QGD&_O\*-J&:7O!FIT4N<35
MU(BC)<AC=>OD@8E;4@=`/RE<69X1YQ8BQ;UEVYO@2"60"F;5X)?EYU77D'LU
MHNBU;_N6L88]R.8PP^,MUCN$VIZ.V:X31.W0](\NT-5*W#0X\E3J25+24`SS
MDU7L6L3=MO0F]B_E=LJ./7G&(E1/,:"2.D8-/9E&^1=MG0D5+WD?5J%2YR5H
M^HK0Q)'RL4TW;FY4=%3]NKF(6PDEK=:$;OI)^PUTDE&\'*%E,!H/D>Y\@@6G
M)8%7TLM6[H0_1--7%$.MIQ-OFD?:D55'0U^E%G-,/8WU`8^'A<T2M3L9H416
MA`"'+MO,Z&0Y4HXO1C@1P97WVV6W:B)!/.9K-#&:FI.PUNE=F,%LQP3Q/W61
M3"+RA>`H*9,DVV,P$)!J@:H8E2@@)/8-SM%6L0UEPPNNYN/Z:5`<T4.D:N7P
MW4]D2ZN=63#KCJ2MW&(IY%/XH8A+BD]J]H5K"2S@F)B3MO*HU+^MXJ8Y-LT:
M$<I)_&I]/6HR-/2:5DQMA=&9=,$#+N/-CVH=+`F\U0MS$U#T$PB.0EDE:5B0
MBWH(!%-^_`UYKI/E@]+7"C8%R)=/RT*VLV122*0TO\L:R9TYR**$(UCTU&5P
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M&BJ^OW8Z:,J)Q0$%M<UE`UA;4<N6K3&\(?-MC)"$LS8\VY;GP*?F)Q@K6E8#
MMZ1T3RQXX3M%/4D;9FB[7!BMBK[@ABI$O-42V&W%`H9'8:SR5G/2$F&MGG2T
ME:E5=Z46_"'O271D#\KV5U3"([SAE\J072GG$3XD3I]1RVH9]'X(]LM?;EM;
MMLB1PYW7QUU=H[9JQS6$[2.X#MI"$'CDC3C&8$87[;Q^1CUZJSB!2$5I=YY1
MI>2%A6'R4A9%[KC*TG,)C2:G*GG<C>4T*=G<<FB<G6VQ9;RVMA[LXDC-:T?Z
MVB]"V,??MMO7@2N6\(ZEXQ'\CIUR2>K`LRL*BMN`TW4C#4SBQP&172]V?7Y=
MPQV3/DED35*B(-&F>JE:58M*3H5BDUP4Z(+$$`.X;=R3L0:/T!Q0MUPN"0TK
M-[1'%X5PEM'D497\N&V;F]5V_7[VR-15<2Z6)XNWQRPH@XHG+3@F7M9"4\U,
M>`LX1)Y8]"6V=_(C%'<7JNLRD*KLJ<6*NK4R<<Z8QQDE$L<5+3J'0^N'FLRY
MHOEAZ9<G3;*?4CD+905"A:!`64+6S0:"$1F6W+GH9LY.<+H#`V<ADB5$\L**
MLAPMR&5M5[E<+S&[<I7D`TS%]''2'UCMBN(4RP^$OZ09R5P"D$O6IUB,\19'
M<:#?;):-BY-^4XV%+;+IYCI+E\QS.NXC-')AY9S,Z#@X[V9-J_8%CZYLNZ]1
MLY,CA=?3,]J4H(\\;>5RP1PTQJDGL.V`,^WG@:CJ:;X=T(.@8#?_`+?7NX[8
M@54W!+)U6\DA;3!:(;+7\T?H$S?4)]B[DZVBX,["<G6OW5V:M;`=LI&+1@>N
M7;>NAC#\S+8M?F!\P-A`(8_;9(NPL/\`N,%YFUZ`$/7R=3-].G_CE_7_`*C8
M=?Q?X75S>,)X56LZ<@#K]DNZ]B<WO>*R"$)JJJZW[1:&9Q88LBJE?&53]-H9
M&%\F0(G=Q&^(EAH]G&)RP!!H.IMLV="#./''C;QYHECM#DVUW5.;$WR+Y%<?
M':L:JF,3A#`L5T@OCJ%=*-S)_B4H7-29L&N.#I(!*>8YG*R-^(D+3G>*VV\#
M6_F/2,6X_P![OL`K]Y?GN".4/K:R((LEY:`,I2Q:U8"PSUF:)1MH`0VJ7IB+
M?-I%!R<!92C9.C`@!W=NK+L'K=&#^.VY3^1F.NH1:['+72;1]7&G.4R^%NC0
M3&4?*&0(IHCER5DA[2XODD<)6`1S0K)/((1-7:G.*..UXN9YY&GMA5!Q*M=N
MYRJ:>3WRW6KQG;9U="J?3B2PU;`[<:6NWT$2G#4DKIJC2-YK[?G<J`>R"V\.
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M]N^N!JY=G"05>5\>1#G%TEMRUKS$F/#ZXV8@\A2PK)`]:3.?'V90]M*;T[HU
M,UB-12U,<4I4*Q:7I^T(B_\`;NR\C9N/?ES5\YR_DS((1".0_)FM>.UHQ7CJ
MSU_3#S$FZ=67<".)$N-N3%TFSA''%KAM1Q*0)%)*/P&Q:O5B4I2?$\AANY]O
M[$_:^*0.+;WR/=FR/V9"H?=7Y5/*"=M%>W,6S:M:M'9AD</CDO@TP51XI,SO
M@6]<G)5MKD00FTO;5I(QE`,"/K-W^QJNOHGA;1SM35,<C!\@GZWK4@=9SB>V
M%64HAC#!*%+N9L0O,):$L'?X>].]GK(XR.R18^C$XMX!A,$6DUWAR[;S.A?'
M'B!QZXZU;>LWY1J[8G,PI7F4^<6V:$5!(XW"FJRRD$`2S!&_J)!)HM*%L00!
M0FC<#C@$K#AEC)2`*",0U`6VWCK!>H=P@XYV3.*CG,<F%O1WC#>'&SDS<2`#
MKJ+O=M5;.N,[8M#.X2Z*4B!#'IVV-KD20J1GED-QKDC4!+$(@S6S-MO\B)#K
M+\O\WC2@Y;IH;RM(C3+<JN@'2E%5HUL>\SF3*80DG[).O:FGKHI)"&=)'BU>
ME[82RN)AR[9!1!Y903#AMNYP,J,_Y;,.D]WVH;!&J][,HV`<=Z$Y%L-90GZJ
MJ>04R'R,:&];!ZG*D"AN#$6XQE/&N4.[]Z/-"2V(-[+3#/,UO'V_L2PK\L"%
MO-J\8S)#$.0_&RL[Y7WG#YM7-O+(P_VC64OJ2J'ZRFN0QR3-+&V-TYKV5-R`
M!Q6S6Y&N"8B5I!""(19H'VHU-/JSAG/^.]EWG6,=Y'L;;QPL&E6BU&N83^OW
M-SN*L;9>'N/&OD+$VP9$AJV>$K&,1A211Z:;TY2@(1#4"`(67G<$P_-LU3Y/
M*CS&LXO-XX]IJMI$Z9&R1\C3C'G%*X4=6*R$ZBS6Q1]F5-"Y!'S/#>3%1JD*
M]QV(\C1!>_#R?IN#R_S08#`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI_CF8
M%-@,!@,!@,!@=RC3B#2CTYQJ90G-*4)E*<P12A,H(,":0H(-!O0RCR#0:&`6
MO*$6M;UY=8'HM*^5/%2_'='9_*?C+9DDOCT:S(YU*Z1NIHK*%7>X,*%*UII-
M847>8'*'",2EW;4)1;JL8%9/GI@1'Z+*,%Y)EG70L+CSR?Y%.+ZED@K]I1,=
MH<3'[B%65>1%T.:8G1U;GG1O<10,05Z1Q5O:&-D,1HU`3-D'N*Q8:>(PKKHO
M3,_L0ZH.8TFI"IZRA,&CQ)4UJOEXW\KF"8N#AH]H5*$%=I("*#N,<+2E*343
MB008)2I"L#L2<\102PBZ&8LV_P`"2SOD;Q=*BUPBHCBU((%9=[-JIDD,@L>S
M6:SXC4+,\OZ:229-0<>^H3$Z,;NZK$@$J5V=%BE>U-^QE)]]1['C+O/0RN#G
MA1KM:,:Y7S;C'(I)S)BZ:-N7UE36T2U4#+[/AC*D98M<4NK0N''2S4E2;:T:
MY6V(GLEM7.";1HM@[Q:R9>O`P$HM6R^3$`X_\:X7$W1]N>.W;?MI-TI)DK.W
M+)U,[N7QB5F%HB';T,VQUQ8W"'GJ-*#G#99XS@Z!HO8-:'<R[X&;OS-+X*G=
M_P`/BC&*)&AI%C9U\_40E8%PADJY1S3;-..24R;EJ4XU,Y`<[!(+;3#R![*'
MIJWX6^SMR?K,@L%M<W:]GLQY@3B)TE)H8[\S*=W!["3.=HI96WL=@K+'BTY=
MIK&^D*8U!$9/118M&2T&;$<4:9L[:O>O^+$G$]"]*N;5`R^71/D';7%MXL+E
M7$(K%V0]V46>@(X]63*(+&4\2A]C6?5*Z%N,@<7A&V-R(QP:TCN2UNJA&$1F
MBPF##C+UX$)J3DYQNC"6K9387'VRTMX5`O/6MUE<;[E:J(2VIH$L4S!I]K;6
M3`Y`X>E6U6K&@&X-*H@Y2U!+($`.B@=%E_@:I7%:CO=-RV1=,@;&IH>[,L*0
M6&ZLS&`TIG;5L@>CG@UM;M'B,/$F3>+X>C#-[,-WK9@^HA;S4F3!OY=O,'@[
MR`N257S9/"^Z'F=3-R9GB1-2?E>C982ZK61E:&,A$<U-U-[=4;,M1LQ05!9"
MS1PM"'VC#L7DS)^TF:,8SOG].[%0\FW-ZC:1HL/D%=G'2XV*11I?I$Q5;_[<
M/3A$-C#0Q*D:E4[I4K<L0$$'F*21`\QV,P)FS>@'U_H9)%SPHUJM&2<L(5QC
MD4<YE2=/(W/4E4VT2ZT#$K1F3,K9I1<<2K,R'E2W<E5B<UBY*V+'LUM1."G9
MH=C[`ZQEZ\#!$=Y9-[!QXIFL2H._DW%QMNF27/1MR-LX)3,S0[3"40B4OR6:
M5\HC2H<H."LA0`ICBG1'H'C=1@%VB".YSZ$RL?D]Q?E(+8GL5XJR-IO*Z&>5
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M)^!Q*`3%7J@S90L;$AK`-$8-UVZN+^4;H?G)(20IQ!$`SQ.H5FT;`3KEWQK?
M'BW+BA_$]R8^1]VL<Q02)PEEDM4WH:OY-9!0BI_8=75DK@Z1])D[D-6L.:RG
M1T5)F-2KV81WB++R9>O`TOGTBK)[8ZN05]6RZ!/,8@:=CL]Z63%SE(+-G1:]
M0>?.4:!P``F')ST!A9&FU-L1`=E]_78M[WO0SY7?*F/PNI*/J>24M&+38ZGY
M$6-=DC9)TM+61"Q6"QJ_CE?N$%6LP6LU0SK&]*R&*TSH$X\1"L9)@".XC]>6
M;1,YWRIIEJXZ61QOXYU9<<2BEPRB`R6:'7?=B&U4,5+KQT6/;0S55&V6&1)K
MCYS@XJ0`7.ZG9[@I1D`)%KR[%J9=VC!%%7D53#!R,9#(T;(MWWQ[D]%E*2W4
M#9J+FR.40^1ZDQI0T*S;N4CU%=D[2!$G$/9^A>+KL[16S1GAEY0\>9U`*9C?
M*KCU.[5EO'N+$5[`I76]P)*V23BL6MY6/L9KNW6ITADK.5M\:4N2E*0XLYZ)
M<-O.\$6NX.C-LLZ%_5<\FRWG'D(S<K:L7V#6/("RHG;I;'5$P)KF5TW.8''A
M0:(GUFZO;'*V14PI*XT4PJD#DC,"I2IRS=#`;H7=/KG0^,;YJU;#[*3E1?CB
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M`:K6*7-N:UKT<V-CH<$X'B:)+#DR];P*-)RTX^S1EIJ0<B..$QL^[:&A</KR
M,RF+V\DA%?VC$ZV,U[-T=UQ4Z%/CZN5QA$`"-2>S.*(UW1E!+.$7\(67QT-9
M.3UQE<B^0=R7F5'SXB3;$V<Y>7&C'0#NH80N)*8G2`3N4C;@+C"/-^NC0D$]
M>O\`MUTRR9,&YQ7.FB7ZQ(/R<L_C%(YIRZ@3=##`2)%;A3)1%A3VMV=`S06T
MK%K@4/6RH4A0%LK>H7H&YY3H'-4CT,?AZ&(.IEG$Z&K%K\D7>WJ*@U4R5J4'
MRR.W=?\`=LFL`UQ*,+E;U?(XLJ<TP&("(H;8-L<8^<;LSSDT)VE.@A`7X?45
MSG1:>35Y%<A[+;;")C)T3`WU73U;;:3W4MY&:95==L$#->-+"T+<$!;X8R;5
M!(\/>TX3-%[&9L/?M)@V&@7-.#19CX/*'NF']WLGA'8"5XCDK:[+):XU-J[%
M:;I:SK%'6'*8>X&MLI4NSEI.0[`7FDDDE]1)1[%T#,[]C"T!Y%IX3OF%XL0/
M<P\JZJGU:$Z+>RT>X0*<69'+"],'BVVJ/3P&XM@VDV2#S01@C=&:&'0>S=SH
M;"K.9G'^<O45N:[.,TJLGDE$XI%8ZO5!N`MKX]6P\0.-I8I#YI;-6J(@X2%6
MO*:&Q#Z6;6UW3-[T:DZF:*"<8')EZEX&D58VK+JCMJ$75##6]'-H!.6JP&+8
MT0=,^GAK=0NFD)S82(L&F17KO3&)P"#K24P0`[UY-ZUV-_(QS1XFUE([=L2J
M.(4Y8;%O"L;@KV0?62]4+_!*Q%;T;=6QY4U"PIZ\;W8M'MX<`&""\+%9I+8`
MQ&GV7XNS@YRWR,>L/*GC_+8A3!/)B@+$M"QJ`A4?K:)2"`7457,1LNO86N4+
M8+$[FC2R&R5>H!'"%8V\:YE5HU2YKT`DW6A@T9C+X%+QHYSJN/UD7?/%E2Q*
M3L]N&I)@R5TRFZB4*K2X(5,!3FE9U%VLM(Y%A;:I>SSBD[?T#M2B-V4(W7EV
M)9L$"I#D=$8S75CT?R!@TOM>H[)F[!:YRN"SX%>VC"[;8$3HT"G$8D3BR29C
M<@21A>E")V;W%&:2I#X1H!EF%:V*V>9V)V5R]K2+.UEH*LH#4*KV6\1;'XKL
M3>MF93[8*Y78SFW.[G;ML3C<=1%3J4^=H]E:1IT:!*F0A)3)Q``5L0V7_(DB
M'E_QXF>ZBGO(KC1+K/O:D8C"(4S2**6\C@];6PS5:22EK0=T1!1"7U[/<(^@
M2)TBTYG<$OI=,G"$[0.N^DR^.AG9NY#UQ87""XIORIABRU7&[?S&72<25NKN
M<-U;V'$'ESI`AU)F,`-<F:6-H&=(8`QG&C<$"A$<B-\/Q`'E%F:F<\?`PD'G
MK&X_*H@W5Y32^+T75?&?D!QVJZNU\["]RPI=R&8WA+-+7G<S''TR-_E3G(70
M"Q2E2H$B4*9,6F($7K6S-W+_`"-607<6'B0;Q>^K9NSS.0Y-[_77TH#P-%%5
M>;7'U8]!>8^+LT0S///._.NW0=>'X77]?+G.C:`SGDQ/LK>TDYJ!RD5*6'Q<
MH'C5:5?-M@#CTK7'\?6EH!#K3@LW3,)Y,:E;9)&K:U*F4H5B7:90<E/V:$?B
M:9_8^4'YDTG2UKT[*Z1X[/C1#*H07$)S5SZQ&Z4W7:#_`&Y7KY`-*I98#?$&
MID:XO"4;H6-K94+;X`1:4#&9LY1L8)ESD:PU_=1,'XW<C./XXX:YF7XKI%27
M*@.@$A<6U3\E?9`8`UH$B/&[;D&GG10=A4$>;;+[MZ,[NFK9MT37EIR%AG)J
M6Q*RFNM'NOK$#!(;$+06*9V5*XQ+5L`A,3@<;=HDQ_5EC5PU/Z(C(AJDYRIQ
MV::?K>AA\/>S$EG`U1RA@,!@,!@,!@,!@,!@,!@,"4?<?`L"W^M6?W:G^.9@
M4V`P&`P&`P&`P&!]RTJLXA0J)2*SDB/905BLE*>:D1B/WVD!5JBRQ$)1'B\@
M-&"#L>_)KK@?#`8#`ZB"$6MA%K0@[^'6]:WK?_CK>!R$.@ZT$.M!"'6M:"'6
MM:UK7DUK6M>36M8'?19FP;-T69LH(M`$;HL>R@F;UL02Q&]OAZ,$'6]Z#UZ[
MUKK@=<#DK0E'72<(C]ZT/>]$!$=O6BNOBBWHO0MZ"5H.^[?P!UKR],#C`8#`
M[#+,+WH)I9A0MA"/032QEBV`>NX`]!&$.]@&'?4._@WKRZP.N`P&`P&`P&`P
M&`P&`P&`P&!V&`PH8BS2S"C`;Z#+-`,HP&_AZ#+,T$8-]-_!O6L#K@,!@=M@
M,T`)FRS-%#$((#=ECT48('3O"`S8=`&('=KNUK>]ZZZZX'7`^A))ZDXI,F(/
M5*5!@2DZ9*2:I4J#1_["B$Y(!G'&B_0$(=BW_I@?;:%?HM4=M`OT0@.`F7G[
M1*M$(%)F]A`F7';*\-$I&+6]!+-V`>]ZZ:UUP*7`8'`=Z&/P@?KFZV#7A@_7
M,ZF?]L/AAZCV(S_Z==.N_P!&!V$$0!"`,(@##O81@&$0!@$'?001@%K0@"#O
M73>MZUO6\#C`8#`8#`8#`Z]@._Q.T/?V]G?VZ[^SKW=O=TZ]O7R]/@ZX';`8
M';PS.SQ?#,\+O\/Q?#'X7B=.[P_%[?#\3M\O;UZ]/+TZ8'7`ZZ$'8A`T(.QA
MT'8@ZWKN#H77MV(/PZT+IY/]<#M@,!@,!@,!@,!@,!@,!@,!@,"4?<?`L"W^
MM6?W:G^.9@4V`P&`P&`P&!>8W'G>722.Q*/I?/G^5O[+&&)%W^'I6]2%S2L[
M4F$9T%X83UZTL.Q=-]NM]>GDP/4,/#+BC(+LD7"J#W%=+ARS85$JA[5/GB-0
M=+QMFUU0MI<G![JYK:TZKVE,32K<V=2U(7Y0><$U:5H0TNBQ@[L[<WP))<LH
MJZ&?E2<9H?7$JY!1M=:]CW<HF454DP5L@]@S:%2.KBYP5:@69>)V>&*%+2@:
MA6PA-/#H.]K0E"T'$_[#3[C[1%7R2K+7Y&\@I7.HY2]52.%U\E8*L;&)=9-F
MVC/D[JYL\1CR^5"U%XRV-$>9%+BYN*PM3L!&@`))&,7DMMZG8V7@7`RF[ILO
MC`OJFV)\CX[\G4UZM0'F=,4>+M*G;%HB$/$LD\/F2=AVJC,E;A$$H5J9P0%D
M[6-J@S6BBSP:WN6V3V,7+N-W'FUJ'F]E<5)3>;O,ZCLJE*ZE;'<K-`VQFLA-
M>T@<H7#Y;`0PU0J7Q+89:W@"<U.9R\XM&I`+QQ&!'EV[R)#9?'?A!74OL_CN
M[7Y<+)?E3M\J:W>VI)&(<3QFD%MPMO//>ZT;V=`(^TF9H6/24YG0/IYAP3%P
M-#,2A)$'JV]^!1`XZ\2:A8J18.4]CWXTVS?->0VU3-5#'8`N@U#0>S!&F5^M
ML`J5*12&>/2UI"!S<D32)#YDC,T``S3>WNFV]9@V$#Q]9:;XXW;QMO\`DZAF
MC<2_-8H&N+`L&'$)A'HXFZTK8):>>L)#R0I)T@-9'1*Z[)4!'L"<0@;ZCUUQ
MNW9\#4XOB"Q0![YH_P#N%D,QC<,XA/C1`UJN!(F0Z23^P)G808W"&2.!DO:T
M]CU`VYUD>A"$'_RJ4O?>$`]BR[UG='H9;E=5"?S88XYQSEMLU-(]?E_/TIEK
M@;$JG3,ZJ()N&25_9&QJ0HTCN08_6)']*")>H.3`,*5*!F-Y^A]#M9YSGY&B
M#7Q\XG5+!J$WRJGE]-EB<B*[CELMB2F&.`JXC2E839Q7ML'D4^U,337V;NKL
MC;3'-0W-?F0DK?T#HPPX0.^[;T--GZ/0J*VFY193-R)O6[#/!LJJQH*0,HJ3
MP1(^!3*9A%$CV1L9)Z^/Z$J3$*B]]AV]%C[M:WO>AN++>%3!`KCYF1*831[W
M4G%NI7FU62>-21MVXV.WS4J-$\;$"?QBS&HH5J+)NVB4C)#OPTY2O9/39>MA
MSMLF=T;#S#BA%;)L"S7J_>0\V;F"B>"G#N[%DV^I\:=7<,5E3!!&@5=-D<9$
M+&E=3X_'73;9'-C&2>J7^;;<%0P[.,VWX\T:6<@:4JF&474G(.GWVQE\2N2S
MN0T3CS!9R>+DR)HC%-J80E85SP9%`^CA2!\%)SQ+0$F#3%>&7HK?^[K=YP;E
MLOY<->EV??\`'3W:]+<;Z-JGC98*"HJ.:H0LY!64??4$894^N+"A?RQM14+K
M-4[;`N-2H'!>(HU/K1?=L0]S[<#&D-X+0"UK[F$4JZ2WZ]536M)D7;9\344J
MZ&<K(:X#="H_NA":TVC;6>1VBMD"M,!.Y)?_`$0+><-6/>])S"]MLG/8R<O_
M`"RV*22+CD\L8^0W'2L[GNM50\V:>75?M42L>`RPJ)+YO'W2,+TY48B4^8+%
M:FI0WM1O:B\T?0!2J=B",(L?;L:W\K^.=-TW%"5\:9^6--V6@FI487TWRTKM
MK:'691<YN7J=V57,YA+.CAJQO:UR,M.N;3333M:5EFICCRPB%NRT8EXQU94E
MF.\S':SW;*SZM,C6KA]04##-S*ZKD?W5V`WG-44\];G*.QMFBZ'N7.K@N*-V
M$G8"R"C#!_JKO@;UJ_RU8.JY`4#!2'N^*^AEZ\?['O1%6%HQ2&M7)U*]UDL>
M6\^DF)J.7,D+=9W/SVXDQC.5!1ATF/$,XC8@:"*?;@:>\K*4J*IDT+4P`CD9
M7DO=U\B:YS0?*>OP12SX64T`;S668M4D961FB4NA\HTK-(#HDLM:B5)A:,"(
ML8!Y9;>PXPTQ3%DL4M?+&%R&L27-C^RL$0X_<5X*1*+3D#>O0*U[O8C^_OC(
M]1J-0AC.(*0EEZ(/7+5QW0(2R@"'M;?`H.;/&Q!Q6NXBMV=QF"UC?ZTKBU&-
M'8C,@C]B1ENL5B]+?4V?-;2<>U$2Z*+23T:W:;821#+ZZ"'?4.DNS1FQKXZ\
M.X!6G%"<WW8?(A<]\I84J?B8I3S#782JZ\SLZ0U\HE;N]3+8M/;&+3>G$F:4
MI&UQQI2L9BHH&DY8YMMN"I=^%5742JY)R[DY/;"65?1/(E9QCAK9333&$]A7
M-8I+4KE9JM,LFAZN-PF-L,)`F7.)QI2XSSA4%.3K8M:V-MO0O#9P3JVP)%7Z
MBIK,GSK`>2M!7G8'&`4J98TV30R\Z'TH/E%`VFD;SE;.>L4%-B@M&XM(R=+!
MGIA%EZUO>AM^>QC>A>$"B]H=QI"W2AR8[/Y27;8L3A3*>U@7L;)2--18EULZ
MV'-O2@W(G=Q22`P]`V(4P@!6FMYY6M^)O6PK<OJ#,EK<!(^T4]8=O5A`.:U;
MGT.X0YVEJ3EM3B&!L-H05ZES=%E,PK9X94",IA?6%R7IE2R.N(U:GT8<(T"@
M0R#0XG[?(P=^:)K1?YA?+S19?D!;2KL*+UH/7I&H[O0`:\@===_!^C+^O4&R
M/'K@'1/(#4.K^&N/+>9S670`<B=.1\-JQG(X@5Y.?JBNE!T%>G&1-B:5/[:P
M+$FFAP="%R;9CD+HF($#IO)?VL&"62@>)U?<>N-M]<B9S?RU5R#W:R,JO*5:
M:^`LCP:SL4^&KY>?)IOH23;(2BV0(#<%,<M7K##.AR8DK]=MW()M*."]647,
M>5SYR`L>?N%'<:K'@-6QPRJV./IK/N>8VQ'-SJ$-*#ZUF*8K"B&N":VO>U2D
M*KPQA\-.4+8O(W>NQ4\LFFH&S@)PF.H^43&30-XO#EJ\)B;$9V=GGD3<U!-2
MIW2'RGZNJU<>=ES0H2=Y*]#LI.M1GDF>"2/8RPINW1">+/"HFUZ8?^1,YA/)
MBRX0FL<53Q*N.*%?I)G8\ADB%@2R23R:1O;PWNT?@\'C*!R2$`-.2J%+FX*?
M`)T6$HPS%N<>1O\`\;>-];<-+\N]ZE#WR28W!;P"M'D-0TDU`XE!K9KZOW%D
M/8YX.3QN7+"E</Y'5X\HS6]K$FZ-2@`S%`C"BSBM9+=F>Q:K`C\2Y`<5^"O'
M7C[9?)`A_P"7]W7@Z+16B"")8W8LB36\S*K$LCD7]47%6Z2-^A.D6UD>$D\Y
M$8G)'H_99NP8ZMM&N-H?EU,I557-*ZFK_F[$I)03#N7NCIR<I1'`*[N^'H'Y
MOCT@<ZT<&]$F5PR2(-N('-*RNQZX]8U`,WHT)Q1F@V?M\X(1.^,/"RIY\^<8
MK0OJWHMR(BS$)/,;>'&H>HXN0^U]Q4J2^SAR:D^U-J.$?1+U!;.ID*<>M!7B
MV8%)LD.^C;>9T,QN\-XXG\6?RO%-=K;@BEP3*^IBSL$V,C-5:*U*";KJ9LL%
MTE;BG&J<G=NA+HM\2#A&4JT,C6PN!9>A"!N<[1K?RAXYA)9>0MSL\[E-DV17
MO.RTJ"N9&]-[$E5N)TD=)"Z5=9:5+'V]`4G4V*\L;JC7$@+"E+<@!`G`6`00
M;LO7X&:&G\MZ.@G]^)#3>05M0OC`34D`L2,<>X$WSBVYOR+G<8`]36"PL@*!
M2Q1>OJU7D+"7%\<B5@RMIP%!+--/!L+[?Y&LW,OB69QLW4,Q8VRWF.NKSC,B
M>XQ&+]A08#<D&?H8^`89?#)RRD%$-J\:,U6D6-SJC+)3.2!8`82P""+K9=$L
MXQ\<:'M"%1UTE2'EM=%BRN6NS"NK;B-7#4^;IR.-ZEN1-TLM&4S!E<698NE(
MUAJE`V(A$A+0IA&*%)8AA#J6V?`RBZ<%:'J17S@7WU<-EZC/#N\:UJMI(K*+
MQ<R46^18Z.3+6IO1D294)HBTC&2V)C#E)IRA$C(+5C\(_>B0;;;F#K7W!6DK
MTL?B8ZT_9EF(./G)V:VC6+V?8#1%2[7IFRJIA2R:/4>>E#+H4+E+0Z,PDB]"
MX)RD_>C&:`PH!H-;QMDY[&+S./\`Q6MFO+R,XOV!>SE:O'>MY!;SJEM^/0)N
MA5UUQ"%B!'/'^O28DK-?X,Y,J5>%S2MSJ:O,5-^MA$8`[0^QM\]#.+[^7U09
M5LUOQPC=Y6"MNNQH97-R/3PY12/EU72=)JZC#:UH.\Z7EJ4<BE<Z1M*):H96
MYK))2Z1[1A5*!'*!;+GVO?@8&=J'XLVU4MX3GB9,[[-EO'**)+'ET1OAE@1*
M>S*GW(6R+/,[@CA`AZ%%72.N#TD4JF=T"HWM$HUV*-F@$'+MEY&P]7<`*'N-
MI<XM7+KRVETD;J@D-A"Y1(*J:6OAJ;,HW7RB=.$&2J'YK0396R:7I3&(IWTM
M"<H<@]Y:79.]=7VP:]LE#<5JOK"A91RLFM^)YGR5AA-H19AHYE@)[35-4.DB
M=(S&II/5,Y$);+W:0*&94N+:6O2392`K]8_9PP:W>=XZ@V.9H5QLBG`:SF>S
M[/F-@53!OS&U2.%2:@V5C)D-S=_'\E,R'LZNP#0-4':1,YQJY>:K(7&$FD>:
ME%F#,";J;=]X-%.6E&1"C9M`?9K)9)*:PN.E*ZOFMUDV0-K;-FV+V&G<M%QV
M8IV08V8Q^8G-F4DF'I.U.>#0!@#KKO++OY&Z<TJ>@Y_P,X%1JJFNT3;ZMN[K
M;KZ&KG9AK=O9Y#8;K+*@8)FV3U_:U!DF.@C`K>=?5,16CE0"C#=K"RNO3<F_
M:[T(L3Q!XGSRT)YQ/IJV[P>N3\&16$C8IC+(W`D5`V]8=4M#R[S*`Q=L:U9L
M_B)"\,=7D,KHN4+"U1J?6S"@A,+[FWNY@\KRQ^(``]:V'O"$7:+700>[6M]!
M:_0+77RYH=\!@,!@,!@,!@,!@,!@,!@2C[CX%@6_UJS^[4_QS,"FP&`P&`P&
M`P+S')`[Q*1QZ61]5YB_Q5_99.Q+>WQ/,WJ/N:5W:E6R][UHP)"]&6+8>NN[
M6NGZ<#U!US3XKL-U2'FC!Z3N-LY;/RB42YOASM,(4LXV0JYIHTN3<_6FRGDM
MNK*>D*=Q=U3H@8502BB5IN@B4[+`#MSES/`TTGMYMTSXR\=:'`RNI#[2DTON
M6/4H5J49C=)`W(\Q%U1E($Q(O/$ZIIW'#=*1&ZT$P1P=@\FMY<YT2WC]?-91
M>KK6X[<@(?-Y52EK2*&3\AXJYY9&FRZTM"!$.K:RS",D2DA1%I$@=&![4MSD
MW+=D:-($`91P!A\JR[L&QT.YW5+45@<;FFI*ML%-Q\XV-=^J43?+Y!&EUMV;
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M>QE\="QVERZDG)R"7E7#Q!5ZZU^3?,F"WPV%1DPM0Q-Y+;`Y#5K!6#.WGC],
MKE^BY`A2H3.G0TM/^OT,'TRYGXP9@_,8LF2IJQXW\?INR$1B\C*ZA-J\NDP%
M7G#VNM5I@J6H*>03DH)@P(YI':1CJ=:Y(]BV).N?!]__`"['O)^OS.A:EG.6
MFS;>A%[H*QM-'/2^)<GXU6:TJY/#W&'KW`7'PJC(7*H$`EM;'IN0%BT->ZD.
M)QYNP["!/^L'?>R_Y$(;.1?%.S8;08^5%87E(;*XX5[&:G:3:AE,#:H1==<0
M-R7.,$CEDAEK:>_Q!:TIEPVQ6O:?/!K&[X"RS=`[&6==#2*QI:GG\^FTW2Q2
M,05%+Y0]R!'"(8W%-40B"%T7'*4<9C;:2644E9F5(,"<D.@AV()?=O6MBWFA
MMQ;_`#*)M#B;6U!D0Y:TV,V(H!%[BM$YP3GE6=`:*)G*&@(]I(6+ST@R'-L\
M-+6B._54#;D0@[WX>NS,G.^!+9]S;BLP:^0#>F@DE1"N7A[Q@XSMABE>T#"R
M/M!+X$L=Y0XZ*-WL]ED(8@;I(45U4%[.!XFM=!='UZ_(B,'O7C;)>,\#X_\`
M)*$WBX'4K8EF3ZM'FE9'!&A+*&^UT\;-E,'GNIJV+E#&3MVC!(T[NW`6*"2#
M1ATGV(.NYEW8,I6#R_XR7G>%H6+9U,6Q`&R9QRC45<SFDIHT(KIHUVJ&NV:"
MNC3'%D@4%1^3P29%M@?&*4G)G`L"=.;HW1O>'3+)P)D^_F0Q=RL!F;%$:O*7
M4AKC*MXM3N43"T6]-RLGK`IFV[#:;-.LMD0Z9VR;024$IM,B(SSQ)IO*-3*#
MQZ4#$!]>/8PY(.2/%UO<JKCC/4=U7[6L<F3Y*[7<.4=IFJI_8+>\QM3%VZ(1
M%OAKDLAU?MT("M,=F];VK5JI["6,[8$P=DB9?Y%RMKEE46^+LKXNTRHY1SN.
M3F?0.<#=N54VATE3U*G@(G<U.QU`PQ,*PMM7R4;IHAU<AJ$H#T9`2PI=;'L6
MDEW:(/Q0Y)UO4=:W]3]EDW;'&:\-UVK#:7'"0QV.VQ'MUZX/*X</4&24:)&Z
MP&8;=];7I0K"!>,F+$()NO(%9;S!F.9\M^'<V:^.<7?>/]UR"%TU7EOTXZH)
M+9D=<9LG8)U*39K%+OA$^3-R(1=[L<L6*%JA*N0:8`EG"3$]P.TT#+_(QOR3
MY60"P./]=\:ZS4\@YU&(-9KQ:`++Y2RN-2>PFP;E%RXL17<#11@2Y)%H`47H
M2Y44-<>)4O[1A*)"'IM)YHYH;D[3\9XRR?C9;!/(V((W"WQ6^3-^,$OB<5D$
M[`.((XH&N+/#*=%%K8PU;2"6-AY8E04BE28+:4>]=1K.=$%YG7_5_(Z55),*
MVA<YK\<,HFOZ<D47F#\T2I`B#6!"ICBQT8DJ(A&[OQ"J.#+$O5.2=,H-6]VP
ME!!Y=V2SL1.T;Y:+`A?$"+HX^ZMRCC36RJ#/JI6H1&$2A6HMR261I>RA(&(Q
M*E"A?`)=A4:"/QBQ;Z=G3>TG-&T\TYLTK><DY/Q2]:[M0NC;VY$#Y,0!;6[U
M$"K<IVP]QX416?\`E9(4?#9:QR:+[`E<$@ST^RS""SB3-CU^K,LZ[&*+`YA(
M&V9\5=<<(M(J^K'ABXB?*B13EY;7Z=RF6O$X33R=S:PE[&C1,0'&;.*,I*8@
M1%B2)6\O1(1CT+>M63Y\B:33GLA1<OJDY"4;61L&JRBV3ZHUW2S\]Z-T7"Y,
M9+7&UV-P?&;6](U,\>;%?1A5I]",2`.3;UH0B-!R9QE$<LV_^-@*\EL:IUFY
M72F2V`X1P1CCR5N!')6"H(VS/J9_<F.NV>(+RBYF^/OFH&\;N_`#HEOT+M2^
M.9LS22[S@P1RYNALY)\DKMO-D9'&+M5K2]1)F]@>#TJQS9R#FEM;=)5RA`/:
M0\X(T.Q]2Q=O06M=>N63)@],67\R#C63?=.<F9#`>5;C+8&P0V*#H]!9\-0\
M<JU1L-?EULZ/]31X)`71P-]$[/7M[,M`V(].B@1JE08'7:+/UN8/.R\;OAUA
MTUQTIF&,,K;6SCZ=?R)(^2Q0RF+Y(QVM:IDZC!AZ=E$).D=VEET6G<=!Z$#5
M]VR.I73>:DYT;6SCG535VSOE$R7/65F^P'DC**CL5L+@C_%TUN5)9]0P%N@3
M7+673V6HA<F;WYG`L2.#>I&3H:4XL19H#0;UN3]<G'8P=R.Y"4;.J%H+CU1%
M;6'"XQ1<RMV2G2>RI#''V36&=9X(B8:_O94:2HFQG>]*X\:`2-,`21,C"F*+
M-.&$PS=DO=%50?)N`1^D'GC?=^KW:H$799EP0"?\<)HUQ:Q8;+W..)8K+&-V
M9Y$>DCDSA<K:FQ&;LDY0G4(%R71Q(A:,&'%GF"1D\PJTC]BVZ\0RMI^C@DOX
M=6-Q5B)4OGQLWL=P=YP@1DFVS9\D=U'HU2\.CF6:H6H6@HA&F)\(E.`6P",&
MR_SHCD0YI.%;,'`TR"1DX$WX73&VY:>L?%1(HY.0V7/4$I]"%%(1Z<T*$;"2
MI;EHQ]#.JCO*Z]N,[^*)'9O(_C<*%V,73C)RS<IY9I)*5L1W[<Z63UU0R4Y[
M2OCH=7R.,K$[K83YH";T<WJG\!!*1"8,1A!YV^N)+Y$XE_+7A]85DO/*J<\>
M;)D_)F1LHU<DJ]Y?("Y<2Y%;1D4!%S+1=V]8U&V`I9CE987DR,"`)*-R#V^=
M>#DS]NO`Q=$N4M6HJ+XN026P6Q55F<4;W=K0ALBC;]%4\#E$6F5FPJP)HRR9
MB<6T3\FD)*>);3-1B-26D`8;H1^A`_5#<NB:4[SJB->\G.35OR^K7.?5/R&F
MKO9`ZM5.3>2L:YS';C37?2KVX*S!>CCS(=*47FR_PM[V>A6*@%]VA]HI9Q(,
M?T7RU;V1EOJO;_';CQ"N0\U9;8DDXI&:$0ZW8=<#$X/ZT$S8CW88&*2M$@2R
MA:C=6E>,DL\H11A9H#20]5GP,8<D+9K6QE4#8:EC]F((?7T?<6PV7W3.3YQ;
M%ER!Z=1N3E*I<)*L/B<:)2$`(0MS8T%Z*3I"-;../-'L0;)@V,B7+&AEW&JD
MZ9M)@Y,MSC0:R=*TD2HZR8O!:DO<Z82TR7$.-P"7HE,B:W]%L0&L]<D2N1YC
M47H!/@BZ=DSG1N-(.0?&B]Z9_,?N^95S;A]7W9R%X<N+ZQ(9'#&BSZ^G:R*6
M02XR*`J]I76*/;6Q.S-X:5(YA+$O;5!P#QD&""($RS)Z$8X7W_53[RSX)4!0
MT/F<=I"GK`NJQ%CI;SPP.-@VC9<\J24(WZ1RM/%R`16.,Z./L29J;V]'M1V)
M^\9IHQCUK2SBV]C3[?(;BY5E>W@7QBK.[V"U>0];2"H7I5;4M@SY!J9KJ;+D
M"R>,5:F1=I12.9+WM*W@;DK@\`1FI&_>]B`8=L>QW+YZ'V<^<P$7,B$\J8I`
M!*VB/5?7-4R>N)8X$`*F<38Z.;*2L1E4.;4%5IN32YF*5C1J`@&:C$828(`A
M`V#;.,'P<N0/%NI:LN>$\3JZO$F4<A8ZVP":R:_I-!G)#`JF3R5KECU7,&;(
M$C3F24Z5.#(D2+7AU&2;Z/([0)]&C$/3+>QMX7^8[Q>5\BTG)=]A/+]UD$AC
M#U"WBJCK0@.Z:I%BE-9+JR?S*+C7FH=O9:%I7&::&YR"T(D85!AAFS30EZU/
MK<SC!J@CY!<2K+@-)1KDM77()VD/&B+F5A7[U4THKUL2VO33/*'B2P:%VN1*
MD)QT4?F`#N:A.=6/:G1R0T7:3H82Q:N?MNSR,?6EREC=CT3.JE:JL:JX.EW+
MYPY)M+1"2FUMKJ%Q0^L!5VVUTQ-!!296$]K"$LW:C1191^M#&+03![UEDR[Z
M$"Y$WBU7:FX]$-;`Y,6Z6XS5E0SF)R4I%&GQV@2N2J5<@;M)!"VG:W`+Z#11
M1O0X.RQ=VO+K$F#*D9Y612/\;Z)@":-3MLOCBU><GNBDI\T/,<,KA4IF4J@<
MG=T-@QI>W"DJA0V&0@`$6V]446/9O4[KKJ'3.?5&:2N8?%6#6;/.5=-TS=+#
MRCG2&PE3/&I5+X.X\?ZBL"UFAY9YI/X@<V-9%@2G24N1+SF9K7@2DHCE&N\T
M82R^V9>KT/+$`-%@`#6][T`(0ZV+?46^W6M=1;\G46^GES0[X#`8#`8#`8#`
M8#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,!@,!@,!@,!@,!@<A&(`@C+
M&(LP`@C`,L0@&`&'?<`8!@WH0!A%KKK>MZWK>O)@=C##3C33SS33SSC!&GGG
MFC./.-'OJ,TXXT0S331[^$0M[WO].\#I@,!@,!@,!@,!@?+9Y(>_J:7KP]ZT
M9O8PZT7L7^W1F^O0&Q?HUOIUP/K@,!@,#KH8!;$$(@B$#>M##H6M[!L6NX.A
M:UOJ'>]>777]&!VP.NQ@T((=B#H0^O8'8M:$/MUU%VZWOJ+IKR[Z?HP.V`P.
MG>#OV7W@\30=#V7W:[]`WOIH6P=>[0=[_3\&!WP.HAA!K6QB"#6Q!#K8MZ#K
M8A;[0AUO>]:[A;WTUK].\`$8!;%H(@BV`7:/01:WL`NFM]HM:WU"+IO6^F\#
MG>]:UO>]ZUK6M[WO>^FM:UKKO>][\FM:U@`BT+6A!WH01:T((@[UO0M;UUUO
M6]>3>MZP.<#J,8"P[$,00!UTZB&+00ZZ[UK77>]ZUKKO?3`[8#`8#`8#`8#`
MY[A=NP:$+0-[UL0-"%H`MA_V[$#6^T6P]?)O>O)@==F>#K9NS=DZ!Y=FZ,V5
MV=?U>OB:$'8>O7I\/Z<#G`8'40P@UK8Q!#K8@@UL6]!UL0M]`AUO>]=1"W\&
MOAW@=L!@=0C"+8M!$$6P;T$>@[UO8!;UH6@BUK?4.]AWUZ;_`$8';`8#`8#`
M8#`8#`8#`8#`8#`8#`8$H^X^!8%O]:L_NU/\<S`IL!@,!@,!@,"YLC,Z21[9
M8XQHS'%\D3PU1]D;RMZ":O>'M>G:VM$6(7ZH1JURHLO6]^36Q==X'H3/.(_%
M^%R&RJ.-Y=KTW)>IV24&2($JK1NBW&]^L&$M@G"4U%%K46S44G+DQ*M,H;6]
MP7,Q*!S<R/!+"#9@-YG;WG`N/';A;0MY*Z?KC5^VB[7C=+.UN)"*FZ++M"G:
M7<Y$-=IDBUXSX$R:79H?D1*0LU\"C0;)9`'AT<,7:(6+;/P(7'N*]&Q:AXU?
MW(R]YK"FE\N6XJ3W`ZKJUOL"9N#_`%.:Q`5/;&L?YA$H^"-`*<3S%YRP99Y6
M])2DY)XU`Q$7;N02QWX#QN%6=?0;#NU0U<;*!@-26>ZW&P0$YUF<UCU_MK0Y
MTM%8G6RU];2";!EH741:DA6Y`1-VD1YPS1EZ#K<WCV(\P\,ZXN:PZE9.,_($
M$U@UB,EDR6;FSZ%>@;=H1@J!!M[G#G8=7P]]EQS\C7Q_83XZ<TJ1@?%(O-"]
M%F!$+&YV):Z<#H7*8[%YU2DYO4^'DWA4%*VLBOSCVLIZ:10FZ),5%HC9T-0!
MDKVQS.(J'8)J8]&)6E<6]2).$_78?H86YV-?^65#U/QPFJZIHC=3C;]H0J7S
M6+VT4D@AT8@L24L;F%&Q-$?D2UU5K9;(0E!-"][`F(1(5H-IR#%&@"-W9=Y&
MSKU37%]T_+[XN2)IF,J17)/>1DYAACN&F&$@]]DJ\BH&Z3P.03(N:>E=P2M$
M+V<O8EHB3_22HXTK:1%WB-W-OVSP*V3?ESUNUWA8%#1KD<^3:1T(58DTY*2"
M.4P].S+6U61!6D11])$FQO>CGNS[IE"QX;DAC$A"2@1+UHB-K!Z2G&[?;C<&
M,[`X2Q!/'JML^MK0FL:IJ;W$WT;/I-RNJP^AWVE96Y-9DB;Y-+$I3S(&)^KU
MWC2-8I3KV]7W%J48T9P0FB"++MZO8NLKX;T(NHNR;YJ>XN0CI!*1F59L-GR&
MR^-Q$$9Y/$+%EPH>=-Z-<$L^=4DK7L9V@K`LK@>C4GI32Q".)[NN3;N#9/D#
MPVXV6CRUAE15!:BVKT^^'C#;\R5NE*M\<A<>;(/QTC<]9I@>5&Y8O6O+O9:<
M"APD@2TH5+8JV/PQ.!@^[:6YM&M^^+'#4RD4/)U'RENDVE6NR5%+2]F4\>6%
M+<3I99D923%B%7\?U:!\.W#'6-"5+%"IV=DZI`%*$G9)QYV@%MNYY%<H_+O3
M)K@L5HU9\F=N/=;T;4_(Q?9\7JAUDUG/L`O%$U&U?%(]4#6[FC5V9(G-S$E&
M0-Q+;T9*4]8<<`H'AX^W'L2%@_+<9[$LCCTAKNSK`9Z>Y#.-O1-+*;JIU;6M
MC5A8=0U\Z6"YQJ>0DQZ6-B]F>69,F5)'AL7'IS$9A^]%[.3;*&MLW>X,/NG&
M?C,^TO,;FJGD5:4IC-)3NJXGR"/?Z0:XVI2Q.U'5U8$5F4NWE6&N42M"A=6@
MT)36\&-2X\L18S!)^[MR[=RB5_FB5Q0=8\C$C#1RUQ3:-K*H'"4P[5;M$!C$
M=$Y4Y7+HQ/+"I:7]T`^ND\3.![J\A&E2;0N)PR]#5=VSLGZVV<C4/CG59-Y\
M@*2IA2XF-"2U+4@\$7NI';YPW-DCD"%O=%B7OZAVL(;C31$ZWUULW0?)OX,M
MX@W?MW\PVZJQMR=5SQT(@53<<ZSF<E@$-H@FKH`\PF1Q6'.ZN-[.M8J0QYU>
MY]()B6V"4NRQ:M$IV<I'HD96PA%DDV;>QDRW.$E)36Q+'MQLFY?&VD#^'O'_
M`)O"C3;$ED\*BB*YI`BB\QKF+M!3LSK>Y#(BU@XZF$8$DTQ0F2F&)TVMGEOM
MQ[W!@S_V)QFU';BZMXMVN_3&`<FI=9T#T[7)"4->26JG^F4*"0V.XS)NC<CE
MC*Y1=LA*_P!+D*4*O8S"RAD"#HSH+&][V,=S&B.+K_#9.Y\:.2\KL&?0V0Q)
MA]G5O5DRU0X6^FE\C*B:1]HI0@G,J.?A(7=4G.4-#B2E<@-IWG/P%C#EY\C-
MXN!E&K;7=^)$>Y.R%VYGLQ3LS?5PZITR'CT^VPP,AST]TLR6>;,=RT,D3&(U
M#<2[*&0#8I<B-DZT'N#DV]^!,_\`VZ,_("D?RZ*O2.Q,&L:4<:^:K_"RRH\@
M5'V+:=>W3+WM@K=_5[7-IZ17(VQD5(4BS>U9A"DLHD!(]&:UIN6_P,(<0.-]
M6R$OC]<]\S9ZC,6L3EY$:3@U?MM>-\Z'8PH^2PO\T/D*9TDL?+;X:2_/[+'E
MYFBU7;IU/,V`>T^R3+;>H,MW-4,3;5GYIJ7C]-3MUY7<WK%ND,$=Z8C#&L62
M%^Y-R"*I*Z@#F"0.ZJ'QFOW@LD*)Q0>"-\2:TG.3)RM:UDEZT0"6<-N-D"F#
M_P`>9MRU717E/%F)4;)`/=<-+?QA8[#1QK4F45&XW`KG!,C(>B];TW;>MLWH
MKTIO1.@[ZZQM[\"XLO!FFV6IJ'FUV7G:%;N7(VOBK`B-ALU%"E_%NN`N"UX;
MVF+6_<)4N0N#9(B5+2'TP%"WFZ9M*0;,":'6Q;;=X&ISQ;[</B]'./`4"=P>
M6"^I3:!TF(9F0A&C:%,3*BJ=G:900:.0RA,_KQF+AZ5%)DR$I,GT1HT1QNR[
MG.B_\>^/T3LJ(VS<EOV&Z5;1-)@AZ&72",10F<3R33*PG!<@A,!@,66/4=;%
M;RZZ:E:E2K6+24B!(GV89W=VM:6^)V-R^,504A';T)D-0VTANVO)_P`.>:3R
M2RS.+M$7M6M)+$J<EB0UELR!I7R5-K6N&<(I:S.:54-,O([C">W96][EMS^1
M&HWQ-7WJW<4(U-+K98='C/R\[)Y#-4A%62(I+!(K6<]G1RZ+R8R/.`'J<^*-
M*J6FO)H1.(2QA3`('HL&]M[_`"(JR\9*F<6RA[VXP7?.)9'S>7U2\>)<"X:;
MC\3?H;/98>@E$*FK9&D$TF$>F,,<$K>I&8W*U)1X1I]$*.H3=["WQ14S/C!`
M&J0\C;MY471)HI`VKEC;-$Q8VHJGCKW/;ALV,/3D\39[8H0MED5A=?PIA0JB
M#S]#6&%%G*P(TP=]FA;;>H,9E<;>.R:T'U$Y<MF5THY!5T>M.-2R$PY._75.
MS92L(;&ZG62F#Y2D`@NEF<!F[>D"AUVG;4)&U>Q"+&$.KM^.1O+QQXDPZGN6
MW"^=1QTG$RJKD377*-\8(_>M4$5K8\><*XJNQ&5S12J&'.DB9UR!2J4)%[4X
M)CME*"A:&$.MA",4MV7Y@\C^.M7!O&ZZ3IDUZ-CH+8L6"UX9(24('0YD#+GE
M`RB=2FTU6@+<#4.EGB:)$>3HS8>W8P]>NK;DT;J*^&''Z5/UO4U1G)B76+R0
MIUCL>0&1U^I]-%:FM<-2EKG"?QJJILEFCW(1R)G96I6H2F.C8E2.NT9FB-@!
ML`\FWN]"J!P`AZEGXSQYKO=4\W]S#KFH)M1E0H:^4>CD.K`7C+E;Q:DVV\&)
M(K"8JW(UAB`Y,G6.+H-`H%M.06`/>^W?Q!&'3B?QTFK+=+5QGY)S.T[8H&%2
MRQI/'9K4"*`0JTH-71N@6*_TM)$DVD3PI,C*/>UY*-Y0I#W%O`(TK8=ZWK3;
MYZ%_CW"JAVZ1TG2MR\E)77G)&]F6LI"U1MDJ-+*:HK,BX-(EM=QJT)PHFC,_
M%2J1LCFD4&[;6Q2B:S%I(5(Q`[S`W;W.A4+>"M1P6!VQ:]S<C7:%0.J.5UP\
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MAEJ33=-`FE,O$-*$Y1HOQAMO?@:O<!HI(+`Y?41%(C*&V%R%_?WTIIE+S#6>
MP6UF-*@DJ<##UD+?SB&9_`<D2F$Z*/&$)8S=&Z_6+#K=O0R''^,/':-4%1'(
M/D)R!L"&M-\K[4:&6#5?439.Y<VK:SFVXLY2%8K>YM&68J&ITIQ!YX_UG`U2
M?I.F3F!+,.U-NY!)WO@7&ZHG/)P=_7,OB](<9Y?`X0=.X#`PRJ=6U)K8902V
MMH_`X2[2!D:VMR<(2(3HZ&N+D%.UE%[!U.V+0M/MN9Y&3N-M0TO%K9GSM5%K
M-=Y5S.OR^.9LP:"9/&FJ-V97,CCU;N[>?';-@9#S*$<;D[>L)"K;5J9680O2
MCTH3[#K7E6WS\C3^8<82(C+^'$2U-#W#7*NJZ.L90X"8BDXH0.X)LYPXUH(3
MZ=#M/X&`+;YP$\8TFU.Q]FP%].[=WOT,T.G#"J*H+NF9<B[KFL5JNO>2EB<7
MZW'6E:L\RLVWIG6BA0.4R(B./TSC<<B<48&H24U6:H<3QF*E6DQ/40>\4W>N
MQLA;W$:.VZ/@)6-36(VO%<-/"^U+BF5WH*Z>P.?LNB]OSR0.L@<*V;!JY,]6
M(A1KTS(!C*4GF&/>])2U&R=:.R;F[\C!JO\`+\8IVFJZ14-8%H)HE,[Y@7'F
M;:Y/4JNI"45U);*\<4,FP4B5\D+)+H&_^CE9`?-%8%J1P**3'`T)06/6MSL8
MYY*\8Z,IQCF9,2MZX4-I5Q+VZ+/M3<D*)W24BG[:L7+VQ9-J<-32J3@D#&RJ
MD83U258$A2!O4%J`C%K]426T:'Y0P&`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?Z
MU9_=J?XYF!38#`8#`8#`8$BA\H=H-+XE-V`91;["Y3'9>R#4!V-.%WC#RB?&
MS:@`=Z$,CSU`#OUK>M[#UZ8'H=:-P\!YE.+BY)D1&[Y5:]OHIR_HN.<VCL03
MT[`+AL=*IV\359:C/+-2291"*2)S5.[,V%LR%48HT04I,"6`69DO7@;%5WS_
M`./$5=^*$\,L'F##VB@8U3S$_<0:N11&,46^RNOO-B9+8ZR5H9HV_6A++5P!
MOBY"X,!SFY+?_*F*R2A^,"?6^AHMR+O&KIS1T5I:MS)JY:AW)GE#;2622Z/M
M<=`[0VZ#(:=%`C0-[^^&HG]*8Q*=+DV^I10?#V`XS8A!!K.=]#8Z1<UJ'LY]
MN2NK'9;2;J%O:A>)4$=)-%VF-JK)KBW>+<+9FADG+3%W"0$L4MBBQU`Y)5"(
MQQ1J5+<I`:#PC@^'J9>_(B5:<J.-_%NUJC7\>8E:DCBT>B=MPN\KE>C6ZK[T
MM1IN9I"P*]P)"PR&2,];`J9`02LC(AK#59SH`9JDT`1!V%9;.1,)'S)JV/$5
M^W,_('G-R>,27W3=FR)\Y"2IVCS%"J]J^8M\M7Q&.UFBMF91RP9S)E:(G9KH
MZB3HT>T9?F991A@S0OK^!YZ7S.VJTKSNFSF%.O2,=CVS8T\94CJ422Z)6F7S
M!XD#<G<B4RA6F)<"4;@`)P2S30!,UO01BUTWO4XF#8Z(7Q2V^*M75+,R[/;K
M.HKDJ\7A!S8TR19V@4S9IDJK0F1,TJ<7*0-D@CKDRML+4F(]I4BLI4>84`P1
M8=C$"9=V#*43YSQJ*\TN6MUM^[:CM0\L5%KQUX=*\>$L.O.!1B>RQ'+HO-(<
MN2O&FM+.(:]-*4X:/:\*560(]/L_6AZ%DSB09#2\WZ4A4\X^'.\]Y<<S8O7]
MS%6G94AY)21:E2C:$,:=H]&8M75*NUE6#!5+O%'9YV_[=W@WQU"],4E)\!,,
MS>V7U!UL#EW0;]0W+&G'3D%S6OZ57S&(:OBECW8R,);#&)!7L]3S9C@3=`06
M7(@L+;(CNX#H_)CB2R0%%%IFW80:[V79<@M:WF;QV-MZ-WNA07*7+'?A%+N,
M-CQ!?'8:..LLN)XZI*6A+["7U++-.3Y'G9T)&K<Q+DR10B([=DE'BWLO3+F>
MQIF1<T9*X1*^-8D+UN<'\HF^[0.NDZ3<9U%TE/*Z^,0"5[6Z<?3@GD_1NB])
M=D^;:V+Q=#_4RYSHWC8?S#H4BG+XVDNM\UQ6MD\.>,/'B73^HG-#&;GKRR>.
MS(@TVV#!PII&A1R",&O12M(J;CW%`:YM"X>M[),#HO<S_D5+!SPJ>`7'Q_>Q
M63R[Y%1FJ=7:\3BSKSE#FMDTG>[,JF35S$V.!U`ZV9*8A#(]#_37B*'`:_;N
MX;5G]XO!**)%/K<O4&AU7W%&87Q3Y7T6ZHGHZ57L;Q\'%'%"G2&L3<&IYD_2
M*0^GE!RU.M3[6(G0L*3P"#^\S0M#\/706]>1L1>ET<.N1%]U_;LZUR0:H^]5
M'&XI=$6C;+7*5VCTTK.GXS7T"'63XM?G1-(XT]OL="I=C'-,@4D)1;"0#8Q=
M`22R9,&A,)F,DKN91"P8@X":9=!9.PS&,NA8>_T?((TZI7EH5^'O8?%+)7(P
M;$#>]:&'J'?DWFAZ!3N:_ES7Q/GF^+"4<H*@E,W=U,QM2@ZOA-?2R'ODT=5!
MCA*A5=:;[,&-7"HS+'4PU1X3FT*SVP2D82>\("]:S_M..!33+G,S68'FB?((
M:OAZ*\:$J"@J$@L:,*>8]5L%IRQ(8^16+O3NY+4"XY(BB<;.\5820<8I=%`M
M^$64/6P/KT%!<WHW0T#XD-26(/,K>Z+NWDA+[(8E0D;8Q3"KN0$%C->NT<C[
MX6L4+DTC&P)G+J,Y(42G/\W%H9FMCT!9NB$/LQX5T_%7U=QO(N:TK=>)7!GR
MO97>L,BL);>/31"I8CF':R$Q";20=A3Q],;4[6H7FEHF\IO\899/C&:Z7FWD
M;%E<J^%[)R+=N>L>9;\.Y#KWA_M!IX[NS!#`T]'[]DS<N*72M1;R>4;DKS6[
M=)'0]X2M>F(EQ&;V$&&:*UO)ESZ^!@I->T[L5!^7W$^/41L.5<AN+N[(>=HV
M&-FO*F2S-^O1?<32JC#<P'.;JO:"6\_L<Q')TX"`[-T+6R=;,QF;;U1E[G1=
MD&@G.*NX_64<)1U/P[L-I<T\*:'4A8C-LERM7VY7VD;G8H`$:D8)^['QY.HU
MK8`I65.'6]@!K>)+GNB*V'RJHA*=SY'3V[>6;Y:R&HK'A*JP8Q$&A7#YS%K^
M<[FEK0^%1Z5NZ8V.MQ*DHAK5%;-4+#`BT>41KH+;+QHNUBWSP-LVTYMRTE\+
MNB26]/V]VD;]Q:=X]&/84HNAZCHF=7)E=NI)D3,%59DOX_3@&D+.6Y#4A"G$
M=HGKC+.)T)1Q@Y=<=**15/,&6T^8E..\+:F(NZ.-E;IV6>T+R0D3&:=Z9=SU
M,ZL=(VPMNM)$()#VC4L:T"#N,$A_^C>EEOP/+29OJ*4S*82AM86^*-TFE<DD
M3=%FC_\`"HR@?'I:Z(XZV?J%_P#I[(F5!3$_JAUX96N@0Z\FM#:'CG<]2LU5
M7;QOO\B=H:JNATKR:M\^K%L9Y#-*TLNKSWK4?>PQ-^>&!LEL9?&B0*D+DD\]
M3*0`V`P@7?K?26>9V,QP3D1Q,HVQ6#510NR'*(,''/DK6,GMB3L3$UVG<-D7
MA!'R-Q]X>(@BEB^.P^`0<]<0C1)B5RE<!'L\\WQCA!+R9;V*V%\SZPCC%4S6
ML8YL<H@OY:U[\.7@2=M:!$GV7:#U-W!A>VX9CX`1T,2)Y&G\Z4F!*5@&$>@)
MC-!#L3+_`)&+*#Y,0:K*,CU9/[5)U;ZT\ZN/?)U0K:D;<>UC@E31]V:I"TDG
M*71(I%*%BA>`20G96DPP:WL9Y>_)NYSOH97DO)KC9R!9+CJZ\SK@KN'.7+2X
MN4%&697D0C4YDC"FN%;LN45]8<`=YA&D:E(X-Z)$K3JT#F,Q(O+&`6C"=]13
M+.9V)%4_*WB=6\FNV,UPRW/QOB4RINL:MK/D?7C)&I7R+97J"2(Q]GT^E36?
M*F-"TN5[$J=I',N/.R4QN1I$Q!1@P^(/%E&6&[GYQN8'_AY(B7OE%8+GQD5\
MI8_)GZUTD<D<UL]EOJ#OJ)!/CGL<X5A9W%)+5Y"8#`(]6!"T!V+STXTO037U
M[Z'GY^7\6,OF_P`-BNNM#!R1I8ONZ=P="#.&0/7IU#L6M;U_TZY?V_ZT;;N=
MV\/..MS<A+NI<J_7*^7@Z_8'!JKF,>A:&L*CE-DFR>#R^7GV4VR9:_6`RLC6
M[N`F-!Z%;E&]GE@5CZE[,W)+9-Z&&U?-!OBMW<%KMK:/N:QRXET)2%82!CE`
M4K<EE;S70Y8DEZ-N5H53F(#!(6&3&)DZHT!9X!CV,1&NW01,XL^1)4MT\+Z(
M;[UF_&H7(.56A==8V%4L/BULQ:$QN(T'%+=3[;IXL.E$<EC^XVE)&Z.FG-C,
M8!"VI]`-V>HULS6M8RWOH;P0&OH_>%Y\)[TMCC]RF4W0LB7'%20BKI@ADGXL
M6XQUFG86>(7+);U1O:\RK&9@B\?(5S%E.1GK$9C:-/O:81NQ:EXE@T#Y;\C8
M!8D`MVGXH:[N3LK_`#%>2W(MMEI2=']5':`SUI*BD>.;5H%XEYKJH5-HE6P;
M3A(\U,`()HA;V'6I,_H;F0#\Q#C9%[*XUVT=/>8D:BM0,=6,"[AI7*&*1B@V
M)WB$>31R2S4A[13M(5.&YR7^._B;U;$6Y.CD/11ZT@O?<'/UN9P/.^]KNK.7
M4?0E*U\*9N)=)VWR?E1DEE3$UQ_ZQ12WI]&)%"E!3<WOSX)$]EM+$/TBE$/9
M28\80%FG:ZBU9*,X/'-&L'+GCR;Y0EL<W+@5T5C>L,C#4-M9_K4A=+-I/V<,
M!SVAT^^C4R%,^Z\16,E6>,M+^N`!@_\`CQ]?]9!K!PJN>,\<.3M,73-4+VZ1
MBNGAV<'I#&DZ-6]JB5\,D<=)"VIG!<V(S3`K7<L0M&'E:T6$6];WO6M;MFS!
MWMRZ(Q/N-'$^F6A`]II-1)?(,$L7."=&6RN&[8L5NET>]`J"%RA8ITB;D@@*
M_'(3]AV]:!X@?UM).;1NE9W-/CMR"EW*2#6BWV[$Z.ON745:<'G$18(P^V)6
M=HTS5+76)ZM[@B^4-S-*8E*VGSU,<20[$JR`:).+WW;$`$RR<=C&T/Y&\4Z8
MG*U+3\#L0<*3\0N1E$N=ER1K8T=H7':MV1MS;&V<2Z,(Y*LCT.A<8-5D($*)
M(L5*D[>2(TWQSS.W3+9_(OT=Y&<0I,@X;6/<8;\)M7B)!*WK515L%C4,40*U
MVVIYVYRV&OWM)=I4C>84`XEU[79+IH6''^!X:89>Q^-IEYSJCB8<H.-7(ENN
MNMKU-N&OH>[<L[AY0419M>P^,S631\FX5NBY97]AU^[3&.(5*)U0H$2LA4@=
M!F(W`L8!;,)WU$RSH9#0?F`4=6=@<=4]*,%],E/5QQ0L[B;8JT;ZP1*[#6:Q
MIL]R8ZTJ[DD<=E#6U3M"[*$<@()$8F3D+=&(-&")UI2)E\_(Q_8O*ZCU+'!8
M0]V5S/YKQ8=N1B<VB/D79,MKEGW7,<3+"=UO!X3'K5FK>9+')>OTX&21:<68
MD4(2"D8"RS3Q;9?4%UMCEY3VN,MN4+$[GY7\G$MFJ88&NF3E!&XDD9>-:6+2
M@$@.>HG)OKS8$F>9DK:"O0VO1WHEL&E-,,,`+>]%[27=X@\I<T&`P&`P&`P&
M`P&`P&`P&`P&!*/N/@6!;_6K/[M3_',P*;`8#`8#`8#`8#`8#`8'&]Z#KKO>
MM:U\.][Z:U_\=X'.`P&`P&!U[P=_A]X>_IW=G=KO[>O3N[>O7IU_3@<]==>W
MKKNZ=>WKKKTZ].O3X>G7`YP&`P&`P&`P&!QK>M]>F];Z;WK?3>M]-Z^'6^GP
M;U@-[T'6]BWK6M>7>][Z:U_X[WY-8'.!>6"1R.)NI#[$Y"_15]2`4E)7R,O3
MG'WE*4L3F)%A:9U:%2->G+5I#AE&A`9K1A0Q!%U#O>MA9MCV9L1FQ[,$8(0Q
MF"'LP1@QBV(PP9F][$,8Q[WL0M[WO>][WORX#`XWOIY=^36O+O>_T8#6];UK
M>M]=;\NMZ\NMZW\&];P.<#KL0=;Z;%K6^FQ=-[UK?37P[Z?Z:P.=;UO6MZWK
M>MZZZWKRZWK?P;UO].MX'.`P&`P.@C2P;Z#,`'?P]!#"'?3_`%Z;WK`JD3@J
M;E25R;5ZIN7(E!*I`Y-ZPY"M1*R1Z&G5(ER4PI0E5$FZT(LPL81@%K6P[UO`
M^9IIIYIIYYIAYYYAAQYYQ@S3CSC1[,-..-,V(PTXTP6Q"$+>Q"%O>][WO>!T
MP&!,FZQK%9XPX0AGL.>M$)=MFB=88U323-L1<]G^51MQC*)T(9%OG&_^YXI`
MO$_^KKC!#-:UK6M:UTUKR:UKR:UK7P:UK`X[P=-;[@]-B[=;[M=-BZ].W7E\
MHNNO@P.=;UO>]:WK>P[Z;UK>M[UOIUZ;_P!-],#G`XWO0==1;T'6OAWO>M:U
M^CX=^3`YP..NNO;UUW;UUUKKKKO6OAWT^'IKK@-[UK>M;WK6Q=>W6]ZZ[Z:Z
M[Z:_3TU@<X'&]ZUK>][UK6M==[WY-:UKX=[W^C6L!K?7RZ\NM^76]?IP.<!@
M,#CKK>]ZUO6]ZZ===?+KK\'77Z.N!S@,!@,!@,!@,!@,!@,!@,"4?<?`L"W^
MM6?W:G^.9@4V`P&`P&`P&!]4Y!JI0G2D:+V>K4$)2-&G%)RO&4F@(*\90>(!
M"<KQ#-=Q@Q!``/40MZUK>\#T34\&:V=6BZ&*K^6L2MF[./U8RBUK'A46JV7^
MRM4QP1(B6SEL@M^;=E,<E+K'R5G:28)N2HW(XH84YHM?K:SM^.!J]QLHM;R3
MM5#3[)*&^,2N1QB:N4(TYMYR]/+)?%HLYRAH@1.R5B(3>Y3$#2:E2*1>*$"G
M8`[*'L>M9;<Y%]KSC2^3^HFVUC9A%X65*>0L-XXP=IFAY;$WOLJ?644BF$B>
M)8N6)VR*1&L&A0A-=E1Y1H0[7`#U`(/03>1EZ;\0:L!3UYVE17*-MO=7QI^K
MBBWV8FG)K7T=.:)%+"H,4^UE/GAU=VB<-Z62G@UVFDMQZA$+SDH`@=-;;\^1
MLU">!15(\JJ>JG7(.C9I?\FD2)9'*DEE-R.Q(8GKV14W(IGJ;VFD4.Z&-I%(
MNSP6Z/[6&N!G<0Y#$27V%"F[/.#4BNN*<`4UC7]I<A.1"#CZSW,JD)=.M1%3
MS:W7N0,D8>1QIYL*8D1-6W$02NB)*4:B)5F#6+E8DQYA20117>*VW>!M+&.$
MU0U[QVY\MW(2RXW&+RHB74PRMKJ@KF<S=)#FU_D#BMB;[$7]E4HD$H8.2+,I
M3)TQH"-#9DN@'JPA"/MU-VS!J\#A)*W#D-0-&,$W9'EEY$UY`K:AUL::%2.-
M(:WE,;<I)+9,[M@W(\\D%7EQMX3NI7G0=^,UCUW%]^M!N\:-;Z]JZ0V_;D5I
MRJ_#EDCGTY30B#*3@^A4CV8XN8T38]+=*#%.V5L-0A\^4[,$9M(FT/8MCV#?
M5N3:-N'[A=6KJP6V"@^5T4OBRJ!C+U-;3KY%5TS@J1QA<06IT$_E5.S%\7KF
M^SFR"F'^.K`).UGJ4(!*4P3`:UK<WY&9N=L9IZJ>+G"NNJ>LB`RINE]3L=KO
M8&WCV="YY8KFZR>SFT^YG:UGU&=*DK2J$D`S`B:A9O96DA:G8-EZ*[$[M$<K
M&G*2F7Y<;//+7L:+4B2R<VY>Q.=C%5JX6/9LF:5%'1)2SU_%&*/#:WA\0I7(
MQ2Y'EJG)&VH``&=O8CC"P#6W[<?`Q7/>"SQ#':\PMUIQR6Q"JN,,"Y:PN9ML
M<>$">V:KLM]B;+%M)F=Q6%N$,?-[E&Q*R%6U7@&HQE_K=X1ZNBPTAPOD%W,7
M&][;9ZSL`>1W)27<;6E,M8EJX46=XE$8]+3)4XG$.2?3FW+R9`$@*4H))A8B
MMBV8+0NW2W!E%LX+TV^02R9ZS<VX"M9^/+Y'VKDHK]C]D%-T12RAQ<X^QKJ@
M4[.$LN\;E+FP32G++3,@#CS`J/$`E_Y=S;\"&R?A9&FRPJ50L7)2NS:*O2J)
M1=4;OV>Q]ZK=(P0J!.#^TSA!)(`Y+'-\,G#4\1TU&A:$"I6:[JCB2R!ZWL>P
M7?[%Y4\'8E+&FA9O0_('VH5E=O)"/<6U$FD]-RNJWZ%V/)$[>XH%PXJ\OKP7
M*XP8RKMJ-*$2\`PF%^`8$!@M]D^WSV.\NX-PAK8>0[7`^444LZ[>++!(YE;M
M8-%:3!DC`HG#I4AB<S40.U79=MIF#U#5KF0)>F"@3IQ[\4*90H"7XHF_U1:O
MRSJ@IV\>8-90"[75M!%'$3X<FACM&'^1(;+=$T;>CRXH<K8E*7ZLZ1$%#==+
M50O`$)!HC6O$-!E_;B"X0WA/6<KK^?7JMY<0R+\=*^N@%0+K0>ZKGA;W(U"V
M!MTR9UD/K(E6=+'5[>'%>8W%-1G@[)*1GKSE($X-!W-\>1<)[QT+DDKH-NLF
MVZ*IF`E\'*[N]RL-'"#XN,JO-+7Y*UHET/0.RA\N>_WY2,!8]HA)U#KW!$(!
M1:88MW1FGC;Q(K>-<H?R^;&C%A-/(OCW?U[2&#A*FU0N]?+_`$]7J,HV21V5
MUW,E<D;'ED5$/*8]*K(5*TA_:,`@A&#IN6W+\C`42X;5\LJZ$W7>?(Q'0D7O
M"Q+'AU3#34W-+.CA!T%EVXN[N5H2Z..30Q5DSEO"@("21^>K=HP"5;)"2'>]
M-\3D:03N+FP682^&*'J.24Z(R)ZCIDCACTFD,2D'H=>>A"]Q=_1;$D>&!U`3
MH](I+_5-(,"+IK?76M#T_N#A4IDMP<R9?:MR4O3$8XSR&AD=DNT'J-^9X<K1
M6Q#DWHC595C''5P7>G@'-R=/IK"=O3BX*S5(U"4D)HPYWC@8@7<!G"06'1#-
M3=Q1:PZDY!5U/[7C=U26,OE:-T)@U/K7A%<;C9<2<5#XZ,*BO1LAHAEIE"S2
M_P`4D)`NXS71]OD5D4XWT<5+J8L.F^2D1Y"P]MY+4?7=DP>4UH]5'-"DTQG#
M62@?&B$3!V?06!6[V6E/2*CR!A.2[,"%6E``S>PK;G\"T\O>.Y<?>>4%],*Y
MB9(8R?F`7)QO9JY:6/3<!H`W!D,X;W%L-2&DM2%A0M9($!*$I,'PNW6PBT#6
M@99?'H?-CX&OJ]YA!L@M>)PVMG/B3$>9%G6@\L3P>V536TM=5S$B81,#<H5.
M\WF:M[3$HV](BV1MP4*=:UHH)8Q8^W_(V*:Z"IIEX9'S"G+0KZ]#97^8!QBA
M4;G$GJ-QA\XA(U,=F)3S"I_"9$I<G,F(/*Y0@7F)D+NH;WM)K81"`<4,()MW
MGX&.Y]PV9ULBY4W)==\5O2\)J;F/.J!F08-3\C7I7.6"*=I"FU357Q]YT%,T
MJSB#"TC,>M3D-;<0,TQ9L).@&-ZSX$(6\!%X+<3QENNN&'4.?QV0<MSN2CK&
MY(T,+5Q]7&FMX)`ZU_H2V4ES4<D)]#D,!1IIZEQ&`(30@V(0'VX]Z(G:_$V!
MQCCN?RBI[D6S7360+?8*6VV**VDE:S]IE;M%9!*UFY1&WQV=B6A*G0,Q0T8R
M%*TIP)6=VC"AD&E9=YP8FHVGH%8Z*>2RUKSBM%5U7*./F.SJO95<ZGLI=Y4X
MJ&UDCM;U@TN;2\R]=H:0T]>HTH3HVQ*'1AYFN\.MK?CL7GDUQU2T`OJQQCEA
MI[3KB[:S26K6DSW#G^NWE9'C7UWC2U!)8-)353E'GEM>&4T.PZ4*4YY(@&E&
MB"+II+H]%N/,=O1!^7=5\SXP<7H3>MC/'**Z(_8#PY\8H7R`D#=#&J'PY7'4
MR@^0QA]7,S84[J#=$]!!+V,8@ZUY=]<V_P"W-X&QL5HN,RNZ^&0;SHVEJ3Y.
MVO0G-TR[JE(AD>A<)1,<8J^4$T5;L[K!*G<&.MY,I'I0K,&6G+/_`/(Z5:*+
M,)"`#>_@>2,VXIP%-1RNZ:(Y'LU]M$)L2"5/::%36DKJ8V-22QTSK]2Y(PN$
MQ<5:>40%]7L*HC3@<%M4$;!HPY.`&Q=FMYRC(CEP>K-?'[Q;ZLY:16WKAXY5
MK)+3LZ'1>JY@35RJ/P?2#<Y1U]>QCLKC\N<8_MPT$@8F]&F=!ECTF,$'7=J;
M?C@5*[@?!HNQUXRV5RJB%97?;%/LMT0*%3"M)>U4\X,<GCBB51B+N7)%P<D$
M+0R]Y:DWA]"D2EO3KS`)1J?%%KJ^W]"`U_Q+@)]=5E/^07(QLX^"O1.Y.-.1
M[V33:UE[C&&Q\518=A6*KB:M"CKF!+9*A4)4J@6W!:H+3'*0I=$`T(5V^!K!
M=M53*B;'L:H9ZF3(IG7+TYQUZTWJ=JVY0>F)"H1.K.N["MK&=Y;5!"Q&=V@V
M8F/`+80[WL.K['MQ+JJK`GD3R]:2:Y@A+5'OR<6:PV%L)B3`4WLD_'4U4KAS
M=I1`0!3MTN&M7''"<B0@6"-.&/9G<,6]XV_Y'GKRQC$:8N/'Y<CLR1YC9G67
M<9YF\RQS:FE`WN$G=T]SRMO3NLA6)""5#TY$("0$`/4B,-"2`(-"[=:UK4[H
MG$;HGC@M_+*G-ZO%G-;?=+5R%9F-*(583=<[H%(:RFCJVT,6_)EH60Q).]-A
M#[M^T3M`WC+TF.ZF]<FW[9XP9G@W`HJD^4E05=_[@Z,F=^REW2.4:J.5TW([
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MK^S^+YHE"G<RM`T28<:4)0`D,^W&^!I_PO:&B1<O^*S#(V9"^,3WR&IYI?8\
M\(4KHVN[6OGK&E<F=T;%@#T3@B6IS!DG$&A&4:`6PBUO6]Y;T-F[JX=5@K7\
MO'NI>24/FUC\=G.Q+.LBFF.L)9'8FR5RWV7Z`?4M=V<M4%L4O65P:_HR%B<I
MM0I!!`/2,TXLL(A27Y%LC?`1B6.4`JB;<CHY7W*>V8W$Y'`:.7UC-WF,I3["
M:4KY6\-L>YVXX$;@DXG36X)3"$FD*\A$)806K/*&9TT^WG.!C>M>+]3KX[''
M*_>3K12$KF\ZD]?Q2K8Y5\BO"QT#I#WXB*OCQ9,?B+\TG5VQ_60\25&$[SI<
MX!)-.(($4'NW;?@2K7!$^$2?D?KD)<L=I^K>,MHHJ7E5DM$/D5DK9U9CV0M<
MXY%JS@[<H87%X5.$;0B=51BQ4B+;D6];-WL7706_`EO,2HJVJ[B/P16UW*(1
M9:::N?*=Y%;L4BBR)NTX8R)Q"01UOF;<](R)*WR&&!/4H#FY::J"W&A,`0:,
MH>ABDMMNCS4S08#`8#`8#`8#`8#`8#`8$H^X^!8%O]:L_NU/\<S`IL!@,!@,
M!@,"10]P8&F7Q)VE;*.2Q5JE,=<Y1&RS_-AR&-H'E$K?F$"CN!HD;PTDG)M"
MV(.M;,Z[WKX<#WE-YL\9@ROD`B'S$N-525[TW=U95;1$9XV'UY4/&QOL*-*$
MD33R^)QQZ1HITY0XLLMJ0#9D)O>8:-:H5@ZBT+&7XY'A37$]DE4V!!+.AZK:
M.65S+XY-HXIZ]H0/$7=DCNA`;TWO_P`NI-2:+-#Y="*&(.^NM[S=Y'I3;?*[
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ME5-B39F+NJP%0N/KLXK&5GLO;<\1K29;,TNR`:4)C#4K0`>R]:-`0#Q669@D
ML"M55!?RU'"<3&,/;+;$;>K/XB\9YBXEC0Z<:JY'((Q8UT:90JR"5CBGKUG;
M'=(D7D?^6(U-=E!%L0N@&?[>AH)Q=NT_C7R&IV]DK-]805?-6Z0K8\$\M(8]
M,8B%+3(&E*K,`84C6K6!R4EIS1!V`L_8!"UVZWELV8-PV"P.&G&4F][*H2W;
M.N2>VW5%G5#5%=2JGU==E5$R7&E]#R9]M"8*Y*Z-$Q>XK%SST:`ED*&0M5BT
M>:(L'D!.;Q1K=R3M^&6E#.'[!$3',:VD>*L9IZ;Z<6XQ`25,&BP+#DBHIJ-,
M&+3FV::Y*EV%2'H$0]B#TZAWEGG\CNXW!#%/!F+\?BC'/=BM'+*6W*K)$VF!
M9=0IZI^.PA$84\;'X1CIM\;#=#3:#W!)Z#Z]-],>?0W(1\M..\P>#H),9)-(
M=`+%_+.I?AQ*;%00=3(UE>6I6KLPR8U\'#R5J1RED+VZ,&DIIB,T!YA9^AEZ
MZ!WO4R_Y%XJ_DYQ(H#_V/0R'3ZR+$9>.7,6;7O:L^<*Q51-+(V65P..,07*!
MQ(UX=7@E`B4M041:-:<%P.VF&J&`H!X"@2RW?P-+JXNJ#Q?CGS>K!T,=0RF_
MG2C%=>EIVPT]O-)KZW'>:2+TRN"/0&D8&1:7LC0]"\8WJ#73>LUEV7X&UE,\
MK>-C41Q!9K#])(UU,\5>0=1[GJ^KT%E(*6O&QK3D<OK6V6N`OFS&ZPDT1:73
MOV$(!F)E)_>6#9A6MZEE\?(S4;S5HPF"TG'YQRQO'D1-J+YV4CR363*;U,^L
MK+*8"PD%L<JBU6,IS^XJH<VPUM`-Q$4X@2&.ZTT1:9,#6]&:F7X\#1NNN0U<
MQBQ^?\H=#GL+5R1I;DE`ZS$G9S3SSG^T[)993%`/I`3-"948VE`9M0:/NT09
MT#OKUS6<08VX37-$^//*VDKGGA#P?#(+*%ZR2A8$93@\E-3O%W^-GK&YO.4)
M0+CT`GH)^R?$`(P!>PAWW;UK:S9@G,]LZEV/B7+N,];S:3V`I*YCH[EC$L>8
M$K@A$AKLNCQ0LUQ7LRAY?-L+V3*51A&D(U)XQ$%^/H>M#[=/.^AM5!N6_&U5
M+*X4/DB=Z^DL3_+QJKCA![S7TVBM7=%7W#)(XN,@EC5`G01QCNB<8XM,;DKT
MB+,6(1*!&$`#O8AAF7/Y&64'.+CXW.7")]F')B];YE7%?EA+K$G<OL2L'I&X
M3F!3N(-:(YWKQ(*0O(HW&(4N8RD25E6F!<5@SS%024Y8O#U,O/'8U[XQ\BZO
MKF#L_P!6.9-Z<490FETL=+BKTZK''D/2MY-3C)37%@>H_`SG0N*QJ1[BPPM;
MDA=47@*C"P'Z5:UO>M6RWP-#>2\ZKNTK\N*PJB@Y5:UG,YR\OD(@Q21"W`CS
M&K$7H@C;6UC,:V@:XXLQ6-&E$),C&HV25O998=[U.)R-\>3',2F;60?F&IXF
MHDYAG)BP^(,FK#TC'3T`3FRDV10@G`G[8SA^A%!2@W7F@!]VU0?*'IF9+,'Q
MJ+FE3T"AO$&#R=!,GB-1"A>9''?D6GC[:F3OK3$N3\R<%Z%_K]2YG%MT@=V!
MM/3K1$B&2`8B1I]C"(>A:9>?R,3H%7"6B%5;N$#L.:<BK%17Y3\\56@JK"35
M&QU/4\!E*9^D[`UQ%WDSBJG,^FH22@J!C*VA1$I>U,9LTS8A7F_@9?DU\\8>
M0<4Y4U78=JS"DFF<<ZIIR\J:PBZD>;+0R".RMJD<76PZ211B>FI\C\B"U+DJ
MQ(9LS:79NQDG#!T[LF7L3*1<P^*DB?`4^%9;3=QNG'`BJ>(LGG)\2;5-EP.:
M4_/G6<PNQ#(@0[:;I2T@=R4QKFWHEP=C(6F%$&&#(UL;+WYT8](MGB%2G'AJ
MI6L[3L"X9H9S.X_<@IE/554.E=PY7":T1R!"N9XFQ/+TZ2#S]A3N&C!C7>`8
MX*%@@$EZ+(T,;FW;\"*\F.4E4VM6/*2)Q,^0F.]N?F02GE'#@N+$>@3&54\0
MJ6L",]R4&&B"W2#;@\D=R$6MC"#N%U\F)+Q^!GFKKZ@UO$QFGT,-MB:5Y_\`
MHO&OCER'<JWB9#U/JL<*XLAVLCVK1.)K7%"9848A#RK;!N"5*8$Y6B/.V7KN
M)R69S[$1MV+TQ6WY8:N.U;*9_.")OS=B#R58]@5THJ)/8ZJ)4U-T;V17,"=7
MI\?MQ.O$SNB3KG-4=U4NKD,H(`!)#K=Y^W\##G"VYJAK2`7?')#:#AQPNN7N
M4!75IR2:Z9(NAQC4281/(IS7C:C(']8H.MEYRI&?IV;`A--TF\`TTL&M=RS;
MZ%7SROJJ;^B_%Q;![BM>VII5=<2VK+#=KFB:MGFS^>1.W>5M5B*GO3X_M*A#
M+`/YA:-I+4J%30D3%DJ#=CUTQ)FC&CMR#9B^#M/T'%Y%+V2R(=R,MNS),!I-
M=V1J-B,QB$89F#8'IO5IBG%7MQ:SN]-OKLG6M"W\.LN?[:+7PVNV+4O?YEH6
M<X/RIJ457>T15.*=.LD;TI?+"IV8P:-^<:-/$K/($]/:<)QHQ[T23U'OR!Q9
MP+KQ]NZJZ\XUVY4MD,SK*%<ZOSB+8`XDC2#]&2F`4V_3-=9K"M>_%*(;%3LS
MOQ:9,$?3Q]G"\H=!WO'G1Z9+>:G&X;WR.9SN95PN=/W[2UV5I5%+1[C4HKRG
M.-R2>-`OJ>DE,,CKTB1S1VBI:4EG0&,Z$1>O$-6*%8._>MYR_'(QA0O+?CQ5
M\;@1JKDY>"JC&F&MJ&T/R]+.IWVZ1:6R0EA-22=B@%B2UW/@\1A,ND9FUR54
M$EO6M!9H@:*'L.@XRW\_(M]7\[6UZH^D:^'S/OWA(X42QO$$=(E6E<KK1AMH
M5_\`6UWDL2=(TJ:G9J5QZRF-E>1,BGTN':!86D3J/%#O1@,7]?6CS#Y)V83=
MMSVE9#<MG3BV2]\4#8%MH2(N56"H8D+>E9&$V8R`DDA.N?!MC>5L[P@^"1UT
M27L8"PC%J3)@]')'S7HYRNCD?.DBN5"8+2_+2;.*L5,'&%1:L=LI:\KZ-')W
M%(([1B&/!=(VIUY^+J7L&@BUK>A:R9?\C37D-<L*LNF.%$%BYSF8_P!#T9)Z
M^L`"YM.0I")$ZV=(96C+:%9@M@=D8FAR*$(XO6@A,WL'PZWEDYHO<"M"G5W!
MR[>.<[E4JAM@*[MC%^5F>U0<4OCLU<(W5\H@?U"?'(A]:3H4-<M?`'^DS"E9
M)18>GA#WUUIG.C9+7,BF?_THL8Y<;4RC=/M#?$DJI1N.J=R0(V7C,BJA8$J/
M[.\X&`,M($$'0>M"3?\`+KR;Z9,OUSR+A2_)ZD(/Q\HQCB_(RU^+,LK;<B/O
MR"TQ22-SL#DJ^*)DI?&9]:[W2/;(8T%J8ILAFTD>59:1H`6(PD@[7D,9=%@Y
M><GZ)L=@YK,E:2J0R@[D5RYISD7#5#A"':+D(H^T5_-&Z8L#MIR/-&2[1E^D
MA*0!G31;AH`CB=:+UB2\?@:J4K;T.@?'?FU63^8Y@E%^5O446K\"-N,5H#7:
M%W&RSA["\K@C"!I3A8D!FRC!Z%HT[H#73>\MG,HVTWS$IC_]*="^7NE$G]CC
M"M@"A>H^KBC4ET"-\?6NM7/9,>\;S@T6I.C&$'0?ZY'0SX-],F7ZYY&C/&.P
MHY4_)>@K6EPUI<2KB[*YGLE,;48W!Q!'XO,FM\=1H4!8@&+5@4"0>RR@[UL8
M^@=;\N6\P9MK:_JZC$K_`#!'9W.>BV_DK1W("O:T$E:#3SC7^RK5C4OC07PG
M1FO0R,3*U';/-'W!)-UH&];WO%G0]!M?F/,4\.K^TI#SAY64B3&X-!6.R^)E
M90<Q8FETG@48;XVK45#;)#JGC4-CUE#:"EJL;NFTL:%*E1LL)_\`Q],_7U!A
MVON7%/):;KU0S\D+@XKV,QRJR99R'CM55"1+K3Y-/DKL)QEK&]I>0I3M'5:)
M>7&%13*,#RI3(T8PC4@3F=W:.Y?X%UO3DSQ-Y%2?EA5TDM:;0VKKNY`0OEK4
M=SHZB>WO<%L?V<[@LWK&Q*Y`[HY,[L9K0>$DEW;1BUI<F\4)6R1_K)+/R-5^
M5-H<=G>@>)]"\?Y/.9J"A5E\GS:836%"@VI6\V=)8F_$2%@91.[V)O95@FH\
MM.D-/$J3)R"MJ.AQ@M:3=MHT,S08#`8#`8#`8#`8#`8#`8$H^X^!8%O]:L_N
MU/\`',P*;`8#`8#`8#`8#`8#`8#`8#`F\MLRQY\VQ!FG4^F,Q9Z^8BHQ`VF3
M2-V>VR%QPD)("F.+('!4>E8FL!:8L/@I@%@V$H&MZZ`#K3!",!@,!@,!@,!@
M,!@,!@,!@,!@,!@,#CKKKTZZZ_#T_3_\L#G`8#`D,2F$L@,C:Y?!)5(H5+6(
M_P`Z9I/$GMRCLA:5`@"*$<WN[0I2."09A0Q`%V&:T,`MA%U#O>MA)K,N.W+H
M=D+]<%GSZT7EL1B;FMRGLK>I0I:V\9GC&(FO;LK4EMJ4T[7>,L@)81C_`%A:
MWORXR3H8XP/F8:65K6S3`%ZWOIK9@P@UO?\`IK8MZUO>!WUOKY=>76_+K>OT
MX'.`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P)1]Q\"P
M+?ZU9_=J?XYF!38#`8#`8#`8'V3ISU:E,C2E"/5+%!"1*0'8`B/5*C@)TY(1
M&"`6$1IQ@0ZV(00ZWOR[UKRX&_K_`,!3&U!;;%'N3M!3^]*'KV0V;;%!Q'5A
M*7R/QJ&)D"R=)V6Q%D22UK,'Z%)G`.UR9"O$#N+,`4:9L/EF_P!"YQW\O%4M
MW1C=-N47'ZL)9R:@E?3:B(7)060Z/<O]H_5,Q-3^?&H:YM5?D[>MA;0N#H>6
MF5K>\*;1H"AF:GV&,H/PV>5T8G<]NZVJYXS0""6H]T:9(['1S*3KY3;T9`H-
MDT/AL1KE@DDC>R8L00$QS<=%%HD@#B]=PQBV$-WX$YYW4;%Z'8.%[$P:KYR=
M)1Q93S"6SJM%?I.-6<Z.-JV&2SSPAW&D0JW3;M$R$&@#4D$JB2@!).++,+$`
M,_6[HBL(X:)'>F:QY`6ER1I>AJPMEXGD:BJ^;(["D4D426`OI3&Z-H8G!HJ^
M.)K?H)NE:AS[P-Z!,(O1YFCC2RA7?$'=1P6GT9L^]8/:UB5A4D(XX*(P5:=X
MR5>_NU<DES\M.JK,J&)(XR.,MG+W93:J"K:&Y&ATI&E`:8?X(2A;QO'`^P.!
MUBOEDUO$:YL*J[(KBUX+,;3B/(AH=WIDJ!+6U9[5!M64311(65#)84HJ\U&(
MIY;52$2XDXT@!0#=GE]6_/8R=4_#N')[=XPS:-7137*FB9)RRI6EK,#$FV:Q
MY8R.DME36H!'I=`K)CT;?E<5F3"0L+2N28"A&I\,90]ECV'0I;Q?P,.W3QC=
M(JFO&YG=RB555F1>=H0>CHD]!<BI1<.X[8+ZT+D=51EN0JC!0J!H4Y9*Y\6C
M2-!)@0I23CE/4K5E\#$=!4'*>0<L?(^Q/D5AD>A4-?+'LNR9ZX*FN#UO7T<V
MF+=I1)%:!$XN1P=K%R=*D2)$YZM:L4%E%`WO>Q!MX&9WKA,]N"ZH3J2NFH+]
MA=T6*JJ5@G<=52:`(8K8+>WEO;BS61'[+9(](H>A(C@Q.12\1*A*I1DCV6+9
MG84.;\\"FL#B$S,543&X*EY,4UR)C573*$P:VDM>M-E1UQ@SK8:YR:8FZ)]3
M^)1Y++HNZ/#0>F"N0#%^MH(M%[!O8@MYRC,<I_+-DL5G=ATB9R3H!ZY)01@E
M,M2T(Q;L19(95&HG%3YPM$AEXX<3!V>5N$02FN*5B6+`.&TV@[/T0(6PAGV\
M^!B.O>&J205]6,_MCDE2?',-Z`5JJ1C-F)[!=GZ<LB5Y''`3%YU!8I(D5=01
MPD)1B1*Z.YA0#]DF&A+\$'B;N^(/@T\+)$SFV<X7_;-7\:8/55HK*3>)W.AR
M:8HI3:R!%MV5Q*N&*MF61OLU`@8!$N2Q>264A1H%1`S#.\T)6-^!,(_^73;4
MDF]FQ)%8=,)F*N*F@M^I[7<9<L15-.*.GS^A9VZTXQ+#V@&RXXTH%"A>O`K3
MD+"`MZE,$DQ6$!0WVD'=!P5C((_&YG+^8W'VOH':4ZEL"H":R1CMU0R70JA#
MDV,4ADJ<QE@[CNNX<FD;H%"%8^B3FB$6,[P=$:T8)O.8-)I]#GFMIK,8#)!-
MAC_!Y&\Q=Y,8W5&^LI[BQKCD*E0S/3>8:A=FI2,GQ$ZDH6P'$B"+73KTU1M'
MKA%8^^8Q/"GZUPGVB'J4Z4,J[WWZEZ&IJ\-K`$(?HGTYVA9!^;[_`/*=?.O_
M`+O]?)O&B]U[PC*E,&IJ5V!R6HVB7WD<4Y*:%A-E$V&:IG*!NDBB(`<WV7QF
M)/$*KMN<Y*E&E3#=%FA]-:,-`47O6]M%[A/%.P+)K6A:\1M-,QM_LSFS97'9
M!/CA/BN>@FK'$HGMP99:^M!;BP.52LYBG1[6)O">J$L./,\I0P;VV=^A&9QP
MJ'&*UMR;17D12-L2OCT2V++ZJV!"G`GZO6MQDZ:%GNC9*'R,-4-L5%'Y2L*1
MNAC(J4%)3!]0#.!K0A-YP9'A_P"6Y(9++ZXIQ[Y(T!7_`"6LU#$GIHX\2XRP
M@2IF99F@3/S03*)@UPY?`6>;&1-4%U#'1+A.)J;82P=5(RR13[>?`T-3L&VB
MR$T2=/-EVVBQ4T4=/#T,2)=MMEI;(X>&$T)9HD:SP!]NAA"+98O+K6^NLT/?
M>^JWM:+\N9_3M8?E#4A/:+:[0112.2?7%RS6L+[!5.FC2]WU<#;(VR-M/@DJ
MU(_3(-EI4FRN\6MA+%K?.9F[=$%K>@J]:VW\R57Q+XV5SS.75'R;J*%4:W3.
M%++K3HJW?A3(,T$Q":GQM6/+:U'H?!+<0JS`J"DA9X]F]W=NV];QP,,D\>K>
MO^_>/-'<B.&U<<(X?(WN=S1]E];4L\5-*)17U:0Q7+['0$+7N1R0EW&W,+>$
M"0`2=>;+EI1HN_7ZFVR39=&$$O-FCETO(BKCP9XO)>+"IX*:QQ5NA;B1>S;!
M3ENDP9.GY!^G=SI39R5I%I6)28/:$Y6'97@!+WW:N7YY&7K;XB07C_3'YG$5
M6MK=,)'1%Y\2F>HK)=41`I.BKJU%4DD28:=46`H*-1)(BN;RW()80@..)WO0
M=!Z:TEW!@'BI!ZWY*UE9/%H^+QADY+*!JK4XO68$@MO?)Y(8VT*#Y=QOD[EK
M78Y)9PPI1JHUXW3:=Y($7H70T!8K=G/@9*=ZFH*BRN,'%F]6YG9K5M.SJTL[
MF39;@F[)3QQJJ2KT!<;HQC=!:/W%W[4.7;?)>>`K9R0U200+>PE"#J=\P;86
MI"I'7DJG#%>_Y:M6!X&CU,D$3NCBM5B:93B&PWS9U)K:VHWR#C,O<5LD=@&@
M0*W0$E4DIE83#P&EE=-`W-XXO^PU@I*G:OD-$?ES/CO"(TZO=H_F+2.KY^]J
MVL@:Z9UZ0XU>0EBC^;K>Q+6$LIU4=J80M@!XX]:_W;WNVW;/0^O,GCC5+-?T
M-N/C_'B4O&^?\E5=(S&O]%`-2TS=$!L<J,SJJG,HG6BD\8FS$CT_Q[KH`#FQ
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MV0LC$\J]K6EK=U`3VLEY\\V7X(AGED"*)",\98!+<&3'/@^K<RJED=,WQ5U[
M5C:MVQ/CR?8L79YY%/9K:4S4HP,+58T'FC`UR]I:79"J&K0KB25!*TE,:$&@
MFA"`3?D2AQ_+NDS1/)'7CIR!H5&\50QS26<EW7TI*%<7XSQ>*.S6S-AM@/R%
MA4D/\OFB]U`G01YB"O<2UFMIC_#,T/LGV$<4\%7IZ?*%,J"Z:SNJKN0=Q-="
M1NW8PUSF/-D-M5S.0](G9,*EC`W3.+KO1C@%P3;"0I+7(0B&2+8M=N[OR+Q)
M.`AZ$%K1>"\EZ+MJ]*09););+H>%DV`GD25C@)H]3D4*F<@BS7![%?(8D+&>
MYMS:JV<262=HL1PBMZVWT+I&N#3Y#"^-5A2^VN/VEU\[H.:TG3TMW+7UUMM/
M8\V8&M4P2./,;5L;/#HT!PT%\6JE"<A<5H],@$<<'>PS?`B[KQ/+7RN])[<5
MM4GQ:JJ)<A[%II%(5+'/GR,2&S&%Y<ECW!Z9KZ),S[-'")0ULV28:J4A*);$
M!Z4!I@SQ]F7?CD;`T-P$K\#SRQC-]V_42$R$\3W&XJ:F2939[S#W>+R4R(.4
M*Y/QMSAL='M\KIJ0.!R%4VJBAN>ERG9>V\SP!C!+^W0UAKSB-#Y)%X;*K(Y9
MT=2:>UY7(XK333(VBQYB_P!@`CDE#$#)6X-D&C3H974/=I`8$E$I>]IU)X>X
MSS<)8=BR[\31+H]^7E/SDUXN]DVW35+1;C?>AU$7%*YT[OI[6PO9;.O<TSVP
M)F-F7.DR2O2M,0A;T*(C;BI4+"Q"**)`<87/L,>.G#.P"[QX]TE%I/$YR/D]
M':[EU26"Q@>TT/=8Q8"M<A-=G(#BWDO+9]1U3.O`^$B($8DVA-Z:%Y.MWC1J
MU(VM*Q2*0,:)Z021&R/KNS))$T@5%M4@3M3@H0$O;46M*(6!;'8"?1Z?Q0`,
M\$P/<'6^NM46;`8#`8#`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI_CF8
M%-@,!@,!@,!@2*'GQE++XDJFR!<Z0M+*8ZIF36V&^`Y.<2(>41LE;F\[O+V4
MN7,@#RB1=P-Z,'K?<'X=![\-W)+C5'9#R/BK-S*IN.<?KMHV]:OHVG*FXL26
MO([69$TBZ@B!FWY(6ZL&F5+W2-D%`0Z\V4R,]P=3Q*CA$%ZZYC+\<CS[GE^5
M4]W]^7;.&R2&*8S0E+\-X?:;AMF>RA1U_J69JW:>(BT9S>6L>`LR`T)@3$1:
M@I3UZ$B,%Y,LERP9/L6T>.O*N&V15$CO=FHAU@_,GDG?5.V!.87/WNNK-K*_
M)"F7.#2[EPB./DNBLS9CV5.L1[5M^RE"0_:<7A&AWVI+/Z&!^;L\HJ3M/$B#
M4'8+M9<=H[C8GJV2R=YBCU#5:N8)K+GDB=%!#*]E:.(:7,+X%8A``T[9*(\H
MHT03P&E@LWG1"+EM&$2WAQP[J9@=Q+9[5#MRD53MFVWN*8#*194WBCQ#1@<E
M24EL<?2K<UGF;TF..V1V=IO8+>M;3NCTZ5\^*T=K;Y;QBO[V:Z:9[O2<6Y76
M-^RFGAV/"F^8TI3+%`IA"9]!Y!")/(6UAD>S5)*5W2-)YJ%8AT/6MIS]B%G+
MP(:OYLUW]<V.I;:Y*R&\J_FG&[D#1-KW5!:;CT&KZLI#?)\;5-LAIVN&>!UW
M.),PQ<Z%-FI&>X%^<._>:)$0#1?8=<\R<C6.NV[AYQJL3CG*=7\BOFQ63E'4
M,\E,^K>*V5'*NJRC83)$#I)$ZQNF<:99/-I])%)0%&B42$938D2B`$9QQNM;
M<T2KD+RN@',6$7LU7?+TB6TJILV<SSAW9A4.6)")G4TEEAA3CQP?TD=9BQ,#
M:4S$)7J-JUY!1:1:%00J-+V<+8TF==#7[A_9]81=-R)IVXI&O@,$Y.4N&L!V
M>@85TH#6TK89G'I[#I"^QUH`8]O$/4.K#M(ZE(0C5A)."8``M`%K+?F>!F2L
M&/\`+TI2S^/:.R["2<FP^T23/UX3F,PV?@HR+P<4/7-=:18,&EC/&IA9QJ"P
MCD[Y(AEI""AMI'F)03]C,ZR_:C8.P>0-:N'$ODS1LPYHU;;$VE#K3$_K*/U+
MQV>J@I9M15M.CWAXAT8TTUE"33K"E"!27OHL0!;425&46)P-'LS1<DYES@04
M'*BC0_FRVKR@W,#?8G)E-SF,TO\`J](_%5AEW'.1P"/BVP>BOK$1M;*EY2;_
M`)$H-E:%X@^TO6QZN7ZYY&.%Z_C-RGJ_B@KLWDLS\<I?QWI>-\?[3ALHK:Q9
M@?+H7!)&_/$>F=/KX(SO;.YR%Z8I":E5-CF:V:)<"PF>((H6QB<RW!FJD^75
M:M%1V%Q]I.[F[ARRQSD3,;5I21WI5:"\X_,*LF#$RQU1"YVY)Z]LIZB%@-*F
M-D.A"M,@&D4EJS48S?\`A*%DLYV\\"QVMR]KZ6,G+J*NE[2:W7"1</ZDHJNI
MV\UPU5^T3^;QZ]&&Q9TA@$-A4)C1,%K-.E-7&M9;^6!<<669LTWN.*(#<Z_(
MLG%.Z8M#J3B,88.:\:I;S>32!;>7'OE'2CK?]&S(E0[@/:)?44>:*UFR-"L<
MXO\`^3=VXXYM<#EY?BEJPEC#VK.>AH-R;D%02^^KAD?'R*F0JF'N8NBRM8L<
MDVV!:H^,H@LL)+3XJC;(@7+RSE*=#W"\Q3G@(\GA]NK.N1Z^L-X<,3N=\5_,
M`D/)Y(@9GQD9E2BC4%66:LLR%3S=#:JMP13)V#'_`*F_4IE=$PU7G[8L<%:T
M)A112;6MF'`SSF#$'%R\J[B=14_&S.:,2AM>,IQIO(;BGRNH5WY!PIT7_6=4
MN?7.@$K36\F;D3-.(L<$'F&G-G7)';9IAJ@0#-"U;/0N59<K>*<2DO&8<75+
M:VKFLOS1[;Y#@ARUBD;@IKSCO(HM#6B%K#AMR)X`O-3^AS2/1R,Y:N3A*T'8
M!!T`8Y9?\#3&E[=@,-A7Y@3:_/H6YRNREUD6J\HQK=%94AD(KYADW*0GC2HC
MR6DOZMM!ZD1BX28GH7LON\000;UG0]4(,S47='YG7'_D9)[)G-<W%.IS14\D
M7#U[I2PDEK--CH8A%P%O:"6*TB:O=T*<C9RY/Z<&M`?IBT,H"41@@[#GF?KG
M@>%4A=F_VTR!_"J+-:-7&\ONEY&A'%&M(;`5.7GI.B]"&<48AUX@-!UO8M;U
MTZ]=9L;M\F.:TR<^>MD7E2-[VD96.[Q9IM!36Z6V`RL:F,MAT?..**A;HK;@
MIFQ8!$H+,0J$1032QB",OH/>MR3_`%RC8EVM;B1.DGYD59,?)9AHB)W_`,HZ
MJN.EIB75]OKV)=$(^HELAD+65'X1%R'V.#3.$CTE"0H*2@[M;V`(RM:WDYXN
M>!K9!YQ6O#&[*5ONO.4<>Y@?5Z3/;/.JW;('<D#4^S>41ARC4U2^F+6:4C6,
M<C8'A0D3A3;&84KT4::'PP[WEO\`M,Z!'1'Y?K=-2+#4\V`NM!)'8J2%TPEI
MJS">3K@R$JPKRJJ4D'M`*M1NYA(=-IL@].";_#ZJ0E]=Z!J;^WP,YMW*.H.5
M,/\`S#6^]KA8^-4EY2W#QYGM?">8+8-C,;-$J>4R9,FBIA==,3@J"H9HOZ,1
M!-,"06<=W&!#V]=!9F8-14<6HJ@;GXY3Z$<KHK>+8QW1!9+-3H?5EOP%7`H]
M$I=&GM0]J!3EC;CGOSQ&4IT60W:.4!VGWU#^N#6[W.A\+2N"GI+S]LR\Y'&Q
MW-0DFY.3B>ND84#=651/JL?IJZJPIB/.S&AW:UQ\<6`-2%'B3"*.+++,[`Z%
MK23CV-N^/+EQGXFWBP<@*[_,05K:9C,A-E?L%BE;76TW'8D<V(Y6"G)K$%[8
MWU'V.A1H6YP<U3L:@\/0U!0=#\/09=LS!"X-R?I9'`N%*1<YD1)?5_YD=@<C
M)]#T#*_*D=>U)))/`GII/1*DC2)"\)FY"UJ4Y21"(Y9H*3RD!T(ON9=OX%AI
M;E;5\4Y8W\CLX;A)^(?)*[9)(IIYBC7Z=(V:@M5UGE/WI%6PU&8Y))9`G$PD
MXPK2;:I2U*E2490Q[`7I9QQV-9>6MGLM@\N>25LU?)'$Z*V#<=AR:*2)MV\1
MY6ZQB0ORI:A/$0>6V/",E<E&$0TZ@LL>O@&#6]=,LG&41^L:AC,[J+D;8SO.
M5T7>J1C$$D49C08HJ=&BP%4QG2.'K619+M*TK?$W5"!>%6C(,">H=`EJ/!+[
M4YY@+O@3[A3:<'I^W9=*K!=S&1C=>._(^!(5A;<Y.@CI38%1R2+1-NVF:DBQ
M26%S?'`DG9P@:(([^\T8`:V+4HS8@L_CA)>/'`1#-[8G<6E/%V93R/6=7M>1
MY_:[151&Q+@%/B;-J6S1(E4%;W>%MVBS@I51@5IJHOL*UK?0>G/(S/R+ORIY
M5Q_MZ-6OR?K3G%9C^*)D<:YBT\<WZO;OJ\YODZ=8^R>T;=?X9"E:Q*MA)9C<
MH91*9`-8L-T/1H"P=^22[\#$'Y>#;7[Q#?S`FJTI&]0^!N/#8]$^RR/L@Y*Y
M1KSFZJL*;'[ZO%*4:A\;VEX$G/6I"3`GGHP&@*ZF;#K;]NY^1/JPMCC?Q0B]
M95;&[T;;X7S+F;QIOZX[#AD#G\=K^MJQH*0J5[>S-".<1]GF$JFCP>]*5BSS
M5!HE.E(TG#LTT6NJRT8ZKZ^Z:?+'Y_5O8\R=(=4G-%X?SH_<J2+O$E,@[_&[
MQ66S6<DDT31A)D[C#WW1FT[J0G*&O3@.`/1(A%B[&7)\C8KC)-*6JF:<,>*-
M1VNCO^433\P^B;[M*RH]$Y=#ZXCP(H-/!H/!(63.VYEE+\YJ`OBM<[.(T"8@
M&M%$%>)T%O)=YOH15O?>*/%:_>07)6'<BS;-DVB^2$4JCCT*L)RR6(V3VU4D
MS@*P%KRAV0>S@J)04N1+#1JVQR7FO`2B1%E%C$(O5YLP8,F5^U:ZW;^6[+F^
M2*549XZ4KQ$A=H+3&=Z*W''RJ+`<7Z=(TJ,Y$%2[@;6]2$[1B(!Y2D0MZ*$,
M7767.*-M8ISB8'Z/7=6$'Y/L'%YQUS!OR]ZZLB?4ENT:]M&M;B?]+1QY[2^S
MN>2Z!2YB5-Y2]&9IN"2L3*Q)C]@,*!VY^O\`P(@7RNIV=7U>#!9/)&9OD%L'
M@J_\36/D9-*E(2M14V<GN.RE:^M5257%&)_CE2FOB5<6U(SDJEV)*&$:DS7B
M:`5<O'Y%'3ET<?:TJ&C3JNY-PGCI)*^62`?)$ELXR+YSR+O)_;Y\L7L<FJ^R
MW2'NR5M8'^!E)$;<W*'R.@8S.\:C0S.O59;>18.:'(:BIQ!^8T7K>RTL\6W9
MS[A/)6&&MD9F+,C4UZII^6-KP4N-D;(U!2O$5DS\0WJ23.FSCP"-3Z-)UXF)
M+Q^!6T+<+?%OR_9A;,C2NB>U>,K_`&1QTXNR@9(0HU(.9<9VJF#:C6&=J@3C
M3C,T25[2^%U"E%(2]]0[$'JLYP>08`!+``L&NT``A`'6OT!#K6@Z_P#AK6:'
M;`8#`8#`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<;UK>MZWKKK?DWK?EUO6_AUO6!L
MZCYH\L6^O2JK1<@+'304B-&PM,U%NJ?;BCA9Q(DQT-02P:(4S01,Q*+9.VTE
MQ+1^#O9?A^'^KDR#6+6M!UH(=:"$.M:"'6M:UK6M=-:UK7DUK6LHYP&`P&`P
M&`P&`P&`P/KH\\)!B4)YX4III)YR8)Q@4QQZ<)P$YYJ?0M$FG)P*3-%C%K8@
M:,'H.]:$+J'RP&`P)1'IM+XFW2]HC,D=F)KG\=^J,W0-JG:=-*HOZ30/7H%Z
M+T'?G39Z7:TRCP^NO^4@&^ODP(O@,"^Q:42.$26/S*'O3A&Y9%'AOD,:D+2?
MYLZL;ZTJ2UK8[-JG6A;(6H%9(3"A]-]HPZW@6UP<%SLX.#LYJCE[FZKUCHYK
MU(_$4KG%Q4FK%ZU29ORF*%:L\9A@O_J&+>\"DP&`P&`P,G3*Z;:L*'5[7DWL
M*3R:"5,VFM%:Q!R7:%'X8WG@**/+9VT@H@@)YI)`"Q*#=&J=E`"7XG9K0<8,
M8X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,
M!@7R,L(93(F.-"D<8AX7YS2M6Y7-G(UGA\;TL,T5Z:E#L0C<#FUB;^[Q%)P2
M#A%EZWO0!?!@>OG,GA*V'<C(OQLXW,W&N/1^LJ>1SJPK&:K"E`'2,Q=+"*_>
M9C9O+*5RT]6S1H@]Y>C%;`%J2:VI;EY0`$B&(!0,R\;1IV^\&+)3N=,B@5AT
MO=,"O6TVNDX7;M5R]X=H`V6HZJ41)4+G>GF,,4NA;L%,O`L!I4U=JE#H1R?9
MO;L.7[03$/Y;5XCDLA@H9YQ\U8,$KZ5V?:L*-MI"2Y4W$8E)XS&UQ]JN0VOZ
MO0YT.(E!;II$>K\X(;4JC9X2E(`IAS[0<K/R])"W,T1GKCRCX>H:2GHE;9$+
MV56G)"H$^S5M<#6UVKU&T"@.K%U*&8XG9RP9K(6VI48@'FJ@A&#6WV_.C#=A
M\/KFJQOY$N$U2QMMWQ@L"MZXLM&0]C6JE#U;`78^$N,3$G0;2/D?<F]H$JVH
M&:F&!.>5OP]B$(`+LHSUQ+XHIG><U`_W$Q1V55O>_'#F!9T":"G5TVM(7T?!
MK`;$;B_$I`-@V]<U3J/%JDA9:A04<46'9ODWLO%O_(QS4O!B;V3$*ED+[=/'
M6GWJ^R0CHJ!V[/WABG-L%#>SHJA<69L8(C)6]@:7^5I36]N4O"EO`N4@WHO6
MP=!;6Y\C)31PDCY7"OD%<<WLNIX7=%1WB@K\Z+2&QW)`\1@B.-MD))C6[Y&D
MC$M:5-ES5^B91T8*T>86N2$C%XY.A;UN?;F01^7\0+`GMV'PJ/1.H*09(CQT
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MA`6`PP8`"6YV,YR;A-(F5%"98Q7QQNL&G9A/TM7.M[PBP'L^M*PFZU`I=$K/
M:9K[#F>50\#DVI##4"P34H1+M:UX1@M[UK;1D_\`-&JNLJ(Y%&TY4T=I5DBE
M=LQ;,G#5<AETDL!P,TB:#S3^0)\H6J4J:SE*H1RD@EN"4E]&JBM[UL6]:#/U
MNS1F%LX-T_'(_P#EFSM;8]/3L7("VF9@N.',UDOSTNL-E=[UC\5*20=C"R->
MR4$(BRTUJEHB5*8Q&Z;V$O9V]:,QO<&&+_X%2&'O?)U]@UC4"^"HJ3SN432@
M(58;@_VS5-2))VH9FMU>T(V,496E19`XMY;JF1O2Y>UZ-"%4'1VA@TEZ$)A?
M`>SYBTPE.=9E!0JV;5C2*85%QUGECFQ^[;+CKRG-5Q=6RLGH%7&F1;.$Q.S&
M%$\NK:L=@"`(DOH8#8KOYP8"H*)M<DY%TC`YLS#4LK]>-:0R91UQ"J1FGMCG
M/V5BDC&X`)&G7)#1ICCTYV@"+.+%UUK81:ZZ7H;A\C.`KY$ICRJ=*ZL.@7;5
M&RJRIE(..\.L-Q?K>K2E6J<*T#8[.;>)D-C2P,78E[?MR1)WQ8YMQ1H=*@:.
M[B]2?MT-8W3BY9K3;-$TPJ/BVYCR)C=*RJOS"7968RE-=]C2@@H9$NVUA/;5
M16U8//P%$J-)_+V"-_3=F:,G1S@G83E$G>Q9I:U!4[6D?NFPJ!>YY:4]=&9J
M2637(VX#BUHVQJBSU(GQ.\^D=F(3$2,_M3I%!RO20HO0AM_L3US_`"R+N9I)
M+*X<K-XY%W:P1^13./44BM,UWLFR8+&V57)C9A"26J.+(UI`]Q=`<YM:1U<6
MQS6H2]G>;%@Z;V^T[\#&U5<)I59,+K2:2"Z^.U($W>N6-]'1ZZ9Z]1Z46L-$
M_P"XF-P8VR/Q*4%,;`IE>MMJ=>\&MY"A6`02]B"'OQO(^L6X(VT[,5ERV;S"
MGZ3B%,70[T):\EMV;J&-%#;"9F\2TY#M(R,DB=)*6N/UYJD+:2%RM0=W#\$*
M<!AX7V@PO?E"S'CM-T,+ESG$I*GD$0C=APF;P!Z,D4%G\`EZ<Y1')?%'@Y$V
MJE+6XZ3'%[">G(/*.)&`8-=-;VEEZ&6V_A!:ZBC(KR&=915,7K^P8J]/E9)9
M%,S4<TM"4,\L>(:&IZ]AQ+0H=I39CDZ,HC2TB;0D9*90F$>J*&H++VV;GD7F
M9\"[+A[!8!A-G4#,[0IZ/K99<W'N!V0;(;HJ^.LP212A>^,X6%-%WL^#:/#Z
M?2LSLY*6?6A>.#_C'VM%;"/R_K.E['6YKO:O'FL+"NMD;Y+2E)6E9"J,6K9S
M$^#,*BKDVMQ,<<HY&"9P<5L#'I]<FP;F+8?#UK0M;VO[8,`3GCW95<U8TVY*
MD"-"P+;6L.D7MET:L^MD%M"LTZ-9((G-V@U`20T+U:!;YPAT4H4:4%%&;WV;
M#TVWP-AI!Q,G]95A>[%+H55[O+X;,N(C8]38N:27ZW5*YWZW/3VP0%$P%,I#
M`Z*WM&J3ERC:H?B,QJ4L"41XA&=&[1<9I^6U>$`EKO7,DG-$E6DPLMP2UZK!
MNL4]VF[-`Z:BCE,72=/C0@CYPF%BFC0UC%'0+=D+7#1I)AI*8DT)F3[0:UUY
MQXLNU*[661!T+<\MZ>XZMHA(P!6F%2AYL.X4[P?"434A,2Z;C&]0-E,*//.5
MD^"887^J(.Q"!=D&8K5X03&LH;9,M;;FX[6VLI!U;V2]814MA.C]-JC<'%^U
M%`B?VM\BT;1OC8@E8M-BQ6S*7$A*LWH(]]O4>DNC2S*&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!38#
M`8#`8#`8'Q4A$-.>`&MB$,DT(0Z^'8A`%K6M?]=[W@>UL^Y%<?+)Y/<WH<LM
M=IC-7<MN.5+U=$[VVSOKG%HA/JSB-0/C>7+$:!O%)"(0[2F&*V9V4ITIPDV]
M!-V6,H.Q:QER7V+12L]HGB*ST54;I?\`6=N/\HYZ<=>1-KS"JSY,_5+3M84J
M>>C)$.5O$:8U$BF$A&^GJ%9;>C&%&WI-%F"$8((=V[>?0U_KFYJ\;I/^:"Z/
M\R1E^WFEKQCU8+5>EYID\D<LY`0^7LJ%"/289FE3M'F\]6$2GP@^&7O0MZ%T
M#MG,&+K)L.$O7!?BS5K7($2RP8+=/*"2RZ,%`4Z7L;%.2ZPU%'%6,9`$@B7O
MT$J\+19@Q:\`7=H/DZW_`->AZ$W#<-!<CIC^8Q5;'?M9P)/?<KX@6/4-F6,=
M)&2KY.;14))9II%G"0H8\Z+HXZ&&.QGF9BE%X)YJ0PO6_+H63F8.D5NSC753
MQPPAS??L1G+71_$CGI5\]F[0TREMCH;'MM#82F+-3.0]LB%X6,TB>Y$!,TK#
M$Q6UB?0%!A9&C-`#,M_L4_'BP>.=4QOAQ85<W5Q)J=GA#%6SMR>U954N%H\Q
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ML]H(^S@-K@\)ZW>Y$YQR1QN2O;8T$J'=;$S'B+EHW4*4LPX*14(>@["`71?D
M91DJJK.-7$FWJ(;+XJV_K1Y%VM2DA<04JHDTBKVLX!2JZ0/I+RZR^1QV,$K9
MM+W>0:3%($B8T:-`6,1Q@1"[-N[HQ%^8'8T)MSFER(LNMY"CED%F,V1.<9D;
M>!46B=T!42C;>-2F`M(2J@EA6HC2_P!<L&^H-^3ITWB3)E&T5<VC2AU:_E<2
M5SN>$1U\XEWT[EVU7+XFEA,S)C4QY*,5BE3MBVECBR..D48HJA&>X"\^`J+W
M^H628/J'4SOV,8UW<58M=N?F7R!WF3<B9KOH3E]$JN=#BUPRYC(['LEH>8<W
M-N@I1G`4R!K(,/*V?HH.@AWWB#OR8SB#?TOE[&+)>J>N]CY'\+*8BL9@-1(K
M.B%E\88=->5]?S*J8NRQUXU5*YTJB3*K/$[J8X4LBRW3T06V[/+).TG`FT')
MF?(\?:WLUK5<Q8!=$Q=Q(6-1R@BMIRJ0.J)&@,2LYULH9<]OCJVL)'HY$<4A
M$:H4D(2MD%CT(!(=AT'6:LXR?`V<@EV58V<E/S(YJYS1L2QBZ:7YOQFKWLXM
M>(B8OMHRT*^!MS=H*0:@"B3(O^0G9X2@Z#_W!`WY,EER#8%AD?'"P+DX!\K9
M%RHJ:OHO05:<4(7:=6/J>;*+L;9GQ\<4Z):C8HJV11<S/48D8TA"K3UMP)2(
MD`SAF!$84$HQS)9@U6Y0V[7$ZXRFPF*2QN?)6+GWR_MG3*C`MTHW7=B-,53P
MN5Z$H2D$^CY`<A."1K8M':[-]X`XDN_P-F2^2E&:_-3CE\[L9DU4*.E&6,JI
MSX#IZ*(?DO"+V7G-HB=-_I#QRIYKT9UT3L'C>76_#_7QE^N>?_Z%`37CY7=8
M\3)M7-S<2*C60YJ8'/E2JMNJ'&VN6BBQFB>K'%X25$U22!S5G(BRR)E)"6(;
M$H:"D9PS%"I0$[0A!7>9=$.YK6]3\@K/E7#(3:L+GCQ8/YF[WR)B94.6NKFA
M=JJE=0OH$;^2O5M:!.8-F=WXMK6E[WWE.`#0`\0L/BB3_P"#5GEY8\'L)CX;
M)(7(43^?6_"NIJTFY2,"D&X[.X_))\M>8VL\Y3D!&M0)G9.,>RMF%;T;KH/>
M^O2SS^1DV1<CH;%XG^56^1]S331XXJM\GDEB0<D2@L;.]D\G'&QDS&HVK)*1
M`<9'%$J8PLTH1@-!$7WBUL/33-M]C>"U.43`B57_`&U&N5?#8Z!6#%+;#5L4
MJ?BE7S=R]?5]JH'5`@@%C;<ZC:Q0HE,F?SD\J?SWI0)<0288GV<<H#K69/5&
MODT3<<^4-DT7R;=N6-5TBS1BO*`CUX59,TLY+MV&OE$1^/Q9S34['&*+N[98
MS5+F^+%*F8TA>EVE4JA:4A!L`M99LXP7JKN57':\;TY@)N2*XZOZ"NJ^HOR]
M@Z1Q2'N"I'.:BG^W$F#*$[:`\LEZN6H'=Q8U9H=>%I;LOJ+>@Z[F629V,-QS
MDZQ3NG.:+[:$K0MML7_R\XJ70CCZ@*L:A<S1BPK$D<Z4(1DIS4I;9"&Q\2$]
M@A@%HC182PBZ=-7,L^,&1FOD'3:W\T+E+9SQ9+<@I^]R^4U<1ZW#T;PXQYI0
MW!7CY#8/+71*E1C>_JLC5')2SA`(V8G2[T+LT`&^DR_6?(M3/KC_`$!Q9>*8
M=^5T4G%A2#F)QJM.1NO&CZROID)KB$,\X:W"5U[+Y/'(PADLZBYB_2\T@HH)
M*4PU&4$PTX1P27-N^AE3D)8]12BG>0:^_;TX<\J9N[1O_P#Y>LJDJ[=(9RT<
MIX*2->VI]NE>Q0"!,:2/BB!:G;\ED'GJDU;O04XQCZ"VF[,V#R<M6%Q""2)K
M9X5:<>M]J71"+R%9)HRTNC,@:7Y\0>=/4*4I7<8U)SK$U7_EU!X-^"<+>A`U
MKRZUJ#&N`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP)1]Q\"P+?ZU9_=J?XYF!38#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"4?<?`L"W^M6?W:G^.9@4V`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P)1]Q\"
MP+?ZU9_=J?XYF!38#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,!@5S4UN+XZM3$S)#'!X
M?'-N96A`3_W5SJ[+"&YM1%;WY-&*UJD!8?T=18'I/:<0X)<4)RY\?+'JNY.2
MUF0;:1ANVTHI=:>HHW&9_P":DGRB*T_#BX5(BY$FA*M1M$):_*0A7K4YFM`*
M*WK8<\WF<00"T^",]%:S/&^+J&3W[7ED4DR<EJD=BD;.VS1=3S\ZIH^I)E#+
MI>0C#,(5*U/HIU(1[%K8PZ4A++)$/12?MQR,*V_Q-OVBRX.HL"$)A-UDN*IC
M@SU!I?"[389')$)Z9*NB2%[K202MM^MR-2L*`-L$8%9O9FNP`M>7++*)59_!
M;E-3D'>;$G]8E-\:BNVL,\TS3FO)A(*S$]F%$-(;0B,0E;Y**]TM5'`)T)U2
M)@%GBT48(!F]!Q+**UEX!\N9#`$%CM%/JE#0\10V>,,;,EL$1VE(X*20-4.9
MQRGELG3V@^QH2,L1Y:E,TF:/(#LPK0R_UL;!(&[B4NL'C7QHG=0L#]+;CMZ9
M\KT<BCP7MJ(1*HCQ\:(7(BCHTV.9C;K;NB875Q4*""SSU2[1.M$D[&'M$W+=
MZ&$:/XXVWR#/4G5K%PO3&SR2#QN2/JN1Q.*MC0OGZUP(CJ+;C,7MB0'N;HG9
MEQI)(!C'VIA"$'0>F]MD&U5_\'EG'*TN7E=O,.FT]8JDKI5.:PG31.ZU($Q1
M<NQH]#T5DVHRMKJ<H/;%9BQ0WB9$Y"=W+5'DJ!)@IPB'J2\2C$,3X#<M9Q`6
MBQXS4ARYEDD<63&),*B80)KLJ;1!`4<H4RJ$U.ZRA%9,L8/-TYAA2A"UG!4E
M`$,GQ`ZZY?M-P4-4\&^45U0MIG]>5ND<(Y)E3LAA.GZ>UU"7ZQEK"<8E>4E:
MQ2:RM@DT].;5I0DYGHQ*H#YR'9(=B-UL&FR#71DA$MDDS;JY:&<6IR[2(,00
MQ]Z5H(T87*!K1-FF=V6R)6U-K$<2Y`V2>-:>G*3B#OQ1`Z;WJC?7DW^6U=E.
M7^Z4S646?[23!KE%94>-1O4%=Y<\,+;&X*HGIXX[&7HU808P3&9@;T:828M8
MY$^&<F+4%[$;F9^VS:,5(.`7*Q?,9W"!5\P-+E6`HVFL!ZDEJU/&H)%7>6M1
M+TP1APL5\FJ&#G2]8WG:$-I3+SUZ<01!.*+V$6M7[00U)P[Y+K;O>..1-3O0
M;?CK:8_2&.*'*.I&MBBI3>F=A39WFJEX*@[?!1-:TA0!Y,<0MQA9P.PT0AA#
MMLS?`SA:O""34EQ&(MFR8TZH+6>^43#5<--CDMC4[KZ9UN\56\24+E$'2#+)
M$PRET%-&L2/QD:\T90P"3#)";DEV\=8,36;P@Y0T[`7*R["K#;/%HZ-I!-@H
M)C`Y+)JU&_"++90VE"HQ)GB75OZ2/-`47MX1)-!/&$HS8#1:!N_:="Y.G`GE
MDS5TNL]PJG93$TPXFQ'M@*FM?*K.8*^/2E+BIN_5"EE)UG,\8]'G@4C4J&H&
MBDP]'&:`7^MC[3<&KD7C,CF\C88?#6)UE,KE+JA8XW'&%$>YO+Z\N1P$Z!M:
MT"4!AZM6J.'H(0AU_P!=]-:WO5Z&P]R\+^25!1$Z>69`$2.'H'@F-R%^BD[K
MVQT4+DRG6]IHU/?9Y*9.=!WU0(.P%IW,*;9AP=E!WLS7;DEE$X'^7+S-*;'I
MQ44R:E/9F(Z4AC2J=5LGG,BC*5D32);(H-`S9>&7SME0-"K1AREH1K"@C`85
MK>SBC2P/M!K;3582&[+0@E71).2L>IL_HFM,`YW8F$`4.][5NRL#I)G!J92#
MT3,G/.*`>>#QC`!*!H9@P@%;P/2YX_+$D#%9/.RG43/)YG-*2AL8EO'#T=+8
M.8JF#&]7HVUV9)9\6S+SF9C)#$P+U:Q.X&M`FO1`E*D)1(.N9^W5&B5G\3>0
M502>NXC+Z].6/%O=H:I-@3_&+19+'4^E"6,YNADBKEYD[&_.Z-Y4%IE"0D_:
MD@TP'>#6A!WN[!<KDX<<BZ#BR>;6;`T;?%!OH(JY/D:G$`L)#%9<:28H*B,Y
M'`)/)A0B3G%$F=B-TTE-,$6,`>X81!TEE%HHE]XU-IK@VW[4%I6<N>7IB21A
M;75R-M6)V!&H,$C<@.R1?7\V$^G*%"@HPH8!IO""6(/07=W:O(WCY-\8*)2<
MB;9X7<2^.5]R>\X#)2&YNG\@O>.O</VP-3<QR*4R*11==`(NWQMC3,[F(DQ<
MN?B$J(SL-&8+J$L69;FT:;S;AER2K^9U;!7^NRE+M=SXFC%1NT5F,&FL'L&1
MJ7)*T;8H]8D3DCQ!S79(Y+22E*<U>2:E\0(C0@!O0LLLLT7XG@1RY.D<(B.Z
M9=4TFL",R2;LS*X2"'-JQHA$24HTKW-9]M?(4Y%910D;@0,A=(1MI*LHT!A&
MS`B#O;[06&5<,>2L.L>LJJ>*V&IEET';3U$?'95#)9#K).`;LA05#[#C<A<X
M*[&H5&O#4@TX!,2CV'1H0=X.YLS1<YIP8Y3U_""K!E58E-\>`^1>-/@")Q7K
MK(((^S984VQ%!:$4:94MDM8B?G`\!)0WU*@++-'H)PBQ;Z8V;@RMRH_+SMSC
MY-J$A$>8'N=N]YU_6REE:&IZ@TID2NX9)&B'J<0)D9H2].*TYBC2P_1:-U.*
MTA6$:$:6K.``8PI=&$[GX;\BZ!C">:V7!$":'&OOU56RF(3NO[+8H]+=EC.#
M$I<XUU*)01$9*866/L1N.TQANP""#N$'>M)91,.$G'>*<A9Q:7UW3SJ01FEZ
M/F]W.%;U5M(&T;9,B2AG0(H!"#EB)T`A4N"QZ`<L5%HUAZ=$09LHD1@@["MP
M7R:-'#NUZWEJFH87-^,?(2&22#MC!3=AVRHLQANMFE[]J-.!+"]2.(Q!WA<V
MAZI00L6`6C`VFH=F"UL`M;\-S.^A(^4WY=]O4!/*'@<:C[W/7B\J_KA4R-#6
M]063R-7;LABY#Y.X*SL\+>G%6-@BZP_L2.IY84"M,$9P%9P`#,"EE&#;IX=\
MB./T82S:S8.WI86>^"BRF71"=P"RXVQ2P))BC<2E3O74GE".*2;9)(Q`1N(D
MQIOABT7H6PBUI+*).IX#<MD=>FV6HJ-0!F30_5B*XWJ7P,RU$5>^;:6[G*ZF
MRY.*TTD6`@WI2)4-HUH";?C"UHO];&P2&PN);BXF\*8M048E<XL3DIQ@9KB?
MV(*Y(K+^LI\WL-E>G!$J5!;6R+0QIC\4(4*5"Y0!(B"$PXY0$&_(WO1J`B8M
M@F3?%W,Q,9OZVMT<<S&IR0N247>]D-2\3:[MAZUL7D]!#\%2G,.(,UT&`0P;
MUO='IOR:CGY=O&_D%;5#J.,_)F8FU5+SXH;*$_*AC92'W9"%`MVN*:1T@Y&(
M`#TM[?#VI-WKMZ]WEZ:S-LT:'+J(M):W5I,8W73\LA=]S1]A])B:U[9+5DAD
M+>_`:=0(X;(<8K3S1O&M3EC3+DR!2J!OSDLGP-]VKL$WA7#3D98$ULZ"1J#-
M@W.EW+;+:[Z\6!7<<KR!//G9[>4SOUH/LJ;Z]"ZJG!*:02F(<CCCC23-`"+P
MQ["V2:,ZT[P%LN2OW*ZJ;#K2;([QJ;CTUVC5D/9G1G&FD+X]V/!HVTO0'A"H
M<(S*8(OC;^L4`7IEX6\("MG#4A`29VRV<6=#7ZS.(/(JIGZM8[*:[&Y+[D6F
M-=4J*]DL1M1DL![(<4K0LCT7D-;OLH9'&1-[FN))4(='Z4DB-!L0-`%H6664
M7BW>$O)6C8:HL"PX*SD1)M?V^*21UB=D5G8NX5*'81A;9'YXAK^7R5PACHN4
M$C)+`X%$!$>'97=XGZN)91+'K\NGF5'6:8/#Y39C:;!FMWD#]&%$YKC=@&1A
M@*T>]RY@KLF7&S64Q%L*[A#<FU"J2#"69LL8]%CWI]H(-4W#/DC=\'U8]<5X
M4YP]4Y+F..NCU,X)##I[(&LOQ'&.UHU3.3,+M8SZCWO0!IF8A89H\6B==3MZ
M+Q?VD'R9N&_)1\MB:4DGK)6WV'6C:B>;*12*0Q*,1ZN6EQ0MS@A<9U.)`^MT
M*BZ960[)PE^=KRS!GF>"$.S@C`%LS1CBX:3M&@IA]1+:B:B)R(UI;Y`VA\_:
M'QFD$;=@F":I+%I/'5[M&Y1'7+P1Z)6H%:@@0RQ@V+0P"#JRZ,68#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8$H^X^!8%O]:L_NU/\`',P*;`8#`8#`8#`E4$EJ
MV`3J$3UM(+5.,%F45FB!(=O6BE:R*/S>_IDIHA:WH):DYOT`6_T:%UP/3OD7
MQ+DG*N[K#Y+\6YQ3T[IN])0X6LM7RNYZSK21TR^34[;W,H9;\7G<F9'^/J8E
M(E*L`%29.M3K$02S2!#V+0=YER9>QG`B[*J93K?I>M;28GR-<;/RD;@X[,EI
MHG<+*TVQ;4AFL:E5@#K<]Q$WKW9E7NKRH0M("P[.7)4AII01%#T+<SY^1B[A
M5<M44U0'%R1V(\LA#/7GYJS58,C8_.4RAY88;OC\WLHIZ&.)QF.VV1A?1$J1
MJ"B-@&<C[`[$:'0<MEWCX&(YCQ@LBB&ODU;%B<BH)'HC,622ML46U?;\'L=T
MYICETX0.R6'"8(E-#9""`2%&$3P]N#VE`!M&G`$1!A^_U&R\#="0P8ZQ_P`P
MZ$?F*1:Z*B9N**::U+<BFS7:VX*T2*K(1`8U&27ZCG&LCWL-C$S)M)854?1L
MJ1I.)7%J0;!O99AFM3_S]?(UPG')IK@-1<+KUJ50TMT@K_G/S7NIK@"=P1Z=
MF*(R.>UL_,+`_,J=1M:UM,GC&U+;K1H`%'D[."#8M!%TN=ST.>=*:L./S767
M'VHWA(N@-N7*9SQD9Y(#0B;Z^LDQ"1QI@SR284`W2J`5@-S6&D[#L(3G4(P=
M?U=[3GFC,7(,ECCUS?G"2HV:5>ZQ_D;QZ<IQ3[G%++@TJ3SEH>[XK`Q`F3;C
MKXX&I)*>F9U!PVM0$MR+3%>,(GPMA'N3J>A0W/4#GR(Y30_F?5O(6M:AXX*(
M93KZ7>2:UX4R3KC$EKFK8]&G^!E5D9*F6RM6%%7IA5$-34W).QU,5EC+.T$T
MP>DXF>16T`UOMIU7QV+D$2XQ\L*EA#U)#`SR5W8W<4N4G$`MSLQS?WU.MF_M
M.CST>D`8;J5MJP3:[)?.3Q%%"[BP]R]^1Y#\C44+(NJ[T%<S1WL^`EV-/"(?
M8$A5FNK[.X^)[</1\F=W(\D@YY<'LL7C&+!E@$M$/Q]AULSIK<Z'N!-I0U0[
MF#RJY!1NS:W(C%R?EG3W5.S.*6="G!S6R=@H"DX<-H,1M+V:]1>:DR!&H3H4
M*TI,X'FIQC3`%X0MAQXD]C3OBQ4\?G/$-T51V)USR(G[??3LJD5"7AR5U2U0
MU1%B((UD-5W*X)[0JO'.WJ3J%2EM4NHG40$"-)LG9(]['O+>QO+?!L7L&3<@
MJ;BL]H5BE7*K@5PV9J(E,7L.-M%02]SH%Y;1V92L?D[H]&A@[;*MMQJ5F3/Y
MR+:XMO**,&+0M"%)_P#1B6K0-/"OCMQA:^0,WKYP=('^:)6]U3&H(=8$+LU[
MJZODU7N3>M?75OA+Z_-X%RE<DTZF)4QINB]EI]&;"H/\/2\VY\"]V:N,J*-<
MO+$-IC@%7<,MNLK9A+/==?7785N37DPAM%X+$WMT'@A-_P`D=!25\,.*?%"]
M\9TY$?5(]F&AT(.@[3QV):?&&R?.3]9'(Y1QO<X*HHMV0(/S,^/5_IJ9NF2H
MTE3#;HS'9M2C=8[FX6!+7T25-$WB.JHXF4J2M"T,6RP]-O4_H>5WY=MF0RIN
M5];2RP9$G@C(LC]DPDB?JBQ>9UK*+#K*4PF*3Q4(ON&B11B1/B<T]2'RHR-C
M.ZZT7O>M?MS.!GZ*TY(^&'''FZ.^I958A7[1R&EZG@D*MN"V<Z6W.%=@1N4-
M]KH6V!OT@,21.!-;$J6ENKKI&<(Y>$H`/%&(&YNV8-AU-CPI3^=]3,]43R*G
M0=FU1S;N:&2AH'$VIK1<4V-M<D&Y'M=MG1($KXI4IU!6S@EA5F&ECUX@AZW/
M_&#Q4B2Q`WV#$G)Q-)):VVPHTYKE!FM"3IV]OEB!:I5"UK0M>"G3$",ZZUOR
M!\F;'L]>PFZ$3[\YM[W/*X4(.0\#8)S4[C"K/A,I+GL0F'*&/FC3HC8J_.`M
MNRV.)U0US2;VKBT&]C.)T0/0A8\3!:^&MXU)3M<_ENOE@R&*IF^)<D.<"!^`
MY.(C-5V"SJSAT1A<VDC>SK"9"P1A/)G(*@Q83X!@"2CSR#-&%=X;9;HH+B"Y
MT?Q?Y'QQ\HC@KQZ27.@@,.9TE,7'-+KG-Z&,\Z0RM'*(4W)KXL-ICK!#P-PW
M(4@>T!)@@J/-``\90,.G=\CQM8AA+?F$PP00%EOK*88,>]!``LMS2C&,8M[T
M$(``UO>][\FM:ZYH>ZEIS."6-S)_-NJ.,657[%*N4D/C47I&Q7>:,[-`I0YQ
M%[KF7R*MMV$)5]6VLFT6-H/;R3U"HI">I3Z(-,UW:#O'4E^!9^/+6CXGQ_B=
M0UY32NT-DRC\S&A;[3P=HL2$3-OI*LH8W!C$IF,VDL4?7J)0]3/ESBG#I)M;
MWF(F_P`X.T'0/U5YYG6#"-72M-=:G\SZEQV)%VN\.4$N9G^MIA.YBTQIDM)-
M6UYR.4R:JC+`?ER5A;S9M'5J8YK`K5$H5NV\";OT#8,MXR^!L=QI`Q\75'`+
MCY=$YKA/:B/G^MY!O#$TV'#I8ST%5AM9AA`DDQF4<>72'1UUL*3!](C;@+Q>
M$2E">=H)AFNLO.Y\#0:AY.T`J+\T8+[(FT#Q/J78O1079W2EN,T?M\G(:]J?
M1X%:@*B1.VD>SU8_"T<=HKQ#=_J]PLU>Y\#?=MEL!C/(_B#=2VSJTC<`LW\N
M>+\5(W:B&=QM<OIN[_\`VY.]?"=IY'V5Q4S"OT$1D[J6C/<%R0@@D*DP8![T
M69VY\7YT:N,-2R#AIQ4YD,-[2BM4;OR(AE8UO4E70JTX%9[C-9+'++:IFHN$
M:6`R%_3LL5AC`UJ=(W-?M.H5'N&B0%ZV+>MW=LP:X<.(O'Y7-YBB2WFOX\WH
MWPHQZXR3\<[#6<15VJW.J(2J&3*=Z3[.C1<LBIBM.VJ/.D*;TAH`%!HBQZ*'
M;_@>B%L/5^!XN<B&7\R^74_.7C=?-Z/B><OE](6%R1'=`I&V:1.$<DU2N#S)
MAU@1&0K1/9[XI\T-+V4`O8A#V$69F_ZB3-\K@,>Y$\6;A5V?6,:@EN?EL1[B
M=$;523Z-JE=.WH+CFN@6W.?,3*X*9?7B"+R5>%`<X+TB<@G2H8@C[2S=A>+/
M8UQ@5=K^#O''DXW\BG>MU"B\3:$C-<TM"K/@%H.,[5UW<+'84AM(]+`Y#($3
M)&&*(LZM&A<%PDYZTYS\`(-:%O6[_P!K,&2+PI:2RSEO=_.!CY30:N>/$W/G
MUI1+DA";6A[G8PF"40M60PTNPU<EF+1:!D^5`5EQ)6RG)$Y*9-HT9@MDAT`4
MER9G(R:P\AZ<<*6XE</9:OA$&9N1O`:/5/-.2,=?C"Y]3\[#;,X=ZW@\\<6Y
MTTC:J>(?T?24,QQ9(ER-]TH5;\%*5T9=WV/$3<:<8#:J:(R(UI`Z0VQVQC>E
M+2[MSRP;4,<G2IEBUK?FU0H:W-E,TGV:0K),$2:GV$S6^F\W['Z'^6DP_,LD
MW).ZG?CYRXJ9)1KQ,E1M:(D_*7B>U)R8H:VMY!9!;:_O_IU&7M4$_P#44_\`
M-KKU^#>LYRR3GL:L<+;8A'#6JSF&[[1,3.'*VR'IABJ.OGF&3%=Q-3Q]GF-8
M.',G9I:>0B8YX<^R+2)I3HC$2M=&DJE;H8PZ2=+9O7@8V24>_P`QXK6+P@@\
MWJI]OFG>93G;,AC^K5@C%';_`*T>JN01*+3ZO9E*9$U1>8ZBJQ.:J$B,7>>)
M4SKLP0-':,#N[SOC!>&$)-*P?F%5S_R9:[2F++^6VPUV8G;IBA=(K7<E=;OA
M;FZ\;ZIEB>0."&>MT3CRPX2T+3VI-*%2P@HH19)A@G>7V.G%(ZKWZBN"4#FM
MS^QHA'S_`+X>7B41F<H8/-80UK:3@/U;<DLBT:)77K=+I6@`U`?!E!3IAJ##
M="V,O>]+NV^AF61P#ZE\,^=5>*:=XK<>ID]D45/6>`5WR(;[<M^:0RNK<$\R
MJ8S:4O-LS9*Y-C:@7A&@3)0-RYQ5&J#2T0M;+UC>911J+(A:W\\6Q+#63Z+J
MH49[4&I#.%$I:3HJ8SBXB/L>:FU+)3%PF@;:->,"(@D)VRA'[T4'6Q[[<G_D
M:Y2>L=\M./\`P@?JEM*F(DW<<:/W4-U,EA6]#JV>:3ES)8TCF#K;1D>E;JU/
M+ZR35I?4SD4J82'!:>J1>;^'LX(0:NY:/1BZ9?#)3>GYDE`I8-1UT6E-+DXQ
M6G$X!R$G3Y5D<N**PVD6EE=T+1(F^<5LF,GT7<7PEY2,[FYDDGEJU(@E#4$!
M\/,ZE'EGS\E1_H3C33SC&..\"=Z?A,]TJK#CU)91/VVI4\[F87TB!RNQ7RPK
M&:']Z&>E.==(&M;M.R^D!DBV(1FM!U^OFCSES08#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,!@,#XF)TYHM#-(),'KX!&%`
M&+73RZZ"$'>]=-X'TV$(NWN"$7:+0@]=:WVBU\`@]?@%KK\.`[0]W?VA[^WM
M[NFN[MZ]>WN^'MZ^7I@=`$$EB$,LDH`Q_P"\8"P!$+R]?UA!UK8O+_K@-D$[
M,T=LDK9NO@-V6#9FNFNFN@^G=\'_`%P)E`90B@\S8)>OA,)L5(RK?.E<(L5L
M7N\)E!&TRA-Z,DS<U.C&Y+6[7G'B:"2K('HT`=Z%TUO6POUQ6W,[ULJ4VM8"
ME`HE$L5(QJ"&=O*9V%G;&EL1,<>C<;9B!#(9HW&6!M3(4"4&Q:)3$`#L0A=1
M;=#&&B2@_P"THL/0?B:Z`#K]?>NFQ^37^_>O)U^'`XV03LS1VR2MFZZ=#=E@
MV9KIY-=![UW:Z:_ZX`9!!H@B-)*,$'_:(98!B#Y>OZNQ:WO7EP/K@?/P2M;W
MO11?40]&"WV!Z[,#U[1[WTZ[&'KY-_#K`X,))-V'9I19FP;Z@V86$>P[\GE#
MW:WV[\GZ,!X)/0P/A%]IN^XT/8'H:+?D[C-=.@]^3X=]<#D!)1?3PRBR^FMA
MUV`"#H'>^[8==NM=-;%Y>G^N!P$@D`Q&`)*`8/KW&!+`$8NN^N^X6M:%OKO_
M`%P'@$>)XW@E>+_]KX8/$^#I_OZ=WP?]<#ZX'R+()*V+91)16Q?[MEE@!L7_
M`.]L.M=?AP.WAE]FR_#!X>^O4OM#V;Z[[M]0].W?47E_\<#O@?,)10>G:46'
MH+8]=H`ZZ#%KH(6NFO((6O)O?P[U@=M!#H6Q:"'0A:UH0M:UW;T'KTUO?P[U
MKKOI@="R"2MBV4247L7^[998`;%^G];8=:WORX'UP.GAE]GA=@/#Z;#X?:'L
M[=_"'LZ=O3?7X,#J$DD`-E@*+`6+KW%A+"$&^[73?4&M:#OKKX<#N(`!@V6,
M`1`WKMV`0="!L.O@UL.];UO6NF!T"22$O902BPE;Z]2P@#HO?7X>H-:[?+@=
M]A#O8=["'>P;ZAWO6M[#OITZAWOX-]-_HP.-%EZ$(>@`T(?D&+00Z$/6O@[M
M].HNG_7`ZEDDD]?"***[M]1>&6$'=O\`UWVZUUW@?3>M"UL(M:$'>MZWK>M;
MUO6_AUO6_)O6\#YED$$]?!)**[O]WAE@!UZ?!U[=:Z],#MHLO0A#T`&A#\@Q
M:#K0A:U\&A;Z=1=/^N!U+)))Z^"445W>47AE@!W=/]>W6NN`T23HS9VBBM&[
M\FS=%@\3?DZ>4?3N^#_K@=^P&N_]4/Z^]['^KK]?>]=-['Y/UM[UKIY<`$(0
MAT`(0A!K7;H(=:T'6O@Z:#KR:UTP/CYHE_\`[9/^Y+__`)<#ZA``'7L`$/=O
M6Q=H=![MZUK6M[Z:UUWK6NG_`(8'41!`@:*$24(K6^NBQ%@V#6_+OKH&]=NM
M]=[P.VBR]:!K18-:+_[>M!#T!TUTUV:Z=`]-;Z>3`YV`&]BWL`=[$'L%O8=;
MV('E_5%OIY0^7?D^#`^04R<&@Z"02'0!^(#02@:T$SIT[PZT'7:/IY.NO+@?
M3PR^SP_#!X>NGZG:'L\F^[7ZO3M\F_+_`..!MM`N7#O$(9`H7*:*XVW434RI
MQ55/(;@K=R>Y1`PNCP9(E#84XQN511/+X\5(3AK26]_(=$Q)PQ!#K16_#R9Y
MY&O=CSV6VY.IA95C/!LHFT]D#C*)6]K"4Y8W-Y=#]GJ3M)4Y12-(G+_5+((*
M``D@D`"RPA`$.M40X``%AT`L(0`#Y`A`'00ZU\/D#K6M:\N!VP&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!38#`8#`8#`8#H/?D++&<
M8+>@EDE![C33!;Z`*+#KRB,,%O6@Z_3O>!MM,>*,Z,M*55+4T6>YD\4ZP1-J
MNJ1+'B/,T28[-7H2C)8@%)9&LCD9CK2VR=2:Q-Y"M:)4X'M9QQ>Q^)LLJ;QM
M&%9G3%LUT"2F3NO)3$RX=*VJ#RDQZ;_-@,<L?F)3)V!F6BT8/7B2"-HC5[>>
M#O2KDA8C2#3`^7+L%TBO'Z[IPB:'*(5?+9`W/K4%^:5[>B)VD5,`I.XPSZP#
M4'J22T4?+E30K1&+E&RDA1J4X0S`EEC'IP,@$<*^5"E\%'2:8D&W$2-G7(%!
MCS#4\?D!$AVL`P%Q"8*9,3#YNO>C6]0!,D9UZY4:808#1?<`6M38+]&.),[G
M%(:FD1B<O<;.:N0,ZJ::QAP$T1QAA4=AD"B,@5.LL7R?;(DB+FFE$B,;SQN:
M].1WZ+("7X^_UF\C#:^A;J;;/04LKJZ9ZM=V\R&SP1,TF.#V])7)")T;G5D]
M'#5(7E@6M18E93DF.-;Q)0#.\?P@#'J[!E2+<3K);KLX^UU<T1?X9$KMMJ%U
MXEEK*Y1J0-:],\RYBCTF)C4OCJZ4Q!1)F!*\Z&:D&<:>E&,L1Q'8+6A31A%'
M7CW)K9*J6$(SGN1/EECK:((33"RSW5V72P<6825!^@`))&J4C*\4SM"`'40N
MF@ZZ9=XT;(25HX/UQ*7*L7HGD/:JB-.2J-2^\J_F5?Q*/#?FQ0-`_.=8U/((
M(_*I/$&QR)-"B,=I$W*W@@K1O1#HT(03F\C,E:<"(G)IAR+@,JM]*UF12M*:
MFW&RSRBB6>N[/4\@9&RMU,*IH0ZIEB^,L$Z(?4S<HWYR2)B>#Q^<&FE)C-#G
MV&JU8T?J0*.3K-8B>20^4<?:+LJPSV`99"!>CG=?R^'1=5&90E7)%)I:-*8_
M*@J2RME'>*2#M,T'KH5WH9$?ZVX\\?T42CE[,UO6?<<EB$7G<LAU<3>*5=%J
MB9)TS(Y/$(VYO[]!+%=IG8RJ)N:1Q<""TS<VM?GA:78U)P3M@<WH<NW'^H7T
MN9#IJQ':;@<J'4<A:L0O!S$DFC`CK]X<"KIIFWXTR[6I4UA1Z+(%KTUKD9Q"
M1S;FT"@LC0%V@$-OGY&HK`PODK?&:,Q=F=)'))$Y(F9@8&)`I=7EZ=G$\"9`
MVM3:B+.5KERQ08$!998!"$+?DUE&?K9X=<HJ)9V20VY24RA+#(7Y/%6MY6Z9
MW-L%*E@1#2Q=P6Q]V=R&21J0`%LM$N$F4C[!=`;[1=)LO0NTAX-<P8G"I78D
MFXZ68Q0^#"=OK<Z.36C(4,25A6G-KV[JV+T@*1&1UJ7IS"CW0E(8W`$6/?C]
MH1;TV=;R+#6W$+E#<4%7675E%S^<05">X)`R)F;4VTSJL:0",=4472+%J-TF
M2YL``7G!+00N-*$'81!T+6PXV07'F92,<XW\FK4I*).3Z[QZ!K(JF;G&3#1&
M/JCTY`XK*5FG$3>@;$?B)W!]-*!H!!?:6`.A:V+0A;2[-"#\+.65EUV"V(#Q
M^LB55ZH2N*YMD+6TI][D"!H$8%V7Q1D4K4\CF"!N$4/1QS4C6%`$`6N[KK>M
M+9+E$?JCBQR,O)`F=ZDIV9SEC4NSRPZD#6E1)HZD>(ZD:5SV@=7]W7-K.R&M
MR9^1;'M:<G`(:HHL&Q&"T#%LG8QK8U=3RH)D_P!>6E$7V!3B+'@3R"+R5$)`
MZM9AR8I:G&<5O8RSDRM$>`\@\H1A)Y(PC+&(`M;W1OX5^6S:##"N%5GSMDGC
M5">3%FL4-L8S3,T-P*L9)=9\6AM>+TKT8XNFG%99D8D`W1N$:BT63LL(1@'K
M>\F]YX&)>0'!'D52ZFVIG[&K)+HB`6%+H\V6(^(6_9VX<VS-SC$4ELB;4AQ#
MRVM$B*2DB*<S6Y*VJ1FZ$4/L&#JEE_(QY".'7*:R:W46]`Z'L255P2F=%I,G
M:VHD9;NA8A&!?%\9:3U9#_+D#,(H851[4D6%$"`((Q:V$6M-G0PC"69-)YI"
M8VJ-.*12:8Q2/*STNR]*2D;\_MS4I.3"-`:5I040L$(O8@B#H>M==;UUUE&[
M_P"8-PN:>(ES%L]=RMPL6BI2_2*-PB=.!B(]Y;YA`'SZJ6?6DQ-;4#:WD36%
M2`K8]Z`F3@5MRI,H++[1"WJ?K=_(^L]X5MR;\QMVX2UX_/9\816BRQ4<PDQC
M>>[LT')BC/-IW,'P]`@;FH((M&!.*P0])RRM%I@Z%K?EWN;_`*Z(3R8XTPR"
MW=4\>H66/$JH_DG&JUF5!SN?C;4[LI99X\!AKDCF1S.C0-B=TATX1K$R\))!
M7A$`+%L/477=EXY\#8V94#^7S7W(!_X;SY_Y/5]8D>DBJN%W*&:/E9LM3))X
MF!YN5*'2H%D=3/2"F%SKT"4XZD0U?F`P*]C\/>]ZF_MFS,&-JOH'BZP<4)-R
M.Y$J+UE2INY4.G&]G:N/LKK1L9E93;7A$V!*]KYW%7T+B@6F$G@),(-!HT@P
MD>@?[M[NW<GP,?W%Q\I\^BDW*/C#-K`D56M]BHJGLV`7"U1MOM&J)H]LJA^B
MBI2Z0Y09&)A"Y8A0J"TR].2D-)5%>$:7L0M^&V[E&2%O"6*)N%`+G*EDE,Y*
M(X"S<EGNIQ%-^HTDXG22QW"JF>7E%Z;]/GUJ"\)2'D_>U.TH6-66/P]"_7R;
MSG@8]J&B*78:(_\`=+RE>+&W7\CGCO6--5/41T?:9_;DIC#<F<IL^K)?*T#L
MR0JO86%>F3*%6D*U8K7'>"2`/;U';;N07&P*(H>Q:#FG)+B>MM%G;Z<?HDRW
MQ25R.,:D\KAC//EJAHAME0R=1-ICR&5PAP?T_HY:2I;DRYO5&%B%L10P[VV[
ME&O-&5RT6)*W\Z5G.26OJWKZ9VQ8RIG.(3.PHK#6\OS=F:%:I.K3)'B82QR:
MV5*<84:$@YQT;L`]%[#NT7)LXN\AGB`>T]NJ:2JH8*-+9L4M)-:/2RR%-VCQ
MN4T:8<<Z%SIYA;>6E-&:[)FTY`$HH9FS>P`A:FSH8\65M/T$Q8J]61!\)G$G
M^I^XW%O-=&NS\&PD+4YP8;220,TM>5+&]\1G(1EB$$X"@&];UUWTHRM&^(O)
MB7E%'1RFI6XEJB3CFK8CF%OW(QIUSNV'((>!T>4(YH]`7L"PKT>T:6KM[(WO
M1.PC+V.;!&Y1QPOJ'5RLM60U;(VF$MZ9K5.;JL$U;61]/(-A+CBV6Q<AS,E\
M/;9`>8`"-2ZH$1"H9@`EC%LP&A79T-@[NX(7)#[(L)HJJN9U-*[BH4:J/O*T
MZ/&2J3M2>%,,DD[K'XP4I:I)-&V/K5ZHM0I9FI40G`F$$P7>4;O4E&N]8<?;
MGN9M<WNLX`Y21A9G!(SN,B-<8_&XV2^N!&U3?'29%+GA@9%TE7)M>(2VIU!J
MXPO>AZ*[=ZWML@E3?12E#4_)R3SUNED/L:@)72L5'#'=%Z'.2+[%DTO8Y(BE
M32Y(=.J=<UDQXD28(!D:T(P0A:,`('1HHJ+J*-3U'9%A6;)'F(4Q2["S/D^=
MHNW(G:9O[O*WCZOP*MX&A=3TK-];9N\`.[52T?F;8WHE:PT!NB0DFK1E6)UO
MQRY$&O4%I!DN*J[H2QR226O(_8L\B5I0^WAQ!E725Y@^W5C@%<.\%L!RCS4J
M/:!:*<FQ>K(TC'YN,XHW',[Z%SL[B0QL?%&D>15;RITDS^\UJT3_`)`0%Q`E
MVL@+!-K$FT$KRQ(R%(B2J%5?.3O#36ES$=M0:V.IJ79ANBEQ82TO."T0WBBD
ML.+<5'%CE)D=6W:DY'R.SI)(P`5Q.M8!Q[?`F2*:$H6],0ZJ4S5"4BM6>F$<
M::M6`*()V5LS6+<T?2,,G!BQ94AJ]H57]5`I`LTPQ+D+9TSKMUAY3ZJWM.R/
M%JU2T0MF-@\#=%VRPK3T$F<53&G-V<9M8$DS0G,&/)K2["71T4N:MW)T?M1^
M2'U+R%CARMN>SH%:HUCF=#)%'%C*C3!=*IMQA1#TR*1!-,*=F]6D&<;L:;8V
M\X,MROB_!(RRR:J-/4F6\KZ]I1=>-D,Q:]I'!(TK8E2202VB$S:0UB=E=BPB
MHEVWMX6;7;)3NJ!4V!([BAF8W^AHEE#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M$H^X^!8%O]:L_NU/\<S`IL!@,!@,!@,"75\YM;)8-?O;Z$(V-EG<,>'L`]=0
M#9FN2M:]U"/6^NM@V@3F==?Z8'J8Z1FPGNR>>\(#4$3Y3QQ=R]>)1../P'J6
MQVXDYI;[9*F#WU63M#G!&]+&%*U2I2U+P%I7E,6!S3&J$82C"S]9XR?@?!QA
MR!WNQTX=I)%)"?\`W-<;*IB,8@=ISABG3[QNY$P4+A(Z'I^0SQC1MK2M)CBM
MN''P#$F2JVYIF'FBPL!Z<T.3QHB<KL=F<8+^8/%8.^Z+@%?4SQ=XY5P$M4!-
MN1P&L[XB[,]KDY&C-;5D3V1)W.0+``T+1FG,>S.H=[R_`UWNEX&IXI\!V,+I
MM0GCJ'DNO):0+/%`QKU]\:&!6!&$S?HU4J2I2A`%V@$(`-;#Y/+EG='H1RPA
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MXZ;#M`",UK3D']`A'KI.99?8O]?SB(<@N/O*Z[9!)&EFY(1/A;-:9N5M<CP)
MUUX-*R15HFJV[FD(M:"Y3=$V1T;!+P?]U4:0WN&^XQ4?U7BR>-&&K]IRR^6<
MX(Y)<>(DX6ZPVG%J^-FL<@YR%YF%26?'H+&X9-87.8D6K`_,36)YCHUS,ZF$
M>B5[4K)$6HT86<679<XHD5-UM!*.Y#5\R@D2:1S2O>,')R=<J3V:1,\G@L7D
M2JF;?(25LQ/3&`YK7*XW&G1G;GLTA6M3#D"TQ.4;_P`.PY+N#`GY>T6*EG+2
MEH^ILY_J%4,^2*&V9Q1]88M+3'UN@TA4M40BLIE!2B/1F1V`N+"R)%ZLLPM*
M8O[]!$9H&MW]NAZ<NU.OL'X0<D(P+BVAXSOJ"_>)=FN\&>KX,MVXW6$1V>/K
M6^V;8;>ZO_9'XZVK78A,D5HFIN"X'&J1]IQ8"A!SO.]B+BF(WG\XKFD[/$J]
M(-JZ%\U8L0XKWH)[:KCJ#C_+FZ.Q\M0<IVC4,Z;S%,6E2ZWLK0R@=@>[6MXR
M?6#%-ATI='*:L.!MD\61(W.OJ=XUUS64H7-T\B\4)XU7+!)"^N=DRJP0NT@:
M%4+3OBY21(`/@B]:6I@Z[3!B++"*[)NC`/YK*XAYY]\FUS<\('XM:]P_93ZU
M*$Q[<[*/9-`R3G%$H1C-2[(5*P"'KPQ;"'KT_1C]?^L&\$^INZ^0/)SBQRIX
MXOK0DXVQ*O\`B^6QVP78D:C\1XMM511>*H;2B$^+<WUM<((OC+XT.JM0CVFZ
M.X5NM$Z/\7>LG$F7L8<YDVE#)UP_L)94[L6DK2ROS7.3DX:8RA-"VD.\1-K.
M*K8B\KHZ6,L0&LU0N/4HP&E^&2,[H'6AA\EG?/>#7[\PYQ2NUB<<EZ=P(=%!
MO!#B"6ZK2E9:X\UW35KYNM`XJ0&&F#<R/""`W1HMFAV'6A?!E_7_`.C:2O(^
M[2:A/RBY^TFMKE#:;Y33&,VNXZDS``V$/,XY2U\ZQ!&_L:EV)?2RWII3F'DG
M`2F)RR-=PQ@#O6]YOD1Z&RT]\Y7?F\.;W)_/QROCESU0$KW)W"<0_FHYJ@!$
M491IQ^R'+2`A$1Z.*!WZ)`2#P`ZT'71X@W@;A(;&G/$?D/2'$R!V/"Z_J"@&
M]FY-._+V=U=#>.#G5T::T4WC=K0IF>DS=7:2"R%"N4+DH4!H9&D4;-"!68J&
M#;Q91X0'R)ID_*T$N:D\?;&20\E4DD0IXUM87%$;:ZVR2Z%?5X3JE;W`J-EI
MS^Y)YR00<%+V>(66+6PZWX_@>ETXLR"3?FKSGX@7%)4#;2O(/E'.GZN;"5*2
MU+32/(QLDJM)7-IIE`!#)*B<L*'J/2;PQ!`<V*BSA"UYMW9B3B6?`V"O&4UA
M0O)/\S;EO8D?+LQ-+)JR\0*LAD;L`F&O3\KLZKXTONR3L<L;T+ZZL2>-5XUA
M0A<"$1G_`".1A&A%C%U"G,D@UB7/W&7ECP]9HW&H3)..;'PBN.)O[RA66D9<
M4QWQLY#2PEFMM_AJR01R-+UHZ\F2=([Z:@EJ`$A,,&#IXPPZ<R_D;.Q2.?F*
MHK"CL"LP%3\Q>"B:4)4>KNO\RC+!J99Q],=`DJ)D&ZW9>5.H8[HH2,2D)'G^
MUZ-Q+T6!.;T#W-_7QQ1A-117MYX0W;67#-J!8$3C7YHL\E,`:ELOB["[[IA-
M3HF"+2$1TY?H\:O0C+6)"2S-B$H,T,(AA[N_>FY^W/P(I"^/9L#I)DX(3B=0
M)-?_`#.Y2TX_3:)QF;Q:9):$HZHT$@4NLHL64QEV=(PRRQT$ZJU)+:!6:>%$
ME[A[T+?9J[_Z\2#+31SWX6/_`#35N1O&B5M<,G"'?#I;99G(-YW$B.-:]J24
MHUN(ZA^HVF!,S)XDB2.NT>EV]D*0[4>,(W6]BF7!AN=<?Y7;E`L?"^N7*.RG
MDKP(OWD(P>S+4D8&9YNJGK3>FF1-%C5@>].;<URYU:E[,#2UO(-\]TC5EFA"
M+]4&[O.^*)7)N*$OX)\&^4TIF[H&5R?DK#N.U3_4MC97,E^H\;G*3+%FAMYM
MHM."2%GI%\:"SL1YBG9;RH.":3V=^R@S=L'GSQU.`?4/.5@2`\1_=>-#"[-Q
M(-ZT>J8X7R#IR339.1\&Q>''DHE1NM?`0E&+?D#O-7N#?N`U_()S)*5E-A5L
M8G:&NFX2TQO\RCC]9KA`VBN(&PUGZ!;E%LLLH&]UTXO]3M'?&G]GV5'7QS`C
M&27HXX\DT^;.O\##=229D5T1$^6RQT;O:'PBA$JH="C/'HIRDDGF?GI7#24(
MT9W12I!!-RN3",%OJ),FAB((NG4.+WGR('+GWQI/^5.D$]:/1Q&J:>,*T)P`
M($?<5G+.RU[NI,'HW_TUP4E)TYR@P6P&B``L0M]H0=$\BJ$^%N=R_FR.KD[%
M+5$GJ+E6(*]4M*-'(%F^1\!6MG8>89OTFHT6D":GT'8Q:"7H0/('KIX@V,Y`
MTG>TV_,`C][0MR)<JWCTAH%^3\@4,E:0U_2L<K.&U[]9FV92K3B!-`UM=[9E
MOC-RG9"A=W!&E+4>>`V8EGU&&KWASMRVKZO5_%"%.,ZA$'M7E&"2U+$DR91)
M8<\6C>LCGD'L!VA&C2G$$<F=4N3(UD.^B!)$0V$Q">:3LL`1)QV)=?+\TF43
MR,B*F4,<HL"`5)^6]5]GR!I?4#\ED=H5^YV>DE*9`_(E*E++#8,SJFU@5N"8
MU02:>U"V$T8-!'M._0U;XY";;%J+D'QET^,,<G5GN%1V74:B4/3;&F"6SNG5
M\Q2JZR621Z4HF1D=IE$K"7&,QBX\A(>ZH"DHC0#4%[W;WHRKQWI&S^*MI,?)
MCD5#W.GH72(7V8,;=.3D#')[6L-+'7=#`Z[KJ,FK!/DK&]2=:F&XKTQ`VQM:
M2E!YZ@/0L)DV7B#B3W>Y4@+@+-V=(T3!N3<*B83:%?+U`#([8,!E%V7LCGE9
M2H@H0MIT<C8E6O#V+6CD*G2985T-)+%C-W\C:23*J&IYGXBPV/VH@74%>5(\
M\:_8;%<A"/>*NB7)-Y;TT)/M)"B*-6-S[6DIVG;I-X(!]Q")6H*T,`M!R<W\
MP:1PG@E<"*=-)M\L&JLH)B<TCM9]ZJ9+%U%<`KMO4`5/CC6\V0.3FR6(_P`B
M:21DQY$S>D%3@M4$!T1V^)VZV>.Q?.`M@E0KE')3(DI`U01_K;D,J3,<W)9G
MU(J2P.M9Q:M."DJ-T2>A'*3Q"P(4PN:,_P``(BW9&$1.@Z'L`I^W_40'A4\+
M%E_/4^E;@L<R6BD>5$^L%W=%!JI4YIEU`68F=U3NL/$(Q2JD$AD1!(QF;V(Y
M4K#KRB%KK;T,!RRH9O7D&J.<RA.SE1^Y8RZ26"FM\@:G9P5-4?=0L#F8]M2%
M0:NCBD+GK82R582S#0:V,.MZUOI1CK`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$
MH^X^!8%O]:L_NU/\<S`IL!@,!@,!@,#@0="UL(M:$$6MA%K>NNMZWKIO6];^
M'6]8$\L&PGJRWADD<C(0_6-IA\5AZU\1A4EN$D*AK.3&V5^?C#5!VCI'N-(4
M:%2H*T4%2!&68,&SA&C&$BIRWUU).CQ)HQ#X:ZS<UI5H(7-)&2_JG:K7-P0.
M;6LEL)0-K\UL!DJTA=3-)5#JD<2T*@!:@@L!X-#Q>1A\)8`!`'0?(7K00;W^
ML(.M:[?]PNHNN]?#OX=X';0=:WO>M:UL73NWK6NN^FNFNN_AWTU@<:``.P""
M$(1%[#LL0=:"(O8=[V'98@]-@V'>]].G3IUP.-EE["(&P`V`6Q;$#8=;"+8M
M[$+8@[UT%L0M]=]?AW@=A!T,0Q#UWB,"$)@A_KB&$(>T(1B%UV((0^36M^36
MO)@<X'399>PF`V`/8:((C0=-=AH@_P"T1@/]I@@]/)O>M[U@=NW6]ZWO6NH>
MO;OIKJ'KKIOIO]'76!QL(1;#L00BV'?4.]ZUO8=].G4.]_!OI@.T/=L>M:T,
M0-E"'KR#V4+_`'%[%KH+98OTA^#>!.HM/G>'16Q(JQ)6Y,"S61EBT@>ME'[>
M4T3:W]')UT::30*`)4;;)GEH;QN.]E#-.)0%DA$`L9P3`@H@A&'81:T(._A"
M+6MZWY>OEUOR;\NL!VZ[A#WY1F?]P>][V,SITZ>(+>^X?3MUTZ]>G37^F!QV
M`[=`[`]FNG0/;KMUV[UL/0/3IKMWKR?Z8#98-]_4(=^)H(3-=/(8$&^X`3-?
M`,(1>76M]=:W@=@A"'6@AUH(=?!H.M:UKKY?)K7D^'`Z[+!O0];"'>C-@V8'
MI^J9LO\`[>S`_`/8/_IWOKT_1@<]H>[8^W7?O7;L737=O6M]=:V+X>G7>`T$
M(>O:'0>N]BWTUK746_+L6^GP[WOX=X'7916Q;'LLO8]A[-CV`.Q;!TWKMV+>
MNNP]-].GP8';8`;T'6PAWH&];#K8==`[#_MV'73R;#^C_3`XV6#>AZV$.]&;
M!LS73R&;+\I>S-?`/9>]?J]>O3]&!VWKKY-^76_)O6_TX'':'0>S00Z!T[>W
MIKM[>G3M[?@Z=/T8'`2RP=.T``]H>P/:$.N@.O=VZZ:UT#U\O3X.N!SL(=["
M+80[$#>]@%O6M[#O>NF]AW\(=[U_I@.P/A[)Z?\``(SQ1$>7P1&]>OBB)_[>
MS.OE[NG7`ZC)),WK9A18]ZUTUL8`BWK7P]-;%K>^G7>!P$DD(-EA*+"7OKO9
M80!T#?7R[Z@UKMWUW@?3IKITZ:Z=.G3]'3_3I_I@==%@UX?:`(?"%H17;K0?
M"$'_`&B+WKIL`@]?)O73>L"O3N+DD3.B-*XN"9&^:2!?$B=<K(2O86]1I6@"
M\)BC@DNND*O6C2/'"9X1NN\'07EP)=6MA/=73%NF;"0WKU"1&]L[DRO)1ZAB
MDL:E#&X1F4Q=^3)E"10I99#'W90E/"6:68$)FAEC`8``M.Q`M%EA#LL(>A6S
M`F>'O>QZV,O70HP?=O?B&EAUK6ABZB_ZX&8'ZWUSK4T8IMGB$0AL79W\N8RA
MPCA<@,D5GS9(SJ(^TRB=.+Z_/!`C6!D7*B$"%M);VU,):I-T1LTX0]3.=&(.
MT/ZVNT/ZV][%Y-?K;WK6M[%_KO>M=,H=H>@==H>@-ZV'7370.]:Z:V'_`$WK
M7^F!QHL&M"#H`=!'L`A@UK6@#$5OJ6(0=?JB$7O?ZN]^77Z,#MTUW=^M=!]@
MB^[7D%X8]=!E]VNF^P>OAU\&_P!.!QH``Z#H(`ZT#7:#6@ZUH`>FM=`]-?JZ
MZ:_1@!!",.PC#H01:WH01:T((M;^'6];ZZWK>`[0]P1;UK8@`T4`6_*(!6O@
M+`+?782]?H#KR8'.M:UUZ:UKNWUWTUK77?36NN_]=]-8'&@A#L6PA#K8]ZV+
M>M:UL6]:Z:V+>O+O>M?ZX'711>@@#H`>TH0AE@[==A8Q_P"X98?]H!B_3O6M
M;W@=]ZT+706M;UUUOIO6MZZZWK>M]-_IUO6!.HS8#S$HI8L494Z`@%GM+'&Y
M&]B+4">RHJSOZ64*HRV'A4`3)6R2/C4WFN.]E#-.`WE%!&`L9P3&"":"$.Q;
M"$.MCWK8MZUK6Q;UKIK8MZ\N]ZU_K@=L!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@2C[CX%@6_UJS^[4_P`<S`IL!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@2C[CX%@6_P!:L_NU/\<S`IL!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@2C[CX%@6_UJS^[4_QS,"F
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!*/N
M/@6!;_6K/[M3_',P*;`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8$H^X^!8%O]:L_NU/\`',P*;`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$H^X^!8%O\`6K/[M3_',P*;`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$H^X^!8%
MO]:L_NU/\<S`IL!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@2C[CX%@6_UJS^[4_QS,"FP&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&!*/N/@6!;_6K/[M3_`!S,"FP&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!*/N/@6!;_`%JS
M^[4_QS,"FP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&!*/N/@6!;_6K/[M3_',P*;`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8$H^X^!8%O]:L_NU/\<S`IL!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@2C[CX%@6_UJS^[4_P`<
MS`IL!@,!@,!@,!@9\057'E/%.8WNH<'4J3QSD1`:B2MVCT@6`V.RJL9_-G!>
MI($D$N$\$.43(+)&%0$G1`S-"+$+81!F\X-M*H_+.L>5NM&*[%F#'!H=:L@J
M)-(Q$-<T-DD/C5W)_/*]<T*Q9"]PB6NSX4<D*/2-3@XC93G%+Z2"G+$<,F?:
M"RHOR_E,RCU3O55V]'9D7+:OL:T[#<"HC:BQ%#8_"[I<:<:%C''V:N%<WDX9
M&]`2I@)$Z`]:!7YP<,!2$L)^VC"MY<19OQWAY4FLJ;UHE>'"<S2#1^!,KL_O
M4KD0H`ZHFV2RM`-/'`1]+$2"79$H)/6+4RH\"O104_CE*"BK+HS'->!:)FD+
M00P<@JR1PMWC_&U`BF<]2S]H2N=Q<C:X33^.5JW(VFOUS@4E&WZ.6^E5*<I`
MWM1B?:X\M4(PD#1C[CM0E>R&<W1"[W7[99I5Q7H&-5JNM>'48VSNQ4,V^JTJ
MBBN[YS'95`HJX1QM1K%:)*J`5Z;.)\(E0#0!]RV^!FRR>`#2VL9YD'E[S$9T
M&:\HDK15MZ$A;IW*8?0-?0"TRDK/NOF63P<B0!ADB<3Q.2EZ)9GP):,Q`(O2
MC8=3["%E?ER6P:V0]]'8=6MT=DS5-G-UDL@*LZ,,$/U`*F%=4@](+9!7+>?)
M&PN#DG"+<6,ER0F+4YB<)F]^&,;[#(E9?EC3=WE=7'3Z7,GLZFSA'C'Q=&RI
ME'W=HB%AQ"226L9H@>)M`4<5>&]^*;4*AR1MYS@Z,25P)"O2D'","2^T&"BN
M$K\!J99DZ7C23/4TGC]9.D4N%P-LLF)29[ME_G,6BL10L8*\.G;>[DOE9OWI
M`]:UIT"!$W[5#/V685H=T3Z6\"ET1C<'>YA/(U4Y:!D]%70ZV,Y.K@RMMNK^
M1-S4K'X#""X)$I(YJ`.C;42M<8L4EF(4I28]2<H`4(LK&B1V7^6;9S,_6RN@
MCJVC@\3L>V&&`HY7J2&R.40"K++5UN\2M=*F:':K9$YD.")0,IL/<$;HZDH5
M)J)&/6B0&S["!R/\OF>L+%=3XBMRGIEJAGN6Q6=HX,"TI,)#+(&@$XRMC7+4
M%;C0QI,F!KS9$[.XT+*Z.`#4R96(1!HPOMZ&@FM]=:W_`*ZUO_YYH<X#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'V3`(,4IBU1
MXDJ4Q006J5`(VJ&E3#-`%0I`E"82)4-.3L0]%:&#9FP]O<'KUT&R'*2FX+2D
MNK9HKF7R.=16>T'4UP))+*6%)%G1<?8K8X.*@`8RD6.FF%$3I*'124U8N/*U
MU[U!F]]=271K3E#`8#`8#`8#`8#`8#`8#`8#`8$H^X^!8%O]:L_NU/\`',P*
M;`8#`8#`8#`K&YM<7A>D:FAO7NSHO."F0-C6C4N#BN4CUO8$Z)"C*.5*CQZU
MOH`L`A;Z>36!MO54QY;4U%)#!8A4;JY0^4R9GF3S'+$XPLUJ-)LH8&IQ8VEZ
M2)+%KV2%-JU*T.RE/W)]%]Y9PM"Z]<G`OY5N\X$XX.J2PB8HGFO'R$/T;E*/
MCDW)YALVLSSCZY:'R5EU_I\D<6@P#]D-K6M..0DI`%D"+&420`MP.&ZUN:#6
MB;FA/5[N?'6U%/&8N*.'&!G<8FLB]CS`FPI)"7:/+*_-;76$$3M.!W:VL\`T
MS,OUXJ'1&\<#&MC:Y46RE9$4]K^S7E+''6;O+*0GIYT9"4"^Q7A*_2W9"=AB
M;8F+2+G)"3LE,$`4Z,HL)2<!9>NW$R=#+3+=O.9B$UB30.2+_0S#6C&W`D/&
M9EDI)"BFD*IIJ>8;3OE=KR#K&KYF6#0ML@&$3H6AT`@PXPH`0Z9!CZO7OEC6
MRV?*FJLIK)T=J^$.S8Y9U$*K1B,]6)7D^1(7:3QF<Q%Z:U[ZVORHY6F7Z`!8
M2:>;VF=II@1.!+'FV>=4A?VZ3O+%:JY\:%-I*6I8*EE2<#;JY(,UUI.T2!$D
MAB=`B:E,$9$;8@1E%`3-"9,7I$`C8>N.!)I#R"YZ2=I?V9VA,DT1+!R-3*ES
M9QD9F5\DKI,:[<JIF#^^OS57J1U=)#*H&ZF(5RPTT1QO848'8#"PBR9^HCS3
M;?.!C20LALA4T3+X&F86]DE&^.Z,Z;JVB)QYUBD08Y--CH$.3RIDB4=>E"1N
M2KU1Y:<KPM=!>`1LJ\"EA=F\U(&SQZ.,T"F+C&8I&(U%(_&)AQX33B-MR*%2
MZ43N%NP&26P1W0&RR(RN:NJIO=A@$O(TM,)\01&]E8X%Q;;EYUH-:`MBL_EJ
M;;?M$>@L"@2I\W+5@+&E-N(9,O;Y;!79(MF;/8TV=G-$[F`$N3&+C2@F>;BV
M5C@<N]R\YY`4^>G8=-7EQ?I-*)6;)'3CLA7RYG7S>7%3R9ML4E:F`&/D3C,H
MF!7GZQL;SDZ,9QAN@```\\)C/U%`U6ES99=3XUO@TS`ZV1(;&E3])C^/"57,
M&U\MY`>U6>JATK4P0U^A9$V:U(TZU.W'D)O"W_Q%EC_7R9^HUK#3%P@"$(:A
MM/00ZT$.M5S,NF@ZUTUK7_HOP:UK-;!V]C5Q^Z*U/PYF7T+C8'L:N/W16I^'
M,R^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+C8'
ML:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^Z*U
M/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<
M;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W
M16I^',R^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^Z*U/PYF7
MT+C8'L:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<;`]C5
MQ^Z*U/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^'
M,R^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+C8'
ML:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^Z*U
M/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<
M;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<;!-)M'>2-BFQ0^85M:3J;"8%%
M*QC(@U9)$/H^$PE*<BC+.+2&.I]*Q-Z90,.U!W>H-Z]3!BWTR<"%^QJX_=%:
MGX<S+Z%R[`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+
MC8'L:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^
MZ*U/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R
M^A<;`]C5Q^Z*U/PYF7T+C8'L:N/W16I^',R^A<;`]C5Q^Z*U/PYF7T+C8/F;
M3]ND%&J#ZGL\@@@HP\\\ZO9>42002`1AQQQIC,$LHDHL.Q"$+>@A#K>][Z:Q
ML&.M;UO6MZWK>MZZZWKRZWK?P;UO].MX'.!*/N/@6!;_`%JS^[4_QS,"FP&`
MP&`P&`P.Y9AA(PFDF&$F@WW`-*&(LP`M?`(!@-A&`6O]=;UO`K?2[O\`*[M\
MYKOC&`]+N_RN[?.:[XQ@/2[O\KNWSFN^,8#TN[_*[M\YKOC&`]+N_P`KNWSF
MN^,8#TN[_*[M\YKOC&`]+N_RN[?.:[XQ@/2[O\KNWSFN^,8#TN[_`"N[?.:[
MXQ@<>EW?Y8=OG-=\8P.?2[O\KNWSFN^,8#TN[_*[M\YKOC&`]+N_RN[?.:[X
MQ@/2[O\`*[M\YKOC&`]+N_RN[?.:[XQ@/2[O\KNWSFN^,8#TN[_*[M\YKOC&
M`]+N_P`KNWSFN^,8#TN[_*[M\YKOC&`]+N_RN[?.:[XQ@/2[O\KNWSFN^,8#
MTN[_`"N[?.:[XQ@/2[O\KNWSFN^,8#TN[_*[M\YKOC&`]+N_RN[?.:[XQ@/2
M[O\`*[M\YKOC&`]+N_RN[?.:[XQ@/2[O\KNWSFN^,8#TN[_*[M\YKOC&`]+N
M_P`KNWSFN^,8#TN[_*[M\YKOC&`]+N_RN[?.:[XQ@/2[O\KNWSFN^,8#TN[_
M`"N[?.:[XQ@/2[O\KNWSFN^,8#TN[_*[M\YKOC&`]+N_RN[?.:[XQ@/2[O\`
M*[M\YKOC&`]+N_RN[?.:[XQ@/2[O\KNWSFN^,8#TN[_*[M\YKOC&`]+N_P`K
MNWSFN^,8#TN[_*[M\YKOC&`]+N_RN[?.:[XQ@/2[O\KNWSFN^,8#TN[_`"N[
M?.:[XQ@/2[O\KNWSFN^,8#TN[_*[M\YKOC&`]+N_RN[?.:[XQ@/2[O\`*[M\
MYKOC&`]+N_RN[?.:[XQ@/2[O\KNWSFN^,8#TN[_*[M\YKOC&`]+N_P`KNWSF
MN^,8#TN[_*[M\YKOC&`]+N_RN[?.:[XQ@/2[O\KNWSFN^,8#TN[_`"N[?.:[
MXQ@/2[O\KNWSFN^,8#TN[_*[M\YKOC&`]+N_RN[?.:[XQ@/2[O\`*[M\YKOC
M&`]+N_RN[?.:[XQ@/2[O\KNWSFN^,8#TN[_*[M\YKOC&`]+N_P`KNWSFN^,8
M#TN[_*[M\YKOC&!QMV=A:V$3LZB"+6]"")R6B"+6]=-A$'9^];#O7PZWY-X%
M!@,"4?<?`L"W^M6?W:G^.9@4V`P&`P&`P&`P/5+AS14'OWB5<=8F1J)ZO"U;
M^BD`HBQ7A.VI7F,S./U1([1318F1*@`4M\=G;=%'%`I)\4!!BHX@8];$`.]9
MMRZ-MI#PVXY\A[/J53`X,^L-.&U#Q_KYN=:G-*8EKDZRRZ;OJ\NYINAC]76>
M^/SH_1JM2W8]:M1M;/L\S0'%W3:V2$R;8-7`\$JI6:2UHWGVN&YP535MHK79
MSDD)9HNI53'EH5QJ>((3%7F.(#F):-M6%NA#@O>O"2+0;)-),)WL>KM[\";3
M[\O.KXFV:FS-#N0\P`=7CX\-5#L3FH1V8_/[%>A%3/3\V2*:T7"W<^.0^,+D
MSZ[I@1,?8)40,M7Z,,VK#/M1767^7#1D$:KC,2SBS7`<0D][-S-(BB%[VV0+
MV/.#.BCT1LPJ+U4[0PQ[L`"_1IRQ5)X[M(4X(C$*)P!HSQ'VHCTMX6<6T3Y+
MH;'MWJF>VVSN;=+LCZ]SZ"KFLA_XF5(3;37.G5F05HB4K6V8"5!:#V@E62).
M4#:L"P1HM$ANT7B1_E[<>XHCTM<)?;;FBC,(L"4+75H\[1L]R(XAQI?[S*D=
M<R.44^QPYD;]/K,2AV0VN,S3FM3@4<):2J+$48VB&2FJ*$HZCY!<T2IJ160Z
M1:R>#=QM0+!?V25-T7KJ[*8E%B/%9V*6BKPIK?H0MDS7MI4K3DZ(+@>I0;["
MS"!D*W-HPWR[XJPBH:0@EMP9%8;>;(W6.-,E'/%0F@*AVF58E6&'49B2NO8P
MB$RH5NE):)PC<BF30)MTG\Z5)5A@2AV7D;U6/2R13([(C<ZXZUS7O'%@H/C'
M(J:NQ!2T6@;PIO24QKC^-N8H[8R9G;1V^JL.0R5_3N[0NV\DB)T<<8`O2;8L
MS+_8@S[^7;4DJ5N"I,^3V'+%W(-SC4IG3Z%DB%>,<4<N4\@I8.H.R%ULUU<_
ME`:BTFDJ9#+T;LB=1F`-826PGQ`W[#`"_A(UR9FERJ(TUR<KF=-""IG1IIVP
MU<9E<V51Z37^\5'-)N%OC\2C\L!%6YD2)U&SG!E:RD*[9AH#5K<(H_&C-3W^
M7+3Z5O?RF<R]%IT:O)[AKQ(1J&E.4I@C1RC4T4$N!)G"O$=;V%)E,<T0:%."
M9-\@]."'KT$)`'0Q/L+J+\OVK`/+M#RW.50R)3=XXZ&M!TDVSNU@>&_S:]X\
M\LS*;9%1U'8$"D$O5UXD;&]$XM+:0I<UP-F#<T($P\?88D/X@T%'8:FM2?Q#
MD1"BG%GI!0JX\R":1-CM2!N%HWU.*:/4RN3.M7%&B8G=BC!3^S!-CZ!8/>QD
MF:&G&4IQM&-Z;X=1:5<BN357R!/.YK#./4Q=8=YS#G(]ED3C_P#[BU6#,_.B
M*.5M;TE4)-(BC5)X6YB,2$*?#VL5HDN]F"MN09BG?`JCX0[R:K7&36>UV"@K
M[D78B6Q)`[1EO@T>:J(Y./5-H02&$:BH7E<FE$';].BI46[I0I3@A,)`82;L
M()MO/@0CE_QZ@=&\>#$T8J.T(4[M7-6PJU;Y?;?H)QE=G0V(58VEMLHASDSQ
M2+FA@,L<^KBG0E^D$`%)VMIEJGJ,04NW^!LT/A)3,[CE(<<DCM6Z>W*0L.@6
MWDFJK9>(=X&L/()Z0L-X;GP7*.A9.ZC+&E$=:&38%+B!*F,5;.`5H0@Y-NV^
M!ABJ^$%)6LE@%A1YDNH^O)3#E@GR,:F[<ZRM@E"+D4Z4<7(AN4'I*9/Z^-NC
M0U#<]IB(UYFUK=Z+7.I"38#1VVP3V0\#JKD3I7M&A=U4)G]=,%GO\AE:E*Q1
MXR:4[4_-BX:ZNN9RU*>ATH73V&4VD;7MK%H[90F]M/)T4:7X/;-SD4E6<(J:
M?F_CY9L.16>F;)C*H0K>E5I@8%K2=';);+'/9435%I+4&JXGR=&6PH=%JVF0
MOJLL>E)CFT-P@`T1=\#5WD?Q0A%4\=:LMZ&IK(*6OAU:M<N5V$L&V%N+K/ZO
M%.ACCD965['FQP:$S@C4!1N4;DTO0#;O"VO,1+#`E"2[1Y]9H,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"Y,K<2\/3,T*'9NCZ=V=FQK4/[QL_30
MPIW!<0C/>W;:4LY3IK:"CMJ%'A@&9X)8NW6Q=-8&_O.6K:AKV!\4W"FE58N,
M==8?;4?42>#R=-)9%98X7:KLS-]FS94F2D%B=9"C!ON*!O9#4/7HTKN`DT8/
M,MVZ//#-!@,!@,!@,!@,!@,!@,!@,!@,"4?<?`L"W^M6?W:G^.9@4V`P&`P&
M`P&!<6A`4ZNB!M/=FIB)6J0)S'E\,7%,[8`?7JK<C&Q`ZN`$I?3];9*8\SR^
M0&\#*Q=7M96@A*Y!T@2$)NCPA)?K4*"$\(=@">'1=5AT$\(!;#H>OUM!WO77
MIO`^Y%<I4NAA2\C:92A,3:1&!32:VD^C$.C='Z1&:)JX&AHPGZ\316^I>A_K
M=.OER#H=6J%08::HY$TJH-.#VGFGR2V#C3P[.\X[3C#:M$,T/G/_`"]!;WKQ
M/U_]WEP,F0!RE%;N;NZL?([CF\C?V_;8]MU@H);9C(YIO/$*\)BAFGE*R!`!
M<6L;"!Z4E`+4;T5HL0Q%;$6((K+6%UG<BE<LEW)^G7R03E_42F7+U,AM$H+_
M`"!2H&J$YKT*2ITS<,\DXS?@:"2$"8'0!00`UH.@CGLS0;%W;Y#TIL6QG&;'
MN16OW[-4@T6I-V/V6=VS51>NTT77N,#Y!;WK`["K9$,I*0/D52PR$*<Y&A)'
M)+8&2A1J1;&I1HBA5;LM(D4B%O9A1>@ECWO?=K?7`ZZK-OT`TK7(>D_"4%$D
M*"OK#:WA'D)A:&E(/+]EG8<0E&'6R@"UL)>]:V'6LH'5H@4D(TJGD/2:E*W%
M&$-R53(K74)F\DT?B&DH$YU6#)1$FF?K""4$`1"\N]=<#N?6Z-4!.6JY%TPJ
M+1BT)&6JDMM*"T8M!T#0DA9U6C`F%H&NFM@T'>M>3(.#*U1')!(#N15+'(!*
MQN`D!TDMDU")P,#L!C@)&95HDPEY@-]!';#XHM>38LH^PJ^+$K-<!<DZ>&X*
M$VT:AP'*[>$O4(A$A3B1J%HJPVI/1B3@T7LH0ME[!K0>G36M9!\1ULC,2C0F
M<BZ7,0F+-N)B$R2VR8B,<=A[-N)B0=6[3C<-@\FS]AV;T_\`JRCLKKA*X''*
M'#D93"]0I\W\Y4+I-;2P]1YH'M2;4'*:N--.VD#Y"N[>_"U_MZ9!PHK=(L/4
M*EG(RF%BI6(D:M4KDUM*E*L:?6@IAJE!]6F'*1I@AUHO8Q"V7TUV],#@FMD2
M8XY0FY%4LF4J2E!"E2FDEL)U"DA7KHK(4GDU:`U00KU_W0#V()G_`-6MX`ZM
MD2D8S%/(JEE)AA8R3#%,DMA0882;Y323##JM&,PDW?E&#>]A%OX=;P.3ZW2*
M]$!5\BZ75A3%DDI0*I+;*D"8E,#PTQ*8)]6F!3E)B_U2P@UK0`^0.M:P.@*T
M0%G&*2^1%*%J3MBV<I+D5KEJ3MC'HT>SE`*LT<;L9H="WW"WU%K6]^777*.Y
M%<)$O=YKR,IA+WIU",?FLEME/W(U>^Y6C%X-6@[DBH6NII6_^,S?E%K>\"?1
M$V1P9NGS=&^2M!)169$U<&E;PM'.WF3#B3H:(Q]8V*3O%.+GR+)9.4+9#H)M
M/3&.*46R#Q#*%L.YV(#JN$@4Z5('D93`4:$XY2@2!DUM!2(5*G7:I4HDVJNT
M0C4*`^0PPL(1CU\.]X'0VM$"A.C2*.1%**$;<`TMN1J)%:YZ1N+/'XAY:!*;
M5@R$0#C-=P]%!!H8O+OKO`I_9.Q^_JA_G>S_`/$^4/9.Q^_JA_G>S_\`$^`]
MD['[^J'^=[/_`,3X#V3L?OZH?YWL_P#Q/@/9.Q^_JA_G>S_\3X#V3L?OZH?Y
MWL__`!/@/9.Q^_JA_G>S_P#$^`]D['[^J'^=[/\`\3X#V3L?OZH?YWL__$^`
M]D['[^J'^=[/_P`3X#V3L?OZH?YWL_\`Q/@/9.Q^_JA_G>S_`/$^`]D['[^J
M'^=[/_Q/@/9.Q^_JA_G>S_\`$^`]D['[^J'^=[/_`,3X#V3L?OZH?YWL_P#Q
M/@/9.Q^_JA_G>S_\3X#V3L?OZH?YWL__`!/@/9.Q^_JA_G>S_P#$^`]D['[^
MJ'^=[/\`\3X#V3L?OZH?YWL__$^`]D['[^J'^=[/_P`3X#V3L?OZH?YWL_\`
MQ/@/9.Q^_JA_G>S_`/$^`]D['[^J'^=[/_Q/@/9.Q^_JA_G>S_\`$^`]D['[
M^J'^=[/_`,3X#V3L?OZH?YWL_P#Q/@/9.Q^_JA_G>S_\3X'855LX@@`*_P"B
MQ@*T+10!O=HB`5H8MC'HH`JIV$K0Q[V+>@ZUU%OKORX'7V3L?OZH?YWL_P#Q
M/@/9.Q^_JA_G>S_\3X#V3L?OZH?YWL__`!/@/9.Q^_JA_G>S_P#$^`]D['[^
MJ'^=[/\`\3X#V3L?OZH?YWL__$^`]D['[^J'^=[/_P`3X#V3L?OZH?YWL_\`
MQ/@/9.Q^_JA_G>S_`/$^`]D['[^J'^=[/_Q/@/9.Q^_JA_G>S_\`$^`]D['[
M^J'^=[/_`,3X#V3L?OZH?YWL_P#Q/@/9.Q^_JA_G>S_\3X'R/JQE)(//#>E&
MJ1$D''!3)G:RA*5(BBQ&!3I@G5802)0?L/8#0Q@!L>]=1!UUWH,0ZWUUK?3>
MNNM;Z;Z===?T;Z;WKKK`YP)1]Q\"P+?ZU9_=J?XYF!38#`8#`8#`8#`G\%JB
MT[1V]!K*M9_8NXVB"Y2'4&A\@EFV-`/Q?#5NOH)O7>8%&Z('V>)V[,[!=NM]
MN^C1!STBM*4F4*DBM*G6EG&HCU24].0M*3J#$B@U&:<6`M46G6$C),$7L6@&
M@$`700=ZT`:166E)7&)%1:%2<H3IEQB8X")2H1A)$L3IE8@:3J#T85)6S0`%
ML16C0;%K7<'J%/UUY/+KR_!Y=>7K\'3_`,<!UUY-]==-[Z:WUUY=_P"FO]=X
M'V3$*%JDA&B3GK%BHXI,E1HR352M4I/,"20F3)2`&'J%!YP]``6`(AC'O6M:
MWO?3`^8];+$,)@1%C+$(!@#`[`,L8!;`,`PBUH0!@'K>MZWTWK>NF\"\_5J1
M[C1TT^KS[]34[R7'#Y=Z(</JN3(340W(I@-D'F_HD#V8W%B4:2;.\?9&MF=G
M;Y<"1^RJTMRLF!:K.PMSI0T`D">%:A<D^MQ["8SBD);X3&_1GIDUF,8`;7!5
M!)V1M'K9VA>'^MDV"`:$'?ET(.]=-;\F];\F_+K?_AO]&4.X/3KW:Z;WTUOK
MKIO?P=.O^O7`YZZZ].NNO^G7R_\`R_\`A@<=P>G7NUT\OEZZZ>3X?_E@<]VO
M+Y=>3X?+KR?^/^F`V(.OA$'7_CO6OT=?T_\`377`OI\7DZ5J7/JJ-R!*R-;B
MUL[F\*F5S3-;:[OC<H=V1J7KSTI:5&Y/+0D-5I"#!A-4IBAFEA$6'8M!60Z#
MS:Q7PN,U[#I7/)*<E5+B8["XZ[RE]-1(0!,6K"VAC1KEXTB,L6A&F:+["];U
ML6]=<#I+X7,J^?#XS/XA*8+)4I2=0ICTSCSO%GPA.L!XJ10:TOB-"O+3JR_U
MBA[+[#->4.]X$9ZZZ[UUUUUKKO77RZU_KO\`Z8#NUTZ]==/@Z]==/]/A_P#'
M`===>G777_3KY?@Z_P#[,"\,L>?Y(:L(CK$\OY[<A$YN)+(V+74Y`V@5HV\;
MBM*0$*!I4(5[BG(V</02]''E@Z]PPZV%05$Y4>[/;`3&9"<_1HEZ421D*97(
MQWCQ$:V,,C/?&T";:UI)CVRA:7"4`+"D[=^+L'3>!5OD$G48\3ZRPF7Q[P=N
MVCO3D9>FK1&V%X#'7WQ]KD1'@>A)"/3>K[^GFRX6B#.TW>@8$4ZZ_P!=?!U_
M^'^O_A@<X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`XWO6M;WO>M:UK
MKO>_)K6M?#O>_P!&M8&2#*;N$F1QR''5):!$OF+<6[Q&*'5]+B9+*FDTHQ06
MZQMA,9PNCXVB(*$/QTI1I6@!WO8M:UO&P0)<A7-:U8V.:)8V.3<J4(7!M<4I
MZ%P;UR0T9"I$N1*BRE2-8E/+$`PHP`3"QAV$6M;UO6!2X#`8#`8#`8#`8#`8
M#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,!@,#TJX2VE`HK`GB(SJS*E8
M&C5ZP*RW.&VJMNFMWEK(B[&I;4EPTA==%Z<)"CM"+`6*4WU><T"A$I").>2$
MTSQ@!S8-A@WCQHFC961BVUZN7):IA/)6/PAON:K6#<Z=WR2<G'&6Q213R0+J
M3LJ*I'R34T]^D@K5#._[6/?GY7FZ-P4:5XRB2O=U<*#WEI@Y$AI1=3<%Y"\P
MI-5\>)@HT3<R[MJM8,Z<?)DXK7BGI*)37[%,43H@=D[@W.1:%>0W!5M2I`A(
MT3,O\B';O#A$SR=I3H(CQX/;7V?6.5;"A36!,V:'!H3\38RDC+E$W1QJR%CC
ML=D7))`:;HI@:68C3B$XU.2G;5'0;*.E9V]P9<6YLDT[8:/+L5[@G'9=<21Z
MA"&(PEZ3-L#D[;>$2AK"R458[<P3=PEA;><N!&4L<7K!&$'-[H7X*@.[9?`M
ME;\CN*<*F5<.:!JJ./L]6G_E[S2)/22HV]7-DTT89`S)N5JIZE'U5,?Y2Y-<
M4.4B6:5F&)S%B,E8W@VM`$X4LM_R-:*TE=:E6QRM<'J7\>4MD216J4T-9UB5
M[]9^.R=<=:*5SF:Q-$/9X[M;4IDM>"-+9SUL:\!.+QR]%IU!Q)H;SD%YYD7?
M3,TI=@J2@S(XCA$>Y,\CYJSQAIA6HXI0Q22QBI4D3?$BUP:RGQ/'I)(TLB$W
M(E*PU8F;"$:=6``4B4`+)SM'HZ3SHXK@OUEO3=@HOKVS`9^,"9]^K;_INWQL
M509GG3G88U/H7:H+FURHA?`_"\':S:17HT(=DA\3>?K<P8%KN6\!6:O*?2S!
M_H"3*82JI%]$G<*W,2/[BB,J*PFNY6*;LC9421W<U0+1=6;2HMYEDEVY!1Z<
M$06\D(2L7["ST-:7#)U4U;/;97\?6*7*Z^HIEOB*.=-L;+'UX6^TK73VHL8$
M2.FK$BR"4;K4F+DKD3"TM;B\$G!.)>4AI"K8[?MX&4VJN..C#3+S/)7!ZS6\
M8&BFZU7)U*.HGT-H/\X_]V,18[*E\6O=SBB`J1(Y[7B=Q(9&Y-(37(+5_P"7
MTVH#4JHW<V[GD8HLJZN'C`":O4&8..+U9"2()4\'=VRNV:91)40JY&UTO9D8
MXHOH"JX$BEL;I9._Z$8<TK%H&T\*5>M5+2B\91<@V]P3>YK)U1S+23,L8K%Y
M<QVA5R"MVB(0EH@2U=4"WCP\SW2ZI+!9'I.)L+F!#4XR*/2!2B7*`;6E%EZ(
M-)N41*77'PLVI4QN(Q&BD$3EB+F7J<'E5F-_6)WX=/1DSCL=#99(*_89-&F!
MTNYO6JV@EO1MA24!XB3R2&_8"=,O\CZO?)FN)IRS<9#(YA24DIJ;TK6+N4UO
MT1*B\.;[?A]#M$$:0R8GV-3-D9;+@\@5/I+8M=HS(XZG)4$%F:V3I,8D9<&*
MH';O'RJ^6?*V8L;LRR&HI-Q^OR)P%,UM4AK)BF,GF\)8B6^&,9,'1,SM$D+C
M)=*TB9>A(:"!`*TI+*1%F@)+<V3Y&Q\1Y#\/9R@K5UF1->L\ECE!U1"F"%VP
MM?9[#JQ;XY=5ONMU0?<SL2G[R>W]ZG\?>F5Z2&GH3W`#>J4MK8Z(32RRA,NB
M_4PX<(;.>..<!:&6D4AKCR"K5*TUXEA"F3RF2LZZXI,9(V6RE<KJUAFK<G25
MNXI@JEYLQ>F9]2)4J8EJ0J_$$3+LY&&Q3CC:%F*2ZEW$`/*/V<RA''[8+I52
M3Q@9]"N*.+HRP2B$'U4)C-M5/3Z=W2@=3XRL*3%'D)%!XW#6E(+S_`[R^W>#
MVU3I$X+&JB1UU+&?FSN1KUM2&CE"20'Q!L5\:C(D_.;,;-H:P++-1J5,>2(E
MJ<]$W*0)5XRBM>&!)?/8GDTM;A*2Z)Y(Q/5+M+N"O9DW,;%6$$4$L+.>">T,
M^05<1(4]1UK(T#UI`S2+2=HD!+^\-)91^SWQ3I04$4GV%/;UQ\3I!)[HE+[+
MZ"F4KF+_`,R7FJ)-4U8/\2VWU[.(MHZI(_9_CPB.*'>S7&QSQJV]2LTXKD.M
M*C%2_P`)00'22P7VT>5-!N2CD^*L)E5:N26_#.2YZ%PF-<*'U#-9*IYI1:T:
MRCBXU[@[PITJF-2-ZS;80,LI.)7I*!0-.I)3C*N7@:??F!L%45Y+837=9P9+
M"71[;5W(2R&19'2V.5UU(;\1,4E8./KF4<6!R;FJEHRA**(;S/#"0<Z&[V6$
M>]ZU8//?*&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!=X^I(1R"/K%3@
MK:$J-^9E:EW;T)#HO:$Z9S2GGNJ!K4FD)G-:VE%[/)3&&`+/,+T6(0="WO0>
MXK?R5I9CA+A7#M>U/6C:<@AW))LC=M2D[D`JJ=[6V=8U&3I',[Z6*FE)8<-L
M.UD$!=D;LR1XT<;;BP)4QI905"D1^,N[X'D]REE$)FW(NXI;7+V\R2$R"9*G
M!A?W]=(7)Q>"Q(D)*]>6OEYRB7*V@YW*4>C1NHQN7HW2?2G>SM#S4Z&!,H8#
M`8#`8#`8#`8#`8#`8#`8$H^X^!8%O]:L_NU/\<S`IL!@,!@,!@,"XM`F<#H@
M%(2790QZ4@VZDL2E$B>34?E\0#8K<D;@WIU>]].T1Q!H->7J'>!E+SKCI]G[
M]]=:R_QYDY#SKCI]G[]]=:R_QYCD/.N.GV?OWUUK+_'F.0\ZXZ?9^_?76LO\
M>8Y#SKCI]G[]]=:R_P`>8Y#SKCI]G[]]=:R_QYCD/.N.GV?OWUUK+_'F.0\Z
MXZ?9^_?76LO\>8Y#SKCI]G[]]=:R_P`>8Y#SKCI]G[]]=:R_QYCD/.N.GV?O
MWUUK+_'F.1]MNG'[:4"';3R'V@+4#5EH-SZN-H2U9@>PQ66CW7_FP%1@/U1&
M:#H>P^3>^F.?0^/G7'3[/W[ZZUE_CS'(>=<=/L_?OKK67^/,<AYUQT^S]^^N
MM9?X\QR'G7'3[/W[ZZUE_CS'(>=<=/L_?OKK67^/,<AYUQT^S]^^NM9?X\QR
M.0+>.Y8@C+8N0!9@-Z$`PN<5F`P`M?`(`P5[H01:_P!=;ZXY''G?'3[/W[ZZ
MUE_CS'(>=<=/L_?OKK67^/,<AYUQT^S]^^NM9?X\QR'G7'3[/W[ZZUE_CS'(
M:5\==;UO3!?VMZWK>MZFU9:WK>M]=;UO5>==;UO'(^ASCQZ4G&J%+-R#4J#S
M!&GJ%,[K90H/-'OJ,T\\ZOAFG&CW\(A;WO?Z=XY'S\ZXZ?9^_?76LO\`'F.0
M\ZXZ?9^_?76LO\>8Y#SKCI]G[]]=:R_QYCD/.N.GV?OWUUK+_'F.0\ZXZ?9^
M_?76LO\`'F.0\ZXZ?9^_?76LO\>8Y#SKCI]G[]]=:R_QYCD/.N.GV?OWUUK+
M_'F.0\ZXZ?9^_?76LO\`'F.0\ZXZ?9^_?76LO\>8Y#SKCI]G[]]=:R_QYCD/
M.N.GV?OWUUK+_'F.0\ZXZ?9^_?76LO\`'F.0\ZXZ?9^_?76LO\>8Y#SKCI]G
M[]]=:R_QYCD/.N.GV?OWUUK+_'F.0\ZXZ?9^_?76LO\`'F.0\ZXZ?9^_?76L
MO\>8Y#SKCI]G[]]=:R_QYCD/.N.GV?OWUUK+_'F.0\ZXZ?9^_?76LO\`'F.0
M\ZXZ?9^_?76LO\>8Y#SKCI]G[]]=:R_QYCD/.N.GV?OWUUK+_'F.0\ZXZ?9^
M_?76LO\`'F.0\ZXZ?9^_?76LO\>8Y#SKCI]G[]]=:R_QYCD/.N.GV?OWUUK+
M_'F.0\ZXZ?9^_?76LO\`'F.0\ZXZ?9^_?76LO\>8Y#SKCI]G[]]=:R_QYCD/
M.N.GV?OWUUK+_'F.0\ZXZ?9^_?76LO\`'F.0\ZXZ?9^_?76LO\>8Y#SKCI]G
M[]]=:R_QYCD/.N.GV?OWUUK+_'F.0\ZXZ?9^_?76LO\`'F.0\ZXZ?9^_?76L
MO\>8Y#SKCI]G[]]=:R_QYCD/.N.GV?OWUUK+_'F.0\ZXZ?9^_?76LO\`'F.0
M\ZXZ?9^_?76LO\>8Y'R/5<>]D'Z2L-[!5;(.TE$IF=;&)@JMEB\W$I+)K\HX
MQ.$[MV8$`PC$#KK0M;Z;TY&(-=>FNO3KTUUZ==:Z_IZ:WO>^G7*.<"4?<?`L
M"W^M6?W:G^.9@4V`P&`P&`P&`P,ZT/QTLOD<Z39GK1*S'K(%!':?/'IQUTT$
MK4K<:0E;XRQF[3*=.<VEC@?I*SMVM`$N4:$'0P]N]Y+<&+"(?+E*`AU(B<F-
M;%,96S5.O+874:,Z'-KF)D<984I"DV29&V][`)$>NUO:4E6'9(QZ,UL.71GL
M7#^^D,,2S:30EZA*5Q73-N9H],(S.6B9/A\)@K-8*PUIC((DJ6J4#RS/I!*!
M7OL2&+>\LXP@(?$W-@L,YXK\B:[E]C0B14[8)KY4B=&ML8Q@B<@D+/%6UP;=
M/")V='EK;#D"9H5-NAG`4C$`H19)HM;[2A[TV41YHX]W[("FT]AHVX7HAY:3
MGYG.::SF;@2[L:=.VJSGEK,2,IH'%J"E>49FE!.QE""K)Z"WX@.K8*MKHB8O
M4RH>!-CA%E<CY#DQ$4+3%NRK0&57-)X[5VTM<W[FP*B/NA+ZSF&*"@%J=`1F
M%FA$/O[=-$\G/$BPHLU-;W#9175]-[E:;A2)@*&=I1-7AKM=N:5+\.%.,;=(
M;&)$8XJF9"H4$&)$JI,,"<S6S`[#TVV#&*.A;T<3I2G;Z5MM<H@RA>CFI".N
M)BJ.B*QK0D.CDCDI1#,,;(K0M:DI4:4IT6,*8P)N]>&+0L;!:4]2VLLC<<F2
M.L+$5Q"8/2>-Q*5)83)5$<E,A6*3$2)CCKV4V#;7IV7+21DD$)C###CBQ%@T
M(81:U1+9[QNO.K*\B-IV/6$P@\,G$@>XQ'5TI8'=A6'NS$VLSN<!6VNR%&J0
M)G-M?"CFXTS6@.`"5&R>[2<WMFRW!A'*&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P*E$C5.*U$W(2=J%SBL2-Z).$998E
M"Q<H+2I"-&'#+)+V<H-"'N&((`]>HMZUUW@;>.G"N;,CU&6IWMWCJC1RYSED
M689.78[TZ1APLB"/D=CLPJI&M8X2Z+W*=,KG*D6@A1I5#6N`9L2-:H[=ZR:-
M=+.K]UJBQ9K63\Z1MZ?(%(W&+/3G#W?3_&5+LTF^;N(&=YTG2:<"$BP(R!C\
M(&PG%#!O74.407`8#`8#`8#`8#`8#`8#`8#`8$H^X^!8%O\`6K/[M3_',P*;
M`8#`8#`8#`8&Y?'SF&Z\98%Z%KFO(4\3URNN%VO(IC8;.GE;;MMJU$(RM(_&
M671B`]C=&.3.SJXGN`CSO$&H("`H/@[$*6:,[F<\*B:!*WN#T3+F.1LU?V?5
M-<,CI.XZZUPP0:=<C=<CF8J0-`(B0^O3A'G50H8S"RE:=*>V:*-T$)VA`R9\
MBDE?/"`JHG8<9A]=6V$=EOG+29O#C8MK-,N.9)7RJK)L@BU''-(8JT")C4)<
M&[SL`C-[7.8!:\411@=;Q]1(UOYB4#<)^18Y]76FG>(M=9_(^#M+9:K*@8W*
MS7RJ8?7$EBMG`+AXE,DJXE9"4RIM"F\W=`-ZM<W'#$!6(X#ZB-0;\P-L:+`4
M2:9PV>/<2W4?&:MDT%;I/#'&/",X[1]F;3`'QZ=0R3,S6U2QW;U"U$M9_1C[
M&U"G9R52:8(S0WUX&F=<VNWP+D9![T!%AF-,.NZ.VT7"$KTK/,VV,$\2S$J)
M)I&[A6KCA`1IM(BURH)IH]ZT:;H0MBUNV<8-V(C^9;*M;4^UR.NUHG>T6YW9
MA=5A\)+<H?6-Z5D\U[+8@RI'"'+F!U>V]4<VN"8]T2+$9X$AZ0TH)2H0PSZ_
M`R45S[J-1%H;-']KM17+ZQY15_8]<U[%YG%(.X*XU3E"Q""PI79:J,5JU0A9
M%'I]9S49J-I3)W!M1:$F)$<4/9VV?\#',,_,.CL4>XI81M72]98A#%QL@LS9
M2)XV)::!#..%HQ"RFURKB$;C8W",S64"A*5+L2E6H0M9RI>J)"8-8(!;/Z&I
MUC7Z79E+1VO)`CF"N:1J]KDMHF7.4J+>&IY9KE21'THSO2!<B,>1R)B<X80)
M,L`LVG,(5'A$5H?8++)E&M>4,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@5K:I3(G)M6K6U,](D;BA5K69::J(1/*-*J)/
M5M"P]":0N(2.:<L1!HR#`'``9O8!!%K6]!Z(J>;%:LKK28X)5-@C8Z`,O%_J
MDFRK#89@_P!;R&S8<!EK>'0IY0Q!G&74=%RY,3(&Q*N\Y<EKEH1PC"!BWL6<
MH\WPZ%H.O$,&:9ORF&F"$,TTS?E,--&+>Q#,,'O8A"WO>][WO>\T.V`P&`P&
M`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!38#`8#`8#`8%P:G$;2Y(G,M
M&UN(T*@"@*![;D[NT*]@Z_\`"XM:O0DRY*+K^L6/6P[Z:P,D>UU=[N*-_!^)
M?%\![75WNXHW\'XE\7P'M=7>[BC?P?B7Q?`>UU=[N*-_!^)?%\![75WNXHW\
M'XE\7P'M=7>[BC?P?B7Q?`>UU=[N*-_!^)?%\![75WNXHW\'XE\7P'M=7>[B
MC?P?B7Q?`>UU=[N*-_!^)?%\![75WNXHW\'XE\7P'M=7>[BC?P?B7Q?`>UU=
M[N*-_!^)?%\![75WNXHW\'XE\7P'M=7>[BC?P?B7Q?`>UU=[N*-_!^)?%\![
M75WNXHW\'XE\7P'M=7>[BC?P?B7Q?`>UU=[N*-_!^)?%\![75WNXHW\'XE\7
MP'M=7>[BC?P?B7Q?`>UU=[N*-_!^)?%\![75WNXHW\'XE\7P'M=7>[BC?P?B
M7Q?`>UU=[N*-_!^)?%\![75WNXHW\'XE\7P'M=7>[BC?P?B7Q?`>UU=[N*-_
M!^)?%\![75WNXHW\'XE\7P'M=7>[BC?P?B7Q?`>UU=[N*-_!^)?%\![75WNX
MHW\'XE\7P'M=7>[BC?P?B7Q?`>UU=[N*-_!^)?%\![75WNXHW\'XE\7P'M=7
M>[BC?P?B7Q?`>UU=[N*-_!^)?%\![75WNXHW\'XE\7P'M=7>[BC?P?B7Q?`>
MUU=[N*-_!^)?%\![75WNXHW\'XE\7P'M=7>[BC?P?B7Q?`>UU=[N*-_!^)?%
M\![75WNXHW\'XE\7P'M=7>[BC?P?B7Q?`>UU=[N*-_!^)?%\![75WNXHW\'X
ME\7P'M=7>[BC?P?B7Q?`>UU=[N*-_!^)?%\![75WNXHW\'XE\7P'M=7>[BC?
MP?B7Q?`>UU=[N*-_!^)?%\![75WNXHW\'XE\7P'M=7>[BC?P?B7Q?`>UU=[N
M*-_!^)?%\![75WNXHW\'XE\7P'M=7>[BC?P?B7Q?`>UU=[N*-_!^)?%\![75
MWNXHW\'XE\7P'M=7>[BC?P?B7Q?`>UU=[N*-_!^)?%\![75WNXHW\'XE\7P'
MM=7>[BC?P?B7Q?`>UU=[N*-_!^)?%\![75WNXHW\'XE\7P'M=7>[BC?P?B7Q
M?`>UU=[N*-_!^)?%\#Y'VPM/(/(W7E)DZ/)-)V<FJ2*$*2M&EB+V:G/`GT,A
M07H7<`8?*`6M;UY=8&*]:Z:UKKO?373KO?7>_P#KO>_+O>!S@2C[CX%@6_UJ
MS^[4_P`<S`IL!@,!@,!@,!@>@'%GBS7-P4C9-NS@-B.JN&6W":V01N#6A0]3
M$F()/"I5+%CXND-\;3LK@J2&QP"<I$B.\Z&$_9GAB`6,09;S@X2\"IC,]P)P
MA,GA$1:+&2TXSPY%:TX'M^E=B7;$I#,H/$V042@RAO*-?6U@&2':GL2HE/3S
MA9X8P&9/L(_!_P`O^\[$B<!EL7<J^5)9[)X5%`(E3Q)4.XJY6$ID"*+;DT@4
M1`$),\19&E!:].U.KHM:!"+\]))T/>PW8+1_[*IJ6WM\L76Q0S35#O%HA)6F
MZG68RA)6KBIG$QF$`8(J2HW!A2LJ2"EM?O9"GQFHI`D2MARTU2%)V&C:)7$^
M!-C62Z5S&X0\P])()E7[+)-;>)2OE;9)7Z0VW9-5LY4,,K.$2<Q/&%KC`1=[
MFM$8SI"Q!5J',LA20`+1#G+CG!(U:W%2!SZQ5=?QBZX#!)?:DV>"&]<DK,]_
MGD\B$FVATD"4E-9V8N'!V6>I&864,T1IQFR`;Z-XX&P$\X(PA*CE[^SR>7U,
MT1;CQ9UU(D]GO\&MJ*3A974TB492E5Q=]$H7&!S*/O;?*BCG`&DJ1R85PTY!
MI9Q2CQRIHBT4_+EFRA;'E5@VA74/A<F@]U/Z&7H=3AR0)993].FW`IB9PET%
M;B7Q"H93"35#RQB=FC24E9I,I4*B2DY[["P-7Y;7)1U:(6[`*A+>"7$1Q:M)
M>G23,I,*;9E`GZRX>Z2EY<H>GCBE`^Q..G&#VS+7<QK4&D$.($AIN@Z?:"VE
M_E]W&[EQ_4"F5.V@Y2HJF7:/L<'EDA&[KX7?CDK8ZVGYA4FAL;3((PO?6]0E
M5@/-+<T7@[.,2:3B+-&^T%>N_+LN5G4Z.D<VJ*)1)0&OM-,^ESK8,:C[VJLR
M:22NHVV(&9XK9)/T[F&:Q90C4E+&5+HLDPI8$0T0_.-7["_E_ES3YU2U>V1^
MQ8&HL&41N[7^Q84L!,URZOC*3MY543ZA:T,/A,H?YZ=I[*"$\#.C7&D#`>=V
M[0$B5XV#0B5QM=#I3)(BZ'MRIRB[ZZQ]P5,ZS3@TJ5C0M.0J3VQ=X9.U:`TT
MC8BC-@`(0-Z[@A%U#JBP8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`J41)"E:B3*E>D"50L2IU2_:8];I`E.4%E*5VT27JI6:
M1DB$9X)7_(;V]H?UMZP/4U%P=I*0L48LB#22^IQ"'Z"VW)H]7K&FJY7<MMJ:
MQF-;QE";`C&TYTC$072)@GQ\E711X3JI4P,S.8-00:6H*4!S]O'D:,\EJ:'Q
MZONTJ6$\&2`JOI+IJ1/1Y"5*J<6I>UMS\SGKTJ%6O0IW334[D@5@(/.("I"/
M18Q`[=[LNS1@_*&`P&`P&`P&`P&`P&`P&`P&!*/N/@6!;_6K/[M3_',P*;`8
M#`8#`8#`J42):Y*T[>VHECDX+#0D(T#>E/7+E9XNO:0D1I2S5*DX73R``$0M
M_P"F!F0I->Q-8.U.AKZ="@+W8#%9[@V&5E(C%9DRC<;?8FT+RW,;+M62F(9)
M(K+$G#O10QCT/>NX.L;!F!!=_,)M3U@F21:6@)IZ2U%+8&$=..IFVY\HV.N<
M5KA0M$)BV)T):F5X/+/*.Z@6"%H9O40=9.!D)GY<\WV)`TI$$"#I:SH:V;R9
M(?QS,/E:PBGS#?9GMR?-L.CE1D10J3D9&M!`6:E.'H\)IN_%U,_48^A=U<KX
M/&XW"TE;*9-"HG'6F-LL-G_'XR;Q@H$=L"56C%WU2TOD</)5RJ+32;.BA"N'
MOO"0L,2FA-2C$4*\"9Q3E7S>B!#2F2P]P>RF%9$G=C#*^/FY`!HDL%G,^L6*
MRU"2HC9:8$C:919[V868,`T_A+-`\'_A(V7,_48T76ERO5VC7EQIXA+V:=54
MA+:H(J9:><TK0S-!;]*9#MG-8%,?6M3LTJ%<T<B#TZPL\L]$HVG,T(O73+QT
M)<?R`Y6:)*:F2G&:&PLF'V)"BZQA7&CZO5GZ.M=5'7">NYL4(8#2U,J>G.'M
M"D+B:<,]*8UI0D>&25X6YD$L>.7/-=^<4[JZ5FW*%NI3,IH[F:XT]@)=(K(K
MMQJJR5DR+"P]L@)G\)<AIG(@SM(V(LH:<"?LZ;9!%2.17,A,5%A$09>6[Q-L
M1,I$LU0!@ID^LS1`GNL8^URN2F1P;@]HHY!I`H0I`]2A"T$@Q1M0:G)&!GZB
MP1BZ>8L+VRF15CGC(JCL1I>#,RY)4CH)8BCE`211*ZQ2Z,41X\L\UM>%9GG@
MS0#]))QB)4:&7O8<O`[R&Y.5,@3+6T%9*8RQ+'.MGC4;A5!*8PPI'&IY2_S6
M'JDB1"P;4;-!)I0M4K!'G'C5A,`2(6B"22BW`OP.0_+<U0E4O=4H9<-(\6<\
M@^M_&\3X8(VW9V&SY>B"M&P$.B%O!8.A.K=I(>F4-QYIH"C=$&F$B<#7ZPT5
M\VM/)?9D]A-CODUGD@<91*'C=<R%#IP>70[9ZM0!$@84Z)&5W;T$!118```'
M6M:\F)DX$.]F=F^[2QO4.6?1&78'LSLWW:6-ZARSZ(QL#V9V;[M+&]0Y9]$8
MV![,[-]VEC>H<L^B,;`]F=F^[2QO4.6?1&-@>S.S?=I8WJ'+/HC&P/9G9ONT
ML;U#EGT1C8'LSLWW:6-ZARSZ(QL#V9V;[M+&]0Y9]$8V![,[-]VEC>H<L^B,
M;`]F=F^[2QO4.6?1&-@>S.S?=I8WJ'+/HC&P/9G9ONTL;U#EGT1C8'LSLWW:
M6-ZARSZ(QL#V9V;[M+&]0Y9]$8V![,[-]VEC>H<L^B,;`]F=F^[2QO4.6?1&
M-@>S.S?=I8WJ'+/HC&P/9G9ONTL;U#EGT1C8'LSLWW:6-ZARSZ(QL#V9V;[M
M+&]0Y9]$8V![,[-]VEC>H<L^B,;`]F=F^[2QO4.6?1&-@>S.S?=I8WJ'+/HC
M&P/9G9ONTL;U#EGT1C8'LSLWW:6-ZARSZ(QL#V9V;[M+&]0Y9]$8V![,[-]V
MEC>H<L^B,;`]F=F^[2QO4.6?1&-@>S.S?=I8WJ'+/HC&P/9G9ONTL;U#EGT1
MC8'LSLWW:6-ZARSZ(QL#V9V;[M+&]0Y9]$8V![,[-]VEC>H<L^B,;`]F=F^[
M2QO4.6?1&-@>S.S?=I8WJ'+/HC&P/9G9ONTL;U#EGT1C8'LSLWW:6-ZARSZ(
MQL%:VP2W&9R;7EI@%FM[JSN*%V:G!+!I6!2@<VQ42N;UR8>V<6@*$:P@!@-[
MUO6A!UY,FP;6N?(WED\N9:QRI:**&<Y5-'9_@O\`[3V<JO9I*;$.8%4UG4RB
M9,2`D>)R_*HLW&"<@#(-3:2!+3Z))&<48X&MTX:+ULB8R:?S:%66^RZ8O*U_
MD+N=7TD3B7.:\SQ#AEI4;$G1(DI0=!+(3D%ED)R``*+`$``ATX@BWLSLWW:6
M-ZARSZ(R[`]F=F^[2QO4.6?1&-@>S.S?=I8WJ'+/HC&P/9G9ONTL;U#EGT1C
M8'LSLWW:6-ZARSZ(QL#V9V;[M+&]0Y9]$8V![,[-]VEC>H<L^B,;`]F=F^[2
MQO4.6?1&-@>S.S?=I8WJ'+/HC&P/9G9ONTL;U#EGT1C8'LSLWW:6-ZARSZ(Q
ML#V9V;[M+&]0Y9]$8V![,[-]VEC>H<L^B,;!T,K:R22S#CJXL(DDDL9IQQL'
ME111110=C----&TA`646`.Q"$+>M!UK>][Z8V"%ZWK?EUO6];\NMZWUUO7^N
MMZ\F]8'.!*/N/@6!;_6K/[M3_',P*;`8#`8#`8#`^R=2I1GE*D:E0C5$#T80
MJ2'FIE)!FO@,(4$#+.),UU\@@BUO6!??KE,OME+_`%H?OI#&0/KE,OME+_6A
M^^D,9`^N4R^V4O\`6A^^D,9`^N4R^V4O]:'[Z0QD#ZY3+[92_P!:'[Z0QD#Z
MY3+[92_UH?OI#&0/KE,OME+_`%H?OI#&0/KE,OME+_6A^^D,9`^N4R^V4O\`
M6A^^D,9`^N4R^V4O]:'[Z0QD#ZY3+[92_P!:'[Z0QD''URF7VRE_K2_?2&,@
MY^N4R^V4O]:'[Z0QD#ZY3+[92_UH?OI#&0/KE,OME+_6A^^D,9`^N4R^V4O]
M:'[Z0QD#ZY3+[92_UH?OI#&0/KE,OME+_6A^^D,9`^N4R^V4O]:'[Z0QD#ZY
M3+[92_UH?OI#&0/KE,OME+_6A^^D,9`^N4R^V4O]:'[Z0QD#ZY3+[92_UH?O
MI#&0/KE,OME+_6A^^D,9`^N4R^V4O]:'[Z0QD#ZY3+[92_UH?OI#&0/KE,OM
ME+_6A^^D,9`^N4R^V4O]:'[Z0QD#ZY3+[92_UH?OI#&0/KE,OME+_6A^^D,9
M`^N4R^V4O]:'[Z0QD#ZY3+[92_UH?OI#&0/KE,OME+_6A^^D,9`^N4R^V4O]
M:'[Z0QD#ZY3+[92_UH?OI#&0/KE,OME+_6A^^D,9`^N4R^V4O]:'[Z0QD#ZY
M3+[92_UH?OI#&0/KE,OME+_6A^^D,9`^N4R^V4O]:'[Z0QD#ZY3+[92_UH?O
MI#&0/KE,OME+_6A^^D,9`^N4R^V4O]:'[Z0QD#ZY3+[92_UH?OI#&0/KE,OM
ME+_6A^^D,9`^N4R^V4O]:'[Z0QD#ZY3+[92_UH?OI#&0/KE,OME+_6A^^D,9
M`^N4R^V4O]:'[Z0QD#ZY3+[92_UH?OI#&0/KE,OME+_6A^^D,9`^N4R^V4O]
M:'[Z0QD#ZY3+[92_UH?OI#&0/KE,OME+_6A^^D,9`^N4R^V4O]:'[Z0QD#ZY
M3+[92_UH?OI#&0/KE,OME+_6A^^D,9`^N4R^V4O]:'[Z0QD#ZY3+[92_UH?O
MI#&0/KE,OME+_6A^^D,9`^N4R^V4O]:'[Z0QD#ZY3+[92_UH?OI#&0/KE,OM
ME+_6A^^D,9`^N4R^V4O]:'[Z0QD#ZY3+[92_UH?OI#&0/KE,OME+_6A^^D,9
M`^N4R^V4O]:'[Z0QD'4<OF!@!EF2^6&%F!$6869)GP99A8P[",`P"7[",`P[
MWK>MZWK>M]-XR"/8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,!@,#THXNU+35G
M\5+`8YPU,C-:%A\GX%5%,6XY&$HM0R:GU7*)E'(E(G$P.O"@5G/3+Z#7"&,)
M2)4X)EHM;TFWO6;Q?X&?;VX+U.9:%VF-;39$:;W"<\QE;*_5XW1M/0O')NXT
MH5;FVPBT?.&9Q4$+YSI!H)(BW!L"WIW)`:02XB,&7B42)[X`\?)]84O<&0JU
M*MA?B<;HC'8RSD.TO7L9MH\=F6S72YUA#!4TM5R2&*'79J<*+>V9(M<DCL(M
MX3Z+(1EMHT[Y%<18?5'':#W!#%UANK@J55FUS5QF*<,>91N5E0%SF"(4?BCQ
M"HNY#:!JFH[T4O9WJ7(5S9K1ZLYN/&`@27;R-AI%PYHZ2&0Z5Q2K^1JIA54Y
MP>*%7U3'L,@F4ED7(J*NADINP"YQA+BE-A\2=F':)S*3I=IE4D7%D;5-9/ZF
MFT8RXT5W4E9S3\P))8JR`SIDX[PDQJB5BOU/L]YL!3@W\E8-6H9DRUHZR:/M
MKN;(F9>:0'>G0O24M6(P(S?#T$:[Q@OCM2]%SNEUG(^5;>!Q-F9[4FB9EI&O
MZ[HE3+$R3DY5=)LJ4;4J;YPEBB`3-+QK0)C#G3;:<`11`AEF#UCG1/)!^63$
MF!GO%.)XM96\5^HNY_@TI`0W*([(873UG-,$"C=&-AA#^C1O+JE/6B6*%\C9
M%*92F"-*U+$>]FBGV$<D'!*C"W2R%<-<KZDK72=B<M*XD<"(40IQLJY'?C:D
MKEP;=U8)GB)J:.FR!'8!BAP3'-[ZH2-K.H5$A,$+P2[M\BH;^#T-=8^V><1:
MXFY@BTCY"/TFBSRV06-7:RM$6BG%U5'6"</D4B]E/C@6B?KBV0(EM8'A<G+U
MHW34WC4+M)6T8PYF<8HGQW15!6K$V;<W<KD5R+@Z^4R`I+$I'-XPUJZ'60A%
M*'D].VID!+:@F2@@M:84F3IPGF*/#)#O8`I=Y'H`OXW4S.K5@Z:5<;RH=73?
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M)O4JC#DZI<G0*0@"W:FT><'*>F4-#W`M@K0!Y`PJXG!YK'_K`[M[VZC9IK&T
M3XF&<X(6*)*#"-FG&>;Z7LK(Z:3Z!M4@3F;V'>I=&NV4,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@7-E;0O3TS,PW1K8P/#NV-(WQ]/&E
M8V0#DN(1#>'I24`TU.T-83]GJC`A$(!!8MZUO>NF![9K^+,*2O?'M-QXJVC[
MB\\H>_`J9V[29-;42+4UU<)$?/Y3VS!8.FE2NP2M1XP](UQ9$0H\)T<$K:46
MI4H=@,SOR/*?DHGAR6_K<(KV#2"M(27-''49@DJ87:*/T<;=E)Q:3K(J^G*7
MJ+$K5&S%:5M5&FGH$:@H@0Q[+[MZFYR,(X#`8#`8#`8#`8#`8#`8#`8#`E'W
M'P+`M_K5G]VI_CF8%-@,!@,!@,!@5[4@TZN2)MVX-;3I:H`G])OBL2!G0]_7
M_P`PY+0$J1)4H.GZP]%CZ=?@P,GZK(\*?:0-RTH%)M0!9M(&R7$*7:PH`BBE
MFTP8]HC:PHH>PA-[?$"'>]:WTWTR\"XBA<@&E=T([^JL:&0*25D@0CMV0"12
M!8G'XB=8_)!,NT[TK('^L`U2$T8-^76];R<#ZEQ&3$A.`3R$K$D"EF!&U(";
MBDA05$<+$(9<<4!+9PZ/CY0QBV%"+JE#L6]Z+UUWC@4JJ!O"YN;6==>U2+F=
MET=IE9UMKO:MI9=*1=RC3.V*&,Q"UZ4"\IG@%E]^_AZXX%6CB4G;A)S&[D+6
M+<8C;%3(C,07')$0T;(N,&:M9$@TK04)*S+33!#.2%["G-&+8A`WO>]XX%G)
MK$Y,4H(37)2:8A64!.L(3V0XD$+$Y9I9Y:=625'0%JB"SR@&!`9H00F`"+6N
M[6MZO`^VJZ7A2^8!NVFPH-@$7M`&SW;2'98U!:P9>T>F#2;98UA(#A![>FS@
M!'O]<.MZ<"[E1J7D)SDA'(VN24BE4K7*4A-TRDI*I7."82)P6J$P&H))ZQP1
M"V2H-&'9AQ.]@'L0=],G`HD\(?4:Q.XH[\JE&XHW$UY2.*2VWY,O2/*@(0*'
MA*M(92U2=V4`#H)BH`PGF!UK0A;UK6.!]DD0DB!7IP0<@ZO0.&CG)1IP0W#(
MT:_2AY`$MY4>>IF<I3YP\EAT%6/N[U0=:T;L>M:QP*1Q@#J\>'Z8O.H7C9(>
MPG;O:CRZ;)!X)";M*VN8E&R@^;)"B^@>FO#*`'_:`.M.!<548EJ_;$)?R+K=
M>*+%@*BXUUSR=8.,%%"`,HN-C4M)HF$!0R@[#I)LG0=AUTZ=-8R#@R,2PY&!
MN.Y%5L<W%Z,"6W'7/)S6\L)S@6[FA+0F-(DH-&NY0%8M:!KN5`"=O_DUH6G`
M^9T2DZ@A2F4<A:Q4)EKP"1+4Q]Q20Y.MD)?39<A6$&LXBE3\7L.NU:9H2D.]
M:Z#\F.!0[KYS%H017C3X@B"X`$'=IO&PB`[;ZNX!:VP]-@=A:ZJ];\BG?_=[
MLO`J%4)?EP$Q2Z_*I7%(FKT"B*6VX_K"T3#L6A[8D9:EE-`E9-B#K>T9>@IM
M[UK?9Y-9.!V)ADA3;$)-?]6)A"4MBT0D]O2$@0EK(#PV1:+93,#>UC*7^JC-
MW_R)0^0K8->3'`HG"N5SLN5.;O=E-.SHO.$I7.;K9SJY.2Y0/IH:A:O6L!ZM
M6>+6M=1F#$+>M?#C@4?LH![VZ*_$%7]VLO`>R@'O;HK\05?W:QP'LH![VZ*_
M$%7]VL<![*`>]NBOQ!5_=K'`>R@'O;HK\05?W:QP'LH![VZ*_$%7]VL<![*`
M>]NBOQ!5_=K'`>R@'O;HK\05?W:QP'LH![VZ*_$%7]VL<![*`>]NBOQ!5_=K
M'`>R@'O;HK\05?W:QP'LH![VZ*_$%7]VL<![*`>]NBOQ!5_=K'`>R@'O;HK\
M05?W:QP'LH![VZ*_$%7]VL<![*`>]NBOQ!5_=K'`>R@'O;HK\05?W:QP'LH!
M[VZ*_$%7]VL<![*`>]NBOQ!5_=K'`>R@'O;HK\05?W:QP'LH![VZ*_$%7]VL
M<![*`>]NBOQ!5_=K'`>R@'O;HK\05?W:QP'LH![VZ*_$%7]VL<![*`>]NBOQ
M!5_=K'`>R@'O;HK\05?W:QP'LH![VZ*_$%7]VL<![*`>]NBOQ!5_=K'`>R@'
MO;HK\05?W:QP'LH![VZ*_$%7]VL<![*`>]NBOQ!5_=K'`>R@'O;HK\05?W:Q
MP'LH![VZ*_$%7]VL<![*`>]NBOQ!5_=K'`O+;#)`S&$FLU_U6S&IR34R<UHM
MV0-9B=,>?YT>F(&A9DXB4QZK_E&6'>@#-_7WK8O+DX%"NK=8Z*U#@Z752[FX
M*S/%5N#E9CFO7JS>F@^*J6JX^<I4F]H=:[AB$+IK6NODQP*3V4`][=%?B"K^
M[67@/90#WMT5^(*O[M8X#V4`][=%?B"K^[6.`]E`/>W17X@J_NUC@/90#WMT
M5^(*O[M8X#V4`][=%?B"K^[6.`]E`/>W17X@J_NUC@/90#WMT5^(*O[M8X#V
M4`][=%?B"K^[6.`]E`/>W17X@J_NUC@/90#WMT5^(*O[M8X#V4`][=%?B"K^
M[6.`]E`/>W17X@J_NUC@?(ZK0$DG'^U>D#_!)-.\!-/51JD[PBQ&>"G*W'`:
M-4&]O:`/77<+>M==9.!BS6^NM;Z;UUUK?3>NF]=?T;U^C>!S@2C[CX%@6_UJ
MS^[4_P`<S`IL!@,!@,!@,!@2V&P">V,YJ&6NX-,Y^\HT)KFK:8/%7Z6N:1M)
M$$!K@J01]`XJDZ$L8M!V:,`0=V]:Z]=ZUCKL14THU.<:G4%&IU!!II"A.H*,
M(4)SR!B*/(/(-"`TD\@T&PC`+6A`%K>MZUO6!TP&!QUZ?#Y,#ZG$GIQ^$H(.
M3F]I9GA*"3"#?#.+"<29X9H0#[#B1A&`73H(`M"UUUO6\"J*:W0]M6/)#8XG
M,[:J1(7%W)0*S6IO6N850VQ$O<@$B1(UCD!">).48,)A^B3-@T+0!=`^S:QO
MCT6Z',K(\O!+&V'O;X<TM2]S*9&5*,LI2\O)J%.>6U-*8TX`3%*C99`!##K8
MM;WKJ%KP&!]"23E!I:=,2<I4'#T62G3%&*%!Q@O]I9)!(1FFF"_0$.M[W@52
MUK=&TIN/<6QQ;R'E#IT9SUZ%4C)=VL2I2A"YM9JDHHMQ;A+D1Y&CR=C*V<28
M#N[@"UH*'`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`Y"$0Q!``(AC&((```'8AC&,6@@``(=;$(8Q;UK6M>7>]X&12*<N%4
MW/+PEJ*U%31'5+DBD3LEKF9J&R/K67KIY1/B\ED&D9UC/T_\V4H&68F__J:#
MDV"TI*[L)?#5]C((#.%U>-2OS!TGZ*(R%7"&U;WEE[2+Y:G;C&!&H"8<`.P&
M*`BT(8=;Z;WK6[HA^`P&`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!
M38#`8#`8#`8#`WLHR3M,@XS3"DH[>42X[6<;R!B=KN,EFTJD]?L%CUZU0A;&
MV]C^N\6:G104[5?*CC7E,U*-%A7:<1FI?$5IP@W+WHV'=)MQ6DK/.GR3635=
MN>E5')X^\+!M.`KF/E+<<Y4L)R;C;.J0+;V<P,9;%K\4B/,`E5H/#,"M.?RS
M-'@#DY&542_CE*B;OFT&B7"*)5O7W)7C'6\0EUF5H;N(.]12"O[%DMQ$E*PL
MKPY.<VE3@S*#0G&%$K`DI`IFL2<XM-K)S[&+=/7!#<>$%BU2J6G-L3L4B8)/
M''Q1RO+NP7(@]3%GM<_'M)ZDRHR*5\UTK+$O$S;:`J$YR83L+0MW_;^1,(_)
M^$<V!?![]KBE$F9^FO)F(02,$PE!#%L?AK%!W1'Q<?V-\<8S*Y&^)Y-+#"5:
MA>UJ8^>G4EC$\J51!A"0#D3D=P<*K$E[I/+1-X[REZ=(=Q42KTSHWH(@U@J.
M+\?V^+VQ"$)1=3RY:T6NT6BTG)A@9DZ62EM(&G36LVE),*#,OC1J-PNL?CQ'
M87.X5=CC&2X=)^4/'28'0V<$+G1`^5U"(GR))>3GHM(EZK$+.X2=F)5;ULHX
M9JH`@!UOKL%N^/@9;K[D3QF0T\<URYOJV.&W+6W%]GY'Q.M:^2QMU=]Q'EO,
M]6:U1]&S(B`,;N5QZ2M"]0%N-)\Y-\-4'8EPA"QET6Z73[BQ$XC8,@5L_#RP
M+W;:XNT=9I:PKU8HI@XE9:=,!H-(YQE8SL3*ZVLQ0X,N5#"I)$?Z*T20\F*%
M'<6)EWS@F0;@X0BG29E'!>,&J^_]P<`B)SF&JDH'#_VZR#CCXUJ/VWCS#:[3
MF5>"8K1+MV^DVM5L1:'9*88PB<^Q,Z5GW"^I$_&B9)9KQU,EU:6CQ3D`Y05%
M4B68$Q5UC$B:.0RR5L&H:OE:EZC$L=T)RDUY>W=3H:#;DTI6]*$!8I9:,4L$
MGXQJ6*&I0O\`Q*W<S3%ZT;IF[6U&W%\HP,7(O?D$Y7BSP-M21Q<R-\L<HFZ1
M10UZ2(DZD;`(932,A9L0=WGW@@=DSGA<J@\[A%91FL44<5<=+1D$&?G2('!N
M(B[D?*^0'5,R+ILI*,?4[H'CR<F`:BV;YHI1#Z+-F*"P;+<Z/+S-!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@7%F.*3/3*I/'
MHLA,\M*D\P77M+(3N*8XXP736]]I98-[WT\O36!^C@GEEQ[46:P3MMNVHT+!
M$^;'+VSWQX?+3O*'RYMK>S)G%UL8F5?5O`F5?#K;<7-B1*U*%NDJ)8E&J)*(
M/)TG//UOGESV-"Y'9,3DC-`+"@7+]-4%:5]Q(5TBY4DG,>AVHMER&*R2.2.)
M-U0#9S*_D[#R!DKD%[<WX2KS5`6YJ3#Q%K$1!>]9_8\IP:V$`-;UH.]!#K80
M[V+6MZUK6]:V+];>M?Z[\N:'?`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]
MVI_CF8%-@,!@,!@,!@5[5Z)])(O3VW73+YP#TGZ#TBV\>:>7Q/1NG+84&U77
MIV^-O0/]<#)/2@?V[V_<UI\8QGL.E`_MWM^YK3XQC/8^NCZ("0-*%5?H4III
M9YJ4/LXTF,/)",LD\Q/I5HDP\DLT80#V'8@A&+6MZUO?5GX'RZ4#^W>W[FM/
MC&,]ATH']N]OW-:?&,9[#I0/[=[?N:T^,8SV'2@?V[V_<UI\8QGL.E`_MWM^
MYK3XQC/8=*!_;O;]S6GQC&>PZ4#^W>W[FM/C&,]ATH']N]OW-:?&,9[#I0/[
M=[?N:T^,8SV'2@?V[V_<UI\8QGL.E`_MWM^YK3XQC/8=*!_;O;]S6GQC&>PZ
M4#^W>W[FM/C&,]ATH']N]OW-:?&,9[#I0/[=[?N:T^,8SV'2@?V[V_<UI\8Q
MGL.E`_MWM^YK3XQC/8=*!_;O;]S6GQC&>PZ4#^W>W[FM/C&,]ATH']N]OW-:
M?&,9[#I0/[=[?N:T^,8SV'2@?V[V_<UI\8QGL.E`_MWM^YK3XQC/8=*!_;O;
M]S6GQC&>PZ4#^W>W[FM/C&,]ATH']N]OW-:?&,9[#I0/[=[?N:T^,8SV'2@?
MV[V_<UI\8QGL.E`_MWM^YK3XQC/8=*!_;O;]S6GQC&>PZ4#^W>W[FM/C&,]A
MTH']N]OW-:?&,9[#I0/[=[?N:T^,8SV'2@?V[V_<UI\8QGL.E`_MWM^YK3XQ
MC/8=*!_;O;]S6GQC&>PZ4#^W>W[FM/C&,]ATH']N]OW-:?&,9[#I0/[=[?N:
MT^,8SV'2@?V[V_<UI\8QGL.E`_MWM^YK3XQC/8=*!_;O;]S6GQC&>PZ4#^W>
MW[FM/C&,]ATH']N]OW-:?&,9[#I0/[=[?N:T^,8SV'2@?V[V_<UI\8QGL.E`
M_MWM^YK3XQC/8=*!_;O;]S6GQC&>PZ4#^W>W[FM/C&,]ATH']N]OW-:?&,9[
M#I0/[=[?N:T^,8SV'2@?V[V_<UI\8QGL.E`_MWM^YK3XQC/8=*!_;O;]S6GQ
MC&>PZ4#^W>W[FM/C&,]ATH']N]OW-:?&,9[#I0/[=[?N:T^,8SV'2@?V[V_<
MUI\8QGL.E`_MWM^YK3XQC/8=*!_;O;]S6GQC&>PZ4#^W>W[FM/C&,]ATH']N
M]OW-:?&,9[#I0/[=[?N:T^,8SV'2@?V[V_<UI\8QGL?(_5#^`?YJ.[_.O!-\
MV\Y*KCS;SGPQ>!YSX*C9WF_B]._L_6[>O3R],#%>NO377IUZ:Z].O3K^GIU\
MO3`YP)1]Q\"P+?ZU9_=J?XYF!38#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"4?<?`L"W^M6?W:G^.9@
M4V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P)1
M]Q\"P+?ZU9_=J?XYF!38#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"4?<?`L"W^M6?W:G^.9@4V`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?
MZU9_=J?XYF!38#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,"4?<?`L"W^M6?W:G^.9@4V`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?
MXYF!38#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,"4?<?`L"W^M6?W:G^.9@4V`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!38#
M`8#`8#`8'&^[IT`6,T>_(644'8S33!;Z`**!KKL9A@MZ"'6O+O>^F!ZY<G?R
MX8[558T*.LI2\/UTBLFLZ`Y6Q^1K2/J[75W79!8?/JZ2M'F34%6W1I.3(CVM
M>8,2T85R?M\AFA%BS/V^>ACA1^5CR"'*(S#8].Z"FS^\WO(>-<C31"P'ER)K
M.XX_$Y!-]Q6P3U$/1;;QND:C*HX@U&%<`LX/@'^$;H80/M!"'?\`+PN-)'DD
MRCD[I&Q(0MIF[+I)F<`F[L]1T39QW7,S9;4-`J515N4&S>/+WY,`HH)6V]9H
M6QE*]@UH6[L%HC'`ZSGU5!2WFPJ:@J&PZ/@%^1M=*)+)U2Y?$K,D;K%HJR-D
M.B4,DT\DDOVZ,QPER9I:UZ5M2]IZA2`L6MXMP2:^^%QG'7C@]2JP1+"+VAW,
M^5\;I6A:7U,Z0$<89:;CUD-KFS`]%I5YZ]>J?`&:4F&E]4HPEC3EFA%TDNWU
M@B#!P6M&4T4]WM&YM4;\AC-;>U^20)FD[\ZS:/5X%\*837)]7-\44URTR1,H
M."<;'3W\$@*2;\0237^W+LT9,FOY7'(R(KGR/-<FI2QYY$K7JZG9O7%=3Y>[
MR^#R:Z1E%5@ME)3M&6)G;F63&&ZZC"K,4(@:V)027H(^U]H/C>/"J'T?Q&57
M`9:\&M:RD/+550K@Y4_,E4EK5L9VNM5LA?&1Q2O$1C;V1.&>6MYA0S]"$A/1
M;`,C9H!Z,Q+MST-AJGX%T%/^+<+M%F8KRNEYD-4RF86?9U"6#6<H/X[62V#>
M=-5;RGBV8W^TZ4,Z4+>1Z2<B5@3Q`4>*0`!>P[UG;HU3</R[KH0P0,K)G%(/
M4L-X]L?*='2C#.'=9<;G1SNU)WA;,6^-'Q5*U&F1]$?L:I`)P"M,+*,,3EGE
MAT,5^TW!?)G^5]RIAS,T*P-42E<G43.L*]EE=Q1W>5$PK>7W(8G3UTU3`YXC
MC+$5);NN5EI52EF=75,UJQ>$K&4+KTOV@N$5X#."2Q!1IVGU,7BTE1'D%IW)
MHZ[-HE\.L*D("[2EY8Y,-[KQ8\=C.>@[RQIFH]J>_"&G(<B1;T;J?;C188=^
M7S8CQ!8I;BB<U9+8*4^T$.TV*OI2]NTJ@\1O2<,$093SI!N)"K)?)"3WH):Y
MM;'QS<&8X8?.D^NT0=/L,D4YPZH^7_F?67Q%G#S.&ZBX#-^1C2:]-KV@3S<F
M-4ZPRYZ:5:IZ&PK$!ROPX^#:L0$`='![M`"#>]=%M^N^1L`V?E95W&8%^8A*
MK1DTR+6<?M6:=Q:`RNS>C3V2P5_7Z"T=S5^*&R+]O[$.*SZ*!'M*-&`2A6<$
M(NH@Z!/M>,&H\C_*[Y71^--;LG98K)Y6<]U1'I35D;=GDV>UZYW>J0H*T+EF
MW>.-$-4%.[@Z)DZT;2\.>F8X\`5W@?K;#?M!F&KORFITYWO3M=VQ:,!:JUL^
M46/`5=AUZY2188VV76T4721XK%`GF%?L_GDK,((TK3*0ICF-P;$JPU,N&,H`
M!K^TS@8T!^7Q(I?7]>R6!R>KVUO]E%]W!/K=E%M+]U=(X'3-S-U8.$PC",=8
MM3Q#VUN`[$CTG5B<%#J6$1Y?FYNP(Q/M\B+NWY<]N1QXGH959M`Q2NX)#*FG
M`+OD,\>D-3S-KO<E4=4"2&.A<142-P<YMIO4[`%0V)2D12<9RDPHGM&)]H-7
MK[I*9\<+>FM)6&:QGS.`JVQ$^FQIP.=6(9[LPM4B2[;G%0B;S596D#P5H0]D
M@UXFA:#W!UH6[+LT8ARA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@2C[CX%@6_UJS^[4_P`<S`IL!@,!
M@,!@,";UG,RZYL:!V$;&669A@DOCTP!$Y()8"/R%1&W-,[I&I[VWFDK1-:E6
MD+T>$L81#+UL/7IO>!OJ+\UOE6_JK,!:CTWW)&K"ET2G33"IP8M#':ME$%L]
MNM**KZX`T"1K6DMJ<6LIOT4::;HQN#H`M]VN[>?K!0P/\S&VJ_FLKG+97M<K
MG&7<O'KF2N1KC)+I$EG;W!YS`U$32;3NA9^XB4VSU2>#8Q"6>.27U,V#OUM]
M9T(O3WY@$ZJ.#5W6`ZRKR=5["8SR6A#]')&IE"$5APSE,ICJN?L3VYL;JC6L
M@VLZ,)MMJMOV4>5^MW[%O>MA?49+)_-%FQ2-P82Z)J]IAI](U+1+3&(9,+B@
M:B/Q:DI=*)?!_,9O&IREL!0WJE4I,3OC::YB3/9!!?C[T/8Q"?7SY&%^2_.B
MQ.4,<F$:E\,A4;2S3D.NY(N2B,F/PE"67.%61RJ%#$ATZ."P`8[IGC92H'?W
MJ0J3!Z\39>@ZRS]9.ADO7YEMB:I,-,ZJN#A+-XTAXKKI*3+K/3HA5\G6IG!$
M^--9$2H%8,4^-5)`#<G<EL$K=1!UXH@![@BGUFZ*`[\S"[RK(ONUV&+P*.S*
M_+;X_7*ZJDQ#TN1Q*3<=7$+C%D#"B7.(PKF20BT(IT+6",&,D8@E"+WOKJ_6
M?T(!>G,S5PU$MI*,\?ZFI&$.MXJ^0[R77[E/'5R=K)=XTX1M]4J5<RD3V`AE
M7$N&QIT2<!)#>`L!1.NWOV))EW1.ZR_,2D57-]=/[7QYHESOVG:[55=5O(T\
MB;LDT8HJ8V/#.W;DL2C4G:8!8+\QMKX>2E7.J$T?;V[."<+6]BGU_H9.M_\`
M,0B_HB'%4A5D7#98.#U9\4Y+R$DR>6M]CQY.3%-L5K,D<CQ<C,@;D%:+6R&U
M^-;]+2$IY@`Z$'LT!/U^>M$-G_YH]X3A9&):EBD5B]LL\YK2Q)!9:656K(BI
M/):K&B/8A(*QE4X=:O@+8_+6XE0^IF5L3@=#@=>I(=[#M]8(OOGUMDENY96/
M%^@*F4.+7>I4L#%R9BYO$N?^04/70V7/#A,9*^NLI;V!@1N)RACCB506S(%1
M@Q[+,$+KI]>,HG3Y^:59CW!5L,]DL`0G/,2X^Q%]=RI=:BIM$DXW2J)2N#FQ
M"OETM/KVN27=5#R0/)#0WD^?C.&<(S0]`UI]1KY&^9$YC/*^QN72:)1%5-++
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M[,\@=/K.A$%WY@,QW6+I3\<J6MXA`E=(WM030TMCA-'(R-0>^+<9K@>!-ZY\
M?%ZU:YQ9W9"D+<8K,.T8C$+:CQ#>@\N#.%1\[83.6B60/DL7"F&$&4?QIJ>-
M1Q[IB5757+RMXT&.Z6*3B2-D;LF!3QCGY#4\&B($B5',BX8QIUJ<)&];R6?`
MTVYKWI'N2W*JZ;QB38Z,\6GLE0*(XA>R4B1XTRL,:8XJWJW)"@/5(FY6Y$,6
ME(DI1II:;QO"T,79W;LF3!JYE#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI_CF8%-
M@,!@,!@,!@7N-O?U;?V=_P#0T>D7H=<2N]`RQL]-1AW\'>]^8OS1YPE])-IW
M7_D)\4ONZ?#K`]:D[=44ZM7C;6[]1M`P6'VAPT<KVGDDA56JD\F;IEJE;RD1
M[NT"*DVS3&EK=(LB7$-0=@":H2`#XH="WO6.9SHP?#>$4-G;*W6A&++F2JEE
M=2L=B:].LM3PNV3GUYMB84Z7#BD4TMZ/U85K3W!E[GI>9(=;$WZ`4!,8I%VZ
MNV=C"N^+;@NY;L/%F,3-DEX)'-XHQ-]@,:MI/:01*2-;;*'"4.!K2\OS(W*H
M?$5B@]W)*<5:9&J0*"]*#2P:-%=XT;@WGP]A<FL^!2YJCP.-=13BIN0<B=F:
M-A9K/W%'SBPRR-^4$%I629*T2I\M6L$,?>AE#<RA!<W16/M`4'IJ2\?-&!U_
M%RE&>$/%TO%NV>139%94U9;`F25?%E=K.H+4L.S:P6Q9>SBL0F&M;C')!5ZQ
M4%;IS-3*F\P/Z@#]Z+W=O7D53[P=*8;?J:J3K,,5ZM#E!/\`CT6_$Q8!`FUI
MB*.IG1HFP6LU[&(]<\MEJ%B4-HC@@2')-@"H-T/NU/MQH^D<X;L*RHBK-4RR
M7$R5E@M>W`YQN1Q.*1Z(2*)2FTX?!%D:C);C/R;;>5*-#+4ZS;Z&,!C:P/>4
MG5"#LE0;=YP0YYHB-S+F7R"J=H)D$7@T&L2_E:-N@$5)E#HV12O)0_$M3`TI
M'9[CL;8T?@$)TGI1\=&]H;BM^(I4>0!9C>)1DJ7<,:CK?3U(Y]<\])@H'3C4
M@C)</@,#F,Q<`<D8+,IBC"['MEJ&5X6=`!PT\I<<WO#@F<`=/-A!,%V@FVB<
MU1PWJ"O>1M'5K?\`/'9_D-A738D9CL.8*_3/-=2**51:$LJ@P4_?5<O:I"SF
MV/*X4X%I$[<@</1:<)1RL8@F[T!MLV#5_B@75I`[7?+-1Q)"N0Q%@;*SG]M5
MS,K-H:!SY[EB+]:U8_"DCFK+.DT4;7)&PGJD3DB)<="&8D,V`(RK=&=;0X]5
M>-'.;PL=4R5-7S#":!=V<CBHD06S7UWN=HN=D1)SG%3_`%OD<))K1C->ZR6F
M+&-T'WM*].K2A++ZIR0R6]>1?F7\N)LVH.5RBZ2&V(2F:LL4JN7IDU8QXI2Q
M2.MJZM)LL>RV.T+>@CHQ1]"P6NRDN#8Q>GG0A1YV(.A`)(\[?88%DW'*M:YT
MQ0^8VL_;O9Q@T1M$B,LM=`E=.JFB5.J-0R1`4\:9-N1'/#G#3PNHW/;06P%Z
M'I(8I!O>U`;O]#.#WP78WU\O$.Y>]Q9_9Y;RVW"B6>OXQ%:B\VXZG31P$SMX
MIE9Z&;/8),5$E)"5-%$$E*CX=%%K5!I@#PE31'F&K*SW^8Q1E9&P5D75H^N7
M&<]]@2@!OH)])E5%5S+I.A<`:-V;LF1/KFI/4]!>49X]ZZ:Z:R_^?8RY67&R
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MJ6L()(JUG]TVW,97$*X@;]7\+\UK^*-,RFTBFECHI6\-2)"BD,FB+`V,C-'X
M0Y+%BM2K[S!`)3D%"&;L96O0V?NFCJOH'C%.&@1^II;J_DPQQ-LL)1`FTE$H
MK!33L.N*&_5UR7RTY_@IK_%IJE6.Q`6\Y2)>(;>8:),2%09F;;O@3*&4;Q95
M5K7[\Y'3E.ND7`J_+AL!X7Q%L=QM,PA=V+X<T2J$M@)_HI9)D6VHYG0$'>C$
M`D6B%J@8#S5)13;_`)%C8>!43>"%T[%:<D#3C@S4BYPM>-KJ*-60I-NV'/4T
M*!)V6Q[F@T)2DP!MCJK2\+8]."IR%LGS4D`1&C(?;^QAFHH%6]:\D+.B%Q&Q
MR=1*JF>U&I//$,:DEHTRURYJ%]7:]M2P6*"*=OC_`$R5(UR0U6!.8:'9BM.$
MT"D'>0;;S.!M&XT[4TCCDZL>?QVF4,)+XKS]^171Q/(52"#S">P2_::8SG.(
MU')OJ"?5EL,\6GA+&ZMSAIN;SBG(IQ"4`(Q^)-YSV(##>!\,DT\]!GV58H85
M)W.@$->RU+7T'9PID/(6!L\\87.RG2=VE$H.V.453/B=*K86-U>'MQ'WGI20
MD=@AOL*2-\#XH[&1!D6W*YZFKG6%CW9,F)NB46;6>,UQ5ME3RIW0E!+IY8D.
M8U\SF,PC"$#.F6&($"9*K//7*RMDE$GOL)(]<5N/U:U?82JP[#>U[8KLGC";
M#)E`6"N9_:$=;K-C]\(I-7$F01VUU]:M3BSO<++6N0TS\M`K2HD@DX0C5=A+
M;X$.,X-Q*.S^)4M/+B>FVW;>LVUJUILJ-5ZE>X"<?7%E/]0LKY93VMEK6_,"
M.P9_'%*8DAK0.AS0DT%4IV8$6B\;Y\#YV=QVIV.PR$VK/9)(:OABVL.+\-(;
M*UA;9.'U_N">4L*PYW+WXA\E\4;T$=;$B7SE8(D\U:XJ5(2TI0=`,&%O.#.M
ME?E[0EVM6UE2&?,E61.1WI<E>TR@(55DT0J,-=9K&YJ+?+!]HMJPF:H8J\R%
MP`C)+86I\6(20C4J`[WX:<QN08,;.'%.[E33!':^7XV=CI&O;E=X@WQJN(N-
MS5V;&8!(6*LJ^E]HVQ"H;(IHT(9:L<%^UBI`2:W(2P(=*U9II1#:,$I^.FC.
M1DZX[J7^0M+RR)+)(A2J10A5&GV42F*0AWFD*C+W$G-S$JC*J?>C"T`!@4+0
M%J%9)A`E1(P&#N\:-FXYP411NQ:H]-3]J>6:1O7%MB`G>80-T8EMQV]9"Z*V
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M7*B?.3#S`;`6$!C;M^!+H[P/8V)#6C[*[!:E4J$5QVL>505U=*J*B,FB-M22
MNU2VN(R%%:JNW%TX:8?.TZE5I7%4;>N++5EIS=:+(.4S["20SBY0+'R/C47L
M>0/)SS9HN2=A0*J&V!I'6L$4`B2R^([7L;E$N,EZ&1))$XKJU-6)MHVQ4B;@
M)DQ:DP0C#=D-N#3/C-1+%="*5/,O?)RRL$1U"$:I5#(Y$5FA+IFM7I`+7V7V
M7.*WK:*-S2G;#5&R5;KZ2=-_\:)./1:@TFVX,K\E./M4493C&@0/<H?KL8>3
M_)BF):^[9$+?"I(T5`=`$*50@%N7N:U"0E+?BE*3M;]&J#7%64H,T!(E,/DM
MM]#,+/1O%+5<L[ZJ/GZ8;C^7<\WA-'E9#F=V<VN>).333`D<D@C;[0MI#Y(X
M)$JUC*)4F-K:0@V0L,WLXY244V_Y%E8N`46<1O$K6VP^D5,L,I<J"O&FVI([
M.51=U56@MM.Y3%BLFYH)%T22`1YQ+*<T[0[.JU>HW_Y4L!>AC"^W]CSYG\1/
MK^=S6!J7=ED)\+E<@BID@C2TMRCK]MA=539IZ87`D0REK.ZA3:/3&!WON*,#
M^G-")8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$H^X^!8%O]:L_NU/\<S`I
ML!@,!@,!@,!@95(N^STSY$I*1*1EO4(K(^G(JMTV,V]M=;JXY)(H?&@D";]I
MU0#(]+G%/YR>`Q7K2COT;W@+$%@ND3Y$VO"VUC8FE_9UT88H<OKQ+#I7#89-
M(8XPYTF:VQC6*0Q26,+NR28!,X7FNB4Y<2>J1J=ZVG-+T'0<8+4*[;1'.)G9
M(Y6<*<3^-RF(2>0:;&4M0HC4SCVXC(&=J2DMI;=&DBB)BVUD:;24FT3?OP$W
MA%_JX"$799M<0V05]#)+IFATG5O2]X90L[&M*,622!OM8OZE$I<&U4M:C7F"
M2-4W*=I3"?%+V4/?_*00,MD%,XW+8[M`]5@X28:B#ACD5B.F';:TE@^KT)E4
MOFL7;O/BD!;EVM<HGKLJT9XWBF[5[`8(9990`!EUBYK<DXX[N$@;9XVCD"Z;
MG6.G?W2OJY?'J.S98R-$:=I!"W)YBB]5"E<@CS`B1.(6L24M:0F!HT(A:[MS
M(+8FY=WTDBYL0*DL:$UJH"TU<Z+CZRK-3*7Z`QQ0UJHE&I%-#XD.6OJ*%*61
M&-FVI6F&-HDA.R1:V47VL@A+'?5GQRQ)O:J5\:ULMLH$P)L44DBD3D\9FZ*>
MN/IB7-LGADA97&(N;4[NP0*MIQH]%$GE%C)T6(L&PL@O5@<FKJM%L1,\UE2!
MP;D!T`/3I6Z'PN-%:'5B*4-==Z&",Q]H`(F(,\Q7H497310$0BB-AV6G("6R
M03./<V^2\7=%#XU3]L'(#)K,K#;9$\5[6\AD,5EEB+3'"P%\&>WZ)N+C!TDT
M6'#,<4;48E1GB&/?A!V,>Q+)1B"K[BGU/+']1!W-L+12QH+C\PC,FC,;G$*F
M#*0M(=$C=*89,6I[C;T6W.:<M4D,-3;/1J`Z,(,+%O>]T;`LO."U$,3M=F=P
MQN0OUC@IEF:TSI`:T75?%J^J)?.G(F!(J<71!1`B(\J<YD!6E+2H4^DJT@:C
M>Q'G",W,$$;>7G(-M>9+(3)RA?7J4R\BP%#A+X-`)D8P3Y&UIF-OFL"*D\7=
M4M<R5K8D"9$E4,8$'FZ1&E*`'0$J?13(+4#E#>((,37OUS(,92&0F*`>#XM$
M%$_%"2)"&5EP`ZS3V$RP5,"^L0-*A,YCD)",7_&(O9/_`!8R"6H.;7(Y&><O
MU,HTY.AZVR5.W][JZK'^0DHK?<'YUM"+HY`[PY:[M\)FKM)W%0N9DYQ3=LU8
M=V%`",0=L@Q"5>5C(;/CEU%RT)%DQD44-CLG$@8]"1"@\::HC%Q%MHT'H91I
MJCK.E3Z\1./1NB]#,[QB$+=P7I#R*N9L8*^C"6>+]1VK(O:<+K]J.1,ZM)'(
MS=B)S;K.:TH5+><-4"3H'A05LQ1LXY(`S6DPB=!#VS(+L?RFO%4PLT?*G!*`
MQ@%!`$RMEB\/9;*7DU@H1+:U026SVEA26!)T$%4M:0UK(<7%060)(GWO0O-R
M?#N"Z*.6UYFR!HDA+]$6I0S))TD*9F&J*I8(8Y^U%J`QV.LDT$:(8CATJ=)P
MTE%IW%4XHE)QI1180B!HL&M3((4\WM:L@:6QB=Y4-6U,SI6;TV(_1+&0!*Y4
M[$#X'6Z@(TS:2</4:B:D:,(!"$6H#OO/":9K0\8-OJOY\+X+&53B]H)O*+:`
MHO)Q2NJDVK#X8O?+U^L!TA=`+W*NE5H5RS;<9*>K=(]&7=&SOZ@L(C`I='*]
M'RS^AII5MQV!3I+ZBA;@RF,TJ1M".41>80Z(V%#9%J/JQ+X\L=XA.6201U2Z
MQ]>8,Y"K\WTI2B-,T`>@&F!';-'6:7+9]C(WI#.I@XR<F16(Y6P]F.A*`:MP
MG[NQHHRN?C5A*0E27H3`W$)"DA8@(DY!(`E$@T'6,@N::_[40P1!79,E1EQ%
MIALVKY"2.-103JF@EB/A$GE\3%*#&7<E.8'"1$>?%IS58P(E)IHT_A;.,[F"
M_,')^Z(MHI&5(&)U;4D6@$2*C4YKV`3B,D-59EN!=:K0Q::QAY902*(E.ZH+
M>[>!IQT6I-`(XPLP81,$4BEV6E"K$=[689>K^O<D%)=2MW>$+3)$DR2S,1PI
M<US)@D+>YQV5,DF$H%M8B7)#DIN^W?9H0`;#<$FE?)BXYBA<65QD#*TQ=QA3
ME7>X5#81"8/!VZ(O4JC\W?&YDB43C[2R,ZM]E<5;EJU>04%Q5F)"PFGB+#H&
M3(+]'>87(*,%-Q#5,V<_<?4P%?%SWROJYE"V$O5911KA$)D<)5R.*NBB(2=J
MA[,D0"<$(B%:HA.6(\9A@`F:9!'U')NYU,Z:+&-E;?J2L[%*HDB)!$(:&+G1
M&;2"52>70YUA.V$41?8J_O,U<QJ6]:B4)A!4^'H.@E$Z+9!:YA?UK3M`X-$@
MD2+;"O=((ZACC)%XI&(VTG5@W2-I@2*.,,<96MKC;/&D,N<@EHD)1"8TQ88:
M<`P[??C()REYD<C$7U@/!/TIKD_R:=30$B7PJ!N,IB,HLW9HK#>ZUE*^-*'Z
ML%4OV:(2ST"H;P;,WXA82S?U\9!9HYRGN^,IQ(T$I9W-I%'*[C)+)*H)`9K'
MDB.IFH]DK-V;V.61IY:D,LA32J-(0O))0'+19PPF'&!&+6V0737,3D*)RE;R
MKG+>[/TOF,FL)5('V"5^_2".SV:(R&Z73&O'EWBRQPK20R-(E)"K4,)C?LP9
M)9NM:.++,"R"+,_(FV69]=7_`$]L;X:_P*(5C(F:80>$32(22"P!M86J%,,@
MALIC[K&G74:2Q=`)*I-3;6%GIM'>+LP1@AL@C:ZX;*<K537<ME:PZTD4F8I>
MAE84C8G-0OL7&W;C9B%J3(B6-$W,1#0E3I4)24"$E(G`0$G1(>S+G@3%1RBO
M@\^.+%5BKS3(?=L@Y'Q[9S:P");+GE"Q`X/DV\$37X*@Q2L;"S`(CM#;D^]F
M>"07HXW0YD$9>[ML^1Q,^#/,H,6Q92S0F/G-6VQG)"-HKEZF,AAB/SI.WE+0
MZ97B?NYVAZ,T8=M7L)HC`EE!`R=B:QOE??$1@\>KV/R]L1,$.8I7&X.L,@L!
M72^!-$[6NZZ:$P6>KXRIFL2/E!K\K"L/0KR3QEF]H1@T$/1D$?=^1%M/M>D5
MNZ2!K/C)K`PPP]T!#(8EFK]#86I2*XO!WRS4T?)GLDB454-R;:1M5.1Z<@*1
M.#8=EIR`%L%FCEU67#]UL9'Y.)MW3R^8NU="]&LRC4:73WP]RY2#SM`>%P]+
M>"'NTK\<!/3_`(M`\N7!+4G*"[4478(HDE384DCB*%M+<_!A,&W/%$;KMZ;)
M%`X@]6-N.;G,BA<5>&5$<C:ES@H1!"C(*$6(DDHL$R"11[F9R,BZ89#3.6S2
MKSBP1M[\YU_7;Y+&!':REY760PQ:6O457R.+Q>8KI"N/5MB!20B\56<(LLOQ
M3.Y]8,;UI=MBU&SR"/PIQ8BV*3+8\[N+1)H3"IVVD2*(A<@126LZ.<,$@3L4
MNC9;RK`B<D@259(%)@>_81=,HN=C<B+;MEOD+7/Y`UOR.462[VZZ](=#6U9J
MQ)&VMS7*)"V.;4PHG1E^M9#0E,=4B,XE$X*B`*#R1GZ\3)F"EW?EK;@R*N=R
M1+N*-T"?:M2I]1F*A=]5W(IFVV$Y0]1)P,@9*N9`3-J+7I2SU9FT)HS@I]E`
M/.`-D$BC_*2[8X/?FTD8GA)IEKED)9YC7U>SJ/(RZB8_JU63PWQZ81=[9D$K
MA;%L29([DD@<=E#&$TXT(Q:VR#!KP[ND@=W5_?'!6[/;ZYKWIZ=EYPE"YT=G
M56:N<G%:>/J(Y6N6'C-,%O\`W#%O>46[`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`E'W'P+`M_K5G]VI_CF8%-@,!@,!@,!@9`J0.AVY4H-@`9H=J5P`19F
MM"+,".:L81`,#O0M"`/6^F]=-]=;^#`]47UAX^@LC\T#4!D-N.<Y)C5K!<FF
M85]`X]#F0`^8]2IW8^,/S%/I&]&J6Y8;HE#LQM3:,2B$(SPA:\/>>>!E*<QF
M#,2"ZF"0UBINI;'89^:@?'#GEZ<RI68X0OD-7:8#P8K86D]6Y250D/\`$VN+
M*+.1Z*-V5H(#C=:G_P#!KR/B53Q\@E=7ZKRQ&DBM83QTG2?DNKEKN;$;H/MB
M54ZS.K"C8#64B(-3).$EF+@Q(;0K&Y$FL^]J1JNJC1%T:_\`(ZL*6:J_E\JJ
MN#2."F5QRSL/C:K`^SU=.13>-L<>7/K'*W<"YK;4[#*"CFD\E02WZ"@-(/!K
M16C"A&FV;Y&W7'"R+FNCC_4%;2F];30-$ZYGN%,O"QGD@"9*Z5BEXT%O*>HF
M!:X$GI202Q>ETV-J<X!J<"]>6/99F_U!2Y.<\#&$5H+CX_UL?>\THVTZG:8]
M`N2KLLH<5C/Y3I+U='`J%7&I,P2N:1D,G9F5P<;"4QR0^(D5IRER09R+19H1
M)BFW<'Q>.--.J$DGBS95<^8B6GB[$^3C7R/'-G]R@CF[2MKB<H+KDEH6L@(L
M?"%"R4F0AK4@6;D0Y$A\8\PP0CDA;;_D9UJ^D>,C+RC(;(Y2KRJ;:2Y]QSC0
M<W3&RG66);-8):S6Z8W/\H:#V(IN0O$:?JV`).B1@\S7I%?@*@F&@\<;;G\#
M!,`XU5'+$])1U?3%DH]\B(-<T_=[A1S23:C7&53!7RQVU)#5K8MCXF9]0U@B
M@R15,#9&>2Y'IW8'F^T8M$C.;1B'C*CK9RXM\R3K6<)DRQLMPXIF:=:^C,>E
M4I2N*B>3S29.D;91(XFW@;U>];"I,\]"8$(0]"Q_!JWN#9JP:MI9SI>I[-8X
M=8MX1NH^'$$<8G7*W_\`US+96*><MK]B[[/;!+K97,79/%H`)&$@P#4L$,T]
MP;]GJ"2M&%"G.Y[$LWQDI$Z-ET6"`OD1W.>8'$!K>[#D4@7.5A4*RWO1#A.'
MBN)/X3"F:S'.&+URB/`"M)3`6KU*52J3>>IPE;FWL1QWI6FH-`+HF%<-+E'W
M!SXV\I(<^1M4DNI9'P_4:0TB>W/S<^WI6%9R`$S;AOQR!]2(B5*$D_1)I/FO
MBF)@V6[R/)_1;I7TK*U*882<ZQ=P(4.\$L)F>T214,DL"K3-*F,"J/OY2)80
M8#9A03TIPRAZV$8=;UO-=CT@M&+02<\M)9,9(.CH&@BW'SC=8\9JJ1R!CJ6M
M9I.'FA*D&PP9M$]+2F]!"&=W<A.CND\X&J4M*$:0`AFJO&!GP-H7[3M`.0_)
MB-MD8N=2NN?FW%8C[7.*6ZJD#9#BG*+N!R.%NB1=&)EX#DD<9OZ6.CY:9D3J
M0(/!TX%C3#+!.Y-^!IGP^2E5CR/Y5I%=C.;:*MN//+A'JW:[:DC^]I%<5/2M
M8;!A#4I>F)(M7*QI]JD@/2*4.@'^0[6O+NWF0;&2(EGO"I(3(0W!.;"3*N/W
M+I`\7Y8S`TP2QE+DQV;0#>?6U@,[8X2PIUK&`LTJ)=T)IKXM4*O2J@&MHRR`
MDB?_`***N*<K*ON3JYF1<<+AA<;IZR+YJ-RL.1SCTDUVRPMW'.]58Q*VZ41Y
M*F9["DB2,A>FQ3'2%3(B;56O."1"\T/4+;@P*GJGCAJCC^2AE0R4#07QP+L5
M%4!%O2,3(&=-'*Q'09IRN<'M`Y<;&'N,*0JU20&PJ"UVA>;J"2QA"6YW!F;?
M$?C/.+8FM11F+SJNRJ]NSC%&C)<HLP<K?9E&>0,1DDJ=X2!L>&!OCC2^HG)N
M2L\:7%%^*8:<$2[2H8_U6W!`8U0%$2:NU]W2FB;-J-)'(ER@4**.<[(DH%LQ
M6T?&:\D,;EC7)Y9&296TMR=XF)S!)@:3GI1+"="1>;&]Y)3:+7)>/]*LU<.]
MXL5)3VRD<B@7%]Y:J$CMA2TSV?&7RQV8=*)4JEK*Q.,Y?&!*_P!=E-D?"I+\
M,IP>``6F*O#)*.;>A)9R@71W\V&4$Q:IE$^61&;%N#94#DNCK7*'#4;HYO6#
M:6@QU:5L=66E&RDHEK2E$W*0+Y"A)*`D-$8$K;_R-@:^*168[TU/9\9:7)6$
M@=.5==L<=Y6011`^1+9+]<99/8'HA#-V!TE:.XZZ;PQ_92,HLE*?&I"X^,4G
M)--3@R;X&OL#XX\9'Y+#D#E%),UR1!PZ9.6,Q`_SBQ5[7(7=_DX8B36C;'*Y
M@4KL-#$H@@7Z?GIP1IE+P:%",D.T*72A4&VW_(R,@X9\74*ERE2G4HD3'(IS
M2T.;J\5D\E6YT@9-FUNDFCBHCYL6H9YL:0.$@<5(RX6IE3,U-ZI(0+2@M>=W
M"#-HU9YBQ&NXE4G&1@@E?G-H6U-R&BKG:AISV0OL'ZE<AK'AZ<V0M2U`F1MT
ME6)6LMQ,3[-&H;"CPHBPZ3$E[S4[&Z;8ECS^SQR9.#:RG+OS1:QK^AFXXU*C
M[FB:5_3[[#YV\-VNS_TU<LY5QV$G&&@[!"T89K>^@A=<_P#P5CIQGH29.$)8
M[`VZ/"J(RYAX1B;XL3<9KQ`E]+5Q`1S9[CC;4E56$R/UD2BUIU(G,HF5*4;:
MI1(-E%@%U4*DK;.AB&.\:Z*98[6DL9JY?)<[P1;QKF]F;G,HLFOWU^9Y]9<5
MB;T]&QMW@9]1RFHY*IE"(Z/"C$B$^@3B!IQ(/#YZ`B[1H?RHBXVR^KX7M%9N
M]=P1/>5EQ)I;34;X9'T#BTORXU0RH7=U;T1&E*EO-+<0-P.FT:)64$L'F^BA
M;LZ'H-QKLNY[?X^U;6DCONS6)HG'."(T2XO+9(RR7LJK%_']W4&5JQJW`L:0
MA*_J$A:)"G.T)*%<>2(8!:UL.\W)=]#'T0X]\?I1!5-S32C+8IEFBT?Y0[<:
M3.L1]]-S85%06'3&/2*/R:;1<I^9-)WJ0CCDFWM(J0`5[`:D*)-"-*&[>A;G
M/CA3:]M<X^UU+/F%.HXEE\K&WD6&=2%U@;<\.<>331+60&Q<Q!B[A!4;BMU`
M"E1BO4C.DY/CF&=PA(M-O8SI7U'\8V'E*4S1VFGHYNHC\P2HN.ZE+,+*=)2C
MM"/6&=9J<ETEC,H9"FQ`MBT@KXDY,D2!\U<41XDJT)H^I^Y;<_@8:@7&JHI@
MKI!@<*1LL@/)8VZW1YLQKFLG*8>*X8)+9G'4D;5-ZV/&-3[[-VR+IWZ6F28X
ME2<TNA04^D>]`/-NW^AY\0..-*:RJH;;=2.D:@DCE5<.,I6.")P9A'U=(9"U
MZ=I.VF*R4YYK&NC(U)Z9:5W%&%![RQ[Z=<UX'J`[/_(1]N/EY5]^M#ZW<8X/
M6?(=<NASG&@M]+U"PQ.+211QKD%/_P#IQ$;C+@=,$\:31M:S&@42(E>(`QJP
M*C]BSXEG8^T>H_C1&[T<HZUU&_*#./?('A*V.BZ3V>ZO"&SF^]I`PM$K:))'
MQLQ;2SL\>?G4E8W!3=QBE*F&E7"4`4;V5+;FCO">)=4V5)I4&2TW(80=:$_Y
M;`@P4TRM)P>8BW4PW/AK7]4(K&ZZ=(TB0HI8UCVZ'3IR0EGIU):=O(++`6H-
MNV"*L5#TFN=Y?3,6,F5:'+..O$*1V?93Y-PN36Z.G(.R.(Q[XF-BJEK2-S3"
MH"*?JUR;1JH:E0N"`1QA9!!96-\C!%_TQ7S%5L[G$>IJQZ`>:QY(!H9*R6%*
M7R2CM-F.89DZ+'S8)$PL9C=.X0=$DPWH+3K;*(A^3:`20()8C[+_`,#1+*&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!38#
M`8#`8#`8'T(..3'DJ4QQJ=2F.*4)E"<P9*A.H(,":0H3G%"":2>0:#0@##O0
M@"UK>MZWK`OJ!?+G)>\B:ETH<75^2.BF1B;5;PM<GQ`G,^LKVH?Q)##5;JB(
M.;?2*P:GQ"P#3><F[ULOO"%Q;9K8@GMO6,\RG>Y(<M="&I8U2:1^GCG&9GZ)
M?"6]2C7^DC%LO5*-`6!*%LQQ,'T-T8(7E"]J'"Z?.V>DU+G:IJV)2_;/':A&
MZ3!09&9\D=#6[T:P0$*DP+/+4CUL9(2TJ0M66IV((=:'O>/8OZZFN1@YOJGW
M.LKC-L)Y,.FWLW71F7&R-U,.2J1*IN*/'IAGKM#1@.T<[[`(/8$81G=-"UDV
M=C'#VFF416.$'D9,IBSA&Y":H=(<]!=V-4P2Q$6!&<K6QY;YJ8UR-*04$K9P
MB0*0EA"'N[=:RBKD%BV%+7%0\2NP)S*7=4S;C2IUDDPD3\Y*8[LP)@HZI7NS
MDK5'L0C@:&)&(>TPAZT+8.NNN!3BG<X,BJ6"#F\Q,@R)Q],H82*5/PX>C=M&
MB/TZI(OMPVQ)W`*@>S-'@3A,T8+8N[NWO>!EFNJCY16TWNDRJN$7-/6PF9)U
MCQ*8D3)7-.&PV]-MT2N"]Y2J/^2:($KQM06I&9M<2!4(81Z\7>Q.!!GV7W!'
M#9W7TDF=ELXG>1./M-ACI+I0G3O<K3*O"=S9PQ&NGFCX_`6D=%!JXLXX1@/U
MQ;WK6..Q#FD4A7>-&F`3ZM^L)Z(M1'&3;BJ]/JFX1REM`>R-_B>EU+>8888G
MT(HP9(A"$#IO>]X%S8I].HPYLSW&)U,HX\Q]N4-4=>(]*WYE=&)H5GJ52IJ8
MW%L<$JMJ:E2E:<:8G3C+),,.&,0=B&+>V"C^MLK\"1)MRN3;32Y20MER?<A=
M]D2M:F6B<TJV4$[6^'(5B9R%M26:LT<86?O9@=Z'^M@9#9!7]?LK`P,CG;5P
M395%E[.!MU(95,9"?"D7A*W-FUYZY+%@HP1L(#3DG=YKW!"(0.NM;QP)K=],
M<JT3U);(O>I+1C[FYE">Y(^RV(N#,44B;AQV,A5*PGD%A1(&\;LU(0['K6@[
M4)P;WL1FM[FP:YKG%>Z'Z5.C@M<U6DZ-'I4XK%"Y3I(@2$H&])H]4::;YLA0
M)RR""^O8426``-:`$.M42AILBQF!5(EC#8D]8ULO3#1RY8RS.2M2R5I#._Q$
MTF4H'-.?("!^*+J%6(X.^\7^N^H1A"XN#7YUZ,<%S9Y^@4M"WT>L4(?/FI:$
M(%K4L\U-*\[;%H`:T<G,[B3=!UH0=ZUK`K2)%(4S8-D32!\3LI@',HQF(>'$
MEI,+>@(2WHH;86I"B&6\EM:4*L.R^BD*8G1O=HH':&P<)KGF)>S$TOL`CO(*
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MEE-UV3)JFBZR:+I@&43B52&M8:S*4I;A*-2`QR6.L386Q8M)T<J+.(*+&:'8
MA:WOKDX%C:A7(%N-NMD5666VP1Z9XL9;#6Y28@$/?WLAQ6,4>+FJ54`]D<G1
M-YV8G3%J"QF`$;O0>@Q=;P+4W6A9K0]2&2M%EV&U2.7%'II9(FN<RA`_2DA3
MO8E)$D>4CL2Y/Q1PO*(*LTW6]_#K`C9\A>QL*2.*G]X,BS4N5NZ"/*7A>..-
MCFM*`2X.J%F.4[:D#BM)*"$]064`TT(=:&+>M8%_4I;$;7>(Q165-T#\C/9%
MD!C)^WY,[(%<U$VR&.JH:S#$!6@5RPQ<C7)!H2P&+AFDG`V,0@"P/LFFUFP]
M7,FM%-+`BJZ2'N#58;>AE4E8E4B5%JE9+LWS9.E<4ICVH"M-4!4%K]&B\09F
MAZZB'U<"9I6+D?(Z:->$;==[[Q[A#D8:8K3ZG;E3T3=$IY6CU1101G0]F4MZ
MMQ!XIY8"_-CE`>\0!F:[IQOL5T]2<D-5='GVSF2U_9;,):.<,$WG;/*3F>7R
MM?%T;`F>"IG(2C=O)YD28PE(NJ@03$90Q%=X`[V%P(&T1&T7E;%("Q1J?.;A
M.-MTOA$+:6N0*U$K$M3K$S5+8U'DA0]NPE")`H"0XIR1[\W),[3/#`+I>!>+
M,=KR;)BYM%R/5M)9^TL^HJ[(++>ICN6(8XO3EJM1Y67)E@W0$<<DAX#=)=_^
M34E#"/01A%K>W`B7UYG'U3!`OKM,?J&6X>ERX/\`6E^^IH'71OCZ<P1;TAZ!
M"X:/_P"31VD_B:,_6Z]WEP*04HE`E"M8*32/:QP>4DD7K-OKKM6ND;>-2:WR
M)8I\[\=4_H#5IPB%I@A*21'&;`/6QBZA>=V998D$J:1618(FJ=K3'*<M8IM)
M]MLU<3NWQG"7H-NNTLG7']NO$.7`/,'TUW;WTU@6^43"13,QA-DCB8Y;C$38
M(,PA,"$(&V*QA.8F96DC6O+LE*$\P>]BWL0C#1;WORZUH*UTL>QGV*-4#?+"
MG;U!6(91C)"7B8R-SA[.,C0PIQ-487.1[(W[3A,%HOPB`>'H6]!Z:WO`LQTE
MDB@UQ/42.0'GNYK:H=SSGIS-/=E#,,!C,>Z'#5",<#V<PL(D@SMC$F$'6RMA
MWK6!+R+GN5-M=M-<%KI]N;ZGE+GLBR)H2)RDZ0!!262.&RWL.UL@3E)2@@6F
M]ZD(2@:T/H`/1D$-42&0+!.(U;\^*QO#>B:'<2EW<5`G9I;=HA-K4Z".4CVX
MMC<)L3;3ISN\DG:8KL"'P@=H7&2SF<34+0"9S:8S$$?0::V`$LE+[)0,39KP
M]>CF4#TO7!:D/0H'_$1HLOH`/D_5UT"+X#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8$H^X^!8%O]:L_NU/\<S`IL!@,!@,!@,"<5@T-,ALRN6!^<HX
MSL3W/8<T/;M,%"Y+$6UH<9$W)');*E38J0N2:-IT1HQ+C$YY!P$VA[`:6+6A
MA4>Z;81$(#)X"_,45X^QZQW1QYM4VK(>8WQ,CB(]BD7'$]QH5H6Q*$R^6Q)C
M891,$RY`SN3^YJG5R0*3D:Y:-.J"`W']CRBXM2&KX5.))++%FZZN+#9_1B2I
M7QMKTV>,$7F#G(/-)-+1M[(^,Q+>\1)B":&/&@$-&C7J@+=:ZHB`CU>1L+8A
M#XY<I+K7TO;%/Q=B?N75Q[A7(1].BL8F"><R:(SM03#T;XX/3H_-=82),XGM
M25_&`,=V\J4ZX2Q*(0?#GCGX&:I&E1N-)#H1A*B59WD[<0U]?,%&%W3$Y<%M
M3,'+&)6G(&@%I.4D,;TTLNZ,#<W?ZL.#P+9*=JT4F"`I62G$G>^QB0AOAUB?
MF,\6H+)S(A92%"V\4*HMT:QT12J%2J9PVJHI&+`;W:0-YZUODC6WN;?MN6KD
MYQY1VT9@RS1ZT$>W7ZT3QO;X*Q10,GONN.*39=;-#>6#K`XA#T55J85(J^8Z
M71.-3O,MCM=O:N*NZY#:VQ%Q!0L'I\>TNCPJ-JB@`$)^-P0&>2ZJIA`IHSGP
M?CLR*G7@=6MSC=H9!()$Y/\`^YL<_@C6^"9G9C+3+&%U4Q=0L+5Q9N\U;/!V
M<<)!HW8SL<^^QUH./,,ZX6MT8-J.(W@^,O*^=R$^*/7(YBH-TC#,YT]6C8FD
M0-.4GCZN0-[VM0&I`[#HPLDQ,+IO6][Q=T98JVG:[#2KQ'9-%Z3T9)JHY6'J
M-$N%#NCU#KFCFK%%5T&>;BE=AN5PNMBQY3&VT3,DBB%M8ES6:2H-/7;4*AB6
M\C-,65U-`[6XT62S,/'6JB&^\()&XXU*V_CU*FAVA<OK*1MKQ(:\MV(R-.]2
MR`-<@2HU"USL:-H)`T.3B2$#D`W:P@4N\P8&:8W0Z?C<<JDE?P1<\&55>!U_
M.C8=QI810KD:B?9Z5'6Q@?=R'=N1<QA,3L'U39X8@/C+TC-V4$*@!RLPB\[_
M`"(E;]CU/%'CF@OKRK.+Q`J@'2<9X_D%U[!Y6@6B?99LZQ)DG0N^W5!8S\M*
M\4)HE!:U`UHS0E$IRBR2MA<W.QI%RX;(0U\@[B15HECR.$#>$CA'T$/.(41=
M$%[BC&].2".[1J%28EI1OCBI*((*,$!,`.B0]-%ZUJSKD;R3\^IIES`YN.TB
M<X._,:QNIP^'.JYV95K4M6FW-Q>:9`;'EIBDQ$O/U##7DM5X(C.U"%5L>M%@
M,WJ<Y!-6VPZ46SZ,MRBK.)"./KOS&)?1"[0*RKL*9)Q+4JV#0`;6*1&["T&#
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M>)/+!F2'N:Y,WDJGAYI"5(&EI3&*C22SW-U7G`(3$!WLT\X6@`"(6]:S5&R[
M74E1GQ$ZU'PBKT53K>!U;(0N**507ZVGWVWRJNF6T!1V%E.YLSU;+0@2O*A0
M:)``W9`_%",83R^_/_Z-IYG'.,+?/(X2V4]4;RSDVQ*DU$:7S'BS"VR9U=[,
M[!VR;9CX\[2M%99:=U+C[FS*K4`G\[DX`-BX_P#\\K*3SG.1BB=P*)H0V.HI
MN-<:)AR)<F*BE[A`+%B=`1@N'5XL;[+;K4\]@8[!DW'M/:BA_:HX?)E$:6$F
M(F%P+4)D;<<:O[+OR-E"8A2DXY(6,^R`''::0*P>2SQ#)\O1G4>]HXY#2*HK
M1CCB999ELSX,CBL#<GU>J^JRB#M8W5>K3FB4N?B%$E$SQ[&@2JK(E-J=A4I@
M<0@0KCY%)89Q:8(,:IC+(CB%Q4@Y#/O:Q&Y6Y*TD=8U\ZBS'#]$N&E`"SU\L
M<P%CV/?EO0A?!*WFBD3^2LX>CD)J(NBV%G<8TL6)TQ\ZC#OR$I1!8<);TAY@
M#'54_5P<[EB(*",>B>\S8>TL6]6S1N&D::>AU:./"YIM>I)%!&._^)<PD$QD
M4B+-KZ<O=FV+9#P[.CX<TO;&XNC!"Z721%G>=IEJ3;>K&K)-4I>\1H9SNCK.
MZLK*<!I^ME,*JF.6;?AW(7C^6]IFCC[$7J`6:6;6TVXPO;W%*"D4FCL+0.#X
ME6LWGAZE6X*(\ZGZ6JC=`*T&;@\P;AF;"RWF]/\`1H$D5C]<N3-&ZW=V1"C*
M/7!K=J0Q=-8*D!B<Y.N?YLYLYSVI..+,V:>NWW:WK6M9J=<C<"7<@)BU_F$5
M'<4>M49$@D#9PR23JQ$CNSJAK"W*L:12V4!Y>3`*$",S:M*J*<QZV28F&6:`
M6R]A'K4R9@TXM&'/+U)+[M%F`V+8&PWU(HTM=4SXSC-TX3>2SMYB@T+3I=MV
M<FET;8VK&%<G)-1@V6$(S0B,+T*[_8W'A+/94+XWLENIW5-:,F6<=[EK"MH@
MCLBJ(Q"*&I^>J)VTSIPG<;62QLF]A65)"WYX<&YB*;?#(\Z1K5:E8:!,@*G=
MP3Z^W[30W\SK?2SB,+*YOMKXN;XSDM<[C#^XNSO"I-7<F:MM\'2.SB^1HZF(
M9&'1I<-.3>C`VGG:1]!><:`-/`IC[176O9\=6/MD-+Q;EK?E;J*M99@^2M@9
M1G7&[$2(!42=I*>K;&2+2.0Q=O5,I0%1J(&AKR4X]@T>'JZG\C6WD[%W91':
M<:SG>*.\HX\<9*TA=T"2SZ(/"YGD4BM*RU\3AK>:C?%>YH[PR)21I0N)3.-P
M"R@+\)0(H!&^VS_Z-)LH8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8$H^X^!8%O]:L_NU/\<S`IL!@,!@,!@,!@?'2=/H/;H@G0=AV
M'8=%`T'8=[[MAZ:#T[=B\N]?ZX'UZ?H_1\'3`Z^&#]@'D!X>OU=?]O\`8^#_
M`&?]/@P.O@DZ+V5HHK16_A+\,/A[\O7R@Z=OP_\`3`DL1E<C@4F8)E#793'9
M1%G%.[QYZ0!3[5-+DDZ^;+$H%)*A-XI/=OIH98@_],"-`))!KM`46`/?W]`@
M#K6QZWUT/>M:_P!^M_I^'`[]@?V0_P"[8_@U_OWY-C^#_=O6_A^'`Z#()-WK
M9A)1F]:Z:V,L`]ZU\/36Q:WO6NN`V01O?79)6]]H0==E@Z]@=ZV$/7I_M#O7
MDU\&L#G1)6MCWHHO6S>OB;T`.MF=>O7O\GZ_7K^G`>$5H0!Z++T(L/:6+L#W
M`#\':#?3J$/_`$U@=M`"'M[0AUV==`Z:UKLZ^3?;TU^KUU\/3`YUK0=:"'6@
MAU\&M:UK6OT^36O)KR[P.O8#H$/8#M#U[==NN@>NMZWVZZ=-=="WK_XX'/8#
MIO78'IL'A[UVZZ;+_8WKI_L_Z?!@<>&7W^+X8/$[>WQ.T/?V_L]_3N[?^F`&
M669L.QE@'L&^X&QA"+81?ZAZZWV[_P##`Y[`[Z]0AWU%H>_)KRC#T[1[\GE%
MKMUTW\/DP.=AT+IW:UOIO0M==:WTV'?76]=?TZWKR8'3PBN_Q/#+\3?3J9V!
M[]]OD#^MT[OU=?!_I@-$DZ[^A1>O%_[O0`=>)\/^_P`GZ_P_IP./`)[-%^"5
MX8=]0E^&#L#O7EUO0>G;K>M[P`B"!=.XDH7:$0`]2P;[0"Z]P===>0(NN^NO
MT]<#(;S:5A/Q$$2N$I7@35BP&QB`$-12"/EQ9H4F&G+@-H8^C:^KDZFGB$M7
MF^(X+=]/'/,[0=K!C_M#^K^J']3_`&>37ZG36PZ[?V>@=]/)^C`XT67KIK0`
M:UK0M:UH.O)H?^_6O)Y-#_3_`*X$S@,_E]6O"N0U\\;B[\L87>-">43<T*')
M(T/R?:1T`TJW%O6FL3@>F$(`%R+:=>G",7@G%]XNK-$-"$(`A`#6@A`'00AU
MY-!"'736M:_1K6M8#M#K6PZ"'0=]W4/373?=O>Q==?!ONWO?7_7K@5H5Z\#>
M8T`6JP-1RTAR.;`*3@MYS@E3GI$J\U&$>DYJQ,D5&E%FB#L999HPAWK0Q:V%
MNVG(V/Q-DD[,ZZ%W[+!L?=KX-]W;W===,#OHLL(Q&!+`$P?^\>@AT,?3X.X6
MM=1=/^N!SL`-Z$'8`["/>]C#L.MZ'L7D%L6NG06]]/+UP.-%EAT#00`#HOKH
MO6@AUH'773?9K6OU>NO],#O@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,"4?<?`L"W^M6?W:G^.9@4V`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!38#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M
M_K5G]VI_CF8%-@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,"4?<?`L"W^M6?W:G^.9@4V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!38#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI
M_CF8%-@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,"4?<?`L"W^M6?W:G^.9@4V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P)1]Q\"P+?ZU9_=J?XYF!38#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`E'W'P+`M_K5G]VI_CF8%-@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"4?<?
M`J%G]8K_`/R/_5*?A^'_`+P_A_ZX%/ZCX#U'P'J/@/4?`>H^`]1\!ZCX#U'P
M'J/@/4?`>H^`]1\!ZCX#U'P'J/@/4?`>H^`]1\!ZCX#U'P'J/@/4?`>H^`]1
M\!ZCX#U'P'J/@/4?`>H^`]1\!ZCX#U'P'J/@/4?`>H^`]1\!ZCX#U'P'J/@/
M4?`>H^`]1\!ZCX#U'P'J/@/4?`>H^`]1\!ZCX#U'P'J/@/4?`>H^`]1\!ZCX
M#U'P'J/@/4?`>H^`]1\!ZCX#U'P'J/@/4?`>H^`]1\!ZCX#U'P'J/@/4?`>H
E^`]1\!ZCX#U'P'J/@/4?`>H^`]1\"3>I/_Y)_P#U_P#X<#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g91036g75a99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g91036g75a99.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0M`4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````.@```(X````&`&<`-P`U
M`&$`.0`Y`````0`````````````````````````!``````````````".````
M.@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"*,````!````<````"X`
M``%0```\8```"(<`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``N`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#L:FY_4.KYN#G]1R,*W'L-F)BXOIULLQ"UK:LAMEM-N1<]EC_3R]E_
MITY&S]'Z=E/J66?5=K+'6MZIU/>_Z1.4YS=3/MIL:^BO_K5;%=ZMTFKJ55?Z
M1V/E8[O5Q,NJ/4ILC;O9N]KZWM/IWT6?HLBG]%8JV!UBUN:.D]7:S'ZB[<[&
M<W2K*K;JZ[#WN>YMM;?Z3A.L??C?3_2T?ITE,1T;K%']$ZW>1[CMS*J;VR8+
M-:J\._:S_CTQZA]8<``]1P69M(#B_(Z<27B/SG=.R?TFUS?^XV5F7?X/T5M)
M)*:G3^J]/ZE6ZS"O;=L,6LU;96X_F7T6!EU%G_!W5L>K:SNI=$Q,ZUF4US\3
MJ%0VTYU!#;6B=WINW!U>11^]C9-=U'_!JOC=6R\*^K`Z]Z;+KW^GB9U37-Q[
MR2?3J>UV_P"Q9NW_`+3VV^GDO_H=UOZ2BA*=E))))2DDDDE*22224I))))3_
M`/_0]55;J'3L7J6,<;*;N9(>QS26O8]ONKOHM;[Z;ZG>ZJVOWL5E))3A#J69
MT1WI=;<;\`N#:.K-:`&!VC6=697[:'-_\L*ZV85G^'^Q?X;<!!$CA+G0K%/2
M\[I#O4Z%MLP]Q=;TFP[6"0/^3;_^T6WZ?V1^_"L_P7V+^>24[:KY^%BY^)9B
M93=U-H@]B#,UV5O_`,'=4_;93:SWU6_I*UF'ZUX5E(;ATW9/4G';^R]HKR6.
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M\=SO96QUOHULCEV!L9^T,C<-WZ[F?9/^Z2Z/`PJ.GX5&#C@BC%K;57N,G:P;
M&[G?))3820<C+Q<7'=DY-U=&.S5]UC@QC9.WW6/+6-]RECY./E4LR,6UE]%@
MFNVMP>QP\6/9N:Y)3__1]522224I9G5+.L79#>G].9]GKL9NR.IO@BH$[?3Q
M:/=Z^8[:[^=_5\?]';9Z_P#1UII)*>*?T#&Z0W(Q\K`R<O'=8ZW#ZO@[G9]?
MJG?95D6T;.HO?5:ZQ]=S/M-=U/Z/(^A^EK=7ZS]9&8OV6N^ZGIN075NZSF4C
M!R*F@\;K?1QO6O;O9C79.-TIC_93ZM6395D+OE&S9L=ZD;(._=Q'YVZ?S4E/
M-=+ZYT'"Z?5T[H%3\W*8T1A5MVW;HAV1U"VP,KI]1PWW9MW\]_@/M'JT^IFV
M_5OK>)@OQOL=74C=97<UE;V-J:VE[LBOI&55D^A]HP&V79'I9F^W)MR;/M>7
MC?X-=;C?LCUJOLOV?UO3L]'TMF[TM[/M'I;/\#]H]/UMO^&5Q)3Y_P!8R\?J
M6=7TB[`=T3I^*6_;\M^.'O\`5#66U8.#DXC<G&QK/0LKM^T^MZW^@]Z+F=0Z
M1B].?TCI_5<5^!<US<1CK&_:L+):1;@O%/\`2LFBO+96_P#24/ZCC7_I[;;J
M/Z)W:B[T][=T;]=DQ/'NV_V4E/-#ZYVBK"L'2LJYF5;7C/L8T-_3.;ZEXQ\>
MTMRKZ<79;ZM_I>C^C_G'J7ULZI0+L+HK&/S+,VUQR<''U>^EE=CVT7.!_5Z,
MG+^RTWOOV8_V7[3Z_P"@]55<K_QOOM%OVG^?W';/VF>;?7_9NW_M-ZGK_;/V
M9^K>I_2E9'_,']E-]+['^S_M.GHQ_2=CYW>A^E^T_9_5^G^D]'_@TE.9TZJG
M%ZQDXC<9N5G8UXLQ^F4`58E-MM=%MF<Z&FNFK%Q[*,6G+LK]:^^K/LP\7[1D
MW5+J^D].^P8SP\A^3DV.R<NQHAKKK(]4U,_,I;M].EO\YZ3/TUEU_J769'3\
M?"<]]_U.R\:NEK:VY&,*]^(XPXLL:^CTG5Y^S^>_36_H_2^TX_\`-6K2Q*OK
M%994_/NQL>NO6RG%:YYL/O;M.1D[?3I_F[/9C^KO_P`/_I4I_]D`.$))300A
M``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P
M````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P````
M`0`X0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("
M`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`#H`
MC@,!$0`"$0$#$0'_W0`$`!+_Q`!\``$``@,!`0$!````````````"`D&!PH%
M`@0!`0$!`0```````````````````0(0``$$`P$``00!`@4%``````4#!`8'
M`0((``D1$A,4%2$6(C87-S@Q)%5E9A$!`0`"`00"`P````````````$1(3%!
M40(287&!(E+_V@`,`P$``A$#$0`_`.F]*U^P.G^M^K>:H=T$#XT9\WEJZW"L
M(]2T1MVSK*K6:-&9UA:+6266]*P,&UD&[)Z*3;8!O=F&,?<KINM]NVD:U)+C
M+/;#^/7H2SUA:\D^57N<;N'2=(M-:\3Y\J)%;1YNANMDHVJBF(4W.*Z9;Z_B
MW>ZN-T,9VPEG3&^^-GY,S^69%N2NTDQK5&(?*A>S`DS<,,ZK33F_C.9"73%K
MMK^PS(,Q%'P<\Y5>):8TRXU*IK:_7.V<[;9^N+^4S/Y>:NR^6*L0Y]R--<;]
M4Z"'<B(!A!T?8W.E@RT.FS>N`8=L:#_ZBUT)DF[E%!!-)TT28+;K9_.0;::_
MFQ-K^OR_2W^1Z-5M(`L0[/I*U^+R1U5%F(L2R_[3EO.!HHKAPKN-:7[74AD<
M4C3MHS;Y7<:RA*/:)I??OINJDDJKK4QVN5A$;DL<F0$3*H@?"2J,'V*!0%(X
MV58G`)H:ZTPHV(B3`Q=T/(L7*>?N3614W3WQ_7&<X\1[?@>!X'@>!X'@>!X'
M@>!X/__0[,NJ.5W%SJQBV:CE3:G^KJD1=+4[<F@[=\SW:KJ_L$ZOM02S5:.9
MS3<Q^NZ)`4JIM^FLKA^SQH\1TVV++CZ>5RUV0QNPP8IBVH24H/K2OA>CNRJ,
ME.RFVCUFB\6&*V!3LH520'6Q4I1VCJHV+C<J_JZN$D7FB"^<:["S&^B;?B'@
M_.[:-7[9=D^;-WK-TEN@Y:.T4W#9PBIC[5$5T%M=TEDM]<_3.NV,XSCP5KR[
MX^-ZL5<SCX]+#UY`G:+Y<XXJE@.=FN1;)=Y_,X<!II0[9ZSC\+<'M_M:;2*+
MI,B8UNIE35!YE!NCH7/=DE.]W:J6&"YUZ\K<ARMTH>>D!4*%'B*)RFK]4%+"
MFV37/UN-=<`9*L9P8;N=(R_V9RH?HKLDNT4V;K*8%G6<+#/$/`\#P/`\#P/`
M\#P/!__1[^/!$OJ7D>%])C@$C;DWM;7]5_[I:A;_`(N@VS-ZIE*OX7.F[?\`
M9TW0/PHX\9H)'P+G_LS0_&Z"F=-LZ*IEEQ]-0<_=8SF+3@-RAW%B,0KJ%RKN
MWKV>102:%4AU''OUR3T9(JO,E,+-`ECHC0[C600]XND0:/&^[ABFN.7;[ZBS
MK.%B?B'@>#4MWT;5G1E<'JHN*(CIE"Y`EC\[%[KLF\&$$=%-6!^/%$,ID(_)
M!"BN5&;]HHDY;*?UTWQ]<XR)<(,\^69=/-5_..-^IIN;LR(V#LY+\1]&RQ5B
M5FEGB`(MR3L.H+S-@(Y$HXRN"#:80=B'&@YNE(PRV^=5%'C-?7:-7%F8M`]6
M3P/`\#P/`\#P/`\'_]+OX\#P:DNVB:FZ-K\G5]T0D3.H6569/%!A/59)=B3&
M.DGHPP&*,E6Q0(9'.T==T7319%;3^NOW9TVVUR.$"1,YZ/X#4V!7NYD'2?%H
M$2A_$=,LF[DO?-!QV/Q_?"C&_*_C<?>%+<B:&HW.^\S#?4JVQM]2+!;[MG>D
M:U>.5E$+G$,LB,BII7TLCDWB!Q'=P&D\3,CY`!)HIK*-UMV)46X=,G/X'*.Z
M2F-=\Y35TVTVQC;7.,5EE/@^%%$T4U%EE-$DDM-E%55-M=$TT]-<[;J*;[9Q
MKIIIKC.<YSG&,8QX*HNP9C5W:'&%R6?S=.-Y#*>5I,]N2K;+8`YF"CJ5L\\Y
M7EKG6&RHE%D!UC18LQ'/PCMX`4)!WW["[3+G[M5<:1J:NUAU&V8PNJE*?N,5
M^'^+MJK:_LP;^LF]1;_H3R)B)2S_``(DD&Q%)']<KK]NKA--?77Z8WUUV^N,
M5FZM;2\#P/`\$>;\ZQYPY=%,R]^W%"ZT0):O=Q;$V0W<2`LF-8KD2*PB+"4"
M,E+-V#)OLHNHW:*Z)8SKC;.,[Z8V+);PVO7\^AMJ0F*V17DA'RR#3<&.DL3D
MPK?=0:=`EF^CL<48[JII*;MG;=37?3.VNN?IG_IXC+_`\#P?_]/OX\#P/!\*
M)IK)J(K)Z*I*Z;)JI*:Z[IJ)[ZYUW34TVQG7?3?7.<9QG&<9QGP5Q3CCZQZ4
MDCBV^`)0'K@J[D+R46#RE,B;H9RS<[\XZ>.)8<1;"@!\]2UIE\.4]TC0%+84
MX69HZOA:WWJ.=2YSR_C3Y1><`4;LM.[/[IH&Z*A6U%2WG*QQ[9I;<LD+M4BS
MC(^AA:+O]._Q]CD!F^D8=1Q5QN127;;N4&.R^J>&3UO1C@>L.ANZ"2,MZ:$2
M/G/E)5DKM%>1V1_=G<-I;H2S5Z-D/5TA!Z98Q0,[`BD,8@,?(OT\;.U,D2R_
MVY9:Q=3CE)3I*9UGR1QS;,E:"XS"8!4]-25A$HJ/;:`H^FX;1UT)AD,#LA+)
M?+3^:-+-6#?1!NIMC=?&?MS_`%]4F[$$>4NKI8SYIH3F_D:BYCTU-J0YVHJL
MY%<I1VRJKDUG*HC5,-#&Q"USOLR5](Y(&=I;:/Q$:#G7`YRDHW>*ME<)X5BV
M;S:R>)=/=E,[*JYC*[-X&N:/ENBA-$WI5G+8*U);/:%<RR.S\N'4DUHDKC(L
MFCV-.8NVU>Y,00'L0QLKIHW99VTW3&)\K'R-]48'(/Q!>Z*G%%13UT.)C"-B
MP]B0'$&*^[9ZP?LG)A)RS>LW*6R:J2FNNZ>^N==L8SC./5G%[/$O^_:?Y^K1
M_/;<M*/5C'B.O\''3I%RBY)&9,69N,A`\)CZ/YRDVE;S*>RK,6/0<NG6$MLZ
MIYTUVS@LF>'/1PV2^6WK6"SA6*=DE:B7C>9C7%F$^E8!7DNMH?,'#Q`E6Y^#
M\^1JK:I/4*W*5D>2+*J2P_(EGKC9DLR;[LU%=M)MN^LYB5M2_$A<#"2JOKWO
MZJYLG+0)F.W9:T(J2>M>I[KCQ9VFZ=0TU>-OW1<*,`A9UMEP*+LXD&!X>`7[
MQFE^NJLD\;,)?*=(N^BD5CL&C$?AD1$,@$6B@8;'HZ#')_B8B0HAHDP&CVJ>
M<[;81:M$-=-?NSG;/T^N<YS]<^K#W_!J%GT'0A&S'5+#[OJ%_<;%%=R^J9G9
M4,=68S;M=]4W*[J!H&MY2W1;[[ZZJ;;M<:Z9SC&<X^OAB]FWO!__U._CP/`\
M#P0#Z;[#/P^?L.7>8X0M<?6DM$L2"0]=B2S4E$Q\TJJDQL?H&8LOQ-@`E-FU
M=/F()!;^;.:-/QH:):KH+[EDZWA3@"XCIGGGH:?M_E9D1R^G=\D*IL"E.[3Q
M*R8&+KV\W(IP/L^!XET.E8*+\ZD&,QC0PI#7HYL,2R(PBV=O=<CF3?2?;6<S
M]4P2?0UF<0PU2<Q7LSGWNSF?54NO&(G<=T577?2(<,#&[Z$H]7EZ`G.U>WN[
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MS'#>=D]K_#A`.38^<I3E6B[7NFQQ@J.UYRT8ID:A<#BPK$P_6<@YZ8D\0>2E
MD/!FE7B3XUHX=(.%DM=&+E3"S=3+28\L\Z;+Y+^+;I.D8Y!NJW,P@Q'J(7_<
MTG$\BRQN1D/*=716<J`7Y>IJ<(EI#+#U066X;B%<*34:N^9?M$5VRX]ZUUP[
MW8+Y2ZZ-T@NEQR/5W-W30RO'%2MN@F]@\3=P0"9J`@Q^G;XI^*22^*N=3`N[
M(L4CK2*1Z-SQNSD8MGD2=CI%NZ<NMDTA"34F-6)<C?E7^/PO;4+I(7TE&7T]
ML60/8K!LMHS82L&D\D'J91=`Q-LZQ#_2AP3T7V22U2_F\;J*NVNFF-MW;;"M
MRGK>S,N_+T?450&C@#,PU=S&X+2J+G.$STT_$,TX(?O:?A*^<6$Q2-YV'$2=
M:1LL0D:2"R3AOC`G95RBHU27UR),U2$/B<48]"\\)\%S4I1T)Z`CUD\Z1_J:
M2&)0>L[H(J@+:WITET+I$[=_#@VQJ:$48[#@)$L-P)?R>P,OV>^1[%MH\C72
MYB<H:D.?NA2-:\[<GU\+'\^<_P!X`+4O+JH6"%X>2JWZ=D@HFM4$"L%XH%G\
MMM:P2:Z#F46(#W>#!H)L]$)/_P"2>Z),"9LW5UWJR__5[^/`\#P/!Y[82*9/
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M\BNK))@R12S91-;$D<HC]F6HBE,+GB$!/,A.[6GEK=.+$YM*H7&9`F4>#\.G
M.FVFI53"VJSK+AZZJ6VIP^(BU=?$_*O1\\"6/?=&5Y;\ECE?2:LPNUAQH7*Q
M@Z,RLR%.D5&8HRV=LFDA9OP>O\>52UT(C$W3O1JLEJ[<84++9Q6G\?&+RF,V
M:+P5*^ZG)---F^INJ.LNGX(:5'[IZI[B%R0>VTW&XG?*:>^6^,XTSNEIGZ?X
M<>&:CA9OPR4=*X?9[I"P;PMJXY6EE:(3+JZ[K%O@/'$6$CP<#0C^*DI!VSTB
MJ4=<E(GH07:$CC6.2`GHHL]W=.-7$POM6MI%\>W;TWM^@;^,R+@$00Y[UF@2
MD.9B5*V-.^>>8P4EW@8C20U47B1R@9'8,Z<`X9A]G8^)9#A!'=-(6@V_$B]1
M&9N;9U<OQBWQTI`0#KIKJZ/]`6Y![AAEL5W#IU3`\?QG&O[5+);O(_(^=8K)
M0QNT_P"Y(PY)"'3R0R9XHB/(;IM4VRF[M=ZP3RDXFFL>I>'.E)J1HVW^B3@;
MINOZ3F1"+F^5.0JI4Y[8-.=[$K0G7MB#X@2<VF:N&9?0XRC19]%4Y<U%$AP=
M=KJQ=[;,T6Q99O":]:_)-\:+&,AHO"^DJ`K$>$"$U6]7E"86IS,&81YD0+'1
M!.N##>/$(@X!-F#E1=JHT1SKA/;;7&VNVNVS,3U\NS;L>[BH"1P6Q+?1+2P7
M15<_VC^U>QR#2<75TLUEAA<#EY`RJP_)F3@(P3PWP6,IL-`C5!XDYU>*MM'"
MR%3%XZO_UN_CP/`\#P/`\#P/`\#P/`\#P/`\#P1[MS_=#G3_`(]_YYD_^[G^
9Z'^2BO\`QT_^Y_\`)_\`I/S^+W2$\1__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g91036g78e73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g91036g78e73.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0M(4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````.@```*<````&`&<`-P`X
M`&4`-P`S`````0`````````````````````````!``````````````"G````
M.@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"*L````!````<````"<`
M``%0```S,```"(\`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``G`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U55<#,.8V]\-#:K[*6AKMQ_1.])QLCZ#W6-?[/]'L5I<G]8\FMOVB
M[!R'8%&*^L=2SJWEK'/>^JM^**JW-;]I]!_ZUG?SV+5Z-=7KW?T1*;O5^K6Y
M?4F?5OI-I;FV`6=0R61^JXVGJ%MCMS?M]^]E>)5LL]/U/M5OZ/T_4W;+*ZJW
M6VN%==8+GO<0&M:!+G.<[Z+6K(^K/3FXV([,=0<:[-._T7;MU=4N=C46>HY[
M_M&U_P!IS]S_`-)U+)S;O\(J76LZKJ62_!:QN3@85C69%,P,K.,68O2?HN:Z
MBG^E]2_P=?Z+UOT%6?6DIZ9)8/0,=K.I]3R38;K;'5X]M[Y!MLH#K+[*6G]&
MS$QW9C,*NJG^9MQKO5LLO]1:O47YS,&]_3JZ[<UK'''KM):POCV>HYOYO^OJ
M5_SB2FRDJN!CY5-1.9DG*R'F7O#176-2YM=%#2_TZV;MOZ2RZ_\`TM]BM)*4
MDA965C8>._)RK6445#=9;80UK1_*<Y1LS<6K#.;98&XP9ZGJ&8VD;@?WO<DI
M.DN8ONZAU/JU%#[;,3%8&9=V,USJG5T,<]U-V7?7M?\`:,^ZKTF8/J>C5AU9
MOK^ID^EZ-PY_4>L.=7T=WV3`!`/57M#S:)]XZ918/3L8YOT.HW[\7_N/CYM?
MZ1)3H9W5.G]/##F7MJ=9(JKU=981^9117ONO?_(IK>]5\7J75,RVMU7378^&
MZ"^W+L%5L'_0XE+<I^[]YF4_#_\`($Z=T7I_3B;:*R_*>W;;F7$VY%@T_G<F
MW=:YOM_FOYFO_!5L5])3_]#T3KF;?C8C:,,QGYKQC89C<&O>"79#VP6^GATM
MMR[-_P#.>CZ/\Y:Q<OC]/JZQUO`Z?0YQZ'T4?:V>X/\`M%K7V5,R\EW^%=EY
MOVJVNQW\[]AR\CW_`+0J>RUUCJ;AFYV3N=4^H_LS"L;)?6QS:LKJW4:Z]N[U
M/?CXF+_.^IGTX>-_VL0/JI>_I_1;.KW8T]0ZY:!T_IS(8\TU,^S].Q!(]E6/
MB5>M;=^D]+'WY"2G9^M76LG!Q?L?2BP]7RME>/ZGT*S<_P"SU76^U[?=9_1Z
MW_SOIVV?T?%R_2I;\7H_2WWU/#ZNDA^+A67N!;=G6'9EYU[]7ML;E/OIR;_4
M_1?Y6]3]&@9F-EXG4JJJHOZFYGVFS*<T0_.RM_3L`LJESVX/3,-O4[_L_P#@
M\2GU/TV1Z]M@^MX^(.J]+Z'</0Z%TK&?EY5M_P!"P5MV-I]6S^>N]/WYFWU/
M4Q<G(]7^<24U*VYF!TJDT%XZWUH,Q<)UP`LQL6RQK+^H7;?=]IS<G)_:>7_A
MOMF511978SIZULKK1KZE5C8UEC.E='K<[)<P^I;DVL+,+%P*I<7N]3*?91[_
M`-)G9^-?B?\`::]';T/-ZELZK=<[`ZA;>VUL,#GU8K:[\:C!VN=Z;<EM.;?D
MV6.^T54]1N_[444TJ>%]7+*>L/ML%(Z7C"C]G4MW&S]#5Z-;,AS_`/!8MMV9
M?1_/;\C+^T?SM-:2D]?UB93T"OJW4JC3<\.G#HFZQUC=\XN.UG](MVU/^C^C
M_1V7^S'K?8L7`ZEU)F9@=1^M=GV!UU65?CXH=LJJ`=CT48EM7TLS/OKRWOV.
M_3?HO3QZ66?:5T.%T'`P\K[37O>YAL^S,L=N90+7>K>W%9^9ZMA^D_U+-GZ"
MM_V;]"M!S&.+2YH):9:2)@QMW-_LN24\KUNJ_J/2+>I=3:<6ASZ68V-</YBB
MRVNG(ZADL;M]//=C66O_`)S_`"=5_HK_`+7ZEC-R?U9_UCZRQ].#@M]7!Z:[
M1[K)BC)RZS_VMN>ZNO"PG_T.S]);^N_T+I%"VFJYH9<QMC0YKPUX#@',<+:G
M^[\^NQC+*W?F/24\UTGH.1U&HY?7*]M>6_[3?@.DBZPAK:7Y[;/\!C4LKHQ>
ME_S57I?:<OU\RS]5ZA)))2DDDDE/_]'I,W$Z=B=?&?4QO4`\O^Q8@R:&5UYY
MM:,QUE=[ZGN=9=]@^A]KLQ\K_M-ZWV5;G3\5U>>[)ZED56]6R*OT=#(#::&%
MOJ58C7_I[*O6LJ^UY3_Z3;]G_1T5UXN/3\U))*?IPX_2OVP,IQ9^T_1%36FP
M[O3E[VG[-OV?Z7]/Z7J?SE?J;$7-_9T4?M#T8]9GV;U]O\_/Z#T/5_[4_P"A
M]/\`2KY>224_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3__
MV0`X0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O
M`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``
M-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`#D%D;V)E`&1`````
M`?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M_\``$0@`.@"G`P$1``(1`0,1`?_=``0`%?_$`(```0`#`0$``P$`````````
M```'"`D*!@($!0,!`0$!`0`````````````````!`@,0``$$`P`!`P,#`@0'
M``````0#!08'`0((`!(3"1$4%187-R$U4F(C9#,D-%1E-C@1`0$``@,!``(#
M```````````!$3$A00)189%QL1+_V@`,`P$``A$#$0`_`._CP(RN.W831-<2
M*TK#<-FV*QO9F')42R+@LUUDK^U12,,;;H:4"(L\224/@;>$DHLEJJ64GIZL
M>KZ^#:3?`CZUK2@E)5Q,[9LZ1MT3@4!839')W]U*'##!;@M,9]/NDJHI;EF+
M[Z(#)>K&ZY"NB>GUWWUQD;4V^.R];QZPK*1]6V6)M!ZKO!X'<^:J4,C[:'(H
M!4T=6=V4.72Z3C[J'R:0V\KIH\>C;/V`(&HV`_4FKNJJ6R2X:%>$/`>`\!X#
MP'@/`>`\!X#P'@/`\C.)_!:QC9TRLB9Q6`1%LV0U<91-)`TQB/@[EK:#")E/
M#T6$WH*EDJ:II:[*8V44VQKKC.V<8\"KE5_(5R/=;9/9)6=FO$C@=8MTP>9M
M;*E37,Q4@T,T"P];2QY1O.1UZT5`\L[2E'C5,E`/9(ZR0^RB.ZFF==LEQ8__
MT._CP*U]<5_:%E46^,%+&1T.T6>:TS9$-Q+-E$V!Q<Z=NJO;;W832$QR\";R
M0*$*MZ"^Z>R*!!2:BN/;UV\+-\H9L/Y+.6*D=LQ2SS[=A5@K2[2",]<.//EW
MN4OEDM/D)4:C3)!4XY`WMCGA<X-&PHQ?ASC=79!9/8?.^VWIPR8K(WHZI>B/
ME.[,I&FKBCLIJ7FZK7UNOF<\]NFK-O@"G0'%_88NY7W(&`E^!ST#=TD;<ZLT
M,',)`CT,'7/664,)6TUFVICS+>W3&$$&VAB-S<(,`W@#(!``!()"AA!BI:("
MB""H:)H###()ZZ)IZ:ZZ:::XQC&,8\K"AG6O5,NA=A5IRAS2C%I7U]</XV5`
ML$IU,4C-540$]DMLXOFP/M=Q]\QQJ6;EFUL"24V-=7=35)%+9-(C=,LG=T^O
MKW5A_P"QX1S+7M4OTMKQU>)_$)CT9HZ@)UZ!8D`KQQG+]`X3H']^1,W*)$)"
M-<A,UV0`9WDK=LW4V<1B1DQCC+03PAX$:L%Q5A+)P_5O%)JR2J91))QS,&F,
M+J2%*%F-9+2*2Q35W9TC66'RM39[04'9W(D5U+'PLN@.HB.0HD$E>`\!X#P'
M@0_<M^5'S^P`R&V)HW1A)Z.V:(LR:I&/,RG+]A'8G$;KZ#,0SE+YY),BZ;+9
M`:`C"M1T]UMM-4DU-]2R6O)\I=+Q/KRD(M?<&AEFP6)S$N0H,C+;<7$B$Q7$
MCS^XQ_+QNS`O+^-JSO"[;NN"K@G;*PV^NVVNFV<Z:BS%P]C=-\4]SO"7*P[I
ML.+5W%FX8M?0R1NP@);T4(/L1HQ19I45_*RR4N6V-406IM1*<3RE$T!T5%5-
M--B8RHBI=7<O7@`RW*L`:^2Z0>R`/M^D.F&7#C<\CBQ>2R$IG2/-`Z+PW)".
M(X:&PREA',2VP+BDM^-V5U510C7$VD6`_&WS\U3W]Z+OS).M;]VV,]%N=&$-
M<N(91S-U_6WP6N6UK9:BK=NU'6]KVF-A!SLGC&F=LIXUTUJ9NII>O].1[]/?
MI'\"S?I3\-^G/TQ^+!_3WZ>^Q_&?@?POL?C?PWXW_E_M?:]CV/\`3]/I_IX1
M_]'OX\"+[HN.`T!64JMRSG95FAD0';]W$D4$IT<37![>&^.1M@96H%)8UVD,
MHDSP&V-PB.N5"CBTDM?Z[X\$F>'/3\@8(U0HT%V#V^\N#C>SGU;6-CT]4;(8
M6;&>;Z?YYDNU]NM9PD-M=#(7,;HL9D@3>PR%X4-Q]Z^/_M-6Q8+>AH5&YSQ-
M-@.`J?LRO::<+(Z!]"W372DI,O2]L??[.V(F^2<((>(T^TN&ZY>B,6I6"!-\
M>##%64;T5Q"5D-U<DJ$+UF_C25.MNH:\X[H:;WQ9&RI37%Q-!V*+@&MH<@GL
MP<L[(1J"Q75T*%',D,B.Q[:2>,[;ZIZJ*^C;5/;'@DS<,SZC@][1(%P+EC\T
MMOR6_(UHK/9B^`Q]C+=.*N;XU'(^U:,Z")"6@<H8N>UWIM9T!U%A<2*<R#W=
M?>'')*3B_P!1.-3+5BKV-.BV@.,U9SUP77L3Y'J$O#K&(]`GF\>@RHI.KACC
M`0@\C;E.<89F2OF/(YZ2ZJ\A<#4!]M#$S=%Q=?FM4?*RI1\@7*<P[/YLD-$0
MRZY#19SZ_1QX<I&P#&D)RAC82]S7"O9!EK>6%W$C<LSA-,D@4GW4-D]-]D2D
ML*"K%EQ<X6`I6CZIYVKUHJRF84SP2#LJII8[.T);^HMS="=S7=[=SR-UG!Z?
MG@U398LTI58DA3/UWWS],?0FTK^`\!X%5:)[4YQZ9LNYJKHR>_N(_4'O&@K+
M=V5C?,0QK?9,5)14HRVR\MO&8Y`^-&8RIL=H"JNBA[Z>F%=UM"4QRV68M2+=
MUV1VD(N"\.34^3"52=Y&B=;5A#4V\R?VC-CD"2Q(I#6US<&L%8E%N")<'`LD
M@9O9V@(IQ.7'"%76T)MD3TS63[9]DP*AI3(27CY`^E8F\N6TYKXLPV+<%\@(
M2:-M=UN]7&N"[*;'#94U$*0\24I`!R&9OKC[:VX+>@F*'&I]Z73L[HP2BE(M
MR!QY4G[\]!12,P=C;ZM$=3XG6M(U\2TG(1^>=`VNA''YDKY@_"1LA5N;?:6D
M$E)3T0!%SA;8I&I)GFZ?RI'@P5MFK!?_`%O89?6/4+*0YG1^:R-N-8ZLJ/#R
MW"-I+)15,*/3S$($.B&/E-=UT3W>717?9<E;&<II(BWJ::&^$/`>!__2[^/`
MR*D,L:+]Z>L?H.VG9KCO$/QO$2@>-GO"YX+3.NJ(6,4I;%H.VS@(@Q/44YY"
MTVC[1A'=7<29(.6^%LKCY'0C76.ZR<Y*@%G_`"J_*YMVA=(ZK/4''J4<>(E4
M;MNL&96DY<CCI51D'(9\.TE!UL-HC8S=*YWZ"4LM,IW_`!>R*:H^=$6ZU<>?
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M\Y2DEFYBBDFUYIYT;RS'B/0HZN*B4<)M+;M=P'MR`"R\S(F7H+K.!C<.JW`(
MZM^%L9%+URB>IB2=OK\N=WV%U-T]U%=F\MCU6_'9R?!6^+L+B\I#-RURRR<1
MZ/68O;$F=9&,VNT3:(=`TQ5`P5-`M=$']+W/N%]E<!BS$D[:8<P]&0#K6BH#
MT/5H\C%@%DBO1T93EC<(TOZ@3))GJ+*%&MP+D[H":&F,:BR&N5]E/MU-,J:I
MJ9W3TJ68N&:'R4_+4=R%;M.\I\W5()TOUK;SHT>U6Z+VL,##V1U.&0:4I%JS
MZ$.24AEJ&RRH2.^1T00$=W$O;`WLZD2U?/G.;=/>_&3'[-(L3N"P+=O*67!8
MF;B@%26$UN>0PH'7MFPBI8S9,\BM0,3))I"RM%;1XB[A&`%);91WPLP+J&D+
M[K8]"'KKXD>32)?Y`9?**CKN2#H<9U\\;QN^[+C:SZ'([ULN/O3(](TW2DZ9
MG,)J"K6'E-"@EB/*6AVSHH7^`;U!U$G4A$:Y[5,X+M:K.6N7+CN5Q@9<,TZ"
M[$N('GBCHFV`/4@DS1&'5JI"GZEJN/02/;.*4:!2K_&F,*";)-Q!1IQ.VFB^
MVV1>:LK"X[GG9@L;Y'OD-GC>WVD#`RM#&=G5='BK>4:F=G!HW_:"JFP(8ETD
MDIE#H&TXD[WMHN1('T=%,/0<))%/<;XFF:_.4AZGZ_L>U)#1FMA4]/[XFK6U
M=L]//V!SQ.0X57HTK*KWBSE9"5-;0/.+.BV#--I@\I`F-#*YR%=33519=)40
MMQ,9;[<]<UTURY!-*^I>'`Q=I(+_`#$D=/I@N43F4KCHHNDTG4B6U_(2B7/B
MB/NEFD;9W45VSZ<::_37%9MMVG;PAX#P'@?_T^RON2\)/451MT8JW9I*OZ_I
MDP430S4[IEE`ZSJ>+Y!)F#R&VG-[EB)UK&\&/SJ0DJG[(P/IQG951))0LGZ8
MR_(1,*@X]HN,<@15P:W.A.2*<;KZZ4BDHWT<2.AK#>WU8#F:GYP]:MDC<R))
M=/0X>9I+1TT/>586W=0G81K)ROK&IS<]M'/AKK)\@W`5/S6>HMY5Q=%K2_I>
MXI4,V;-)\QEUVR]\G36ZO0.0&M`)S`A#LU-Z@XHR`".PF<#:>WG&^Z)ZVA#M
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M=ZB$0?V2%N#\#J$`7873\I8ST#/?SH04WB."ZBH/OB+*OPD^W:.*#+A4KXEI
M;GCTY;Z!BE+!=<?)G,0W%NCH+4ZVE&BN@W[D9!#1R8'M@E$UETUU*<-QC45V
M6)L>&T_?!#RDIX6[SWT^?)5-E=(0.GN8YHS,)<`E&&[OCY`%(9B1MD)E,NN<
MW,]Y.Y685$'5!-A;H)!VZ+.3N",HFGAABS3IN)G\ZL2F+<9OZ2ISUT#9=<<U
MJ\.TK`92U]W1ZTKMKA./R:#N^:]I!OE]G3^P(WT+8<P_$&P!PJ0&%2<%Q;4F
MXQQ*D!2FH`8ZJB9OVA+.<]+8<L?%1S1S-<\BZ>VQ-;<Z8FS2TZ2:V+=D^LU=
M&Z2Y:=@)I(X4FHU-B<<,G1*NVQ6<:[X$&UU#`U""SN-O<)?5O'3\=;X[)L'/
M>@F*$](.-7<J=16[+[[NJIZZ@0+';LFL*Q(3'H78D=;KV+?G1:)5W-U8V@\'
M9:&0&2ZN"JZ8[J@@MOKF+G7'+1V`0"%U9"XU75=1IIAT(AS2*QQJ-,8NHC8T
MM@FOI2''2U^NV^^^V=E%55-MUEUM]E%-MU-]MLUE43G+@&I^=YR78B4DF]HR
M=J$ET<J@FR%HT4+2,`G$\D%F2B'5VW1N.QP%,B0324%D.#Z>F;(31-!05#?L
MA$4-2VY>#^0SB&:]XE<ZU.\3]NC?)S%8CI.>J8$.=*6N9W"W1X)K,K&%,3A'
MU1!$H]F2)EJNWW)`ZP^WVA@>V21-==A+C/U?*O*Z@]30R/UY6\9:H?"HJW#M
M,?CK,AE`!M`%3U2002QOLHLKMKIIC&=U-]U-\_UVVSG^OA'M/`>`\!X#P/_4
MZ5[>N=LB_>_0]^VL\D"TQ\>'*D7%C,>%?!7,5TNKI#+J\+'(PW#.0YI6`]Q!
MB%CS6L,1JM]L?NGG_2-4US&NI.ZYZK`H#H[Y"[ZYBYKE4$D2C3-K^L>TNZ;]
M:8^[BL+7T0*W`.5KTEL\I.RL:6%Y*I_\3!&OZHB)ZRI=U$"W6]Q4HN-YDEKJ
MAZ0N*2S.9B<'\GO@T6M]W8V_]W+(:XMJ^1?E&D7%G7QL\*I"DBM+;;TK:?:&
M@K.2DJ-LKO\`?%)ZA#XPMISGVZ5N[FI^O8!6O#'#M<M397O/,ANX![M]CCHC
MJD;F@N<(>]W3/WAW2CQ0FSP*_2M@:M)$X.(SC]ZX.VA!&BI2V-]HLYS;M:7C
M2$/*;#=79,SBSV-<W6KHE.BHP86?@UGI:N-)(Q\O5Z,S+D$B1YTTJ\Y)U=!T
MQD5]9%(3]2-=U=/5FI?G3"/X\YGIS3?O=O97>(*T6Z[F`4==*TY^=B'ERN9W
M9.B'YXGD9B42CIA9ASE*9`0VL$+2';6O*3*WQD4#.4=1BD<1N\XDTWTY*Y-+
MK>L;6<>@RVFS[UZW?'&P^J3E@]B(B<ZR2,"11&GHH$Z.#^X_M#64+'3CS,&8
MX'YR(FKOKNFDOH,C6+?FGI'WAF@L\D6GQG6L92IRI[4AT]BSKF$:X7>A3K"$
M*0?)80YR/9Y-D<D67)QNH2Y*E+JZ):)9WQIIIC09N<OV.,^1X+Q91[!34+?Y
M9-BQ?MG&96//75=YFD_DR#,TQ[1X>"UU5=0P&F/,0#2TMZ.?MVMG;Q1=,[Y2
MV54%N:M;X0\!X#P'@/`>`\!X#P'@/`__U=S_`)1.-F=PZ%K6;O5_/E$<]=<7
MC6N>JWT:&0QS:VR=T!4TB;Z!?#)I+/>:8BWNGVNP2JSF&6`.:,&9MG7<1+3:
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M+(FZ*IFHQR1F`K/#(D6FNIJKJ,LEA37?;&WUQG/@>T\!X#P'@/`>`\!X#P'@
M/`>`\!X#P/_6[K+D_B^:?QG_`&93^9/XO_XR/_NG_AO\7^?T^%CS7.G\4L?\
M'?\`6O?_`,Z?Q3_=B_['_O?^]_W?N>"IQ\(>`\!X#P'@/`>`\!X#P'@/`>`\
(!X#P'@/`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g91036g78e78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g91036g78e78.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0?R4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````'0```($````&`&<`-P`X
M`&4`-P`X`````0`````````````````````````!``````````````"!````
M'0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!58````!````<````!D`
M``%0```@T```!3H`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``9`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P"DDDHV$BMY&A#3K\D4-W'P*SC-S<V_[+BO);3#?4NN+?YS[-3+/T;/
MHOR+7^EO1&X72\EWI8.9:S(=I77F5MK98X\5,R*7O958[\SUF_I'_HT_U@`;
MU9]+/YG'JHJQQV%0J8]FW^LY[WK.<`6D'4$00DED]CZWNKL:66,):]CA!:X&
M'-<F6Y=C8V9U&BS.?9#^DUYF4^H@VNLK8?=^DW;K'X]=;]J"_HV&S+Z9C/S&
MFK/;8^S+:1LVAQ&/Z0LV^DZ]FVO9;O\`3R$E.2DM*OIM3\[$QLJC(Z77>]S'
MOOL98XEH_FZCZ=5;+=WZ+>_]#OL2R.FUUXM5]E-V#:_*9C'&OL98Y[7']+;5
ML94YGV?_``OM]#_1I*<U)7\WI[.G=0LKSJ[V8`MLKJN;MWEC3[+V:;;MK?>^
MO:SU$^7AX.!GLP+?4R;*B&9=C'BIAL?M<P8VYEWZ.AC_`-(ZS^=L_P!$DIST
MEJNZ;@/ZUD=/K]5E.,V\%[K&N<]U376,=/IUM8S3W5_]-#HZ8VSIV/E5T7YK
M\ACG6.HLK8RAS9_065N9;;ZK6_I;/4].O9_-)*<Y):^-T?'NZ6,DBUM_HON<
MZUWI5$-^@_'>W'R:7UN_T61?3>__`(-8X,@'Q20__]"DDDDBAO,R<++HIQ^H
MO?1;C-%6/FUM-H](&68^50#ZCVU?X&ZG^W_+=M'1<>+,C+/48,C$QZWUM?'`
MORL@#TZO](VMGJ*@D4DML9M5_4+,WJ=`RQ;)=2Q[J0#[6U>FZL[VLIK9Z5;%
M5_0[+6^G[K'--;MT[&CU/4K<WZ-WJ;JO>[_0_P#"IDDE);783L>NNK%]*X!H
MMNWN=O`!#OT;_8WU''?[6_HOY:3;,,9%-CL4>BQK6W4M>\&R!^D_2N<^RK>_
MW[:_YM"224FJLPF9%CWXV^AX<*Z0]PV$D;';@[?;Z;?;L?:EBV8E1=]HQOM#
M26[6^HZO:`[=:WV?2]5GZ/\`D(*22F.WV!O<#GS\4?=A?:?4=BAU.P-=07N&
MYP;MW^M]/^<_2[$)))29K\`6Y#G8NYEFN.SU'?HC,[G$;/M#MOM_2?UT%)))
M3__9.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@
M`#8`+@`P`````0`X0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D0```
M``'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`__``!$(`!T`@0,!$0`"$0$#$0'_W0`$`!'_Q`![``$``@,!`0``````````
M````!P@$!08)`@$!`0$!`0````````````````$"`P00```'``(`!@(!!`,`
M``````$"`P0%!@<`"!$2$Q05%R$6,2(C)!@E"1D1`0$!``(!!`,!`0``````
M```!$2$Q05%AD1)Q`B(R4O_:``P#`0`"$0,1`#\`J]STN1P)#RS*=`VJ[P^=
M9C6GUKMTX9;V<8S%!%-)LU2,X?24D_>*MXZ(B(UJ0RKEVY52;H)E$QS@'%LG
M9)JT[_K#UMISH*]H_>G.6-S:N#M9R/S+*M-UNHPBQ2>(I&OT4UA(B;.BJ`IJ
MFC$GJ)#A_0HH'B(3;_RN3U1IM?5>X9)5X73X*ST_9,0LT@>(@MCR]\]DZNG/
M$1!T:J6V.DF,;8J'<",S`K\?*M&YU2>84#K`102I=X\EGPK!RH<!P'`<!P'`
M<!P'`<!P/__0J]STN1P+[5":=8UT)MULJQS1EX[,[5+8S-V)L(A(-<9S*H5J
MVV*KL'R(@O%IW>W7)D613\Y?>,HT$SD.F;Q+GO\`;\+U%">:1?7_`*\IEU/;
M:MUQESB^S/M+6Y[)KU`N"D79A(N8*7D,^N;5!8%$6UAH-U;M7[-V4@KHI^N1
M,0]4?'/[=;YBST<-C_3#4]TQ*Y[+G+VMS+BH6A_6$,R]V[3T.XJPU99V^=6I
M$7[(S*Q.HBNNCNSL4UP?+(-5Q124,0"&MLERF;-?+CIOHB.XVK#QL5+;O*'F
M43L-ZN\D]EV5-J.>O<VJVG2D_)^G#/+*Z"`AK8W07;,8YV\6=@)$$50$!%]I
MFICD(#KX.CZ?G.2XCI%2UVUZ1,.8-DC%0]\JJ$$Y;B547DZK=JG!)A$J1Q5G
M?K-!=*)(-5?633,"956Y+;#/1T#GJ\67IVH7#+-ES/7D\8BD;#H4166>B0$D
MVJRLI'PBEMK9[U1ZNPLM?9RT@1-<2+(O2$,10K8Q#^(-ZV&(\V/$;#BZ&0N)
M^5AI0FR8Q4=N@`AS/C&C*]<)*Q1;**F`>LV@$F6KBMK"J"(K(>0Y!*H(B8"V
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M2U67(;W_`)7I6GG153;KN%"D*HEWQP9[I9N716\4K*RZLZN]?L,`>D,;NE*4
M>E['>*.HF_8)2I:TKJ-6S>5H$79V;-8I')'[UFQ;NBJ)'=`"1SA/MMS%Q1OF
MD.!__]&KW/2Y'`OSUL7J^Z8A=^F]AL,)3;Q)Z''[/UTL=C=(Q5=E=.+70I]L
MS"PSC@IF\.71JRU8A%KK&1;!+1R*:JG]TA1EXOV6<\*F7W(-3RVUJT?1,]M]
M.MJ3H698*>@9%B^=K>IZ:8QA%$/)+-W!O`45FIED5RB!DS&*("-V7JHO7@N<
M3G32OR';?<&#BBW9&J66(ZNY78$?87VZ:#:X66JS?29&INCHS$)G>>LGZ[X7
M;U%N5^\!N5J8PB05,W^N(LXY1/D#G:6W7"PS]$VW+L^K63ZX7:(RK2%D3KFQ
M.]%J]9A:ZVG*.Y)`JKND%X2V>FBR-)()OU6;@"HJ*(E`UN;S#G.VAL/8O?GE
MW_V\<Z35OL;39"T9A8XR,BJT9=_`4;/LP@';*[Y@M7U*0\SJVUBP,F#9NY;.
M6DDYBGP*(%,W*<[)_GP;>VVTEYI>?IY=M$%>^OM?GZ],0<W4B=?HFM52UP\S
M:H%E>0D988"FP!;"C`>0L8]2%Y),H9\11@":0+*`LF78,+3MRTY*BKL65WQ-
M".[!Q!+'HT9C&<0E'LS]M&VF3:D@-#D(_.JFK&IJ6.`5>'B(]V+%R447*B1T
MU&YQ23X-=1V'OFKUAE2,1O5HZWZJSKV85[/JE>:E2ZO8WU6I$:^D4XF!9Z9,
MTB$L#5:+<N7"YEVRJA2>Y,<%1,8WA)G-FE1/J[S0\MHQ.LKZ^46XYVQTF7UA
MN>B>K+P[BZ*0Z>?N9F/MDA`0S^5BGT'!I"W!`RK!5(2K$'S'$>69>4]F9>$]
M$Q#-K;CC;3\PMM"T?0B&M,7G\LQM2B\_D+1BO#S*DHXA&<G&0KT+\<K,R:A`
M>J-5P.F4$@$Z9;N<G3G*/?=,N->H6!1]Y@:G5:WH$]J%4D9Q9M76U<NKB`:@
M[EUK:R8+3+<RK:MH$:D$QRD=B3R`43>(,G-/9,,9<]5[;J6QK;;=UDK]HE%J
MNUL%ZT>FY=GUVN*SV34.:01O;*B@\-,,4(XSN5?D7:2K]NC[<%7B[DK1RXGJ
MO-9%$U_9+)F^QO:E8>O.7(.Z4AG-[1@,QS^AZ'?:59(V=<S$1!M:+GQG`13Y
MO!&;S#Q$(],3.FR*RW@L`!,FSLY49YI#@?_2J]STN1P'`]2\?_\`7CZ[1^IO
M]N/KOXUM\+Y?VOV/P_H']G^E?L?^;\;Z/CZ?Q']KQ\/#\^7F;]/.+_3S^UO[
M>_?)K[U^Q?LSU"_L'VK^R?NWJ?U>G\K^V?\`-_QX^3U?QX?Q^.:F>.D_*->`
0X#@.`X#@.`X#@.`X#@?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g91036g91g08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g91036g91g08.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0EF4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````*P```-8````&`&<`.0`Q
M`&<`,``X`````0`````````````````````````!``````````````#6````
M*P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!LH````!````<````!<`
M``%0```>,```!JX`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``7`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#O>J_6&G%.3BXFVW-QZ]UCGN:S'H<\3C_;\FU]3*VO]MGHU.LR_0_2
M^@@_5M]UKK;,S,IR\RMK:[G49;[FS&][GX?I8N-A^X_HO3Q_5]'^=NL4V?5I
MAZMF=6MN<S-OL`HOHAKFT-KKJ&/978VVBQ_JMN=]I]/[1Z?Z/U?2_1(]OU<Z
M=DO%F:;<NR-NZVQT&LEECL=U5/I4OQ[+*:WW4NKV7_X?U*TE-FKJW2[L5N;7
METNQ7O-3;][0PO#C3L;83M<[U6[&_OJ=G4>GU5NLMR:F5LL]%SG/:`+/]$XS
M[;/Y"SG_`%2Z)8W*;?6^X9C[7V;['G:+W>IE58\.;]FKR/\`#^C_`#M?Z+^:
M]-1N^IOU<L)>S#&/87A_J8[G5.!#?1>&.J<WTVWT_HLK9_26?SR2E\[ZU=/Q
M<YO3:F796>7M%F/53:YS*BYK+<Q^RI_ZO5N^G7_.V_HOZFGD9V#BN:S)R*J'
MO!<QMCVL)#=7N:'D;MGYRH'ZN8C<IN5BVVXMQ#FY+ZRUS[VN(?LR,F]EV3^C
M<W]%Z5U6S^;_`)M2^L'U=Z;]8<'['U!DM#FN9:T-]1D.:]WHV6,L]+U?3].W
M9_@TE-W$S,?.Q:\O$L%U%[0^JP<.!^BLFCZPWL/4+NIU48V)@.;2VRFUUQNO
M+6V6X]`?5C.LL8^QF-74QGJ6Y/Z'^<6O99BX.*^U^VC&QV.L>0(:UC07O=M:
MN1JZ/3U;K[#E8%.-BO:[/R\%]0>YY>[T\"S.LL]E-]]C,K(MQ,9G^`_7+\A)
M3M]'ZU5=B7V]1S,=F32^<JAEC"S%WGTZL1UW^&=6]OH69'^%S?M%=?\`-^A5
MJ/RL9@L+[6-%)`M)<!M+HV"S7V;MS?I+(=]3>A.QJ*34XV8AJ.+E%TWU-H=Z
MF-31D.W/KHI^BVKZ'_7?TB3?J;T1E>74&6&K--CWL?8YX:^UOI9%]7K>I^L6
MM_P[_4M9_@O324ZYRL4,N>;JPS')%[BX160!8[UC/Z/;6[?[_P`Q1Q\_"RL7
M[9C9%=^*0XB^M[7UD-):\BQA<SV.:N3^LO2.A].QG'!P@[)QZ?M9QA?95CEN
M*WT:'Y=-9L9=:YWIU8OZ'[3E75_TBOTK+:];I_U6KQNBCH^1EVY&/]F^R.8T
M,I9L+?3MV5TMW;[?S[+;;[?TEGZ1)3?9UC%LQ<#*8VPLZF6#&;M]WZ1CL@.L
M;_@VLH8^VQ5,GZSXV+UQG1K,>XVV&H,M9Z;V_IO4]-WHLM^U[&_9[_6L^S[*
M/3]6W]#^D4[?JWA6LQF^ME,.$7G&>V^S<SU`*S[W.=OV5#TJ_5]3V/\`WU9Q
M>DX>+U#+ZC6TG*SMGK/=!(%;&TUUL=&]M?LW[-W\XDI__]#U5)?*J22GZJ27
MRJDDI^JDE\JI)*?IGK^,<GI5M0NKH>'5/K?<8K-E=M=U-5SO]'?;6RE^W_2(
M/0Z[/M'4,K+:VK.RKFO?C>HVQ]-#&C'PZ[/3<]C?5]*[*_\`0BQ?-B22GZJ2
M7RJDDI^DLOIF`_K!SLG,+0&XWJX;GM%9>RRX=.L?/Z3^DW6^C5_-W95=?^%J
M6POE5))3]5)+Y5224__9.$))300A``````!5`````0$````/`$$`9`!O`&(`
M90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T
M`&\`<P!H`&\`<``@`#8`+@`P`````0`X0DE-!`8```````<`"``!``$!`/_N
M``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!
M`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`__``!$(`"L`U@,!$0`"$0$#$0'_W0`$`!O_Q`!]``$`
M`@,!`0$`````````````"`D&!PH%!`,!`0$!```````````````````!`A``
M`00#``("`@$"`PD`````!`,%!@<!`@@`"1(3$105)!8C-QA!4V,T)39F%S@1
M`0$!``(#`0$``P$````````!$2$",4$246&!D2)"_]H`#`,!``(1`Q$`/P#O
MX\"-/7G5-8\6\^S_`**MQ9QUB,%!&^(+0WFN#F_2%X+1:8O&@M`A"\!D2%^+
M0$U*(QH(+]OVK[Z)Z[;8+)MQ5"/VG?'1K)$W7;V(>N?USGSS=N<Z_J5*54OV
M!<;ZRNA'\4SJ/$U<[[@%<..[^[I+HHAL#`5L@0CE#!Y&_P`]4XN2>K5]("18
MX(2!YFK@<B(,D:?J-H'J<6FCIH29J(GNHF+J2MKG?">NVV-/E\<9SC'Y\K+Z
M_`>`\!X#P/,:WIF>]#%65V;'=-N<W!E<%&L\5PT!>6DC81U:3-Q%5=17-M+T
MV2(0W^*J*F,Z[ZXSC\>!Z?@/`>!ALAL:O8BL[#RN=PV,$,,3<IZ^(2&4,C*L
MS05FU*W>)H[).1PV[=$VK0%;)+BMC0-#".^=U-?AM^`PRG>B**Z&$E+E1%MP
M"XF:&/@T:D<AK63-<RC(+\4RMLA3:T9.PD',#F5HTNXZBN!"5\(;[Y24SHKI
MOIJ7+/+1'3_<$&Y\LBE.?8RQ;W)U%T%)FYMKBAXW(VIG?AH4EEX/F5P3MP*2
M<5X?6$/CL7=R/W/T3"70MO5&"'6P@<N$)-Y])N>$/`>`\!X#P'@/`>`\!X'_
MT.J+V:>Q1[XF/YFJ6N(/%93=_8%@/%=UE(+3E2D,I.O,L9,.:G2764\-8SI)
MS1QWJQ&?1!N!&2P0-L8MN8BH,@,=*UUF[^(022/U??Z:<<ZFM_JCVVS8.2,3
M1+^<N.8H17G(==2AZL1Z6:6Z3;Q&24_5CRW5V_QG]/4FRY^ZNPXC=DXM!%`G
M\:%\>.$CHK;/%7(,]/EDE]55E<-#1"%G.;]TX)R+SVY0.*1PS1(9=N>[;Y#F
MMUO(&KM^-="==\902_&-CMT=<Z[9?X3F_P#K5BMN]:T33%4,MQ2.9COT:F8C
M$I5[7!4\3"6W`Z2X7!,)CE61UJ4W*EKW,\[Z:@?7G07&NWW$+H#:*K)U,M:"
MXH]A4'ZMHJV+BG$<WYW=:(L^S:UN^`V$Y&C'5`Y5\ZDZ?J3=^>6&,M";SO'/
MUC#T1/V$&XE;<39;=9'?P69CP(S[;N)9+9"\%WL)SBD7+ALXFT&O:?L>T&H6
MW&ZK2_UK0%J:>R4QN7FRT"1_JRBD`=6LUOQN4W%FCIJJ:35^:R:LO:APE;%5
M6S>4:O5O:ZAI:3"Q*;3V>Q:;5LTZO)3?'B]!64*>1V/OST2F=)AF_<5$/)NI
M^VFGT?`@10BZGS?QZG/G>D?Z:=Y`PU]15YQ8S-2[W-5CW;S7!H7#KFA);T9'
M(ZZQ5S89S.)-'QWUV&34^M\9FT\5O*0)6%U^W1+(LSVI"OOW.^PQUOIMX4HO
MF_FB,=/68\K12*R:,])1N_FV`'?JF%.VT@;D&&+-;+(HJUH;&J9>Q_U]DA]]
M]`#-=L)^36YUF;O"WGU><X=9\G4>/1_1Q/-SHTQS=W>&"0TD\6L_2J5S*:S*
M4S.PI38SK8S)'`B#7QV?=5D=&X(=)#;;=+735%-'7%C':RWAL?LOV1\J<$EP
M0+I*2S>+J6(1G6/F,E56+*F'^/&7V&=W0J5,D<)BOYCZNR&36U`U=\32,'5U
M!W26TWR)+?"#3/[VN4+<ZDIVG>?YF=-JI=`7)SLVRT*0Z5?'EYDSL&_1ROZ3
MJZ!1VGCY4M-S9/N$]N3JZ#!LJ3,/D414LXA30.:OS9.5ZWE94N^Y2ON.(AS5
M9-[6SS32]IW[-VQLH6F7Z60AKS*WRS)^B:PP-L6GZ;9DIA1CB6Q3B@:X&AB"
M:@Y3U)0W43_,K76W<WAAE867Q)Z+_7]74=GDFCADOW9OY65-58@-KU8]WW*4
M$$3)R/U@7YY%_P"F+&#M^I[DZHM``20R&BZ>NPR&SPME[5`7C7O.+[VQ/NFX
M)4KCWE[(.YVYHE"U2T*1#6F%<<<RQ]S9&2O*1M/H"51R,@Q.0Z"Z8(D1&PJV
MAYC$!EV3#3&!='`MGK<BS=E]]OK:<^;?]1KE<"L77V:Y(<AS\]:QHWI(AP8G
MQY8&V._^N(G*9,WB.DQ):4UVU<ET0:TP3ARCRPD,K*(MC/QVW$VKI[FYXYRK
M:!6)>\F<:N,LD2+_`-J5=(&=<RX39!+!@%@X7F`1Q1\<?[G;5S\#N&NFZ@0*
MJ2NRI.$4]E<5)+?#)^C^Q.:^2(ZC)^@K4:8$WDK80$"2:9-,9.=M_@Y54`A4
M$9)/,3Q1$E]52%D0-T1D?RJKMHGKMM@26^$?I![9.`&%]I:.H]#1R5.-\2:*
MQ:%:01JD4UU`-G39@Z&%31..M)Y,,"DQI08`N#TT5\EFZ;;I:##G$"-/F_C=
M/5W;7-O%D-VE]^V(#'"#0328C!6Q%5^LFQ3Q5A1$F*`0IO\`L=I`Z&.!Z".-
MOBD&+A3*Y9`XJ2ZZ0DM\(]^N_P!IE*>RO-K$4E65YPYEJ<B,CN<@M:-0YG:'
M@B3C'+#-K27$IY-$\O8&S6ON2,IG7&@NXZN%-LK;)I3=6]<\I#]O=*M'(?*U
MU]!.>[6H9`(0\'15H=7L:/IR:;$"J"Q"+!.);<\):NC\^JHCC)_J$Y55VQIA
M/;\_CRI)MD?OQ$]W+)^1.=)7T')@9A<LNJ6'R^>R1N:V]D&<W65M:4A0WV9V
MF/11L;"QVQR01(00;QDDR$]]=<;8Q\]A<VYX:'X2O:UNG)[UY;SK,2W3G1LO
M,^G>9XXC$&2/,:L=JMK!99[.AG`U@;;-='5]L-1P`+U=E]P456S/Z*2:>=LY
MBV9GZJ:]VMNQRM.Q^-(:7VYU[0&EL+!%7.RT5=UD1.(UOSY"71\W,DHM14U"
MI!+Y-8MO/KFX`M;RIH=LCM'%$%M?U$T]@U7KXO$9748GLDU]>O5^UL:=O;Q5
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ME>C*V7((Q)$=L(%M6)`@-NAKC7.<_G?.]3<\1Z%"^LGFV@+98+I:5[$L&:P2
M!`U=4F+1DK7(H[2<!;1!6X6.U+%VF.QYCB./XT)-!8S5%5Q)URINL0HJN0HJ
MPO:WA&ZF/2_5M>6#:3U9-Z6[>=/V'T-*.E4^<)8L&T5.XV-)78!Y3<[E`;5U
MR[]58#F)K7!1?=M6M(L#[\@[;D$_;,7Z_C?$Y]4W(=M=,1_IVXH5M93U74+A
ME;TO5SOJ`U4I4L$@:"2T>86:NX\$U-LC'#?3G<O0=YV/;-$W79#4/&HPVR=Q
M/JYD?<^>I7UWR>YK#OJ3\O0"26%:(IJ4N4??YASC)!KNS.<??WULAA+GO%6-
M_D#6Y_U188B*F"T=#DOJ/V6)58?5S-1)YH]%-2\U%6/K'NJ^LR6.?,8,&39F
M*=,D*):*P;9"[2<.`(RAKCYDK!;T7AUV7P2R&,1&%]EM\9QE??'DQ;VM]-G7
M5ZS5:_(H*?\`K=CG,5!VK1#S*?TT;6J<.5QN5LDW87)I?'613EN9G*Y#YP&L
M5KN,<J\***:*K:J*8QNIJLP^O.IX\]5O?$,!>7[H6]D[@GLK'8%CF:*PMN@5
M40$D!H'&<VJO&/*[O*2@2W/"JJAKLY$DD_G7/U#X_P`+6I<]1GESUG'K8KN1
M11^@=96(5EN<3XFPV]%FR7P-*:H-3@/&G)[:7-K>==1!32_BLJB/N3H,HKA/
M&<[?C)%7'I@]8,O]9U37''++FT5G5B6S8C2]DN<$*>U8H+"XK&AP8N!J-(6!
MB<T9#H^/+VH7OC"J"@R@F-/COHI^9)C7;M]+FO*RAMW85QO_`*?WYI[C'AKI
M2SL>UZ9CTJ2<C'%^DJ!B.&$"$MT=VQ,#9>2<OH.+HT?@U3]C*/Y^M7?78LW>
M',]!>61KQ[5KCB./<'5]Q]Q!;$23ZDL$8U'$HZ(M*G(-(4-XBU3"<NS_`"R3
M5,W3ZRXDR(%1D`UN)T!25)V4V4QOIM&]R;O*\A7U)5&P7U.+.I2RIUS=4MRP
MZ)Q"_><*(:XE7L'MI&&@REO;#%Y(RM`TLA);@C)-LN!3&L$YE*9)6P8F07NM
MHQGZXY>=V#Z9^3.EZ/A=1UQ#X'S$]UM*8=)X18=:U'`7%Y2Q$`"&5!AEZ1X(
M3G.H^<SF*86'.<LX7.30))R1LC\-V$[65K.\?2+7ELRFM[W9NE;QC/:%?S**
M3#?K*3$A6+(7G^U&["`#$/5AI##4L59@'=/4\%-K:QOUU]E<+_M_=OGQA]?S
MA+UH]?,!B54VRR1"7OB_1ETUZ\PB=]>6@.K;MONI,C;-VQZ<D<2EWT#8(_NB
MMO\`J1ME4:F`'&J.$AL81U_-3?\`36;7Z@.16OC^$\<MX$RC47ADOBEG:V;`
M7]*$V\ZVS$E7(ILL<N8@`DK_`,X*6\$Y$QOHKH`CMHFA\?JTVQ,7ZNZI@[6X
MUXH]<%OA=(W?[`.HWA_?:GDT/K.H)"1%[EZ->D`ABC458%<$Y8I.?5C8/-"$
MU1'D9J:R&TH@C09R3^TG/CPU+>W&-^^G3E+V2U/Q]5L*CA=`<AUQ+RY%;TBD
MCW$7ZZ[YM-PLEDB<AA,S<X<9*V."U]@.(_HQLIM(71<D$V3YK!ID;[*JHG:S
M:L\ZD]<977-`UMSQ;?4=Q/<98+5CUGVE*B&6OAIS:.6!O*31C;8X1J.1AAK5
ML1>B?WQ-@&TG853373.JNN,9\8DN79&TZEX\FE2P6<P/7L3IBRVQ]A<J@L%S
M;;U#9:17C:^-*0#$\:R`*(L4_E4JBA6JBJ)Y;YIE9-3ZMM-?@FIK4W^(N\M^
MJ>8\BC5_'JG[[ZA&KIDD>)I9=</`E<2&/6;+C77=TDQPI<EC+X^5^TR[?&F#
MPV\I3957*Q&5OV%]U<3%O;?3?DHX8!EOLOKWOU[>8VZ`5WRHX4+'X0Z1I%P>
MV2<;V,_RD"Q6%]+PNBU*_P!K35W:U-D-$C-=%LZZJ;(KK:>7VF_\XL'\(__2
M[^/`>`\!X#P'@/`>`\!X#P'@>>[.K<Q-3F]O!B+>TLS>8ZNAY.WP'!;F\90L
MTQ??\9^*(PR.V^V?]FNN?`J!Y6B07:]EOGL8OS5K=JEC[C)6KB6#2+<4F"P>
MLHP[$BJ]*[AN?].+/;(';-B4CB\(D-+9G9'"0^V=\[1J\<1Z/JT#=+O>>G?8
M++2G`USZ@MN316I!CEW;"<6YKIN1.\+K)E`$*T&9U1GU<`M[_>"1QJ;APUSN
MHK\-=O$_3MQG5;[Y63P'@/`TYT+=L2YNHZU+XG.RO]JU3"'Z9NJ"'SP0X:M`
M2BP;0+OH@1]1;RX?4(EOMIE--1;7;?\`&F-LX+)MQSU].<[.,^X;A$+M1@3F
M7L)]I]KU(S.CO*DH4^V-4D81=6RV[#C]>)%&K*MM.<\U'%G9/01J*3$',=ON
MWVPL?A-6-2\_R.G?RL'@/`>`\!X'_]/OX\!X#P'@/`>`\!X#P'@/`>!A=D1+
M:?UW/8)H?JU[S6%RF):N>PV3-6[:1L9S/J?L)A<;)6H>3/LRGA1/Y_'X_+7\
M_G`<Q;AU,IS#ZKY9ZX94[LU9=WQ,T#B"#5F0X9<WRP`[:EFT6B]YQ=L=XGJN
M[5/+H.]FFY/;!'?1OSC039?1S521UGIO-[;Z=&G,=),?-W/5-T3'0Q@&RKJ]
MC42^@)R=G@/9R;VY++X4(Y/F?Y4L8]\4(73V6U3SC13&,)IZXPGK6;=NMZ>$
M/`>`\")7=?*C9VYR9<_+SI+W2!)6FPM(P,O:!ASEV-_BTJ89S&"C6XCX:NK#
MO)(P(FYB:*#K%MNZZ*1`ZN^BZ99<NL#Y;X\D=6SN6W]T-90-^=*RMG:X2VS0
M>,JQV$U+5T>U71:Z\I&*O;O+7V!M#]E30R2*?RY2\A<TDB2M]MTM?!;^>$\?
M"'@/`>`\!X'_U._CP'@/`>`\!X#P'@/`>`\!X#P(GWE_G-S=_P#)_P#WD;_G
JE_G-_P`@M_\`-W_F7^^_X'R\+/:6'A#P'@/`>`\!X#P'@/`>`\!X'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g91036g92h46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g91036g92h46.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0KZ4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````.0```%P````&`&<`.0`R
M`&@`-``V`````0`````````````````````````!``````````````!<````
M.0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"%T````!````7````#D`
M``$4```]=```"$$`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``Y`%P#`2(``A$!`Q$!_]T`!``&_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDE1ZIU2KIU3/8;\J\[,7%9].Q_P"Z/W*V_P"%M_P3$E-Y
M5\_-IP,*_-O,58['6/CDAHG:W^4Y<_U3IN:WI.7U+K'4+OM-=#WUTXMCJ:*G
MQ^B;4VLLLO?ZGL]3(=[UG_6B_,SZ.B?5=[R[.SA39U!S>S6#]*XB/](VV_Z/
M_:=)3V>+>,C&JR`TL%S&V;3R-P#MI15D971^I[W/Z;U:W":XMBA]55]30T!F
MVMEC66L9M;_ID,=#ZS:S9F]=R'`G7[-53CZ?UMEUO_@J2FYUCK.!T?$.3FVA
M@XK9R][OW*V#W/6?]2>H=2ZGT=^=U%Q+[LBPU`@`"L0STVQ^:RQMK5@YO2NF
MX_6,G.JWV_L'&=;D9618^VRW+>V<*HNM<6_H&[;/T6S],^M=9]7\%W3^BX>(
M_5]=0]0_RW?I+?\`P1[DE.BDDDDI_]#U5)),YS6M+G$-:T22=``.Y24U>I]2
MQNF8CLK(DM!#65L$O>]WMKIJ9^?98Y5.C],O%S^K=3AW4LAL;1JVBKZ3<6G_
M`-'V?X6Q4^CVU?6#.LZW8X/PL2QU/3:CP"W2[-L:?\+9_@/]#4B6YV5UN\X?
M2WNIZ<PEN7U)NA?!AV/T]WYSG?1LR_YNO_!?I$E+9MO[9Z@,9CMO2>FO]7/N
MX;9=40^K##O]'2X>MD_]M*C]4\:SJG5LWZU9+2&Y!-/3VNY%+?:;./S]NW_M
MU/\`6"^B@X/U0Z0!2_/<&9`K/NKQOI9#MSO\+=6+/>_W_P`XNGQL:G%QZ\;'
M:*Z:6AE;!P&M$!)254>L]39TOI]F46^I9HS'I'-EK_912W^N]7E@X[AUCK=F
M8XAW3>D$UXW[K\F(R<CZ6UWV6O\`0U>SZ=EJ2FD,![!TWH#W>IE9-O[2ZN\`
M$.%;A<[?/YMN9]FHKV_X*E=6L/ZN`YMN9UU\G[<_9B3VQ:993M_.;Z]GJWK<
M24I))))3_]'U5<C];>IOS<EGU?P1ZK['-&0T3#GD;Z<5[F>YM.GVG._<Q6;/
M\,MSZP]:HZ)TJ[.M(WM&VBL_GVD?HZ_^_/\`^#6+]1OJ_D8M+NL]3W.ZEG;G
MD/$.8UYWG=_PMWTW_P#;:2F\_P"J6([ZOU=%9=94VN'FUGY]GTGNOJ/MNJLL
M^E2Y`LZ[U#`#.BNQ:SUE[0W!;3(QK&:M^T?O8]6,UF^ZA_\`UI:/5NMUX5C<
M/&K.9U.\31B,.L?Z6]_T<>AO^DL7+6`XG5[.KV6?;,WI-=C\^\`EAR+F?9<+
MI6(T?F5OM]W_`()[TE.C]6.DULZYG9SWG(NQ6C%MRG#6S(=%V98W7V,J_1X]
M3/W%UBSN@].=T[I=./:9R'`VY+OWKK#ZESO\]R)U?JE/2\,Y%@+['$5X]+?I
M6VOTJHK_`)3W)*:G7<[)FOI'371U+-&CQKZ%,[;LRS]W;]"C_27JKU7'KQNG
MX?U8Z?-;\^:2]OTF8[1OSLAQ@^][/T?N_P`+>KO2,!^!1?G]2L:[/R?TN9<=
M&L:T>RAA_-HQF?\`DU7^K\]2RLGZP6-+6Y$48`<"",9AW>H)_P"Y=OZ7^Q6D
MIVJ:JZ*F4U-VUUM#&-'8-&UH4TDDE*220/MN'MW^O7L]3T=VX1ZD[/2W?Z3?
M[-G[Z2G_TNLOZ9E?6#ZR>IU"AU72.DNC'JL$#(NTFW:[Z='^O^D0NK_6IUG4
M+^DX]K\$4.V67-I?=D6$_FX6.QCFM;_W9M_ZVNN224\K@=+ZC=OKP:G](PKS
M.3FW'?U'(\9<\O\`LV[]^S]+7_@F5JYU3H3ZNFX>'T:BOT\7+JR+*'N+18VL
MFQV^V+'.L=;Z=CGO6\DDIJX#>HBMS^H/K-KSI72"&,'[N]_OM=_+_P#`UF=0
MZ7UB_KM.?2_'?C8]1;CUW[SZ=KOYS(].N/4?L]C?TBW4DE.9U?H]W5>COZ;9
MF/J=;'J7L:T%PG<6>G_H_P`WZ2!3B_6JAK*696`::QM:XX]@=`^B/3JR65?Y
MJVDDE.0<3ZSV.]_4,:EH!_F<9Q)/\KU\BU0'2OK"7`NZXZ!.C<6D3/\`6WK:
M224XIZ!U"_\`1Y_6,G(QS]*EC:J-P_<?;CULM]-WYS=ZTOL&%]C^P>@S[)L]
M/T-HV;?W=BL))*?_V0`X0DE-!"$``````%4````!`0````\`00!D`&\`8@!E
M`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`
M#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!
M`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#_\``$0@`.0!<`P$1``(1`0,1`?_=``0`#/_$`'@```(#
M`0$````````````````)!@@*!P0!`0$!```````````````````!`A```00#
M``$#!0`!!`,`````!`(#!08!!P@`$Q4)$1(4%A<B(3(C)"48&1$!`0`"`@("
M`@,```````````$1(3%!40)A(H$2<:%2_]H`#`,!``(1`Q$`/P#?QX!X!X!X
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M17JM.(<4K*,9\D7VDEQ#=O*R/`__T-_'@'@'@5@ZAZBJ_-59@<8@)79>X-E2
MZJ=HK1=3)&:NNW+Z\SEQB)`=(2ZQ7JK#MYP7/V`IM0$#%H<*>PM6&V72R9_@
ML7I_F[<L;R7T5U-VQU[N9.W:CHS8=PJ.M>9MJWO0G/.F+V/6SRZ#!4*$I,M7
MK9MJSA6]8@`DK;SI!R3((]/`C#;B6DQ9=R2*;?*)=MQ=#T3XP/B7GI^3D>BN
MH`M"WOL*9K1*&'@*O3JZ%B]RLC'XCFVUQA=UBIRSIP\"VVPY4FU>A_KA"5ZB
M^N/M[=');.X^Z7S-3DORY\@>T^=(F6+K;L?J^SZ;TGT!I^H1]>K\36/8:3`7
M&NU^^5:!*C89IW`8EG:&:.<>?]-675)\K.9W$,&XB[*N,.[#[R^5;H*8'(.8
M>(;YXTMSUS3G\$=25X$%G!J;LR_`D$*1CU76IS"%XRK&&DI5C&)^5S/\DT;J
MY4YKUKV%NSH&H(OES_\`EQS19=G[?WMO/:.R-S[%WGVCL"G>Y<TT.0FKO-R4
M3B0U-&@@S0K\`F*>#L,G'CJ8PO"'F36;B3RT+_'YHX_F_BSFS3,T\LBQU#5L
M"[;R''''G'[O9\/V^[O./.O/N/+=ML^:K*\K5E6<_7Z_Z^5BW-JX?A!X'__1
MW\>`>!P'IGI'7'*>I)K;NRW98F/#-BZ]5ZE5X]4W>MDWZRE)C*;K;7M=:6V1
M8KK<)=Q`P0R5)0GZK>>6T.T\\V63.HKGR!S5?`[;8>Q.J\@S76^W8%B)1"!O
M9-J7->IG'VY*&T-K%#J<_CJ&7AIZT2J<Y>GIEM3JE>BVRGP6]3AQ;<]F1W!T
M`!JN&G'H?B7CVW_U#K'9R'V0ZSM7=VIY:.L5(YS!EGRP_5J&M):.59KN:RV:
M)^1'!Q:\L.*<7Y%XGRJG\3VMYWK7J_J#Y>MFPTB%$;4E3]0<?0EC:8</@]+5
M=],)(W,="HT/`F;"+#C!!N,?:K&%RJ5K(00EY2>5]M2>K0_Y6%6^RNF8CDOG
MZY[=)BUVFVH_`I^H]>"Y4J6VEN>Z$I@=8:XAQF58,))LUI*80_D=+CPX""",
M(5AE6/"R9I4+6A)J`%XB^.>>FLV;<.Y=NK^1'Y$K0%'1,H%:X/5-OB-C3#%F
M?/=><;B[UT8Q2ZE#N`)PK$#77&ON9:;2AV-9YOXC0%Y6!X!X'__2W\>!Y#SP
M8H$V4E#1(V,C1"3Y&1/)9#!`!#9606::60ML<404=M3CCCBDH0A.5*SC&,Y\
M!./'EFJ_R0[ON/>UBE!;'S_H&_VK4_$=((<*:@XR3K@8X6S>G;=#R((K15\N
M#I*1*LM[[%UZ!]?[FL&$>LU.6K]9CM.K3N[:??%Y.TKR//3U`Y2@CI*&Z"[9
MA&B(R1NKT3)YCY;3G'4P8W@:>EY-\,@*8V`,R7#PPBG513STA^*YX,8YY5/[
M_OE)H!7*WPJ\:"0]!F^HK#'4_;\=2S$.6+5/)>63I3;\IB2F"37W-@[%IL?+
MO+/E')"2.`%D'7,++,%+P^%G?M3VM;:ZIFHM?TS5VNX$*L437U9AJA4J_'HR
M@6)@8$%F.C1$95E3CRT#,)RXZO*G7G,J6M2EJ5G-837P%*Z_D1.W>VK;NR6.
M"D^3^`Y::H.E/6<3FJ7_`*U)`+C]S;D*(3/9BY<+0-57BMP!!0#C#$C-2A@C
MZ'1TK\C7$QW4C^.IDK>EGZ.^06P-DO-]/786E\]^XH'4Y!\D:0<DZSK9V):=
M%;E()G:%S+L%K+'4YA!2)`-U2,90G/@NL0T?RLCP#P/_T]_'@9U?ELZ:F]Z[
M&J_QN:$CWKU.6FTUB*W)#QI4@U%6NY3`:[1KK15FE8!DR8B=>QH@";KM,UE+
M"8ZBQN05%#F3`:')6_6=U<68^)/4TAP!1N$H+8U]H<33E1]HD;O5WV5C;&V<
MAUV9L$YMFBR"W(+8]%M=L)64?6S'&V%#):'9('RRTZAA/VWES">[KW[SV/`<
M*R6@:$;WW8J]`P/+4%JQB:C^5=FTI2I2'(W"^5^*[-:@I&F(.N$R%GJY_P#W
M$X&:$B2C&2,&#C$N\Z<I^,GDV!A^Y.J=\S4^3M?8&E(.+YOO>]++%DN3>WNF
M+5F/V/T?=(<HN5-%K=9H[;T+4H2*#:3B/CFR!U*PKU5$"W4C05Y62Y>ZMZ;%
M474>+N7)EP'K/HR.?>%M`0SY;'.>AQSE1FQND+4^TC\:)3#LI=BZLT^ZR[+6
MA]EH;#N1WTI+)W>'">J]?5S5>@>;OBBYK<DZ=-=5/&ZB+GH-Q"K#1^;ZA'M6
MCJW<TK(&1TA'E6FQ54EV':=-6PLZP6IM;2UN-^GF?"SF^U-OJ-4K]$JM:I-3
MC!X6KU"!B*S78@7&<#1D'!`,1D6`QA65*RT($,A&,YSE6<)^N<YSY64A\`\`
M\#__U-C_`,A7:%(X+Y5V3T!;2XQR<C(PB`U559`C#3E^VS,@'?I=3&80ZT62
M,X6*LV24Q]SHL.$63A.<,YQX63-P6=\'/`-]U/3YWN7JSWR3ZVZ=_9;42%<`
M<"6#7M2OEA19)%V7#=0AT.^;)("$D9/+B&BP@$!QSB6LCNL(D:]KG4X,CZM[
M;@=$3L#I'5=2.Z`[`V1'/$ZLYVJ!:&S\BX?8$S>]L63#;\7J35,4X1ETF9EE
M,));'>0&E]QIW#=9DSOH@RP,O:@ZZMO:5ENK/0F_>#->[9MG7.V8D.?E=?6#
MIO?-#+T5R_P#S]%`^A(1]6JEFOA.36$#NE,&$C9D%BG/K;S&^L=5H7X+YXDN
M8^6]:ZWM3[,AL^1%D=C;LG&5+<_8-U[+D"+GLZ54^I\C!*,6B7?&9=3E*7!Q
MVU80CZ_;BL6YJ4]:]/5#D[4!NQK"$;9K/-S,5K[3^LX5*GK3N#<UP4\%KW5]
M5&;0ZXY+6>7;^U;OVY;"#;?*=^C3*\^"3-<<Y#T+,\[4G9_1'4MOKTUTMN)K
M.R.C]FD$#"5>B5BKQ91=?U55Y)]30L5JG3%?R0VROZH00^HHUU6?5Q]@MSJ<
M./\`Q]J)ZAVANSY([3`R$='[99$TAR:)884V+E87E#7\J3*-W*/1(&J)%9W]
M?C'9Q]M0@ZEB1D>O"EMJ2E$6ZT:[Y61X!X',_P"SZA]M]Z_J%`]D_?\`^4^]
M_MT%[-_3O=?8/Y][M^=[?^Y_L7_C?;?4_+]S_P"GZ?Y/_%X,/__5T'WSF3:7
MR0_(XY8NE-7VND\-\'SS\?J2BWJ$,CXWJ'=+WM14AL(J%F@_;K+JF,4SEL<A
MGUQ)!@5ECZY07(,HG+6?UFN:@W6ORIR5HZ#VQQKK>[WKF%K6\VW2[9L>#T%L
M_=/3>UI8L9YDN%Y?U#`4N4AX>(=(PMAJ\3KN0\Y]%V.9<R4&3EE9ZZRE>B^7
M^BKLBS5?0%#O'Q^<_;-D/==U=.;:G7+S\GG4+R<GBR!ALW89*RFZ5)E7#3,C
MRDR^_.0^'D$10,?]WV9&9WN_TL?U#PO-57FOFO2?#6K]>-5G2?6ND=YW'5UP
MN$E50=H5774S+VV918]@E1ELG)6W2M_9A98V0/282:@%Q+F7OJEAPDN[:OKH
MJ/Z':@Y28Z/L>M3+A.%BOQ],U'"S`='H$6PPM.(EBR6@DBTWB;*>>RHR2?:C
MA7/3;2,`-C#BGJEQTH[T'S!V'L'NG7/1-'GN<Y_5&HM43,%I^I;EQL<S&KMO
M6U_(ENVVU3*</'AW6T$UU#<<$X]-1OXD>LAII;#SN7U199C';N'7''UNZZY"
ML_+EEZ+N5,F+NB/9N>U:E4ZV&58XYF;S,256+J0[@0XU-DFOL"4(P>T8X&PV
MV487A9?Y527%SAR^H:O^5&AQD!18+>?Q^R%'JT2Q!PDO)\J;JA;`S$1C*AH2
M.S4:/TM6*.`-&@-,"MM@)#8;8;Q]K7UQ_E-K]?E*'-5?)K99-E4]V'S!KZ(&
MCC&THU-Q_;#3I"3>("R*])9VITA=V4#B#(?PG`V6/JM>/O2O'^V[3Z^$=;Y6
M^0MXT9X_Y4["T&PT8VZ%`\9<VQ^3%E,>BR^05-BV=:'8Y?\`RL8:2VC+G^CR
M7D?X>#,\/*7P5T!L-**]T-\DO3FUM8O*S[]KNETO0G/";@(O'I%U^U7;3.MJ
M[?"JC+!+<8.`$D`LDM.93EU./KA47,ZB\/\`"-,?QW_U[_EU&_AWZG^B_P`I
M_7(S]&_4O0_']B_7OQ_P/P_M_P`O]GW^K_R?=ZG^7E9SWV__UM_'@'@'@'@'
..@'@'@'@'@'@'@'@?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
